-DOCSTART- -X- - O

Nitroglycerin NNP - B-MEDICINE
as ADP - O
a DET - O
comparative ADJ - O
experimental ADJ - O
model NOUN - O
of ADP - O
migraine NOUN - O
pain NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

Treatment NOUN - O
of ADP - O
Hypertensive PROPN - O
Cardiogenic PROPN - O
Edema PROPN - O
with ADP - O
Intravenous PROPN - O
High PROPN - O
- PUNCT - O
Dose PROPN - O
Nitroglycerin NNP - B-MEDICINE
in ADP - O
a DET - O
Patient PROPN - O
Presenting PROPN - O
with ADP - O
Signs NOUN - O
of ADP - O
Respiratory PROPN - O
Failure NOUN - O
: PUNCT - O
A DET - O
Case PROPN - O
Report PROPN - O
and CCONJ - O
Review PROPN - O
of ADP - O
the DET - O
Literature PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Different ADJ - O
Spasmolytic JJ - B-PERSON
Regimens NNS - I-PERSON
( PUNCT - O
Nitroglycerin NNP - B-MEDICINE
vs IN - I-PERSON
Verapamil NNP - I-PERSON
) PUNCT - O
and CCONJ - O
the DT - B-ORG
Incidence NNP - I-ORG
of IN - I-ORG
Radial NNP - I-ORG
Artery NNP - I-ORG
Occlusion NNP - I-ORG

-DOCSTART- -X- - O

Nitroglycerin NNP - B-MEDICINE
increased VERB - O
ADP NNP - B-ORG
/ SYM - I-ORG
O NNP - I-ORG
ratio NOUN - O
at ADP - O
the DET - O
higher ADJ - O
concentration NOUN - O
( PUNCT - O
250 CD - B-CARDINAL
μg PROPN - O
/ SYM - O
ml PROPN - O
) PUNCT - O
after ADP - O
stimulation NOUN - O
via ADP - O
complex NOUN - O
I PRON - O
and CCONJ - O
at ADP - O
the DET - O
lower ADJ - O
concentration NOUN - O
( PUNCT - O
25 CD - B-QUANTITY
μg NNP - I-QUANTITY
/ SYM - I-QUANTITY
ml NNP - I-QUANTITY
) PUNCT - O
via ADP - O
complex ADJ - O
II NNP - B-PRODUCT
. PUNCT - O

-DOCSTART- -X- - O

Nitroglycerin NNP - B-MEDICINE
and CCONJ - O
Iloprost PROPN - O
Improve PROPN - O
Mitochondrial PROPN - O
Function PROPN - O
in ADP - O
Colon NOUN - O
Homogenate PROPN - O

-DOCSTART- -X- - O

The DET - O
instrument NOUN - O
used VERB - O
was VERB - O
the DET - O
modified ADJ - O
Sublingual NNP - B-NORP
Nitroglycerin NNP - B-MEDICINE
Interview NNP - B-PERSON
Schedule NN - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Nitroglycerin NNP - B-MEDICINE
( PUNCT - O
or CCONJ - O
glyceryl NOUN - O
trinitrate NOUN - O
, PUNCT - O
GTN NNP - B-ORG
) PUNCT - O
has VERB - O
been VERB - O
long ADV - O
considered VERB - O
an DET - O
endothelium NOUN - O
- PUNCT - O
independent ADJ - O
vasodilator NOUN - O
because ADP - O
GTN NNP - B-ORG
vasodilation NOUN - O
is VERB - O
intact ADJ - O
in ADP - O
the DET - O
absence NOUN - O
of ADP - O
the DET - O
endothelium NOUN - O
and CCONJ - O
in ADP - O
the DET - O
presence NOUN - O
of ADP - O
endothelial ADJ - O
dysfunction NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Nitroglycerin NNP - B-MEDICINE
ointment NOUN - O
has VERB - O
been VERB - O
shown VERB - O
to PART - O
reduce VERB - O
the DET - O
incidence NOUN - O
of ADP - O
mastectomy NOUN - O
flap NOUN - O
necrosis NOUN - O
in ADP - O
a DET - O
randomized VERB - O
controlled VERB - O
study NOUN - O
, PUNCT - O
using VERB - O
45 CD - B-CARDINAL
g NOUN - O
per ADP - O
breast NOUN - O
and CCONJ - O
treating VERB - O
one NUM - O
side NOUN - O
only ADV - O
in ADP - O
bilateral ADJ - O
cases NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Nitroglycerin NNP - B-MEDICINE
Ointment NNP - I-ORG
for IN - I-ORG
Reducing VBG - I-ORG
the DT - I-ORG
Rate NN - I-ORG
of IN - I-ORG
Mastectomy NNP - I-ORG
Flap NNP - I-ORG
Necrosis NNP - I-ORG
in ADP - O
Immediate NNP - B-ORG
Implant NNP - I-ORG
- HYPH - I-ORG
Based VBN - I-ORG
Breast NNP - I-ORG
Reconstruction NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Safety PROPN - O
and CCONJ - O
Effectiveness PROPN - O
of ADP - O
Field PROPN - O
Nitroglycerin NNP - B-MEDICINE
in ADP - O
Patients PROPN - O
with ADP - O
Suspected PROPN - O
ST PROPN - O
Elevation PROPN - O
Myocardial PROPN - O
Infarction PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Nitroglycerin NNP - B-MEDICINE
Ointment NNP - I-ORG
for IN - I-ORG
Reducing VBG - I-ORG
the DT - I-ORG
Rate NN - I-ORG
of IN - I-ORG
Mastectomy NNP - I-ORG
Flap NNP - I-ORG
Necrosis NNP - I-ORG
in ADP - O
Immediate PROPN - O
Implant PROPN - O
- PUNCT - O
Based VERB - O
Breast PROPN - O
Reconstruction PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Nitroglycerin NNP - B-MEDICINE
ointment NOUN - O
is VERB - O
commercially ADV - O
available ADJ - O
, PUNCT - O
and CCONJ - O
it PRON - O
has VERB - O
less ADV - O
systemic ADJ - O
side NOUN - O
effects NOUN - O
than ADP - O
other ADJ - O
topical ADJ - O
formulations NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Nitroglycerin NNP - B-MEDICINE
Ointment NNP - I-ORG
for IN - I-ORG
Reducing VBG - I-ORG
the DT - I-ORG
Rate NN - I-ORG
of IN - I-ORG
Mastectomy NNP - I-ORG
Flap NNP - I-ORG
Necrosis NNP - I-ORG
in ADP - O
Immediate NNP - B-ORG
Implant NNP - I-ORG
- HYPH - I-ORG
Based VBN - I-ORG
Breast NNP - I-ORG
Reconstruction NNP - I-ORG
: : - I-ORG
Correction NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Previously ADV - O
we PRON - O
have VERB - O
shown VERB - O
that ADP - O
non ADJ - O
- ADJ - O
antibiotic ADJ - O
, PUNCT - O
Nitroglycerine NNP - B-ORG
+ CCONJ - O
Citrate PROPN - O
+ CCONJ - O
Ethanol PROPN - O
( PUNCT - O
NiCE NNP - B-ORG
) PUNCT - O

Shareholder NN - B-ORG
, PUNCT - O
Licensing NN - B-ORG
agreement NOUN - O
or CCONJ - O
royalty NOUN - O
; PUNCT - O
The DT - B-ORG
Unversity NNP - I-ORG
of IN - I-ORG
Texas NNP - I-ORG
MD NNP - I-ORG
Anderson NNP - I-ORG
Cancer NNP - I-ORG
Center NNP - I-ORG
: : - I-ORG
Shareholder NN - I-ORG
, PUNCT - O
Dr. PROPN - O
Raad NNP - B-PERSON
is VERB - O
a DET - O
co NOUN - O
- NOUN - O
inventor NOUN - O
of ADP - O
the DET - O
Nitroglycerin NNP - B-MEDICINE
- PUNCT - O
Citrate PROPN - O
- PUNCT - O
Ethanol PROPN - O
catheter NOUN - O
lock NOUN - O
solution NOUN - O
technology NOUN - O
which ADJ - O
is VERB - O
owned VERB - O
by ADP - O
the DT - B-ORG
University NNP - I-ORG
of IN - I-ORG
Texas NNP - I-ORG
MD NNP - I-ORG
Anderson NNP - I-ORG
Cancer NNP - I-ORG
Center NNP - I-ORG
( PUNCT - O
UTMDACC NNP - B-ORG
) PUNCT - O
and CCONJ - O
has VERB - O
been VERB - O
licensed VERB - O
to ADP - O
Novel NNP - B-ORG
Anti JJ - I-ORG
- JJ - I-ORG
Infective NNP - I-ORG
Technologies NNPS - I-ORG
LLC NNP - I-ORG
, PUNCT - O
in ADP - O
which ADJ - O
UTMDACC NNP - B-ORG
and CCONJ - O
Licensing NNP - B-ORG
agreement NOUN - O
or CCONJ - O
royalty NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Nitroglycerin NNP - B-MEDICINE
- PUNCT - O
Citrate PROPN - O
- PUNCT - O
Ethanol PROPN - O
Catheter PROPN - O
Lock PROPN - O
Solution NOUN - O
Is VERB - O
Highly ADV - O
Effective ADJ - O
in ADP - O
Eradicating VBG - B-GPE
Candida NNP - I-GPE
auris VERB - O
Biofilms PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Subcutaneous NNP - B-ORG
Injection NNP - I-ORG
of ADP - O
Nitroglycerin NNP - B-MEDICINE
at ADP - O
the DT - B-ORG
Radial NNP - I-ORG
Artery NNP - I-ORG
Puncture NNP - I-ORG
Site NNP - I-ORG
Reduces VBZ - I-ORG
the DT - I-ORG
Risk NNP - I-ORG
of IN - I-ORG
Early NNP - I-ORG
Radial NNP - I-ORG
Artery NNP - I-ORG
Occlusion NNP - I-ORG

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
Nicorandil NNP - B-ORG
Versus NNP - I-ORG
Nitroglycerin NNP - I-MEDICINE
on ADP - O
Arterial NNP - B-ORG
Oxygenation NNP - I-ORG

-DOCSTART- -X- - O

Nitroglycerin NNP - B-MEDICINE
( PUNCT - O
NTG)-induced PROPN - O
migraine NOUN - O
- PUNCT - O
type NOUN - O
headache NOUN - O
is VERB - O
the DET - O
most ADV - O
prominent ADJ - O
side NOUN - O
effect NOUN - O
of ADP - O
nitrate ADJ - O
therapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Open ADJ - O
- PUNCT - O
Label PROPN - O
Study PROPN - O
of ADP - O
the DT - B-ORG
Stability NNP - I-ORG
of IN - I-ORG
Sublingual NNP - I-ORG
Nitroglycerin NNP - I-MEDICINE
Tablets NNS - I-ORG
in ADP - O
Simulated NNP - B-ORG
Real NNP - I-ORG
- HYPH - I-ORG
Life NNP - I-ORG
Conditions NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Nitroglycerin JJ - B-MEDICINE
inhalation NOUN - O
may VERB - O
provide VERB - O
dilation NOUN - O
of ADP - O
the DET - O
pulmonary ADJ - O
artery NOUN - O
, PUNCT - O
reduction NOUN - O
of ADP - O
pulmonary ADJ - O
artery NOUN - O
pressure NOUN - O
, PUNCT - O
and CCONJ - O
improvement NOUN - O
of ADP - O
oxygenation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effectiveness NOUN - O
of ADP - O
Nitroglycerin NNP - B-MEDICINE
in ADP - O
Managing VBG - B-ORG
Subacute NNP - I-ORG
Lung NNP - I-ORG
Bleeding VBG - I-ORG
Induced VERB - O
by ADP - O
Balloon NNP - B-ORG
Pulmonary NNP - I-ORG
Angioplasty NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Oral ADJ - O
Nitroglycerin NNP - B-MEDICINE
Solution PROPN - O

-DOCSTART- -X- - O

Does VERB - O
the DET - O
Use PROPN - O
of ADP - O
Nitroglycerin NNP - B-MEDICINE
Patch PROPN - O
Improve PROPN - O
Local PROPN - O
Anaesthetic PROPN - O
Effects PROPN - O
in ADP - O
Bier NNP - B-LOC
's POS - I-LOC
Block NNP - I-LOC
? PUNCT - O

-DOCSTART- -X- - O

Dobutamine NNP - B-GPE
and CCONJ - O
Nitroglycerin NNP - B-MEDICINE
Versus NNP - I-GPE
Milrinone NNP - I-GPE
for ADP - O
Perioperative NNP - B-ORG
Management NNP - I-ORG
of IN - I-ORG
Pulmonary NNP - I-ORG
Hypertension NNP - I-ORG
in ADP - O
Mitral NNP - B-ORG
Valve NNP - I-ORG
Surgery NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Nitroglycerin NNP - B-MEDICINE
and CCONJ - O
remifentanil VERB - O
are VERB - O
among ADP - O
the DET - O
drugs NOUN - O
used VERB - O
to PART - O
induce VERB - O
controlled VERB - O
hypotension NOUN - O
. PUNCT - O

Controlled VERB - O
hypotension NOUN - O
, PUNCT - O
Middle ADJ - O
ear NOUN - O
surgery NOUN - O
, PUNCT - O
Nitroglycerin NNP - B-MEDICINE
, PUNCT - O
Remifentanil NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-ORG
Unversity NNP - I-ORG
of IN - I-ORG
Texas NNP - I-ORG
MD NNP - I-ORG
Anderson NNP - I-ORG
Cancer NNP - I-ORG
Center NNP - I-ORG
: : - I-ORG
Shareholder NN - I-ORG
, PUNCT - O
Dr. PROPN - O
Raad NNP - B-PERSON
is VERB - O
a DET - O
co NOUN - O
- NOUN - O
inventor NOUN - O
of ADP - O
the DET - O
Nitroglycerin NNP - B-MEDICINE
- PUNCT - O
Citrate PROPN - O
- PUNCT - O
Ethanol PROPN - O
catheter NOUN - O
lock NOUN - O
solution NOUN - O
technology NOUN - O
which ADJ - O
is VERB - O
owned VERB - O
by ADP - O
the DT - B-ORG
University NNP - I-ORG
of IN - I-ORG
Texas NNP - I-ORG
MD NNP - I-ORG
Anderson NNP - I-ORG
Cancer NNP - I-ORG
Center NNP - I-ORG
( PUNCT - O
UTMDACC NNP - B-ORG
) PUNCT - O
and CCONJ - O
has VERB - O
been VERB - O
licensed VERB - O
to ADP - O
Novel NNP - B-ORG
Anti JJ - I-ORG
- JJ - I-ORG
Infective NNP - I-ORG
Technologies NNPS - I-ORG
LLC NNP - I-ORG
, PUNCT - O
in ADP - O
which ADJ - O
UTMDACC NNP - B-ORG
and CCONJ - O
Licensing NNP - B-ORG
agreement NOUN - O
or CCONJ - O
royalty NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-ORG
Unversity NNP - I-ORG
of IN - I-ORG
Texas NNP - I-ORG
MD NNP - I-ORG
Anderson NNP - I-ORG
Cancer NNP - I-ORG
Center NNP - I-ORG
: : - I-ORG
Shareholder NN - I-ORG
, PUNCT - O
Dr. PROPN - O
Raad NNP - B-PERSON
is VERB - O
a DET - O
co NOUN - O
- NOUN - O
inventor NOUN - O
of ADP - O
the DET - O
Nitroglycerin NNP - B-MEDICINE
- PUNCT - O
Citrate PROPN - O
- PUNCT - O
Ethanol PROPN - O
catheter NOUN - O
lock NOUN - O
solution NOUN - O
technology NOUN - O
which ADJ - O
is VERB - O
owned VERB - O
by ADP - O
the DT - B-ORG
University NNP - I-ORG
of IN - I-ORG
Texas NNP - I-ORG
MD NNP - I-ORG
Anderson NNP - I-ORG
Cancer NNP - I-ORG
Center NNP - I-ORG
( PUNCT - O
UTMDACC NNP - B-ORG
) PUNCT - O
and CCONJ - O
has VERB - O
been VERB - O
licensed VERB - O
to ADP - O
Novel NNP - B-ORG
Anti JJ - I-ORG
- JJ - I-ORG
Infective NNP - I-ORG
Technologies NNPS - I-ORG
LLC NNP - I-ORG
, PUNCT - O
in ADP - O
which ADJ - O
UTMDACC NNP - B-ORG
and CCONJ - O
Licensing NNP - B-ORG
agreement NOUN - O
or CCONJ - O
royalty NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-ORG
Unversity NNP - I-ORG
of IN - I-ORG
Texas NNP - I-ORG
MD NNP - I-ORG
Anderson NNP - I-ORG
Cancer NNP - I-ORG
Center NNP - I-ORG
: : - I-ORG
Shareholder NN - I-ORG
, PUNCT - O
Dr. PROPN - O
Raad NNP - B-PERSON
is VERB - O
a DET - O
co NOUN - O
- NOUN - O
inventor NOUN - O
of ADP - O
the DET - O
Nitroglycerin NNP - B-MEDICINE
- PUNCT - O
Citrate PROPN - O
- PUNCT - O
Ethanol PROPN - O
catheter NOUN - O
lock NOUN - O
solution NOUN - O
technology NOUN - O
which ADJ - O
is VERB - O
owned VERB - O
by ADP - O
the DT - B-ORG
University NNP - I-ORG
of IN - I-ORG
Texas NNP - I-ORG
MD NNP - I-ORG
Anderson NNP - I-ORG
Cancer NNP - I-ORG
Center NNP - I-ORG
( PUNCT - O
UTMDACC NNP - B-ORG
) PUNCT - O
and CCONJ - O
has VERB - O
been VERB - O
licensed VERB - O
to ADP - O
Novel NNP - B-ORG
Anti JJ - I-ORG
- JJ - I-ORG
Infective NNP - I-ORG
Technologies NNPS - I-ORG
LLC NNP - I-ORG
, PUNCT - O
in ADP - O
which ADJ - O
UTMDACC NNP - B-ORG
and CCONJ - O
Licensing NNP - B-ORG
agreement NOUN - O
or CCONJ - O
royalty NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Nitroglycerin NNP - B-MEDICINE
administered VERB - O
in ADP - O
high ADJ - O
doses NOUN - O
for ADP - O
pulmonary ADJ - O
edema NOUN - O
is VERB - O
safe ADJ - O
and CCONJ - O
effective ADJ - O
in ADP - O
reducing VERB - O
the DET - O
need NOUN - O
for ADP - O
intensive ADJ - O
care NOUN - O
unit NOUN - O
admission NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Shareholder NOUN - O
, PUNCT - O
Dr. PROPN - O
Raad NNP - B-PERSON
is VERB - O
a DET - O
co NOUN - O
- NOUN - O
inventor NOUN - O
of ADP - O
the DET - O
Nitroglycerin NNP - B-MEDICINE
- PUNCT - O
Citrate PROPN - O
- PUNCT - O
Ethanol PROPN - O
catheter NOUN - O
lock NOUN - O
solution NOUN - O
technology NOUN - O
which ADJ - O
is VERB - O
owned VERB - O
by ADP - O
the DT - B-ORG
University NNP - I-ORG
of IN - I-ORG
Texas NNP - I-ORG
MD NNP - I-ORG
Anderson NNP - I-ORG
Cancer NNP - I-ORG
Center NNP - I-ORG
( PUNCT - O
UTMDACC NNP - B-ORG
) PUNCT - O
and CCONJ - O
has VERB - O
been VERB - O
licensed VERB - O
to ADP - O
Novel NNP - B-ORG
Anti JJ - I-ORG
- JJ - I-ORG
Infective NNP - I-ORG
Technologies NNPS - I-ORG
LLC NNP - I-ORG
, PUNCT - O
in ADP - O
which ADJ - O
UTMDACC NNP - B-ORG
and CCONJ - O
Licensing NNP - B-ORG
agreement NOUN - O
or CCONJ - O
royalty NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Nitroglycerin NNP - B-MEDICINE
is VERB - O
commonly ADV - O
used VERB - O
as ADP - O
an DET - O
antispasmodic NOUN - O
for ADP - O
treating VERB - O
spasm NOUN - O
of ADP - O
coronary ADJ - O
artery NOUN - O
bypass NOUN - O
grafts NOUN - O
. PUNCT - O

Nitroglycerin NNP - B-MEDICINE
induced VERB - O
a DET - O
concentration NOUN - O
- PUNCT - O
dependent ADJ - O
relaxation NOUN - O
, PUNCT - O
which ADJ - O
was VERB - O
significantly ADV - O
augmented VERB - O
in ADP - O
patients NOUN - O
with ADP - O
severe ADJ - O
but CCONJ - O
not ADV - O
moderate ADJ - O
renal ADJ - O
failure NOUN - O
than ADP - O
in ADP - O
those DET - O
without ADP - O
renal ADJ - O
failure NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Nitroglycerin NNP - B-MEDICINE
application NOUN - O
and CCONJ - O
coronary ADJ - O
arteriogenesis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Poor ADJ - O
Compliance NOUN - O
With ADP - O
Carrying VERB - O
Nitroglycerin NNP - B-MEDICINE
and CCONJ - O
Aspirin NNP - B-NORP
in ADP - O
Patients PROPN - O
With ADP - O
Coronary PROPN - O
Artery PROPN - O
Disease PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Nitroglycerin NNP - B-MEDICINE
injection NOUN - O
enabled VERB - O
blood NOUN - O
aspiration NOUN - O
and CCONJ - O
vasodilator NOUN - O
injection NOUN - O
, PUNCT - O
but CCONJ - O
not ADV - O
sheath NOUN - O
removal NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Nitroglycerin NNP - B-MEDICINE
and CCONJ - O
the DET - O
enduring VERB - O
principles NOUN - O
of ADP - O
coronary ADJ - O
procedures NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Differential NNP - B-ORG
Development NNP - I-ORG
of IN - I-ORG
Facial NNP - I-ORG
and CC - I-ORG
Hind NNP - I-ORG
Paw NNP - I-ORG
Allodynia NNP - I-ORG
in ADP - O
a DET - O
Nitroglycerin NNP - B-MEDICINE
- PUNCT - O
Induced PROPN - O
Mouse PROPN - O
Model PROPN - O
of ADP - O
Chronic PROPN - O
Migraine PROPN - O
: PUNCT - O
Role NOUN - O
of ADP - O
Capsaicin PROPN - O
Sensitive PROPN - O
Primary PROPN - O
Afferents PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-ORG
Unversity NNP - I-ORG
of IN - I-ORG
Texas NNP - I-ORG
MD NNP - I-ORG
Anderson NNP - I-ORG
Cancer NNP - I-ORG
Center NNP - I-ORG
: : - I-ORG
Shareholder NN - I-ORG
, PUNCT - O
Dr. PROPN - O
Raad NNP - B-PERSON
is VERB - O
a DET - O
co NOUN - O
- NOUN - O
inventor NOUN - O
of ADP - O
the DET - O
Nitroglycerin NNP - B-MEDICINE
- PUNCT - O
Citrate PROPN - O
- PUNCT - O
Ethanol PROPN - O
catheter NOUN - O
lock NOUN - O
solution NOUN - O
technology NOUN - O
which ADJ - O
is VERB - O
owned VERB - O
by ADP - O
the DT - B-ORG
University NNP - I-ORG
of IN - I-ORG
Texas NNP - I-ORG
MD NNP - I-ORG
Anderson NNP - I-ORG
Cancer NNP - I-ORG
Center NNP - I-ORG
( PUNCT - O
UTMDACC NNP - B-ORG
) PUNCT - O
and CCONJ - O
has VERB - O
been VERB - O
licensed VERB - O
to ADP - O
Novel NNP - B-ORG
Anti JJ - I-ORG
- JJ - I-ORG
Infective NNP - I-ORG
Technologies NNPS - I-ORG
LLC NNP - I-ORG
, PUNCT - O
in ADP - O
which ADJ - O
UTMDACC NNP - B-ORG
and CCONJ - O
Licensing NNP - B-ORG
agreement NOUN - O
or CCONJ - O
royalty NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-ORG
Effect NNP - I-ORG
of IN - I-ORG
Low NNP - I-ORG
- HYPH - I-ORG
Dose NNP - I-ORG
Nitroglycerin NNP - I-MEDICINE
Ointment NNP - I-ORG
on IN - I-ORG
Skin NNP - I-ORG
Flap NNP - I-ORG
Necrosis NNP - I-ORG
in ADP - O
Breast NNP - B-GPE
Reconstruction NNP - I-GPE
after ADP - O
Skin PROPN - O
- PUNCT - O
Sparing NOUN - O
or CCONJ - O
Nipple NNP - B-ORG
- HYPH - I-ORG
Sparing NNP - I-ORG
Mastectomy NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Valproate NNP - B-ORG
Plays VBZ - I-ORG
a DT - I-ORG
Protective JJ - I-ORG
Role NNP - I-ORG
against IN - I-ORG
Migraine NNP - B-ORG
by ADP - O
Inhibiting NNP - B-PERSON
Protein NNP - I-PERSON
Kinase NN - I-PERSON
C NN - I-PERSON
Signalling NN - I-PERSON
in ADP - O
Nitroglycerin NNP - B-MEDICINE
- PUNCT - O
treated VERB - O
Mice NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Letter NOUN - O
by ADP - O
Jin PROPN - O
- PUNCT - O
shan PROPN - O
and CCONJ - O
Xue NNP - B-PERSON
- HYPH - I-PERSON
bin NNP - I-PERSON
Regarding NN - I-PERSON
Article NNP - I-PERSON
, PUNCT - O
" PUNCT - O
Physiology NOUN - O
of ADP - O
Angina PROPN - O
and CCONJ - O
Its ADJ - O
Alleviation NOUN - O
With ADP - O
Nitroglycerin NNP - B-MEDICINE
: PUNCT - O
Insights NOUN - O
From ADP - O
Invasive PROPN - O
Catheter PROPN - O
Laboratory PROPN - O
Measurements PROPN - O
During ADP - O
Exercise PROPN - O
" PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Role PROPN - O
of ADP - O
Nitroglycerin NNP - B-MEDICINE
and CCONJ - O
Other ADJ - O
Nitrogen PROPN - O
Oxides PROPN - O
in ADP - O
Cardiovascular NNP - B-ORG
Therapeutics NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Nitroglycerin NNP - B-MEDICINE
was VERB - O
found VERB - O
to PART - O
be VERB - O
the DET - O
most ADV - O
acidic ADJ - O
among ADP - O
the DET - O
nitrogen NOUN - O
- PUNCT - O
rich ADJ - O
explosives NOUN - O
studied VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Nitroglycerin NNP - B-MEDICINE
is VERB - O
a DET - O
prototypic ADJ - O
NO DET - O
- PUNCT - O
donor NOUN - O
, PUNCT - O
and CCONJ - O
triggers NOUN - O
migraine VERB - O
in ADP - O
humans NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Nitroglycerin NNP - B-MEDICINE
ointment NOUN - O
has VERB - O
a DET - O
rapid ADJ - O
onset NOUN - O
of ADP - O
action NOUN - O
and CCONJ - O
time NOUN - O
to ADP - O
full ADJ - O
clinical ADJ - O
effect NOUN - O
with ADP - O
high ADJ - O
efficacy NOUN - O
and CCONJ - O
relatively ADV - O
low ADJ - O
adverse ADJ - O
event NOUN - O
rate NOUN - O
for ADP - O
patients NOUN - O
with ADP - O
SCI NNP - B-ORG
experiencing VERB - O
AD NN - B-CARDINAL
. PUNCT - O

-DOCSTART- -X- - O

et PROPN - O
al PROPN - O
to ADP - O
Letter PROPN - O
Regarding VERB - O
Article PROPN - O
, PUNCT - O
" PUNCT - O
Physiology NOUN - O
of ADP - O
Angina PROPN - O
and CCONJ - O
Its ADJ - O
Alleviation NOUN - O
With ADP - O
Nitroglycerin NNP - B-MEDICINE
: PUNCT - O
Insights NOUN - O
From ADP - O
Invasive PROPN - O
Catheter PROPN - O
Laboratory PROPN - O
Measurements PROPN - O
During ADP - O
Exercise PROPN - O
" PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Commentary NOUN - O
: PUNCT - O
The DT - B-ORG
Effect NN - I-ORG
of IN - I-ORG
Systemic NNP - I-ORG
Nitroglycerin NNP - I-MEDICINE
Administration NNP - I-ORG
on ADP - O
the DT - B-FAC
Kynurenine NNP - I-FAC
Pathway NNP - I-FAC
in ADP - O
the DET - O
Rat NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Nitroglycerin NNP - B-MEDICINE
- HYPH - I-PERSON
Derived VBN - I-PERSON
Pd NNP - I-PERSON
/ SYM - I-PERSON
Pa NNP - I-PERSON
for IN - I-PERSON
the DT - I-PERSON
Assessment NNP - I-PERSON
of IN - I-PERSON
Intermediate NNP - I-PERSON
Coronary NNP - I-PERSON
Lesions NNPS - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Co PROPN - O
- NOUN - O
Inventor PROPN - O
of ADP - O
the DET - O
Nitroglycerin NNP - B-MEDICINE
- PUNCT - O
Citrate NNP - B-ORG
- HYPH - I-ORG
Ethanol NNP - I-ORG
catheter NOUN - O
lock NOUN - O
solution NOUN - O
technology NOUN - O
which ADJ - O
is VERB - O
owned VERB - O
by ADP - O
the DT - B-ORG
University NNP - I-ORG
of IN - I-ORG
Texas NNP - I-ORG
MD NNP - I-ORG
Anderson NNP - I-ORG
Cancer NNP - I-ORG
Center NNP - I-ORG
( PUNCT - O
UTMDACC NNP - B-ORG
) PUNCT - O
and CCONJ - O
has VERB - O
been VERB - O
licensed VERB - O
by ADP - O
Novel NNP - B-PERSON
Anti NNP - I-PERSON
- JJ - I-PERSON
Infective NNP - I-PERSON
Technologies NNPS - I-PERSON
, PUNCT - O
LLC NNP - B-ORG
in ADP - O
which ADJ - O
Dr. PROPN - O
Rosenblatt NNP - B-PERSON
is VERB - O
a DET - O
and CCONJ - O
Shareholder NN - B-NORP
, PUNCT - O
Licensing NOUN - O
agreement NOUN - O
or CCONJ - O
royalty NOUN - O
; PUNCT - O
UT NNP - B-ORG
MD NNP - I-ORG
Anderson NNP - I-ORG
Cancer NNP - I-ORG
Center NNP - I-ORG
: PUNCT - O
Co NNP - B-PERSON
- NN - I-PERSON
Inventor NNP - I-PERSON
of ADP - O
the DET - O
Nitroglycerin NNP - B-MEDICINE
- PUNCT - O
Citrate PROPN - O
- PUNCT - O
Ethanol PROPN - O
catheter NOUN - O
lock NOUN - O
solution NOUN - O
technology NOUN - O
which ADJ - O
is VERB - O
owned VERB - O
by ADP - O
the DT - B-ORG
University NNP - I-ORG
of IN - I-ORG
Texas NNP - I-ORG
MD NNP - I-ORG
Anderson NNP - I-ORG
Cancer NNP - I-ORG
Center NNP - I-ORG
( PUNCT - O
UTMDACC NNP - B-ORG
) PUNCT - O
and CCONJ - O
has VERB - O
been VERB - O
licensed VERB - O
by ADP - O
Novel NNP - B-PERSON
Anti NNP - I-PERSON
- JJ - I-PERSON
Infective NNP - I-PERSON
Technologies NNPS - I-PERSON
, PUNCT - O
LLC NNP - B-ORG
in ADP - O
which ADJ - O
Dr. PROPN - O
Rosenblatt NNP - B-PERSON
is VERB - O
a DET - O
s NOUN - O
and CCONJ - O
Scientific NNP - B-ORG
Advisor NNP - I-ORG
, PUNCT - O
Licensing NOUN - O
agreement NOUN - O
or CCONJ - O
royalty NOUN - O
; PUNCT - O
I. NNP - B-PERSON
Raad NNP - I-PERSON
, PUNCT - O
Merck NNP - B-ORG
: PUNCT - O
Grant NNP - B-PERSON
Investigator NNP - I-PERSON
, PUNCT - O
Research NNP - B-ORG
  _SP - I-ORG
grant NOUN - O
; PUNCT - O
Allergan NNP - B-PERSON
: PUNCT - O
Grant PROPN - O
Investigator PROPN - O
, PUNCT - O
Research NNP - B-GPE
  _SP - I-GPE
grant NOUN - O
; PUNCT - O
Infective NNP - B-ORG
Technologies NNPS - I-ORG
, PUNCT - O
LLC NNP - B-ORG
: PUNCT - O

Co PROPN - O
- NOUN - O
Inventor PROPN - O
of ADP - O
the DET - O
Nitroglycerin NNP - B-MEDICINE
- PUNCT - O
Citrate NNP - B-ORG
- HYPH - I-ORG
Ethanol NNP - I-ORG
catheter NOUN - O
lock NOUN - O
solution NOUN - O
technology NOUN - O
which ADJ - O
is VERB - O
owned VERB - O
by ADP - O
the DT - B-ORG
University NNP - I-ORG
of IN - I-ORG
Texas NNP - I-ORG
MD NNP - I-ORG
Anderson NNP - I-ORG
Cancer NNP - I-ORG
Center NNP - I-ORG
( PUNCT - O
UTMDACC NNP - B-ORG
) PUNCT - O
and CCONJ - O
has VERB - O
been VERB - O
licensed VERB - O
by ADP - O
Novel NNP - B-PERSON
Anti NNP - I-PERSON
- JJ - I-PERSON
Infective NNP - I-PERSON
Technologies NNPS - I-PERSON
, PUNCT - O
LLC NNP - B-ORG
in ADP - O
which ADJ - O
Dr. PROPN - O
Raad NNP - B-PERSON
is VERB - O
a DET - O
s NOUN - O
and CCONJ - O
Shareholder NN - B-ORG
, PUNCT - O
Licensing NN - B-ORG
agreement NOUN - O
or CCONJ - O
royalty NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Co PROPN - O
- NOUN - O
Inventor PROPN - O
of ADP - O
the DET - O
Nitroglycerin NNP - B-MEDICINE
- PUNCT - O
Citrate NNP - B-ORG
- HYPH - I-ORG
Ethanol NNP - I-ORG
catheter NOUN - O
lock NOUN - O
solution NOUN - O
technology NOUN - O
which ADJ - O
is VERB - O
owned VERB - O
by ADP - O
the DT - B-ORG
University NNP - I-ORG
of IN - I-ORG
Texas NNP - I-ORG
MD NNP - I-ORG
Anderson NNP - I-ORG
Cancer NNP - I-ORG
Center NNP - I-ORG
( PUNCT - O
UTMDACC NNP - B-ORG
) PUNCT - O
and CCONJ - O
has VERB - O
been VERB - O
licensed VERB - O
by ADP - O
Novel NNP - B-PERSON
Anti NNP - I-PERSON
- JJ - I-PERSON
Infective NNP - I-PERSON
Technologies NNPS - I-PERSON
, PUNCT - O
LLC NNP - B-ORG
in ADP - O
which ADJ - O
Dr. PROPN - O
Rosenblatt NNP - B-PERSON
is VERB - O
a DET - O
and CCONJ - O
Shareholder NN - B-NORP
, PUNCT - O
Licensing NOUN - O
agreement NOUN - O
or CCONJ - O
royalty NOUN - O
; PUNCT - O
UT NNP - B-ORG
MD NNP - I-ORG
Anderson NNP - I-ORG
Cancer NNP - I-ORG
Center NNP - I-ORG
: PUNCT - O
Co NNP - B-PERSON
- NN - I-PERSON
Inventor NNP - I-PERSON
of ADP - O
the DET - O
Nitroglycerin NNP - B-MEDICINE
- PUNCT - O
Citrate PROPN - O
- PUNCT - O
Ethanol PROPN - O
catheter NOUN - O
lock NOUN - O
solution NOUN - O
technology NOUN - O
which ADJ - O
is VERB - O
owned VERB - O
by ADP - O
the DT - B-ORG
University NNP - I-ORG
of IN - I-ORG
Texas NNP - I-ORG
MD NNP - I-ORG
Anderson NNP - I-ORG
Cancer NNP - I-ORG
Center NNP - I-ORG
( PUNCT - O
UTMDACC NNP - B-ORG
) PUNCT - O
and CCONJ - O
has VERB - O
been VERB - O
licensed VERB - O
by ADP - O
Novel NNP - B-PERSON
Anti NNP - I-PERSON
- JJ - I-PERSON
Infective NNP - I-PERSON
Technologies NNPS - I-PERSON
, PUNCT - O
LLC NNP - B-ORG
in ADP - O
which ADJ - O
Dr. PROPN - O
Rosenblatt NNP - B-PERSON
is VERB - O
a DET - O
s NOUN - O
and CCONJ - O
Scientific NNP - B-ORG
Advisor NNP - I-ORG
, PUNCT - O
Licensing NOUN - O
agreement NOUN - O
or CCONJ - O
royalty NOUN - O
; PUNCT - O
I. NNP - B-PERSON
Raad NNP - I-PERSON
, PUNCT - O
Merck NNP - B-ORG
: PUNCT - O
Grant NNP - B-PERSON
Investigator NNP - I-PERSON
, PUNCT - O
Research PROPN - O
grant NOUN - O
; PUNCT - O
Allergan NNP - B-PERSON
: PUNCT - O
Grant PROPN - O
Investigator PROPN - O
, PUNCT - O
Research PROPN - O
grant NOUN - O
; PUNCT - O
Infective NNP - B-ORG
Technologies NNPS - I-ORG
, PUNCT - O
LLC NNP - B-ORG
: PUNCT - O

Co PROPN - O
- NOUN - O
Inventor PROPN - O
of ADP - O
the DET - O
Nitroglycerin NNP - B-MEDICINE
- PUNCT - O
Citrate NNP - B-ORG
- HYPH - I-ORG
Ethanol NNP - I-ORG
catheter NOUN - O
lock NOUN - O
solution NOUN - O
technology NOUN - O
which ADJ - O
is VERB - O
owned VERB - O
by ADP - O
the DT - B-ORG
University NNP - I-ORG
of IN - I-ORG
Texas NNP - I-ORG
MD NNP - I-ORG
Anderson NNP - I-ORG
Cancer NNP - I-ORG
Center NNP - I-ORG
( PUNCT - O
UTMDACC NNP - B-ORG
) PUNCT - O
and CCONJ - O
has VERB - O
been VERB - O
licensed VERB - O
by ADP - O
Novel NNP - B-PERSON
Anti NNP - I-PERSON
- JJ - I-PERSON
Infective NNP - I-PERSON
Technologies NNPS - I-PERSON
, PUNCT - O
LLC NNP - B-ORG
in ADP - O
which ADJ - O
Dr. PROPN - O
Raad NNP - B-PERSON
is VERB - O
a DET - O
s NOUN - O
and CCONJ - O
Shareholder NN - B-ORG
, PUNCT - O
Licensing NN - B-ORG
agreement NOUN - O
or CCONJ - O
royalty NOUN - O

-DOCSTART- -X- - O

Co PROPN - O
- NOUN - O
Inventor PROPN - O
of ADP - O
the DET - O
Nitroglycerin NNP - B-MEDICINE
- PUNCT - O
Citrate NNP - B-ORG
- HYPH - I-ORG
Ethanol NNP - I-ORG
catheter NOUN - O
lock NOUN - O
solution NOUN - O
technology NOUN - O
which ADJ - O
is VERB - O
owned VERB - O
by ADP - O
the DT - B-ORG
University NNP - I-ORG
of IN - I-ORG
Texas NNP - I-ORG
MD NNP - I-ORG
Anderson NNP - I-ORG
Cancer NNP - I-ORG
Center NNP - I-ORG
( PUNCT - O
UTMDACC NNP - B-ORG
) PUNCT - O
and CCONJ - O
has VERB - O
been VERB - O
licensed VERB - O
by ADP - O
Novel NNP - B-PERSON
Anti NNP - I-PERSON
- JJ - I-PERSON
Infective NNP - I-PERSON
Technologies NNPS - I-PERSON
, PUNCT - O
LLC NNP - B-ORG
in ADP - O
which ADJ - O
Dr. PROPN - O
Rosenblatt NNP - B-PERSON
is VERB - O
a DET - O
and CCONJ - O
Shareholder NN - B-NORP
, PUNCT - O
Licensing NOUN - O
agreement NOUN - O
or CCONJ - O
royalty NOUN - O
; PUNCT - O
UT NNP - B-ORG
MD NNP - I-ORG
Anderson NNP - I-ORG
Cancer NNP - I-ORG
Center NNP - I-ORG
: PUNCT - O
Co NNP - B-PERSON
- NN - I-PERSON
Inventor NNP - I-PERSON
of ADP - O
the DET - O
Nitroglycerin NNP - B-MEDICINE
- PUNCT - O
Citrate PROPN - O
- PUNCT - O
Ethanol PROPN - O
catheter NOUN - O
lock NOUN - O
solution NOUN - O
technology NOUN - O
which ADJ - O
is VERB - O
owned VERB - O
by ADP - O
the DT - B-ORG
University NNP - I-ORG
of IN - I-ORG
Texas NNP - I-ORG
MD NNP - I-ORG
Anderson NNP - I-ORG
Cancer NNP - I-ORG
Center NNP - I-ORG
( PUNCT - O
UTMDACC NNP - B-ORG
) PUNCT - O
and CCONJ - O
has VERB - O
been VERB - O
licensed VERB - O
by ADP - O
Novel NNP - B-PERSON
Anti NNP - I-PERSON
- JJ - I-PERSON
Infective NNP - I-PERSON
Technologies NNPS - I-PERSON
, PUNCT - O
LLC NNP - B-ORG
in ADP - O
which ADJ - O
Dr. PROPN - O
Rosenblatt NNP - B-PERSON
is VERB - O
a DET - O
s NOUN - O
and CCONJ - O
Scientific NNP - B-ORG
Advisor NNP - I-ORG
, PUNCT - O
Licensing NOUN - O
agreement NOUN - O
or CCONJ - O
royalty NOUN - O
; PUNCT - O
I. NNP - B-PERSON
Raad NNP - I-PERSON
, PUNCT - O
Merck NNP - B-ORG
: PUNCT - O
Grant NNP - B-PERSON
Investigator NNP - I-PERSON
, PUNCT - O
Research NNP - B-ORG
  _SP - I-ORG
grant NOUN - O
; PUNCT - O
Allergan NNP - B-PERSON
: PUNCT - O
Grant PROPN - O
Investigator PROPN - O
, PUNCT - O
Research NNP - B-GPE
  _SP - I-GPE
grant NOUN - O
; PUNCT - O
Infective NNP - B-ORG
Technologies NNPS - I-ORG
, PUNCT - O
LLC NNP - B-ORG
: PUNCT - O

Co PROPN - O
- NOUN - O
Inventor PROPN - O
of ADP - O
the DET - O
Nitroglycerin NNP - B-MEDICINE
- PUNCT - O
Citrate NNP - B-ORG
- HYPH - I-ORG
Ethanol NNP - I-ORG
catheter NOUN - O
lock NOUN - O
solution NOUN - O
technology NOUN - O
which ADJ - O
is VERB - O
owned VERB - O
by ADP - O
the DT - B-ORG
University NNP - I-ORG
of IN - I-ORG
Texas NNP - I-ORG
MD NNP - I-ORG
Anderson NNP - I-ORG
Cancer NNP - I-ORG
Center NNP - I-ORG
( PUNCT - O
UTMDACC NNP - B-ORG
) PUNCT - O
and CCONJ - O
has VERB - O
been VERB - O
licensed VERB - O
by ADP - O
Novel NNP - B-PERSON
Anti NNP - I-PERSON
- JJ - I-PERSON
Infective NNP - I-PERSON
Technologies NNPS - I-PERSON
, PUNCT - O
LLC NNP - B-ORG
in ADP - O
which ADJ - O
Dr. PROPN - O
Raad NNP - B-PERSON
is VERB - O
a DET - O
s NOUN - O
and CCONJ - O
Shareholder NN - B-ORG
, PUNCT - O
Licensing NN - B-ORG
agreement NOUN - O
or CCONJ - O
royalty NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Nitroglycerin NNP - B-MEDICINE
attenuated VERB - O
the DET - O
shock NOUN - O
- PUNCT - O
induced VERB - O
impairment NOUN - O
of ADP - O
the DET - O
mucosal ADJ - O
barrier NOUN - O
integrity NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Topical PROPN - O
Iloprost PROPN - O
and CCONJ - O
Nitroglycerin NNP - B-MEDICINE
on IN - I-ORG
Gastric NNP - I-ORG
Microcirculation NNP - I-ORG
and CCONJ - O
Barrier NNP - B-ORG
Function NNP - I-ORG
during ADP - O
Hemorrhagic PROPN - O
Shock PROPN - O
in ADP - O
Dogs NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Physiology NOUN - O
of ADP - O
Angina NNP - B-GPE
and CCONJ - O
Its ADJ - O
Alleviation NOUN - O
With ADP - O
Nitroglycerin NNP - B-MEDICINE
: PUNCT - O
Insights NOUN - O
From ADP - O
Invasive PROPN - O
Catheter PROPN - O
Laboratory PROPN - O
Measurements PROPN - O
During ADP - O
Exercise PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Novel ADJ - O
Nonantibiotic ADJ - O
Nitroglycerin NNP - B-MEDICINE
- PUNCT - O
Based PROPN - O
Catheter PROPN - O
Lock PROPN - O
Solution PROPN - O
for ADP - O
Prevention PROPN - O
of ADP - O
Intraluminal PROPN - O
Central PROPN - O
Venous PROPN - O
Catheter PROPN - O
Infections PROPN - O
in ADP - O
Cancer PROPN - O
Patients PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Nitroglycerin NNP - B-MEDICINE
is VERB - O
widely ADV - O
used VERB - O
as ADP - O
a DET - O
coronary ADJ - O
vasodilator NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
ischemic ADJ - O
heart NOUN - O
diseases NOUN - O
. PUNCT - O

Nitroglycerin JJ - B-MEDICINE
concentration NOUN - O
dependently ADV - O
relaxed ADJ - O
endothelium NOUN - O
- PUNCT - O
intact ADJ - O
rabbit NOUN - O
coronary ADJ - O
arteries NOUN - O
, PUNCT - O
which ADJ - O
were VERB - O
not ADV - O
different ADJ - O
under ADP - O
normoxic ADJ - O
and CCONJ - O
hypoxic ADJ - O
conditions NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Responsiveness PROPN - O
of ADP - O
Coronary PROPN - O
Arteries PROPN - O
to ADP - O
Nitroglycerin NNP - B-MEDICINE
under ADP - O
Hypoxia NNP - B-PERSON
: PUNCT - O

-DOCSTART- -X- - O

They PRON - O
are VERB - O
analyzed VERB - O
with ADP - O
a DET - O
narrow ADJ - O
- PUNCT - O
band NOUN - O
mobility NOUN - O
filter NOUN - O
( PUNCT - O
SEADM NNP - B-ORG
's PART - O
P5 ADJ - O
DMA NNP - B-ORG
) PUNCT - O
and CCONJ - O
a DET - O
triple ADJ - O
quadrupole NOUN - O
mass NOUN - O
spectrometer NOUN - O
( PUNCT - O
Sciex NNP - B-ORG
's PART - O
5500 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
configured VERB - O
in ADP - O
series NOUN - O
to PART - O
transmit VERB - O
precursor NOUN - O
and CCONJ - O
fragment NOUN - O
ions NOUN - O
of ADP - O
the DET - O
explosives NOUN - O
Nitroglycerin NNP - B-MEDICINE
, PUNCT - O
PETN NNP - B-ORG
, PUNCT - O
RDX NOUN - O
, PUNCT - O
and CCONJ - O
TNT NNP - B-ORG
. PUNCT - O

For ADP - O
Nitroglycerin NNP - B-MEDICINE
and CCONJ - O
PETN NNP - B-ORG
the DET - O
combined ADJ - O
filtering NOUN - O
techniques NOUN - O
have VERB - O
not ADV - O
lowered VERB - O
ambient ADJ - O
chemical NOUN - O
noise NOUN - O
down ADV - O
to ADP - O
0.01 CD - B-CARDINAL
ppq NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Nitroglycerin NNP - B-MEDICINE
is VERB - O
one NUM - O
of ADP - O
the DET - O
most ADV - O
commonly ADV - O
used VERB - O
antihypertensive ADJ - O
drugs NOUN - O
in ADP - O
our ADJ - O
hospital NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Nitroglycerin NNP - B-MEDICINE
hypotensive ADJ - O
effect NOUN - O
and CCONJ - O
application NOUN - O
in ADP - O
a DET - O
combined ADJ - O
surgery NOUN - O
for ADP - O
reconstruction NOUN - O
after ADP - O
ipsilateral ADJ - O
maxillectomy NOUN - O
and CCONJ - O
orbit NOUN - O
evisceration NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

" PUNCT - O
A DET - O
Novel ADJ - O
Nonantibiotic ADJ - O
Nitroglycerin NNP - B-MEDICINE
- PUNCT - O
Based PROPN - O
Catheter PROPN - O
Lock PROPN - O
Solution PROPN - O
for ADP - O
Prevention PROPN - O
of ADP - O
Intraluminal PROPN - O
Central PROPN - O
Venous PROPN - O
Catheter PROPN - O
Infections PROPN - O
in ADP - O
Cancer PROPN - O
Patients PROPN - O
" PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
assessed VERB - O
patient NOUN - O
- PUNCT - O
reported VERB - O
ease NOUN - O
of ADP - O
use NOUN - O
and CCONJ - O
satisfaction NOUN - O
with ADP - O
the DET - O
eFlow NNP - B-ORG
CS NNP - B-PRODUCT
nebulizer NOUN - O
in ADP - O
the DET - O
GOLDEN PROPN - O
( PUNCT - O
Glycopyrrolate NN - B-MEDICINE
for ADP - O
Obstructive PROPN - O
Lung PROPN - O
Disease PROPN - O
via ADP - O
Electronic PROPN - O
Nebulizer)-5 PROPN - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Glycopyrrolate NN - B-MEDICINE
and CCONJ - O
ipratropium NOUN - O
efficiently ADV - O
antagonized VERB - O
an DET - O
ACh NOUN - O
- PUNCT - O
induced VERB - O
airway NOUN - O
contraction NOUN - O
in ADP - O
VX NNP - B-GPE
- PUNCT - O
poisoned VERB - O
PCLS PROPN - O
( PUNCT - O
EC50 PROPN - O
glycopyrrolate NN - B-MEDICINE
15.8 CD - B-CARDINAL
  SPACE - O
nmol NOUN - O
/ SYM - O
L PROPN - O
, PUNCT - O
EC50 PROPN - O
ipratropium NOUN - O
2.3 CD - B-CARDINAL
  SPACE - O
nmol NOUN - O
/ SYM - O
L NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Glycopyrrolate NN - B-MEDICINE
, PUNCT - O
or CCONJ - O
glycopyrronium NOUN - O
bromide NOUN - O
, PUNCT - O
like ADP - O
other ADJ - O
LAMAs NOUN - O
, PUNCT - O
inhibits VERB - O
parasympathetic ADJ - O
nerve NOUN - O
impulses NOUN - O
by ADP - O
selectively ADV - O
blocking VERB - O
the DET - O
binding NOUN - O
of ADP - O
acetylcholine NOUN - O
to ADP - O
muscarinic ADJ - O
receptors NOUN - O
. PUNCT - O

Glycopyrrolate NN - B-MEDICINE
is VERB - O
unusual ADJ - O
in ADP - O
that ADP - O
it PRON - O
preferentially ADV - O
binds VERB - O
to ADP - O
M3 PROPN - O
over ADP - O
M2 PROPN - O
muscarinic ADJ - O
receptors NOUN - O
, PUNCT - O
thereby ADV - O
specifically ADV - O
targeting VERB - O
the DET - O
primary ADJ - O
muscarinic ADJ - O
receptor NOUN - O
responsible ADJ - O
for ADP - O
bronchoconstriction NOUN - O
occurring VERB - O
in ADP - O
COPD NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Glycopyrrolate JJ - B-MEDICINE
facilitated ADJ - O
tracheal NOUN - O
intubation NOUN - O
with ADP - O
a DET - O
rigid ADJ - O
video NOUN - O
- PUNCT - O
stylet NOUN - O
by ADP - O
decreasing VERB - O
oral ADJ - O
secretions NOUN - O
and CCONJ - O
providing VERB - O
better ADJ - O
visualization NOUN - O
and CCONJ - O
faster ADJ - O
intubation NOUN - O
with ADP - O
hemodynamic ADJ - O
stability.www.clinicaltrials.gov NOUN - O
; PUNCT - O
Identifier NN - B-ORG
: PUNCT - O
NCT03050242 NNP - B-PRODUCT
. PUNCT - O

-DOCSTART- -X- - O

Inhalation NNP - B-ORG
Solution NNP - I-ORG
, PUNCT - O
a DET - O
drug NOUN - O
/ SYM - O
device NOUN - O
combination NOUN - O
of ADP - O
the DET - O
long ADV - O
- PUNCT - O
acting VERB - O
antimuscarinic ADJ - O
glycopyrrolate NN - B-MEDICINE
administered VERB - O
using VERB - O
the DET - O
eFlow NNP - B-PRODUCT
® NN - I-PRODUCT
closed VERB - O
system NOUN - O
( PUNCT - O
eFlow NNP - B-PRODUCT
CS NNP - I-PRODUCT
) PUNCT - O
nebulizer NOUN - O
, PUNCT - O
on ADP - O
HRQoL NNP - B-CARDINAL
from ADP - O
the DET - O
Glycopyrrolate NNP - B-MEDICINE
for ADP - O
Obstructive PROPN - O
Lung PROPN - O
Disease PROPN - O
Via PROPN - O
Electronic PROPN - O
Nebulizer PROPN - O
( PUNCT - O
GOLDEN PROPN - O
) PUNCT - O
clinical ADJ - O
studies NOUN - O
. PUNCT - O

Glycopyrrolate NNP - B-MEDICINE
/ SYM - I-ORG
eFlow NNP - I-ORG
CS NNP - I-ORG
significantly ADV - O
improved VERB - O
SGRQ PROPN - O
Total PROPN - O
and CCONJ - O
component NOUN - O
scores NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Health NN - B-ORG
- HYPH - I-ORG
Related VBN - I-ORG
Quality NNP - I-ORG
of IN - I-ORG
Life NNP - I-ORG
Improvements NNP - I-ORG
in IN - I-ORG
Moderate PROPN - O
to ADP - O
Very ADV - O
Severe ADJ - O
Chronic ADJ - O
Obstructive ADJ - O
Pulmonary PROPN - O
Disease PROPN - O
Patients PROPN - O
on ADP - O
Nebulized PROPN - O
Glycopyrrolate NNP - B-MEDICINE
: PUNCT - O
Evidence NOUN - O
from ADP - O
the DT - B-LAW
GOLDEN NNP - I-LAW
Studies NNPS - I-LAW
. PUNCT - O

-DOCSTART- -X- - O

Glycopyrrolate NNP - B-MEDICINE
/ SYM - I-ORG
eFlow NNP - I-ORG
CS NN - I-ORG
: PUNCT - O
The DET - O
First PROPN - O
Nebulized PROPN - O
Long PROPN - O
- PUNCT - O
Acting PROPN - O
Muscarinic PROPN - O
Antagonist PROPN - O
Approved VERB - O
to PART - O
Treat VERB - O
Chronic PROPN - O
Obstructive ADJ - O
Pulmonary PROPN - O
Disease PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Effect NOUN - O
of ADP - O
Glycopyrrolate NNP - B-MEDICINE
on ADP - O
the DT - B-ORG
Incidence NNP - I-ORG
of IN - I-ORG
Hypotension NNP - I-ORG
and CCONJ - O
Vasopressor PROPN - O
Requirement PROPN - O

-DOCSTART- -X- - O

An DET - O
Open PROPN - O
- PUNCT - O
Label PROPN - O
Study NOUN - O
Evaluating VERB - O
the DET - O
Performance PROPN - O
of ADP - O
the DET - O
Dose PROPN - O
Indicator PROPN - O
in ADP - O
a DET - O
Metered PROPN - O
Dose PROPN - O
Inhaler PROPN - O
Delivering PROPN - O
Glycopyrrolate NNP - B-MEDICINE
and CCONJ - O
Formoterol PROPN - O
Fumarate PROPN - O
in ADP - O
Patients NOUN - O
with ADP - O
Moderate PROPN - O
- PUNCT - O
to ADP - O
- PUNCT - O
Very ADV - O

-DOCSTART- -X- - O

A DET - O
total NOUN - O
of ADP - O
2379 CD - B-CARDINAL
patients NOUN - O
from ADP - O
3 CD - B-CARDINAL
phase NOUN - O
III CD - B-ORG
studies NOUN - O
( PUNCT - O
12-week CD - B-CARDINAL
, PUNCT - O
placebo NOUN - O
- PUNCT - O
controlled VERB - O
Glycopyrrolate NNP - B-MEDICINE
for ADP - O
Obstructive PROPN - O
Lung PROPN - O
Disease PROPN - O
via ADP - O
Electronic PROPN - O
Nebulizer PROPN - O
[ PUNCT - O
GOLDEN PROPN - O
] PUNCT - O
-3 PUNCT - O
and CCONJ - O
-4 NOUN - O
, PUNCT - O
and CCONJ - O
48-week CD - B-CARDINAL
, PUNCT - O
active NOUN - O
- PUNCT - O
controlled VERB - O
GOLDEN-5 NNP - B-PERSON
) PUNCT - O
stratified VERB - O
by ADP - O
high ADJ - O
( PUNCT - O
n=1526 NUM - O
) PUNCT - O
or CCONJ - O
low ADJ - O

-DOCSTART- -X- - O

Efficacy PROPN - O
and CCONJ - O
Safety PROPN - O
of ADP - O
Nebulized PROPN - O
Glycopyrrolate NNP - B-MEDICINE
/ SYM - O
eFlow PROPN - O
® NOUN - O

-DOCSTART- -X- - O

Atrio PROPN - O
- PUNCT - O
ventricular ADJ - O
Block PROPN - O
Following VERB - O
Neostigmine NOUN - O
- PUNCT - O
Glycopyrrolate NN - B-MEDICINE
Reversal NOUN - O
in ADP - O
Non ADJ - O
- ADJ - O
heart NOUN - O
Transplant PROPN - O
Patients PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

Glycopyrrolate NNP - B-MEDICINE
/ SYM - I-ORG
eFlow NNP - I-ORG
® NN - I-ORG
is VERB - O
an DET - O
investigational ADJ - O
drug NOUN - O
- PUNCT - O
device NOUN - O
combination NOUN - O
of ADP - O
the DET - O
LAMA NNP - B-ORG
glycopyrrolate NN - B-MEDICINE
administered VERB - O
by ADP - O
an DET - O
eFlow PROPN - O
® NOUN - O
Closed PROPN - O
System PROPN - O
( PUNCT - O
eFlow PROPN - O
® PUNCT - O
CS PROPN - O
) PUNCT - O
nebulizer NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

III CD - B-ORG
clinical ADJ - O
studies NOUN - O
: PUNCT - O
results NOUN - O
from ADP - O
GOLDEN PROPN - O
( PUNCT - O
Glycopyrrolate NN - B-MEDICINE
for ADP - O
Obstructive PROPN - O
Lung PROPN - O
Disease PROPN - O
  SPACE - O
via ADP - O
Electronic PROPN - O
Nebulizer PROPN - O
) PUNCT - O
phase NOUN - O
II CD - B-ORG
dose NOUN - O
- PUNCT - O
finding VERB - O
studies NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Glycopyrrolate NN - B-MEDICINE
administered VERB - O
by ADP - O
a DET - O
novel NOUN - O
, PUNCT - O
investigational ADJ - O
eFlow NN - B-ORG
® NN - I-ORG
Closed NNP - I-ORG
System NNP - I-ORG
( PUNCT - O
CS NNP - B-ORG
) PUNCT - O
nebulizer NOUN - O
( PUNCT - O
eFlow NNP - B-ORG
CS NNP - I-ORG
) PUNCT - O
is VERB - O
being VERB - O
evaluated VERB - O
for ADP - O
the DET - O
maintenance NOUN - O
treatment NOUN - O
of ADP - O
chronic ADJ - O
obstructive ADJ - O
pulmonary ADJ - O
disease NOUN - O
( PUNCT - O
COPD NNP - B-ORG
) PUNCT - O
. PUNCT - O

Glycopyrrolate JJ - B-MEDICINE
concentration NOUN - O
and CCONJ - O
impurity NOUN - O
levels NOUN - O
of ADP - O
nebulized ADJ - O
samples NOUN - O
were VERB - O
statistically ADV - O
similar ADJ - O
to ADP - O
those DET - O
of ADP - O
non ADJ - O
- ADJ - O
nebulized ADJ - O
samples NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
Vitro PROPN - O
Characterization PROPN - O
of ADP - O
the DET - O
eFlow PROPN - O
Closed PROPN - O
System PROPN - O
Nebulizer PROPN - O
with ADP - O
Glycopyrrolate NNP - B-MEDICINE
Inhalation PROPN - O
Solution PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Hyperinflation PROPN - O
of ADP - O
Glycopyrrolate NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Long ADJ - O
- PUNCT - O
term NOUN - O
safety NOUN - O
of ADP - O
glycopyrrolate NN - B-MEDICINE
/ SYM - O
eFlow NOUN - O
® PUNCT - O
CS PROPN - O
in ADP - O
moderate ADJ - O
- PUNCT - O
to ADP - O
- PUNCT - O
very ADV - O
- PUNCT - O
severe ADJ - O
COPD PROPN - O
: PUNCT - O
Results NOUN - O
from ADP - O
the DT - B-ORG
Glycopyrrolate NNP - I-MEDICINE
for IN - I-ORG
Obstructive NNP - I-ORG
Lung NNP - I-ORG
Disease NNP - I-ORG
via IN - I-ORG
Electronic NNP - I-ORG
Nebulizer NNP - I-ORG
( PUNCT - O
GOLDEN PROPN - O
) PUNCT - O
5 CD - B-CARDINAL
randomized VERB - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Glycopyrrolate NN - B-MEDICINE
/ SYM - O
formoterol NOUN - O
fumarate NOUN - O
( PUNCT - O
GFF NNP - B-ORG
) PUNCT - O
metered VERB - O
dose NOUN - O
inhaler NOUN - O
( PUNCT - O
MDI PROPN - O
) PUNCT - O
is VERB - O
a DET - O
fixed VERB - O
- PUNCT - O
dose NOUN - O
combination NOUN - O
of ADP - O
the DET - O
long ADV - O
- PUNCT - O
acting VERB - O
muscarinic ADJ - O
antagonist NOUN - O
( PUNCT - O
LAMA PROPN - O
) PUNCT - O
, PUNCT - O
glycopyrrolate NN - B-MEDICINE
( PUNCT - O
GP PROPN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
the DET - O
long ADV - O
- PUNCT - O
acting VERB - O
β2-agonist PROPN - O
( PUNCT - O
LABA NNP - B-ORG
) PUNCT - O
, PUNCT - O
formoterol NOUN - O
fumarate VERB - O
( PUNCT - O
FF PROPN - O
) PUNCT - O
, PUNCT - O
delivered VERB - O
via ADP - O
metered VERB - O
dose NOUN - O
inhaler NOUN - O
using VERB - O
innovative ADJ - O
co NOUN - O
- ADJ - O
suspension ADJ - O
delivery NOUN - O
technology NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Glycopyrrolate NN - B-MEDICINE
dose NOUN - O
was VERB - O
not ADV - O
significantly ADV - O
correlated VERB - O
with ADP - O
decreased VERB - O
sweat NOUN - O
rate NOUN - O
and CCONJ - O
maximal ADJ - O
core NOUN - O
temperature NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
case NOUN - O
report NOUN - O
: PUNCT - O
Glycopyrrolate NN - B-MEDICINE
for ADP - O
treatment NOUN - O
of ADP - O
exercise NOUN - O
- PUNCT - O
induced VERB - O
hyperhidrosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Effect NOUN - O
of ADP - O
Nebulized PROPN - O
Glycopyrrolate NNP - B-MEDICINE
on ADP - O
Posterior PROPN - O
Drooling PROPN - O
in ADP - O
Patients PROPN - O
with ADP - O
Brain PROPN - O
Injury PROPN - O
: PUNCT - O
Two CD - B-CARDINAL
Cases NOUN - O
of ADP - O
Different PROPN - O
Brain PROPN - O
Lesions PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Glycopyrrolate NNP - B-MEDICINE
and CCONJ - O
placebo NOUN - O
were VERB - O
received VERB - O
by ADP - O
96 CD - B-CARDINAL
and CCONJ - O
100 CD - B-CARDINAL
patients NOUN - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

Glycopyrrolate NN - B-MEDICINE
may VERB - O
be VERB - O
a DET - O
promising ADJ - O
premedication NOUN - O
to PART - O
ensure VERB - O
safe ADJ - O
and CCONJ - O
stable ADJ - O
ESD NN - B-ORG
procedures NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Glycopyrrolate NN - B-MEDICINE
( PUNCT - O
Seebri NNP - B-PERSON
Neohaler NNP - I-PERSON
) PUNCT - O
for ADP - O
Maintenance NNP - B-ORG
Therapy NNP - I-ORG
in IN - I-ORG
Patients PROPN - O
with ADP - O
COPD NNS - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Glycopyrrolate NNP - B-MEDICINE
was VERB - O
used VERB - O
in ADP - O
a DET - O
0.2 CD - B-CARDINAL
mg NOUN - O
dose ADV - O
in ADP - O
74 CD - B-CARDINAL
  SPACE - O
patients NOUN - O
( PUNCT - O
97.37 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
. PUNCT - O

Glycopyrrolate NNP - B-MEDICINE
was VERB - O
the DET - O
preferred ADJ - O
anticholinergic ADJ - O
agent NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Glycopyrrolate NN - B-MEDICINE
was VERB - O
not ADV - O
associated VERB - O
with ADP - O
severe ADJ - O
adverse ADJ - O
events NOUN - O
or CCONJ - O
worsening NOUN - O
of ADP - O
cognitive ADJ - O
adverse ADJ - O
events NOUN - O
. PUNCT - O

Glycopyrrolate NN - B-MEDICINE
1 CD - B-CARDINAL
mg NOUN - O
was VERB - O
not ADV - O
superior ADJ - O
to ADP - O
placebo VERB - O
, PUNCT - O
whereas ADP - O
2 CD - B-QUANTITY
mg NN - I-QUANTITY
showed VERB - O
a DET - O
significant ADJ - O
clinical ADJ - O
improvement NOUN - O
of ADP - O
nocturnal ADJ - O
sialorrhea NOUN - O
compared VERB - O
with ADP - O
placebo NOUN - O
. PUNCT - O

Glycopyrrolate NN - B-MEDICINE
seemed VERB - O
to PART - O
be VERB - O
a DET - O
tolerable ADJ - O
anticholinergic ADJ - O
agent NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
clozapine NOUN - O
- PUNCT - O
associated VERB - O
sialorrhea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Effect NOUN - O
of ADP - O
Glycopyrrolate NNP - B-MEDICINE
on ADP - O
Nocturnal PROPN - O
Sialorrhea PROPN - O
in ADP - O
Patients PROPN - O
Using VERB - O
Clozapine NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

Baseline JJ - B-ORG
Symptom NN - I-ORG
Score NN - I-ORG
Impact NOUN - O
on ADP - O
Benefits NOUN - O
of ADP - O
Glycopyrrolate NNP - B-MEDICINE
/ SYM - I-ORG
Formoterol NNP - I-ORG
Metered NNP - I-ORG
Dose NNP - I-ORG
Inhaler NNP - I-ORG
in ADP - O
COPD NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Glycopyrrolate NN - B-MEDICINE
is VERB - O
a DET - O
long ADV - O
- PUNCT - O
acting VERB - O
muscarinic ADJ - O
antagonist NOUN - O
( PUNCT - O
LAMA PROPN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
formoterol NOUN - O
fumarate NOUN - O
is VERB - O
a DET - O
long ADV - O
- PUNCT - O
acting VERB - O
beta2 ADJ - O
agonist NOUN - O
( PUNCT - O
LABA NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Efficacy PROPN - O
and CCONJ - O
Safety PROPN - O
of ADP - O
Glycopyrrolate NNP - B-MEDICINE
/ SYM - O
Formoterol PROPN - O
Metered PROPN - O
Dose PROPN - O
Inhaler NOUN - O
Formulated VERB - O

-DOCSTART- -X- - O

Glycopyrrolate NNP - B-MEDICINE
( PUNCT - O
Robinul PROPN - O
) PUNCT - O
, PUNCT - O
which ADJ - O
has VERB - O
been VERB - O
in ADP - O
short ADJ - O
supply NOUN - O
in ADP - O
recent JJ - B-DATE
years NNS - I-DATE
, PUNCT - O
is VERB - O
one NUM - O
of ADP - O
the DET - O
most ADV - O
widely ADV - O
used VERB - O
anticholinergic ADJ - O
agents NOUN - O
, PUNCT - O
especially ADV - O
in ADP - O
conjunction NOUN - O
with ADP - O
the DET - O
anticholinesterase NOUN - O
neostigmine NOUN - O
, PUNCT - O
for ADP - O
reversal NOUN - O
of ADP - O
neuromuscular ADJ - O
blockade NOUN - O
( PUNCT - O
NMB NNP - B-ORG
) PUNCT - O
drugs NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Glycopyrrolate NN - B-MEDICINE
: PUNCT - O
It PRON - O
's VERB - O
time NOUN - O
to PART - O
review VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Glycopyrrolate NN - B-MEDICINE
given VERB - O
as ADP - O
reversing VERB - O
agents NOUN - O
of ADP - O
muscle NOUN - O
relaxants NOUN - O
has VERB - O
been VERB - O
reported VERB - O
to PART - O
be VERB - O
effective ADJ - O
in ADP - O
reducing VERB - O
postoperative ADJ - O
catheter NOUN - O
- PUNCT - O
related VERB - O
bladder NOUN - O
discomfort NOUN - O
( PUNCT - O
CRBD PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Glycopyrrolate NNP - B-MEDICINE
killed VERB - O
all DET - O
of ADP - O
the DET - O
examined VERB - O
strains NOUN - O
( PUNCT - O
P NOUN - O
< X - O
.05 PUNCT - O
) PUNCT - O
, PUNCT - O
whereas ADP - O
in ADP - O
atropine NOUN - O
, PUNCT - O
only ADV - O
the DET - O
clinical ADJ - O
isolates NOUN - O
of ADP - O
Staphylococcus NNP - B-PRODUCT
and CCONJ - O
Acinetobacter NNP - B-PERSON
were VERB - O
killed VERB - O
( PUNCT - O
P NOUN - O
< X - O
.05).Drawing PUNCT - O
up PART - O
atropine NOUN - O
or CCONJ - O
glycopyrrolate NN - B-MEDICINE
at ADP - O
the DET - O
beginning NOUN - O
of ADP - O
the DET - O
operating NOUN - O
list NOUN - O
and CCONJ - O
use VERB - O
within ADP - O
24 CD - B-TIME
hours NNS - I-TIME
if ADP - O
needed VERB - O
are VERB - O
a DET - O
safe ADJ - O
practice NOUN - O
and CCONJ - O
do VERB - O
not ADV - O
pose VERB - O
infection NOUN - O
hazard NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Glycopyrrolate NN - B-MEDICINE
on ADP - O
induction NOUN - O
had VERB - O
lower ADJ - O
POH NNP - B-ORG
( PUNCT - O
17.4 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
and CCONJ - O
LOS NNP - B-ORG
( PUNCT - O
1.9 CD - B-ORG
  _SP - I-ORG
days NNS - B-DATE
) PUNCT - O
, PUNCT - O
compared VERB - O
to ADP - O
no DET - O
glycopyrrolate NN - B-MEDICINE
( PUNCT - O
21.6 CD - B-PERCENT
% NN - I-PERCENT
; PUNCT - O
p X - O
  SPACE - O
= SYM - O
  SPACE - O
0.0849 NUM - O
; PUNCT - O
2.7 CD - B-CARDINAL
  SPACE - O
days NNS - B-DATE
; PUNCT - O
p VERB - O
  SPACE - O
< X - O
  SPACE - O
0.0001 CD - B-DATE
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Glycopyrrolate NN - B-MEDICINE
in ADP - O
comparison NOUN - O
to PART - O
hyoscine VERB - O
hydrobromide NOUN - O
and CCONJ - O
placebo NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
hypersalivation NOUN - O
induced VERB - O
by ADP - O
clozapine NOUN - O
( PUNCT - O
GOTHIC1 PROPN - O
) PUNCT - O
: PUNCT - O
study NOUN - O
protocol NOUN - O
for ADP - O
a DET - O
randomised ADJ - O
controlled VERB - O
feasibility NOUN - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Glycopyrrolate NN - B-MEDICINE
- PUNCT - O
induced VERB - O
craniofacial NOUN - O
compensatory NOUN - O
hyperhidrosis NOUN - O
successfully ADV - O
treated VERB - O
with ADP - O
oxybutynin NOUN - O
: PUNCT - O
report NOUN - O
of ADP - O
a DET - O
novel ADJ - O
adverse ADJ - O
effect NOUN - O
and CCONJ - O
subsequent ADJ - O
successful ADJ - O
treatment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Glycopyrrolate NN - B-MEDICINE
/ SYM - O
formoterol NOUN - O
( PUNCT - O
Bevespi NNP - B-PERSON
Aerosphere NNP - I-PERSON
) PUNCT - O
for ADP - O
COPD NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Glycopyrrolate NN - B-MEDICINE
demonstrated VERB - O
statistically ADV - O
significant ADJ - O
( PUNCT - O
P<0.001 PROPN - O
) PUNCT - O
improvements NOUN - O
in ADP - O
lung NOUN - O
function NOUN - O
versus ADP - O
placebo NOUN - O
. PUNCT - O

Glycopyrrolate NNP - B-MEDICINE
showed VERB - O
statistically ADV - O
significant ADJ - O
improvement NOUN - O
in ADP - O
the DET - O
transition NOUN - O
dyspnea NOUN - O
index NOUN - O
focal ADJ - O
score NOUN - O
, PUNCT - O
St NNP - B-PERSON
George NNP - I-PERSON
's POS - I-PERSON
Respiratory NNP - B-FAC
Questionnaire NNP - I-FAC
total ADJ - O
score NOUN - O
, PUNCT - O
COPD NNP - B-ORG
Assessment NNP - I-ORG
Test NNP - I-ORG
score NOUN - O
, PUNCT - O
rescue NOUN - O
medication NOUN - O
use NOUN - O
, PUNCT - O
and CCONJ - O
daily JJ - B-DATE
total ADJ - O
symptom NOUN - O
score NOUN - O
versus ADP - O
placebo NOUN - O
at IN - B-DATE
week NN - I-DATE
12 CD - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

Glycopyrrolate NNP - B-MEDICINE
( PUNCT - O
0.01 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
kg NOUN - O
[ PUNCT - O
0.005 NUM - O
mg NOUN - O
/ SYM - O
lb NOUN - O
] PUNCT - O
) PUNCT - O
was VERB - O
administered VERB - O
IM NNP - B-ORG
to ADP - O
all DET - O
dogs NOUN - O
( PUNCT - O
3 CD - B-CARDINAL
dogs NOUN - O
received VERB - O
an DET - O
injection NOUN - O
of ADP - O
saline NOUN - O
[ PUNCT - O
0.9 CD - B-PERCENT
% NN - I-PERCENT
NaCl NNP - B-NORP
] PUNCT - O
solution NOUN - O
on ADP - O
an DET - O
earlier ADJ - O
occasion NOUN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
final ADJ - O
STT NNP - B-ORG
I PRON - O
measurements NOUN - O
were VERB - O
recorded VERB - O
20 CD - B-TIME
minutes NNS - I-TIME
later ADV - O
( PUNCT - O
at ADP - O
T4 PROPN - O
) PUNCT - O
. PUNCT - O

Glycopyrrolate NNP - B-MEDICINE
had VERB - O
no DET - O
effect NOUN - O
on ADP - O
intraocular ADJ - O
pressure NOUN - O
or CCONJ - O
respiratory ADJ - O
rate NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-ORG
Glycopyrrolate NNP - I-MEDICINE
Effect NNP - I-ORG
on ADP - O
syMptoms NOUN - O
and CCONJ - O
lung NOUN - O
function NOUN - O
( PUNCT - O
GEM2 PROPN - O
) PUNCT - O
study NOUN - O
assessed VERB - O
the DET - O
efficacy NOUN - O
and CCONJ - O
safety NOUN - O
of ADP - O
twice ADV - O
- PUNCT - O
daily ADJ - O
glycopyrrolate NN - B-MEDICINE
15.6 CD - B-CARDINAL
μg NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
moderate ADV - O
- PUNCT - O
to ADP - O
- PUNCT - O
severe ADJ - O
airflow ADJ - O
limitation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Efficacy PROPN - O
and CCONJ - O
Safety NNP - B-ORG
of IN - I-ORG
Twice NNP - I-ORG
- HYPH - I-ORG
Daily NNP - I-ORG
Glycopyrrolate NNP - B-MEDICINE
Versus PROPN - O
Placebo PROPN - O
in ADP - O
Patients NNS - B-GPE
With ADP - O
COPD PROPN - O
: PUNCT - O
The DT - B-GPE
GEM2 NNP - I-GPE
Study NNP - I-GPE
. PUNCT - O

-DOCSTART- -X- - O

Efficacy PROPN - O
and CCONJ - O
Safety NNP - B-ORG
of IN - I-ORG
Glycopyrrolate NNP - I-MEDICINE
/ SYM - I-ORG
Formoterol NNP - I-ORG
Metered NNP - I-ORG
Dose NNP - I-ORG
Inhaler NN - I-ORG
Formulated VBN - I-ORG
Using VBG - I-ORG
Co NNP - I-ORG
- NN - I-ORG
Suspension NN - I-ORG
Delivery NNP - I-ORG
Technology NNP - I-ORG
in ADP - O
Patients NNPS - B-ORG
With IN - I-ORG
COPD NNS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Long ADJ - O
- PUNCT - O
term NOUN - O
Stability NNP - B-ORG
of IN - I-ORG
Zonisamide NNP - I-ORG
, , - I-ORG
Amitriptyline NNP - I-ORG
, PUNCT - O
and CCONJ - O
Glycopyrrolate NNP - B-MEDICINE
in ADP - O
Extemporaneously PROPN - O
Prepared NNP - B-PERSON
Liquid NNP - I-PERSON
- HYPH - I-PERSON
dosage NN - I-PERSON
Forms NOUN - O
at ADP - O
Two CD - B-CARDINAL
Temperatures PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Contact NOUN - O
leukoderma NOUN - O
induced VERB - O
by ADP - O
rotigotine ADJ - O
transdermal ADJ - O
patch NOUN - O
( PUNCT - O
Neupro NNP - B-MEDICINE
® PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Clinical ADJ - O
pharmacology NOUN - O
and CCONJ - O
efficacy NOUN - O
of ADP - O
rotigotine NOUN - O
( PUNCT - O
Neupro NNP - B-MEDICINE
® NN - I-ORG
patch NOUN - O
) PUNCT - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
restless NOUN - O
leg NOUN - O
syndrome NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Rotigotine VERB - O
transdermal ADJ - O
patch NOUN - O
( PUNCT - O
Leganto PROPN - O
( PUNCT - O
® PROPN - O
) PUNCT - O
, PUNCT - O
Neupro NNP - B-MEDICINE
( -LRB- - I-PERSON
® NNP - I-PERSON
) PUNCT - O
) PUNCT - O
is VERB - O
indicated VERB - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
restless NOUN - O
legs NOUN - O
syndrome NOUN - O
( PUNCT - O
RLS NNP - B-ORG
) PUNCT - O
; PUNCT - O
this DET - O
article NOUN - O
reviews VERB - O
the DET - O
pharmacological ADJ - O
properties NOUN - O
of ADP - O
rotigotine ADJ - O
transdermal ADJ - O
patch NOUN - O
and CCONJ - O
its ADJ - O
clinical ADJ - O
efficacy NOUN - O
and CCONJ - O
tolerability NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
RLS NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
bioavailability NOUN - O
of ADP - O
the DET - O
rotigotine NOUN - O
- PUNCT - O
loaded VERB - O
microemulsion NOUN - O
gel NOUN - O
was VERB - O
105.76%±20.52 CD - B-PERCENT
% NN - I-PERCENT
with ADP - O
respect NOUN - O
to ADP - O
the DET - O
marketed VERB - O
rotigotine NOUN - O
patch NOUN - O
( PUNCT - O
Neupro NNP - B-MEDICINE
( PUNCT - O
® PROPN - O
) PUNCT - O
) PUNCT - O
. PUNCT - O

The DET - O
microemulsion NOUN - O
gel NOUN - O
irritated VERB - O
the DET - O
skin NOUN - O
less ADJ - O
than ADP - O
Neupro NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Neupro NNP - B-MEDICINE
( PUNCT - O
rotigotine NOUN - O
) PUNCT - O
is VERB - O
a DET - O
dopamine NOUN - O
agonist NOUN - O
available ADJ - O
as ADP - O
a DET - O
patch NOUN - O
that ADJ - O
has VERB - O
been VERB - O
approved VERB - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
RLS NNP - B-ORG
as ADV - O
well ADV - O
as ADP - O
Parkinson PROPN - O
disease NOUN - O
. PUNCT - O

Neupro NNP - B-MEDICINE
( PUNCT - O
rotigotine NOUN - O
) PUNCT - O
and CCONJ - O
Horizant NNP - B-PERSON
( PUNCT - O
gabapentin ADJ - O
enacarbil NOUN - O
) PUNCT - O
provide VERB - O
additional ADJ - O
treatment NOUN - O
options NOUN - O
for ADP - O
patients NOUN - O
with ADP - O
RLS NNP - B-ORG
who NOUN - O
are VERB - O
in ADP - O
need NOUN - O
of ADP - O
medications NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
brief ADJ - O
: PUNCT - O
transdermal ADJ - O
rotigotine NOUN - O
( PUNCT - O
Neupro NNP - B-MEDICINE
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
new ADJ - O
and CCONJ - O
unique ADJ - O
methodology NOUN - O
was VERB - O
developed VERB - O
to PART - O
evaluate VERB - O
the DET - O
association NOUN - O
between ADP - O
periodic ADJ - O
limb NOUN - O
movements NOUN - O
( PUNCT - O
PLMs PROPN - O
) PUNCT - O
and CCONJ - O
nocturnal ADJ - O
blood NOUN - O
pressure NOUN - O
( PUNCT - O
BP NNP - B-ORG
) PUNCT - O
excursions NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
restless ADJ - O
legs NOUN - O
syndrome NOUN - O
( PUNCT - O
RLS).All NN - B-ORG
data NOUN - O
were VERB - O
collected VERB - O
at ADP - O
baseline NOUN - O
of ADP - O
the DET - O
ENCORE NNP - B-ORG
( PUNCT - O
Effects PROPN - O
of ADP - O
Neupro NNP - B-MEDICINE
on ADP - O
Cardiovascular PROPN - O
Observations PROPN - O
in ADP - O
Patients PROPN - O
with ADP - O
Restless PROPN - O
Legs PROPN - O
Syndrome PROPN - O
) PUNCT - O
study NOUN - O
, PUNCT - O
a DET - O
placebo NOUN - O
- PUNCT - O
controlled VERB - O
polysomnographic ADJ - O
study NOUN - O
of ADP - O
rotigotine NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
idiopathic ADJ - O
RLS NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
provide VERB - O
real ADJ - O
- PUNCT - O
world NOUN - O
data NOUN - O
on ADP - O
caregiver NOUN - O
and CCONJ - O
physician NOUN - O
perceptions NOUN - O
of ADP - O
the DET - O
advantages NOUN - O
and CCONJ - O
disadvantages NOUN - O
of ADP - O
rotigotine NOUN - O
transdermal ADJ - O
patch NOUN - O
( PUNCT - O
Neupro NNP - B-MEDICINE
* PUNCT - O
) PUNCT - O
versus ADP - O
oral ADJ - O
Parkinson PROPN - O
's PART - O
Disease PROPN - O
( PUNCT - O
PD PROPN - O
) PUNCT - O
medication NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Transdermal NNP - B-PERSON
Rotigotine NNP - I-PERSON
( PUNCT - O
Neupro)]. NNP - B-ORG

-DOCSTART- -X- - O

These DET - O
amines NOUN - O
are VERB - O
precursors NOUN - O
of ADP - O
important ADJ - O
active ADJ - O
pharmaceutical NOUN - O
ingredients NOUN - O
such ADJ - O
as ADP - O
rotigotine NOUN - O
( PUNCT - O
Neupro NNP - B-MEDICINE
) PUNCT - O
, PUNCT - O
robalzotan NOUN - O
, PUNCT - O
and CCONJ - O
ebalzotan NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Rotigotine VERB - O
transdermal ADJ - O
patch NOUN - O
( PUNCT - O
Neupro NNP - B-MEDICINE
( PUNCT - O
® PROPN - O
) PUNCT - O
) PUNCT - O

-DOCSTART- -X- - O

Rotigotine ADJ - O
transdermal ADJ - O
patches NOUN - O
( PUNCT - O
Neupro NNP - B-MEDICINE
) PUNCT - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
Parkinson PROPN - O
's PART - O
disease NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Transdermal ADJ - O
rotigotine NOUN - O
( PUNCT - O
Neupro NNP - B-MEDICINE
) PUNCT - O
for ADP - O
Parkinson PROPN - O
's PART - O
disease NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
transdermal ADJ - O
patch NOUN - O
formulation NOUN - O
of ADP - O
the DET - O
non ADJ - O
- ADJ - O
ergolinic ADJ - O
dopamine NOUN - O
agonist NOUN - O
rotigotine NOUN - O
( PUNCT - O
Neupro NNP - B-MEDICINE
® NNP - I-PERSON
) PUNCT - O
is VERB - O
indicated VERB - O
as ADP - O
monotherapy NOUN - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
early ADJ - O
Parkinson PROPN - O
's PART - O
disease NOUN - O
and CCONJ - O
as ADP - O
combination NOUN - O
therapy NOUN - O
with ADP - O
levodopa ADJ - O
throughout ADP - O
the DET - O
course NOUN - O
of ADP - O
the DET - O
disease NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
transdermal ADJ - O
route NOUN - O
is VERB - O
an DET - O
advantageous ADJ - O
alternative NOUN - O
, PUNCT - O
as ADP - O
shown VERB - O
by ADP - O
the DET - O
recent ADJ - O
commercialization NOUN - O
of ADP - O
a DET - O
passive ADJ - O
patch NOUN - O
containing VERB - O
rotigotine NOUN - O
( PUNCT - O
Neupro NNP - B-MEDICINE
® PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Rotigotine PROPN - O
( PUNCT - O
Neupro NNP - B-MEDICINE
) PUNCT - O
is VERB - O
a DET - O
non ADJ - O
- ADJ - O
ergolinic ADJ - O
dopamine NOUN - O
agonist NOUN - O
available ADJ - O
as ADP - O
a DET - O
transdermal ADJ - O
patch NOUN - O
that ADJ - O
can VERB - O
be VERB - O
applied VERB - O
once ADV - O
daily ADV - O
. PUNCT - O

-DOCSTART- -X- - O

UCB NNP - B-ORG
has VERB - O
been VERB - O
developing VERB - O
rotigotine ADJ - O
transdermal ADJ - O
patch NOUN - O
system NOUN - O
( PUNCT - O
Neupro NNP - B-MEDICINE
; PUNCT - O
SPM-962 NNP - B-PERSON
) PUNCT - O
as ADP - O
a DET - O
treatment NOUN - O
for ADP - O
RLS NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
nonergoline NOUN - O
dopamine NOUN - O
agonist NOUN - O
rotigotine NOUN - O
, PUNCT - O
is VERB - O
delivered VERB - O
transdermally ADV - O
using VERB - O
a DET - O
silicone NOUN - O
- PUNCT - O
based VERB - O
patch NOUN - O
( PUNCT - O
Neupro(R PROPN - O
) PUNCT - O
; PUNCT - O
UCB NNP - B-ORG
Pharma NNP - I-ORG
GmbH PROPN - O
) PUNCT - O
, PUNCT - O
which ADJ - O
promotes VERB - O
unidirectional ADJ - O
drug NOUN - O
flow NOUN - O
from ADP - O
the DET - O
transdermal ADJ - O
system NOUN - O
to ADP - O
the DET - O
skin NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
transdermal ADJ - O
patch NOUN - O
formulation NOUN - O
of ADP - O
the DET - O
non ADJ - O
- ADJ - O
ergolinic ADJ - O
dopamine NOUN - O
receptor NOUN - O
agonist NOUN - O
rotigotine NOUN - O
( PUNCT - O
Neupro NNP - B-MEDICINE
) PUNCT - O
is VERB - O
indicated VERB - O
for ADP - O
use NOUN - O
as ADP - O
monotherapy NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
early ADJ - O
- PUNCT - O
stage NOUN - O
Parkinson PROPN - O
's PART - O
disease NOUN - O
or CCONJ - O
, PUNCT - O
in ADP - O
the DET - O
EU NNP - B-ORG
, PUNCT - O
as ADP - O
an DET - O
adjunct NOUN - O
to PART - O
levodopa VERB - O
across ADP - O
all DET - O
disease NOUN - O
stages NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
transdermal ADJ - O
patch NOUN - O
formulation NOUN - O
of ADP - O
the DET - O
non ADJ - O
- ADJ - O
ergolinic ADJ - O
dopamine NOUN - O
agonist NOUN - O
rotigotine NOUN - O
( PUNCT - O
Neupro NNP - B-MEDICINE
) PUNCT - O
is VERB - O
indicated VERB - O
for ADP - O
use NOUN - O
as ADP - O
monotherapy NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
early ADJ - O
- PUNCT - O
stage NOUN - O
Parkinson PROPN - O
's PART - O
disease NOUN - O
or CCONJ - O
, PUNCT - O
in ADP - O
the DET - O
EU NNP - B-ORG
, PUNCT - O
as ADP - O
an DET - O
adjunct NOUN - O
to PART - O
levodopa VERB - O
across ADP - O
all DET - O
disease NOUN - O
stages NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Rotigotine PROPN - O
( PUNCT - O
Neupro NNP - B-MEDICINE
) PUNCT - O
is VERB - O
a DET - O
non ADJ - O
- ADJ - O
ergoline ADJ - O
dopamine NOUN - O
agonist NOUN - O
developed VERB - O
for ADP - O
the DET - O
once ADV - O
daily ADJ - O
treatment NOUN - O
of ADP - O
Parkinson PROPN - O
's PART - O
disease NOUN - O
( PUNCT - O
PD PROPN - O
) PUNCT - O
using VERB - O
a DET - O
transdermal ADJ - O
delivery NOUN - O
system NOUN - O
( PUNCT - O
patch NOUN - O
) PUNCT - O
which ADJ - O
provides VERB - O
patients NOUN - O
with ADP - O
the DET - O
drug NOUN - O
continuously ADV - O
over ADP - O
24 CD - B-CARDINAL
h. VERB - O

-DOCSTART- -X- - O

The DET - O
new ADJ - O
dopamine NOUN - O
agonist NOUN - O
Rotigotine NNP - B-PERSON
( PUNCT - O
Neupro NNP - B-MEDICINE
) PUNCT - O
can VERB - O
be VERB - O
transdermally ADV - O
applied VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Rotigotine NOUN - O
is VERB - O
a DET - O
new ADJ - O
, PUNCT - O
non ADJ - O
- ADJ - O
ergoline ADJ - O
dopamine NOUN - O
receptor NOUN - O
agonist NOUN - O
developed VERB - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
Parkinson PROPN - O
's PART - O
disease NOUN - O
in ADP - O
a DET - O
transdermal ADJ - O
formulation NOUN - O
( PUNCT - O
Neupro NNP - B-MEDICINE
) PUNCT - O
to PART - O
provide VERB - O
sustained ADJ - O
drug NOUN - O
delivery NOUN - O
for ADP - O
24 CD - B-CARDINAL
h NOUN - O
with ADP - O
a DET - O
once ADV - O
daily ADJ - O
dosing NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
assess VERB - O
the DET - O
response NOUN - O
to ADP - O
the DET - O
rotigotine NOUN - O
transdermal ADJ - O
system NOUN - O
( PUNCT - O
Neupro NN - B-MEDICINE
; PUNCT - O
Schwarz NNP - B-PERSON
Pharma NNP - I-PERSON
Ltd NNP - I-PERSON
, PUNCT - O
Monheim NNP - B-PERSON
, PUNCT - O
Germany NNP - B-GPE
) PUNCT - O
, PUNCT - O
a DET - O
nonergolinic ADJ - O
dopamine NOUN - O
agonist NOUN - O
, PUNCT - O
in ADP - O
patients NOUN - O
with ADP - O
early ADJ - O
Parkinson PROPN - O
disease NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Rotigotine PROPN - O
( PUNCT - O
Neupro NNP - B-MEDICINE
) PUNCT - O
is VERB - O
a DET - O
novel ADJ - O
dopaminergic ADJ - O
agonist NOUN - O
with ADP - O
24-hour CD - B-CARDINAL
transdermal ADJ - O
delivery NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Rotigotine PROPN - O
( PUNCT - O
Neupro NNP - B-MEDICINE
) PUNCT - O
is VERB - O
formulated VERB - O
as ADP - O
a DET - O
transdermal ADJ - O
delivery NOUN - O
system NOUN - O
designed VERB - O
to PART - O
provide VERB - O
a DET - O
selective ADJ - O
, PUNCT - O
non ADJ - O
- ADJ - O
ergot ADJ - O
D3/D2/D1 NOUN - O
agonist NOUN - O
to ADP - O
the DET - O
systemic ADJ - O
blood NOUN - O
flow NOUN - O
over ADP - O
a DET - O
24-hour CD - B-CARDINAL
period NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Rotigotine PROPN - O
( PUNCT - O
Neupro((R NOUN - O
) PUNCT - O
) PUNCT - O
) PUNCT - O
is VERB - O
a DET - O
new ADJ - O
non ADJ - O
- ADJ - O
ergolinic ADJ - O
dopamine NOUN - O
agonist NOUN - O
transdermal ADJ - O
patch NOUN - O
that ADJ - O
can VERB - O
be VERB - O
applied VERB - O
once ADV - O
daily RB - B-DATE
. PUNCT - O

-DOCSTART- -X- - O

Four CD - B-CARDINAL
types NOUN - O
of ADP - O
titanium NOUN - O
- PUNCT - O
based VERB - O
orthodontic ADJ - O
wires NOUN - O
( PUNCT - O
2 CD - B-CARDINAL
nickel NOUN - O
- PUNCT - O
titanium NOUN - O
alloy NOUN - O
wires NOUN - O
[ PUNCT - O
nickel NOUN - O
- PUNCT - O
titanium NOUN - O
and CCONJ - O
copper NOUN - O
- PUNCT - O
nickel NOUN - O
- PUNCT - O
titanium NOUN - O
] PUNCT - O
and CCONJ - O
2 CD - B-CARDINAL
beta NOUN - O
- PUNCT - O
titanium NOUN - O
alloy NOUN - O
wires NOUN - O
[ PUNCT - O
titanium NOUN - O
- PUNCT - O
molybdenum NOUN - O
and CCONJ - O
titanium NOUN - O
- PUNCT - O
niobium NOUN - O
] PUNCT - O
, PUNCT - O
all DET - O
from ADP - O
Ormco NNP - B-GPE
, PUNCT - O
Glendora NNP - B-GPE
, , - I-GPE
Calif NNP - I-GPE
) PUNCT - O
with ADP - O
similar ADJ - O
sizes NOUN - O
were VERB - O
prepared VERB - O
and CCONJ - O
immersed VERB - O
in ADP - O
5 CD - B-CARDINAL
fluoride NOUN - O
prophylactic ADJ - O
agents NOUN - O
( PUNCT - O
2 CD - B-CARDINAL
acidulated VERB - O
phosphate ADJ - O
fluoride NOUN - O
agents NOUN - O
[ PUNCT - O
Nupro ADJ - O
APF PROPN - O
( PUNCT - O
Dentsply NNP - B-ORG
International NNP - I-ORG
, PUNCT - O
York NNP - B-GPE
, PUNCT - O
Pa PROPN - O
) PUNCT - O
and CCONJ - O
Florentine NNP - B-PERSON
III NNP - I-PERSON
( PUNCT - O
Confi NNP - B-ORG
- HYPH - I-ORG
Dental NNP - I-ORG
, PUNCT - O
Louisville NNP - B-GPE
, PUNCT - O
Colo NNP - B-PERSON
) PUNCT - O
] PUNCT - O
, PUNCT - O
1 CD - B-CARDINAL
neutral ADJ - O
agent NOUN - O
[ PUNCT - O
Neupro NNP - B-MEDICINE
Neutral NNP - I-ORG
( -LRB- - I-ORG
Dentsply NNP - B-ORG
International NNP - I-ORG
) PUNCT - O
] PUNCT - O
and CCONJ - O
2 CD - B-CARDINAL
stannous ADJ - O
fluoride ADJ - O
agents NOUN - O
[ PUNCT - O
Florentine NNP - B-PERSON
II NNP - I-PERSON
( PUNCT - O
Confi NNP - B-ORG
- HYPH - I-ORG
Dental NNP - I-ORG
) PUNCT - O
and CCONJ - O
Perio NNP - B-ORG
- HYPH - I-ORG
Med NNP - I-ORG

-DOCSTART- -X- - O

Rotigotine PROPN - O
( PUNCT - O
Neupro NNP - B-MEDICINE
) PUNCT - O
( PUNCT - O
Transdermal NNP - B-ORG
Patch NNP - I-ORG
) PUNCT - O

-DOCSTART- -X- - O

Efficacy NOUN - O
of ADP - O
Prolonged NNP - B-ORG
Exposure NNP - I-ORG
Therapy NNP - I-ORG
, PUNCT - O
Sertraline NNP - B-PERSON
Hydrochloride NNP - I-PERSON
, PUNCT - O
and CCONJ - O
Their ADJ - O
Combination NOUN - O
Among ADP - O
Combat PROPN - O
Veterans PROPN - O
With ADP - O
Posttraumatic PROPN - O
Stress PROPN - O
Disorder NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

Preparation PROPN - O
and CCONJ - O
Optimization PROPN - O
of ADP - O
Sertraline NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
Tablets PROPN - O
with ADP - O
Improved PROPN - O
Dissolution PROPN - O
Through ADP - O
Crystal PROPN - O
Modification PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Stability NOUN - O
of ADP - O
Allopurinol PROPN - O
, PUNCT - O
Amitriptyline NNP - B-PERSON
Hydrochloride NNP - I-PERSON
, PUNCT - O
Carbamazepine NNP - B-GPE
, PUNCT - O
Domperidone NNP - B-PERSON
, PUNCT - O
Isoniazid PROPN - O
, PUNCT - O
Ketoconazole NNP - B-ORG
, PUNCT - O
Lisinopril NNP - B-ORG
, PUNCT - O
Naproxen NNP - B-PERSON
, PUNCT - O
Paracetamol NNP - B-PERSON
( PUNCT - O
Acetaminophen NNP - B-PERSON
) PUNCT - O
, PUNCT - O
and CCONJ - O
Sertraline NNP - B-PERSON
Hydrochloride NNP - I-PERSON
in ADP - O
SyrSpend PROPN - O
SF PROPN - O
PH4 PROPN - O
Oral PROPN - O
Suspensions PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Fetal PROPN - O
Exposure NOUN - O
to ADP - O
Sertraline NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE

-DOCSTART- -X- - O

Stable ADJ - O
Sertraline NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
Formulation PROPN - O
and CCONJ - O
Method PROPN - O

-DOCSTART- -X- - O

The DET - O
present ADJ - O
invention NOUN - O
relates VERB - O
to ADP - O
the DET - O
improved ADJ - O
, PUNCT - O
scalable ADJ - O
and CCONJ - O
efficient ADJ - O
manufacturing NOUN - O
procedure NOUN - O
for ADP - O
the DET - O
preparation NOUN - O
of ADP - O
the DET - O
antidepressant ADJ - O
Cis-(1S)-N NNP - B-PERSON
- HYPH - I-PERSON
Methyl-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1-napthaleneamine JJ - I-PERSON
hydro NOUN - O
chloride NOUN - O
, PUNCT - O
Sertraline NNP - B-GPE
Hydrochloride NNP - I-GPE
polymorphic ADJ - O
form NOUN - O
II NNP - B-ORG
. PUNCT - O

The DET - O
present ADJ - O
invention NOUN - O
further ADV - O
relates VERB - O
to ADP - O
the DET - O
improved ADJ - O
and CCONJ - O
modified ADJ - O
procedures NOUN - O
for ADP - O
preparing VERB - O
, PUNCT - O
separating VERB - O
and CCONJ - O
isolating VERB - O
the DET - O
key ADJ - O
intermediates NOUN - O
involved VERB - O
in ADP - O
the DET - O
preparationof NOUN - O
Sertraline NNP - B-PRODUCT
Hydrochloride NNP - I-PRODUCT
polymorphic ADJ - O
form NOUN - O
II NNP - B-ORG
. PUNCT - O

The DET - O
present ADJ - O
invention NOUN - O
also ADV - O
further ADV - O
relates VERB - O
to ADP - O
the DET - O
use NOUN - O
of ADP - O
novel ADJ - O
reagents NOUN - O
or CCONJ - O
a DET - O
combination NOUN - O
thereof ADV - O
and CCONJ - O
new ADJ - O
methodologies NOUN - O
to PART - O
prepare VERB - O
some DET - O
o'f NOUN - O
the DET - O
key ADJ - O
intermediates NOUN - O
involved VERB - O
in ADP - O
the DET - O
preparation NOUN - O
of ADP - O
Polymorphic NNP - B-PRODUCT
Form NNP - I-PRODUCT
II NNP - I-PRODUCT
of ADP - O
Sertraline NNP - B-GPE
Hydrochloride NNP - I-GPE
. PUNCT - O

-DOCSTART- -X- - O

PREDNISOLONE JJ - B-MEDICINE
SODIUM NNP - I-MEDICINE
PHOSPHATE NNP - I-MEDICINE
FORMULATIONS NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

PREDNISOLONE JJ - B-MEDICINE
SODIUM NN - I-MEDICINE
PHOSPHATE JJ - I-MEDICINE
FORMULATIONS NOUN - O

-DOCSTART- -X- - O

STABILIZED PROPN - O
PREDNISOLONE NN - B-MEDICINE
SODIUM NN - I-MEDICINE
PHOSPHATE JJ - I-MEDICINE
SOLUTIONS NOUN - O

-DOCSTART- -X- - O

LIQUID NOUN - O
PREDNISOLONE NN - B-MEDICINE
SODIUM JJ - I-MEDICINE
PHOSPHATE JJ - I-MEDICINE
PREPARATION NOUN - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
is VERB - O
beneficial ADJ - O
in ADP - O
learning NOUN - O
and CCONJ - O
memory NOUN - O
, PUNCT - O
although ADP - O
the DET - O
underlying VERB - O
protective ADJ - O
mechanism NOUN - O
of ADP - O
testosterone NN - B-MEDICINE
on ADP - O
cognitive ADJ - O
performance NOUN - O
remains VERB - O
unclear ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
52-Week CD - B-CARDINAL
Study NOUN - O
of ADP - O
Dose PROPN - O
Adjusted VERB - O
Subcutaneous PROPN - O
Testosterone NNP - B-MEDICINE
Enanthate PROPN - O
in ADP - O
Oil PROPN - O
Self PROPN - O
- PUNCT - O
Administered VERB - O
via ADP - O
Disposable PROPN - O
Auto PROPN - O
- PUNCT - O
Injector PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Implementation NOUN - O
of ADP - O
a DT - B-ORG
Pilot NNP - I-ORG
Pharmacist NNP - I-ORG
Testosterone NNP - I-MEDICINE
Therapy NNP - I-ORG
Management NNP - I-ORG
Service NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
( PUNCT - O
17β NOUN - O
- PUNCT - O
Hydroxyandrost-4-en-3-one NOUN - O
) PUNCT - O
is VERB - O
the DET - O
main ADJ - O
sex NOUN - O
hormone NOUN - O
in ADP - O
males NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
in ADP - O
Males PROPN - O
as ADP - O
Enhanced VERB - O
by ADP - O
Onion PROPN - O
( PUNCT - O
Allium PROPN - O
Cepa PROPN - O
L. PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
activates VERB - O
singing VERB - O
within ADP - O
days NNS - B-DATE
in ADP - O
castrated VERB - O
male ADJ - O
songbirds NOUN - O
but CCONJ - O
full ADJ - O
song NOUN - O
quality NOUN - O
only ADV - O
develops VERB - O
after ADP - O
a DT - B-DATE
few JJ - I-DATE
weeks NNS - I-DATE
. PUNCT - O

Testosterone JJ - B-MEDICINE
action NOUN - O
in ADP - O
the DET - O
song NOUN - O
control NOUN - O
system NOUN - O
works VERB - O
in ADP - O
parallel VERB - O
to PART - O
control VERB - O
song NOUN - O
quality NOUN - O
. PUNCT - O

Testosterone NNP - B-MEDICINE
- PUNCT - O
treated VERB - O
females NOUN - O
from ADP - O
a DET - O
previous ADJ - O
experiment NOUN - O
had VERB - O
a DET - O
smaller ADJ - O
POM NOUN - O
volume NOUN - O
in ADP - O
similar ADJ - O
conditions NOUN - O
suggesting VERB - O
the DET - O
existence NOUN - O
of ADP - O
a DET - O
stable ADJ - O
sex NOUN - O
difference NOUN - O
potentially ADV - O
affecting VERB - O
singing VERB - O
behavior NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
- PUNCT - O
treated VERB - O
trained VERB - O
rats NOUN - O
had VERB - O
significantly ADV - O
lower ADJ - O
claudin NOUN - O
levels NOUN - O
than ADP - O
vehicle NOUN - O
- PUNCT - O
treated VERB - O
trained VERB - O
rats NOUN - O
. PUNCT - O

Testosterone NNP - B-MEDICINE
treatment NOUN - O
did VERB - O
not ADV - O
exert VERB - O
a DET - O
significant ADJ - O
effect NOUN - O
on ADP - O
ZO-1 NNP - B-GPE
protein NOUN - O
levels NOUN - O
. PUNCT - O

Testosterone NNP - B-MEDICINE
and/or CCONJ - O
training NOUN - O
had VERB - O
no DET - O
significant ADJ - O
effects NOUN - O
on ADP - O
ZO-2 NNP - B-NORP
protein NOUN - O
levels NOUN - O
in ADP - O
the DET - O
rat NOUN - O
spinal ADJ - O
cords NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Hackett NNP - B-PERSON
G. NNP - I-PERSON
Metabolic NNP - I-PERSON
Effects NNP - I-PERSON
of ADP - O
Testosterone NNP - B-MEDICINE
Therapy PROPN - O
in ADP - O
Men PROPN - O
with ADP - O
Type NOUN - O
2 NUM - O
Diabetes PROPN - O
and CCONJ - O
Metabolic PROPN - O
Syndrome PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Metabolic NNP - B-ORG
Effects NNS - I-ORG
of IN - I-ORG
Testosterone NNP - I-MEDICINE
Therapy NNP - I-ORG
in ADP - O
Men PROPN - O
with ADP - O
Type NOUN - O
2 NUM - O
Diabetes PROPN - O
and CCONJ - O
Metabolic NNP - B-ORG
Syndrome NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
's PART - O
effects NOUN - O
were VERB - O
rapid ADJ - O
( PUNCT - O
~30 NOUN - O
min NOUN - O
after ADP - O
administration NOUN - O
) PUNCT - O
and CCONJ - O
mediated VERB - O
, PUNCT - O
in ADP - O
part NOUN - O
, PUNCT - O
by ADP - O
subjective ADJ - O
reward NOUN - O
associated VERB - O
with ADP - O
aggression NOUN - O
. PUNCT - O

Testosterone NNP - B-MEDICINE
thus ADV - O
appears VERB - O
to PART - O
promote VERB - O
human ADJ - O
aggression NOUN - O
through ADP - O
an DET - O
AR PROPN - O
- PUNCT - O
related VERB - O
mechanism NOUN - O
and CCONJ - O
to PART - O
have VERB - O
stronger ADJ - O
effects NOUN - O
in ADP - O
men NOUN - O
with ADP - O
the DET - O
select ADJ - O
personality NOUN - O
profiles NOUN - O
because ADP - O
it PRON - O
more ADV - O
strongly ADV - O
upregulates VERB - O
the DET - O
subjective ADJ - O
pleasure NOUN - O
they PRON - O
derive VERB - O
from ADP - O
aggression NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Using VERB - O
a DT - B-ORG
Psychopharmacogenetic JJ - I-ORG
Approach NNP - I-ORG
To PART - O
Identify VERB - O
the DET - O
Pathways PROPN - O
Through PROPN - O
Which PROPN - O
- PUNCT - O
and CCONJ - O
the DET - O
People PROPN - O
for ADP - O
Whom PROPN - O
- PUNCT - O
Testosterone NNP - B-MEDICINE
Promotes PROPN - O
Aggression PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
induced VERB - O
TECs NOUN - O
apoptosis NOUN - O
and CCONJ - O
necrosis NOUN - O
and CCONJ - O
increased VERB - O
BNIP3 PROPN - O
expression NOUN - O
in ADP - O
a DET - O
dose NOUN - O
- PUNCT - O
dependent ADJ - O
manner NOUN - O
. PUNCT - O

Testosterone NNP - B-MEDICINE
also ADV - O
increased VERB - O
Bax PROPN - O
expression NOUN - O
, PUNCT - O
decreased VERB - O
Bcl-2 ADJ - O
expression NOUN - O
and CCONJ - O
induced VERB - O
a DET - O
loss NOUN - O
of ADP - O
ΔΨm NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
induces VERB - O
renal ADJ - O
tubular ADJ - O
epithelial ADJ - O
cell NOUN - O
death NOUN - O
through ADP - O
the DET - O
HIF-1α NNP - B-ORG
/ SYM - I-ORG
BNIP3 NNP - I-ORG
pathway NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Risk NOUN - O
of ADP - O
Erythrocytosis NOUN - O
During ADP - O
Concomitant PROPN - O
Testosterone NNP - B-MEDICINE
and CCONJ - O
SGLT2-Inhibitor PROPN - O
Treatment PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

Letter NOUN - O
to ADP - O
the DET - O
Editor PROPN - O
: PUNCT - O
" PUNCT - O
Long PROPN - O
- PUNCT - O
Term PROPN - O
Testosterone NNP - B-MEDICINE
Administration PROPN - O
on ADP - O
Insulin PROPN - O
Sensitivity PROPN - O
in ADP - O
Older PROPN - O
Men NOUN - O
With ADP - O
Low ADJ - O
or CCONJ - O
Low PROPN - O
- PUNCT - O
Normal PROPN - O
Testosterone NNP - B-MEDICINE
Levels PROPN - O
" PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
and CCONJ - O
Benign NNP - B-FAC
Prostatic NNP - I-FAC
Hyperplasia NNP - I-FAC
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
and CCONJ - O
Benign NNP - B-ORG
Prostatic NNP - I-ORG
Hyperplasia NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
, PUNCT - O
testosterone NN - B-MEDICINE
therapy NOUN - O
and CCONJ - O
prostate NOUN - O
cancer NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
levels NOUN - O
in ADP - O
castrated VERB - O
patients NOUN - O
are VERB - O
therefore ADV - O
routinely ADV - O
measured VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Focus VERB - O
on ADP - O
Catabolic PROPN - O
/ SYM - O
anabolic PROPN - O
Interplay NNP - B-ORG
Between IN - I-ORG
Cortisol NNP - I-ORG
, PUNCT - O
Testosterone NNP - B-MEDICINE
, PUNCT - O
and CCONJ - O
Sex NN - B-FAC
Hormone NNP - I-FAC
Binding NNP - I-FAC
Globulin NNP - I-FAC
in ADP - O
Professional NNP - B-ORG
Athletes NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Optimal PROPN - O
Indication PROPN - O
for ADP - O
Testosterone NNP - B-MEDICINE
Replacement PROPN - O
Therapy PROPN - O
in ADP - O
Late PROPN - O
Onset PROPN - O
Hypogonadism PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Predictive PROPN - O
Factors PROPN - O
of ADP - O
Efficacy PROPN - O
Maintenance PROPN - O
after ADP - O
Testosterone NNP - B-MEDICINE
Treatment NNP - I-LAW
Cessation NNP - I-LAW
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
has VERB - O
effects NOUN - O
on ADP - O
many ADJ - O
organs NOUN - O
and CCONJ - O
systems NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
Replacement PROPN - O
Therapy PROPN - O
for ADP - O
Sexual ADJ - O
Symptoms NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
Replacement PROPN - O
Therapy PROPN - O
for ADP - O
Sexual ADJ - O
Symptoms NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
in ADP - O
Men NOUN - O
With ADP - O
Chronic PROPN - O
Hepatitis NNP - B-ORG
C NNP - I-ORG
Infection NNP - I-ORG
and CCONJ - O
After ADP - O
Hepatitis NNP - B-ORG
C NNP - I-ORG
Viral NNP - I-ORG
Clearance NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Testosterone JJ - B-MEDICINE
treatment NOUN - O
appears VERB - O
to PART - O
be VERB - O
effective ADJ - O
and CCONJ - O
efficacious ADJ - O
in ADP - O
reducing VERB - O
depressive ADJ - O
symptoms NOUN - O
in ADP - O
men NOUN - O
, PUNCT - O
particularly ADV - O
when ADV - O
higher ADJ - O
- PUNCT - O
dosage NOUN - O
regimens NOUN - O
were VERB - O
applied VERB - O
in ADP - O
carefully ADV - O
selected VERB - O
samples NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Association NNP - B-ORG
of IN - I-ORG
Testosterone NNP - I-MEDICINE
Treatment NNP - I-ORG

-DOCSTART- -X- - O

Testosterone JJ - B-MEDICINE
therapy NOUN - O
for ADP - O
women NOUN - O
is VERB - O
in ADP - O
widespread ADJ - O
use NOUN - O
, PUNCT - O
primarily ADV - O
in ADP - O
the DET - O
form NOUN - O
of ADP - O
compounded ADJ - O
preparations NOUN - O
and CCONJ - O
off ADP - O
- PUNCT - O
label NOUN - O
use NOUN - O
of ADP - O
formulations NOUN - O
for ADP - O
men NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
, PUNCT - O
cortisol NOUN - O
, PUNCT - O
and CCONJ - O
status NOUN - O
- PUNCT - O
striving VERB - O
personality NOUN - O
features NOUN - O
: PUNCT - O
A DET - O
review NOUN - O
and CCONJ - O
empirical ADJ - O
evaluation NOUN - O
of ADP - O
the DET - O
Dual NNP - B-GPE
Hormone NNP - I-GPE
hypothesis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NN - B-MEDICINE
- PUNCT - O
boosting VERB - O
supplements NOUN - O
( PUNCT - O
T NNP - B-ORG
- HYPH - I-ORG
Boosters NNP - I-ORG
) PUNCT - O
are VERB - O
prominently ADV - O
featured VERB - O
on ADP - O
Amazon.com NNP - B-ORG
, PUNCT - O
with ADP - O
numerous ADJ - O
dedicated ADJ - O
pages NOUN - O
and CCONJ - O
claims NOUN - O
that ADP - O
they PRON - O
" PUNCT - O
naturally ADV - O
" PUNCT - O
increase VERB - O
testosterone NN - B-MEDICINE
levels NOUN - O
. PUNCT - O

Testosterone NNP - B-MEDICINE
Imposters PROPN - O
: PUNCT - O
An DET - O
Analysis NOUN - O
of ADP - O
Popular PROPN - O
Online PROPN - O
Testosterone NNP - B-MEDICINE
Boosting PROPN - O
Supplements PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
Imposters PROPN - O
: PUNCT - O
An DET - O
Analysis NOUN - O
of ADP - O
Popular PROPN - O
Online PROPN - O
Testosterone NNP - B-MEDICINE
Boosting PROPN - O
Supplements PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
injection NOUN - O
to ADP - O
wild ADJ - O
type NOUN - O
mice NOUN - O
increased VERB - O
the DET - O
levels NOUN - O
of ADP - O
testosterone NN - B-MEDICINE
and CCONJ - O
Gas6 NNP - B-PERSON
in ADP - O
serum NOUN - O
and CCONJ - O
decreased VERB - O
cardiac ADJ - O
apoptosis NOUN - O
and CCONJ - O
fibrosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Response NOUN - O
to ADP - O
Letter PROPN - O
to ADP - O
the DET - O
Editor PROPN - O
: PUNCT - O
" PUNCT - O
Long PROPN - O
- PUNCT - O
Term PROPN - O
Testosterone NNP - B-MEDICINE
Administration PROPN - O
on ADP - O
Insulin PROPN - O
Sensitivity PROPN - O
in ADP - O
Older PROPN - O
Men NOUN - O
With ADP - O
Low ADJ - O
or CCONJ - O
Low PROPN - O
- PUNCT - O
Normal PROPN - O
Testosterone NNP - B-MEDICINE
Levels PROPN - O
" PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone JJ - B-MEDICINE
insufficiency NOUN - O
may VERB - O
play VERB - O
a DET - O
role NOUN - O
in ADP - O
age NOUN - O
- PUNCT - O
related VERB - O
decreases NOUN - O
in ADP - O
bone NOUN - O
mass ADJ - O
density NOUN - O
( PUNCT - O
BMD NNP - B-ORG
) PUNCT - O
and CCONJ - O
osteoporosis NOUN - O
in ADP - O
aging VERB - O
men NOUN - O
. PUNCT - O

Testosterone NN - B-MEDICINE
replacement NOUN - O
therapy NOUN - O
( PUNCT - O
T NOUN - O
therapy NOUN - O
) PUNCT - O
seems VERB - O
to PART - O
be VERB - O
a DET - O
simple ADJ - O
and CCONJ - O
convenient ADJ - O
way NOUN - O
to PART - O
increase VERB - O
BMD NNP - B-ORG
and CCONJ - O
improve VERB - O
the DET - O
condition NOUN - O
of ADP - O
osteoporosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
Replacement PROPN - O
Therapy PROPN - O
Has VERB - O
Limited PROPN - O
Effect NOUN - O
on ADP - O
Increasing VERB - O
Bone PROPN - O
Mass PROPN - O
Density PROPN - O
in ADP - O
Older PROPN - O
Men PROPN - O
: PUNCT - O
a DET - O
Meta PROPN - O
- PUNCT - O
analysis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Breast NNP - B-ORG
Cancer NNP - I-ORG
Development NNP - I-ORG
in ADP - O
a DET - O
Transgender NNP - B-ORG
Male NNP - I-ORG
Receiving VBG - I-ORG
Testosterone NNP - I-MEDICINE
Therapy NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Pubertal ADJ - O
Testosterone NNP - B-MEDICINE
Correlates PROPN - O
with ADP - O
Adolescent PROPN - O
Impatience PROPN - O
and CCONJ - O
Dorsal NNP - B-ORG
Striatal NNP - I-ORG
Activity NN - I-ORG

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
cypionate NOUN - O
and CCONJ - O
Stanozolol NNP - B-PERSON
are VERB - O
Anabolic NNP - B-PERSON
- HYPH - I-PERSON
Androgenic NNP - I-PERSON
Steroids PROPN - O
( PUNCT - O
AAS NNP - B-ORG
) PUNCT - O
which ADJ - O
are VERB - O
synthetic ADJ - O
substances NOUN - O
that ADJ - O
possess VERB - O
functions NOUN - O
similar ADJ - O
to PART - O
testosterone VB - B-MEDICINE
. PUNCT - O

Results NOUN - O
demonstrated VERB - O
that ADP - O
both DET - O
AAS NNP - B-ORG
changed VERB - O
significantly ADV - O
the DET - O
heart NOUN - O
morphology NOUN - O
: PUNCT - O
Testosterone NNP - B-MEDICINE
cypionate NOUN - O
led VERB - O
to ADP - O
an DET - O
increase NOUN - O
in ADP - O
the DET - O
ventricular ADJ - O
lumen NOUN - O
and CCONJ - O
stanozolol NOUN - O
increased VERB - O
left VERB - O
ventricle NOUN - O
myocardium NOUN - O
thickness NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
could VERB - O
mimic VERB - O
the DET - O
action NOUN - O
of ADP - O
LH NNP - B-ORG
on ADP - O
oocyte NOUN - O
maturation NOUN - O
, PUNCT - O
and CCONJ - O
its ADJ - O
action NOUN - O
appears VERB - O
to PART - O
be VERB - O
independent ADJ - O
of ADP - O
the DET - O
classical ADJ - O
nuclear ADJ - O
androgen NOUN - O
receptor NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
inhibits VERB - O
the DET - O
transcriptional ADJ - O
activation NOUN - O
of ADP - O
AMH NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Serum PROPN - O
Testosterone NNP - B-MEDICINE
Level PROPN - O
Within ADP - O
Normal PROPN - O
Range NOUN - O
Is VERB - O
Positively ADV - O
Associated VERB - O
with ADP - O
Nonalcoholic NNP - B-ORG
Fatty NNP - I-ORG
Liver NNP - I-ORG
Disease NNP - I-ORG
in ADP - O
Premenopausal NNP - B-GPE
but CCONJ - O
Not ADV - O
Postmenopausal PROPN - O
Women PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NN - B-MEDICINE
deficiency NOUN - O
can VERB - O
be VERB - O
the DET - O
reason NOUN - O
for ADP - O
such ADJ - O
failure NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Serum PROPN - O
Testosterone NNP - B-MEDICINE
Levels PROPN - O
and CCONJ - O
Prostate PROPN - O
Cancer PROPN - O
Risk NOUN - O
: PUNCT - O

A DET - O
Single PROPN - O
Post PROPN - O
- ADJ - O
Hoc PROPN - O
Testosterone NNP - B-MEDICINE
Measurement PROPN - O
is VERB - O
Not ADV - O
Informative ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
and CCONJ - O
the DET - O
monoamine ADJ - O
oxidase NOUN - O
- PUNCT - O

Testosterone NN - B-MEDICINE
and CCONJ - O
cortisol ADJ - O
levels NOUN - O
as ADV - O
well ADV - O
as ADP - O
subjective ADJ - O
anger NOUN - O
were VERB - O
assessed VERB - O
prior ADV - O
and CCONJ - O
after ADP - O
the DET - O
task NOUN - O
. PUNCT - O

Testosterone NNP - B-MEDICINE
administration NOUN - O
increased VERB - O
activation NOUN - O
in ADP - O
this DET - O
network NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
Replacement PROPN - O
Therapy PROPN - O
and CCONJ - O
Rehospitalization PROPN - O
in ADP - O
Older ADJ - O
Men PROPN - O
with ADP - O
Testosterone NNP - B-MEDICINE
Deficiency PROPN - O
in ADP - O
a DET - O
Post NNP - B-ORG
- JJ - I-ORG
Acute JJ - I-ORG
Care NNP - I-ORG
Setting NN - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Coenzyme NNP - B-ORG
Q10 NNP - I-ORG
Supplementation NNP - I-ORG
on IN - I-ORG
Testosterone NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
levels NOUN - O
were VERB - O
significantly ADV - O
higher ADJ - O
in ADP - O
adult NOUN - O
compared VERB - O
to PART - O
immature VERB - O
males NOUN - O
as ADP - O
measured VERB - O
by ADP - O
LC PROPN - O
- PUNCT - O
MS PROPN - O
but CCONJ - O
not ADV - O
as ADP - O
measured VERB - O
by ADP - O
EIA NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
was VERB - O
significantly ADV - O
lower ADJ - O
than ADP - O
BL NNP - B-GPE
at ADP - O
1 CD - B-MONEY
d CD - I-MONEY
( PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
confidence NOUN - O
interval NOUN - O
[ PUNCT - O
CI NNP - B-ORG
] PUNCT - O
0.10 CD - B-CARDINAL
- SYM - O
0.34 NUM - O
, PUNCT - O
P NOUN - O
  SPACE - O
< X - O
  SPACE - O

-DOCSTART- -X- - O

Testosterone JJ - B-MEDICINE
replacement NOUN - O
in ADP - O
castrated VERB - O
males NOUN - O
restored VERB - O
Ang NNP - B-PERSON
II NNP - I-PERSON
- PUNCT - O
induced VERB - O
hypertensive ADJ - O
responses NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
plays VERB - O
a DET - O
permissive ADJ - O
role NOUN - O
in ADP - O
angiotensin NOUN - O
II NNP - B-ORG
- PUNCT - O
induced VERB - O
hypertension NOUN - O
and CCONJ - O
cardiac ADJ - O
hypertrophy NOUN - O
in ADP - O
male ADJ - O
rats NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone JJ - B-MEDICINE
to PART - O
cortisol VERB - O
ratio NOUN - O
and CCONJ - O
aggression NOUN - O
toward ADP - O
one PRON - O
's PART - O
partner NOUN - O
: PUNCT - O
Evidence NOUN - O
for ADP - O
moderation NOUN - O
by ADP - O
provocation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Early ADJ - O
Pubertal PROPN - O
Timing PROPN - O
and CCONJ - O
Testosterone NNP - B-MEDICINE
Associated PROPN - O
With ADP - O
Higher PROPN - O
Levels PROPN - O
of ADP - O
Adolescent PROPN - O
Depression PROPN - O
in ADP - O
Girls PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NN - B-MEDICINE
and CCONJ - O
cortisol NOUN - O
modulate VERB - O
the DET - O
effects NOUN - O
of ADP - O
empathy NOUN - O
on ADP - O
aggression NOUN - O
in ADP - O
children NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
and CCONJ - O
its ADJ - O
binding VERB - O
protein NOUN - O
sex NOUN - O
hormone NOUN - O
- PUNCT - O
binding VERB - O
globulin NOUN - O
have VERB - O
been VERB - O
associated VERB - O
with ADP - O
cardiovascular ADJ - O
disease NOUN - O
and CCONJ - O
dysglycaemia NOUN - O
. PUNCT - O

Testosterone NN - B-MEDICINE
and CCONJ - O
sex NOUN - O
hormone NOUN - O
- PUNCT - O
binding VERB - O
globulin NOUN - O
were VERB - O
measured VERB - O
at ADP - O
baseline NOUN - O
and CCONJ - O
used VERB - O
to PART - O
estimate VERB - O
free ADJ - O
testosterone NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
, PUNCT - O
sex NOUN - O
hormone NOUN - O
- PUNCT - O
binding VERB - O
globulin NOUN - O
and CCONJ - O
risk NOUN - O
of ADP - O
cardiovascular ADJ - O
events NOUN - O
: PUNCT - O
A DET - O
report NOUN - O
from ADP - O
the DT - B-ORG
Outcome NNP - I-ORG
Reduction NNP - I-ORG
with ADP - O
an DET - O
Initial NNP - B-ORG
Glargine NNP - I-ORG
Intervention NNP - I-ORG
trial NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
promotes VERB - O
anxiolytic ADJ - O
- PUNCT - O
like ADJ - O
behavior NOUN - O
in ADP - O
gonadectomized VERB - O
male ADJ - O
rats NOUN - O
via ADP - O
blockade NOUN - O
of ADP - O
the DET - O
5-HT1A NNP - B-ORG
receptors NOUN - O
" PUNCT - O
[ PUNCT - O
GCE PROPN - O
Vol PROPN - O
254 NUM - O
( PUNCT - O
1 NUM - O
December NNP - B-DATE
2017)14 CD - I-DATE
- SYM - I-DATE
21]. CD - I-DATE

-DOCSTART- -X- - O

Testosterone JJ - B-MEDICINE
levels NOUN - O
were VERB - O
negatively ADV - O
correlated VERB - O
with ADP - O
cortisol ADJ - O
levels NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
administration NOUN - O
to ADP - O
prepubertal ADJ - O
males NOUN - O
led VERB - O
to ADP - O
a DET - O
higher ADJ - O
body NOUN - O
mass NOUN - O
and CCONJ - O
greater ADJ - O
expression NOUN - O
of ADP - O
Bip NNP - B-GPE
, PUNCT - O
Ire1α NNP - B-ORG
, PUNCT - O
Atf4 NNP - B-PRODUCT
and CCONJ - O
Xbp1s NNP - B-PRODUCT
in ADP - O
the DET - O
liver NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
affects VERB - O
insulin NOUN - O
resistance NOUN - O
, PUNCT - O
but CCONJ - O
the DET - O
effect NOUN - O
of ADP - O
testosterone NN - B-MEDICINE
treatment NOUN - O
on ADP - O
type NOUN - O
2 CD - B-CARDINAL
diabetes NOUN - O
( PUNCT - O
T2D NNP - B-ORG
) PUNCT - O
remains VERB - O
controversial ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
has VERB - O
been VERB - O
associated VERB - O
with ADP - O
MDD NNP - B-ORG
and CCONJ - O
metabolic NOUN - O
syndrome NOUN - O
( PUNCT - O
MetS PROPN - O
) PUNCT - O
in ADP - O
men NOUN - O
, PUNCT - O
although ADP - O
associations NOUN - O
in ADP - O
women NOUN - O
are VERB - O
less ADV - O
clear ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
( PUNCT - O
T NOUN - O
) PUNCT - O
has VERB - O
been VERB - O
suggested VERB - O
as ADP - O
a DET - O
promising ADJ - O
agent NOUN - O
in ADP - O
the DET - O
bone NOUN - O
osteointegration NOUN - O
when ADV - O
incorporated VERB - O
in ADP - O
a DET - O
bioceramic ADJ - O
/ SYM - O
polymer ADJ - O
combination NOUN - O
for ADP - O
the DET - O
local ADJ - O
application NOUN - O
. PUNCT - O

Testosterone NNP - B-MEDICINE
was VERB - O
successfully ADV - O
incorporated VERB - O
and CCONJ - O
composites NOUN - O
showed VERB - O
a DET - O
homogeneously ADV - O
distributed VERB - O
porous ADJ - O
structure NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
improves VERB - O
the DET - O
osteogenic ADJ - O
potential NOUN - O
of ADP - O
a DET - O
composite ADJ - O
in X - O
vitro NOUN - O
and CCONJ - O
in ADP - O
vivo NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
( PUNCT - O
5 CD - B-CARDINAL
and CCONJ - O
10 CD - B-QUANTITY
mg NN - I-QUANTITY
/ SYM - I-QUANTITY
kg NNS - I-QUANTITY
) PUNCT - O
or CCONJ - O
control NOUN - O
oil NOUN - O
was VERB - O
administered VERB - O
to ADP - O
AAA PROPN - O
- PUNCT - O
induced VERB - O
mice NOUN - O
with ADP - O
castration NOUN - O
for ADP - O
8 CD - B-DATE
weeks NNS - I-DATE
. PUNCT - O

Testosterone NNP - B-MEDICINE
administration NOUN - O
significantly ADV - O
prevent VERB - O
AAA NNP - B-ORG
formation NOUN - O
. PUNCT - O

Testosterone NNP - B-MEDICINE
administration NOUN - O
significantly ADV - O
inhibited VERB - O
expression NOUN - O
of ADP - O
inflammatory ADJ - O
cytokines NOUN - O
including VERB - O
IL-6 PROPN - O
, PUNCT - O
IL-1b PROPN - O
in ADP - O
aorta NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
has VERB - O
been VERB - O
explored VERB - O
for ADP - O
treating VERB - O
postmenopausal NOUN - O
symptoms NOUN - O
, PUNCT - O
such ADJ - O
as ADP - O
vaginal ADJ - O
atrophy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ex NNP - B-ORG
Vivo NNP - I-ORG
Evaluation NN - I-ORG
of IN - I-ORG
Intravaginal NNP - I-ORG
Progesterone NNP - I-ORG
and CCONJ - O
Testosterone NNP - B-MEDICINE
to TO - I-WORK_OF_ART
Treat VB - I-WORK_OF_ART
the DT - I-WORK_OF_ART
Luteal NNP - I-WORK_OF_ART
- PUNCT - O
phase NOUN - O
Deficiency NNP - B-NORP
and CCONJ - O
Vaginal PROPN - O
Atrophy PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Long PROPN - O
- PUNCT - O
Term PROPN - O
Testosterone NNP - B-MEDICINE
Supplementation PROPN - O
in ADP - O
Older PROPN - O
Men PROPN - O
Attenuates PROPN - O
Age NOUN - O
- PUNCT - O
Related VERB - O
Decline PROPN - O
in ADP - O
Aerobic NNP - B-GPE
Capacity NNP - I-GPE
. PUNCT - O

-DOCSTART- -X- - O

Does VERB - O
Transdermal PROPN - O
Testosterone NNP - B-MEDICINE
Increase VERB - O
the DET - O
Risk NOUN - O
of ADP - O
Developing VERB - O
Breast PROPN - O
Cancer PROPN - O
? PUNCT - O

-DOCSTART- -X- - O

Low ADJ - O
- PUNCT - O
Dose NOUN - O
Testosterone NNP - B-MEDICINE
and CCONJ - O
Evoked PROPN - O
Resistance PROPN - O
Exercise PROPN - O
after ADP - O
Spinal NNP - B-PERSON
Cord NNP - I-PERSON
Injury NNP - I-PERSON
[ PUNCT - O
TEREX NNP - B-WORK_OF_ART
- HYPH - I-WORK_OF_ART
SCI NNP - I-WORK_OF_ART
] -RRB- - I-WORK_OF_ART
on IN - I-WORK_OF_ART
Cardio PROPN - O
- PUNCT - O
metabolic PROPN - O
Risk NNP - B-ORG
Factors NNPS - I-ORG
: PUNCT - O
An DET - O
open ADJ - O
- PUNCT - O
label NOUN - O
randomized VERB - O
clinical ADJ - O
trial NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Re ADP - O
: PUNCT - O
Testosterone NNP - B-MEDICINE
Therapy PROPN - O
in ADP - O
Men PROPN - O
with ADP - O
Hypogonadism PROPN - O
: PUNCT - O
An PROPN - O
Endocrine PROPN - O
Society PROPN - O
Clinical PROPN - O
Practice PROPN - O
Guideline PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Methods NOUN - O
and CCONJ - O
results NOUN - O
: PUNCT - O
Testosterone NNP - B-MEDICINE
and CCONJ - O
oestradiol NOUN - O
concentrations NOUN - O
were VERB - O
determined VERB - O
in ADP - O
blood NOUN - O
samples NOUN - O
of ADP - O
611 CD - B-CARDINAL
male NOUN - O
carotid NOUN - O
endarterectomy NOUN - O
patients NOUN - O
included VERB - O
in ADP - O
the DT - B-ORG
Athero NNP - I-ORG
- HYPH - I-ORG
Express NNP - I-ORG
Biobank NNP - I-ORG
Study NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Testosterone VB - B-MEDICINE
to PART - O
oestradiol VERB - O
ratio NOUN - O
reflects VERB - O
systemic ADJ - O
and CCONJ - O
plaque ADJ - O
inflammation NOUN - O
and CCONJ - O
predicts VERB - O
future ADJ - O
cardiovascular ADJ - O
events NOUN - O
in ADP - O
men NOUN - O
with ADP - O
severe ADJ - O
atherosclerosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
Profiles PROPN - O
After ADP - O
Brachytherapy NOUN - O
for ADP - O
Localized PROPN - O
Prostate PROPN - O
Cancer PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Ethylene NOUN - O
dimethane NOUN - O
sulfonate NOUN - O
( PUNCT - O
EDS NNP - B-ORG
) PUNCT - O
ablation NOUN - O
of ADP - O
Leydig NNP - B-GPE
cells NOUN - O
in ADP - O
adult NOUN - O
rat NOUN - O
depletes NOUN - O
testosterone VBP - B-MEDICINE
resulting VERB - O
in ADP - O
epididymal ADJ - O
sperm NOUN - O
granuloma NOUN - O
: PUNCT - O
Testosterone NNP - B-MEDICINE
replacement NOUN - O
prevents VERB - O
granuloma NOUN - O
formation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NN - B-MEDICINE
, PUNCT - O
risk NOUN - O
, PUNCT - O
and CCONJ - O
socioeconomic ADJ - O
position NOUN - O
in ADP - O
British JJ - B-NORP
men NOUN - O
: PUNCT - O
Exploring VERB - O
causal ADJ - O
directionality NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
Levels PROPN - O
in ADP - O
Women PROPN - O
: PUNCT - O
Implications NOUN - O
for ADP - O
Fatty NNP - B-PERSON
Liver NNP - I-PERSON
and CCONJ - O
Beyond NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
levels NOUN - O
were VERB - O
elevated ADJ - O
in ADP - O
4/5 CD - B-CARDINAL
patients NOUN - O
associated VERB - O
with ADP - O
normal ADJ - O
prepubertal ADJ - O
gonadotropin NOUN - O
levels NOUN - O
and CCONJ - O
adrenal ADJ - O
androgen NOUN - O
precursors NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Premature PROPN - O
Pubarche PROPN - O
due ADP - O
to ADP - O
Exogenous PROPN - O
Testosterone NNP - B-MEDICINE
Gel PROPN - O
or CCONJ - O
Intense PROPN - O
Diaper PROPN - O
Rash PROPN - O
Prevention PROPN - O
Cream PROPN - O
Use PROPN - O
: PUNCT - O
A DET - O
Case PROPN - O
Series PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
had VERB - O
highest ADJ - O
positive ADJ - O
correlation NOUN - O
with ADP - O
testicular ADJ - O
length NOUN - O
followed VERB - O
by ADP - O
testicular ADJ - O
width NOUN - O
, PUNCT - O
length NOUN - O
, PUNCT - O
body NOUN - O
weight NOUN - O
and CCONJ - O
scrotal NOUN - O
circumference NOUN - O
, PUNCT - O
mass ADJ - O
activity NOUN - O
, PUNCT - O
live ADJ - O
sperm NOUN - O
count NOUN - O
, PUNCT - O
initial ADJ - O
motility NOUN - O
, PUNCT - O
while ADP - O
it PRON - O
had VERB - O
highest ADJ - O
negative ADJ - O
correlation NOUN - O
with ADP - O
dead ADJ - O
and CCONJ - O
abnormal ADJ - O
sperm NOUN - O
count NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Sleep PROPN - O
and CCONJ - O
Salivary PROPN - O
Testosterone NNP - B-MEDICINE
and CCONJ - O
Cortisol PROPN - O
During ADP - O
a DET - O
Short PROPN - O
Preseason PROPN - O
Camp PROPN - O
: PUNCT - O
A DET - O
Study NOUN - O
in ADP - O
Professional NNP - B-ORG
Rugby NNP - I-ORG
Union NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Testosterone JJ - B-MEDICINE
therapy NOUN - O
seems VERB - O
promising VERB - O
to PART - O
improve VERB - O
the DET - O
success NOUN - O
at ADP - O
IVF NNP - B-ORG
in ADP - O
POR PROPN - O
patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone JJ - B-MEDICINE
therapy NOUN - O
for ADP - O
women NOUN - O
with ADP - O
poor ADJ - O
ovarian ADJ - O
response NOUN - O
undergoing VERB - O
IVF NNP - B-ORG
: PUNCT - O
a DET - O
meta ADJ - O
- PUNCT - O
analysis NOUN - O
of ADP - O
randomized VERB - O
controlled VERB - O
trials NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Are VERB - O
Both DET - O
Effective ADJ - O
in ADP - O
Restoring VBG - B-GPE
Testosterone NNP - I-MEDICINE
in ADP - O
Hypogonadism PROPN - O
: PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
disruptor NOUN - O
effect NOUN - O
and CCONJ - O
gut NOUN - O
microbiome ADJ - O
perturbation NOUN - O
in ADP - O
mice NOUN - O
: PUNCT - O
Early ADJ - O
life NOUN - O
exposure NOUN - O
to ADP - O
doxycycline NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Exogenous ADJ - O
Testosterone NNP - B-MEDICINE
Increases PROPN - O
Decoy PROPN - O
Effect PROPN - O
in ADP - O
Healthy PROPN - O
Males PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Ginger PROPN - O
and CCONJ - O
Testosterone NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
is VERB - O
important ADJ - O
for ADP - O
the DET - O
development NOUN - O
of ADP - O
secondary ADJ - O
sexual ADJ - O
characteristics NOUN - O
in ADP - O
female NOUN - O
- PUNCT - O
to ADP - O
- PUNCT - O
male ADJ - O
transsexuals NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
The DT - B-WORK_OF_ART
Role NNP - I-WORK_OF_ART
of IN - I-WORK_OF_ART
Testosterone NNP - I-MEDICINE
in IN - I-WORK_OF_ART
The DT - I-WORK_OF_ART
Improvement NN - I-WORK_OF_ART
of IN - I-WORK_OF_ART
Sexual JJ - I-WORK_OF_ART
Desire NNP - I-WORK_OF_ART
in IN - I-WORK_OF_ART
Postmenopausal NNP - I-WORK_OF_ART
Women NNP - I-WORK_OF_ART
: PUNCT - O
An DET - O
Evidence NOUN - O
- PUNCT - O
Based VERB - O
Clinical PROPN - O
Review]. PROPN - O

-DOCSTART- -X- - O

Testosterone JJ - B-MEDICINE
supplementation NOUN - O
did VERB - O
not ADV - O
increase VERB - O
hatchling VERB - O
body NOUN - O
growth NOUN - O
, PUNCT - O
did VERB - O
not ADV - O
result VERB - O
in ADP - O
the DET - O
overproduction NOUN - O
of ADP - O
pro ADJ - O
- ADJ - O
oxidant ADJ - O
molecules NOUN - O
nor CCONJ - O
a DET - O
reduction NOUN - O
of ADP - O
antioxidant NOUN - O
capacity NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Hyperandrogenism NOUN - O
in ADP - O
a DT - B-ORG
Postmenopausal NNP - I-ORG
Woman NN - I-ORG
Secondary JJ - I-ORG
to ADP - O
Testosterone NNP - B-MEDICINE
Secreting NNP - I-ORG
Ovarian NNP - I-ORG
Stromal NNP - I-ORG
Tumor NNP - I-ORG
with ADP - O
Acoustic NNP - B-PERSON
Schwannoma NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Testosterone JJ - B-MEDICINE
replacement NOUN - O
in ADP - O
androgen NOUN - O
insensitivity NOUN - O
: PUNCT - O
is VERB - O
there ADV - O
an DET - O
advantage NOUN - O
? PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
has VERB - O
a DET - O
variety NOUN - O
of ADP - O
functions NOUN - O
and CCONJ - O
is VERB - O
commonly ADV - O
used VERB - O
in ADP - O
older ADJ - O
men NOUN - O
to PART - O
treat VERB - O
symptoms NOUN - O
of ADP - O
hypogonadism NOUN - O
, PUNCT - O
such ADJ - O
as ADP - O
decreased VERB - O
libido VERB - O
, PUNCT - O
decreased VERB - O
mood NOUN - O
and CCONJ - O
erectile NOUN - O
dysfunction NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
Is VERB - O
a DET - O
Contraceptive PROPN - O
and CCONJ - O
Should VERB - O
Not ADV - O
Be VERB - O
Used VERB - O
in ADP - O
Men NOUN - O
Who NOUN - O
Desire PROPN - O
Fertility PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
is VERB - O
a DET - O
nuclear ADJ - O
androgen NOUN - O
receptor NOUN - O
ligand NOUN - O
that ADJ - O
controls VERB - O
multiple ADJ - O
pathways NOUN - O
in ADP - O
brain NOUN - O
. PUNCT - O

Testosterone NNP - B-MEDICINE
and CCONJ - O
its ADJ - O
level NOUN - O
must VERB - O
be VERB - O
regulated VERB - O
in ADP - O
brain NOUN - O
; PUNCT - O
because ADP - O
, PUNCT - O
it PRON - O
directly ADV - O
and CCONJ - O
indirectly ADV - O
affects VERB - O
memory NOUN - O
and CCONJ - O
several ADJ - O
key ADJ - O
behavioral ADJ - O
characteristics NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
is VERB - O
an DET - O
essential ADJ - O
hormone NOUN - O
to PART - O
maintain VERB - O
bone NOUN - O
integrity NOUN - O
; PUNCT - O
however ADV - O
, PUNCT - O
the DET - O
effect NOUN - O
of ADP - O
aromatase NOUN - O
enzyme ADJ - O
in ADP - O
androgen NOUN - O
- PUNCT - O
induced VERB - O
bone NOUN - O
maintenance NOUN - O
remains VERB - O
somewhat ADV - O
unclear ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
and CCONJ - O
Proactive NNP - B-ORG
- HYPH - I-ORG
Reactive NNP - I-ORG
Aggression NNP - I-ORG
in ADP - O
Youth PROPN - O
: PUNCT - O
the DT - B-FAC
Moderating NNP - I-FAC
Role NN - I-FAC
of IN - I-FAC
Harsh NNP - I-FAC
Discipline NNP - I-FAC
. PUNCT - O

-DOCSTART- -X- - O

Case NOUN - O
Study NOUN - O
: PUNCT - O
Absorption NOUN - O
of ADP - O
Testosterone NNP - B-MEDICINE
Cream PROPN - O
via ADP - O
Scrotal PROPN - O
Delivery PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
is VERB - O
implicated VERB - O
as ADP - O
a DET - O
potential ADJ - O
contributing VERB - O
factor NOUN - O
to ADP - O
heat NOUN - O
- PUNCT - O
induced VERB - O
injury NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
mediates VERB - O
hyperthermic ADJ - O
response NOUN - O
of ADP - O
mice NOUN - O
to ADP - O
heat NOUN - O
exposure NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone JJ - B-MEDICINE
production NOUN - O
and CCONJ - O
steroidogenic ADJ - O
enzyme ADJ - O
expression NOUN - O
were VERB - O
not ADV - O
altered VERB - O
in ADP - O
GATA4 NNP - B-GPE
S261A PROPN - O
males NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Anti JJ - B-NORP
- JJ - I-NORP
Müllerian JJ - I-NORP
Hormone NNP - B-GPE
as ADP - O
a DET - O
Diagnostic PROPN - O
Marker PROPN - O
in ADP - O
Egyptian NNP - B-NORP
Infertile PROPN - O
Polycystic PROPN - O
Ovary PROPN - O
Syndrome PROPN - O
Females PROPN - O
: PUNCT - O
Correlations NOUN - O
with ADP - O
Vitamin NN - B-PERSON
D NNP - I-PERSON
, PUNCT - O
Total PROPN - O
Testosterone NNP - B-MEDICINE
, PUNCT - O
Dyslipidemia NNP - B-PERSON
and CCONJ - O
Anthropometric PROPN - O
Parameters PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Impact NOUN - O
of ADP - O
Testosterone NNP - B-MEDICINE
on ADP - O
the DET - O
Chests PROPN - O
and CCONJ - O
Abdomens PROPN - O
of ADP - O
Transgender PROPN - O
Men PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-ORG
Physical NNP - I-ORG
Function NNP - I-ORG
Trial NNP - I-ORG
( PUNCT - O
PFT NNP - B-ORG
) PUNCT - O
was VERB - O
one CD - B-CARDINAL
of ADP - O
seven CD - B-CARDINAL
Testosterone NNP - B-MEDICINE
Trials PROPN - O
( PUNCT - O
TTrials PROPN - O
) PUNCT - O
, PUNCT - O
the DET - O
aim NOUN - O
of ADP - O
which ADJ - O
was VERB - O
to PART - O
assess VERB - O
the DET - O
effect NOUN - O
of ADP - O
testosterone NN - B-MEDICINE
on ADP - O
mobility NOUN - O
, PUNCT - O
self NOUN - O
- PUNCT - O
reported VERB - O
physical ADJ - O
function NOUN - O
, PUNCT - O
falls VERB - O
, PUNCT - O
and CCONJ - O
patient VERB - O
global ADJ - O
impression NOUN - O
- PUNCT - O
of ADP - O
- PUNCT - O
change NOUN - O
( PUNCT - O
PGIC PROPN - O
) PUNCT - O
in ADP - O
older ADJ - O
men NOUN - O
with ADP - O
low ADJ - O
testosterone NN - B-MEDICINE
concentrations NOUN - O
, PUNCT - O
self NOUN - O
- PUNCT - O
reported VERB - O
mobility NOUN - O
limitation NOUN - O
, PUNCT - O
and CCONJ - O
walking VERB - O
speed NOUN - O
of ADP - O
less ADJ - O
than ADP - O
1·2 CD - B-NORP
m NOUN - O
/ SYM - O
s NOUN - O
. PUNCT - O

Testosterone NNP - B-MEDICINE
- PUNCT - O
treated VERB - O
men NOUN - O
with ADP - O
baseline NOUN - O
walking VERB - O
speed NOUN - O
of ADP - O
1·2 CD - B-QUANTITY
m NN - I-QUANTITY
/ SYM - I-QUANTITY
s NOUN - O
or CCONJ - O
higher ADJ - O
had VERB - O
significantly ADV - O
greater ADJ - O
improvements NOUN - O
in ADP - O
6MWT NUM - O
distance NOUN - O
( PUNCT - O
treatment NOUN - O
effect NOUN - O
14·2 PROPN - O
m NOUN - O
, PUNCT - O
6·5 NUM - O
- SYM - O
21·9 PROPN - O
; PUNCT - O
p=0·0004 PROPN - O
) PUNCT - O
and CCONJ - O
PF10 NNP - B-ORG
( PUNCT - O
4·9 CD - B-CARDINAL
, PUNCT - O
2·2 CD - B-CARDINAL
- SYM - I-CARDINAL
7·7 CD - I-CARDINAL
; PUNCT - O
p=0·0005 PROPN - O
) PUNCT - O
than ADP - O
placebo NOUN - O
- PUNCT - O
treated VERB - O
men NOUN - O
. PUNCT - O

Testosterone NNP - B-MEDICINE
- PUNCT - O
treated VERB - O
men NOUN - O
reporting VERB - O
mobility NOUN - O
limitation NOUN - O
showed VERB - O
significantly ADV - O
more ADJ - O
improvement NOUN - O
in ADP - O
6MWT NUM - O
distance NOUN - O
( PUNCT - O
7·6 CD - B-QUANTITY
m CD - I-QUANTITY
, PUNCT - O
1·0 CD - B-DATE
- SYM - I-DATE
14·1 CD - I-DATE
; PUNCT - O
p=0·0237 PROPN - O
) PUNCT - O
and CCONJ - O
PF10 PROPN - O
( PUNCT - O
3·6 CD - B-CARDINAL
, PUNCT - O
1·3 NUM - O
- PUNCT - O
5·9 PROPN - O
; PUNCT - O
p=0·0018 NOUN - O
) PUNCT - O
than ADP - O
placebo NOUN - O
- PUNCT - O
treated VERB - O
men NOUN - O
. PUNCT - O

Testosterone NN - B-MEDICINE
therapy NOUN - O
consistently ADV - O
improved VERB - O
self NOUN - O
- PUNCT - O
reported VERB - O
walking VERB - O
ability NOUN - O
, PUNCT - O
modestly ADV - O
improved VERB - O
6MWT CD - B-PRODUCT
distance NOUN - O
( PUNCT - O
across ADP - O
all DET - O
TTtrials NNS - B-NORP
participants NOUN - O
) PUNCT - O
, PUNCT - O
but CCONJ - O
did VERB - O
not ADV - O
affect VERB - O
falls VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
testosterone NN - B-MEDICINE
replacement NOUN - O
on ADP - O
measures NOUN - O
of ADP - O
mobility NOUN - O
in ADP - O
older ADJ - O
men NOUN - O
with ADP - O
mobility NOUN - O
limitation NOUN - O
and CCONJ - O
low ADJ - O
testosterone NN - B-MEDICINE
concentrations NOUN - O
: PUNCT - O
secondary ADJ - O
analyses NOUN - O
of ADP - O
the DT - B-ORG
Testosterone NNP - I-MEDICINE
Trials NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
assess VERB - O
the DET - O
impact NOUN - O
of ADP - O
systemic ADJ - O
comorbidities NOUN - O
on ADP - O
a DET - O
validated ADJ - O
health NOUN - O
phenotype NOUN - O
score NOUN - O
( PUNCT - O
ACTIONS PROPN - O
: PUNCT - O
Anxiety PROPN - O
, PUNCT - O
Cardiovascular PROPN - O
, PUNCT - O
Testosterone NNP - B-MEDICINE
, PUNCT - O
Insulin NNP - B-ORG
/ SYM - I-ORG
diabetes NN - I-ORG
, PUNCT - O
Obesity NNP - B-ORG
, PUNCT - O
Neurologic NNP - B-ORG
, PUNCT - O
Sleep NNP - B-NORP
apnea NOUN - O
) PUNCT - O
on ADP - O
outcomes NOUN - O
of ADP - O
transurethral ADJ - O
resection NOUN - O
of ADP - O
prostate NOUN - O
( PUNCT - O
TURP NNP - B-ORG
) PUNCT - O
for ADP - O
benign ADJ - O
prostatic ADJ - O
hyperplasia NOUN - O
( PUNCT - O
BPH PROPN - O
) PUNCT - O
for ADP - O
symptoms NOUN - O
and CCONJ - O
medication NOUN - O
discontinuation NOUN - O
. PUNCT - O

Comorbidities NOUN - O
of ADP - O
men NOUN - O
undergoing VERB - O
TURP PROPN - O
for ADP - O
BPH PROPN - O
from ADP - O
2004 CD - B-DATE
- SYM - I-DATE
15 CD - I-DATE
were VERB - O
assessed VERB - O
with ADP - O
the DET - O
validated VERB - O
ACTIONS PROPN - O
phenotype NOUN - O
totaling VERB - O
a DET - O
score NOUN - O
from ADP - O
0 CD - B-CARDINAL
- SYM - O
2 NUM - O
for ADP - O
each DET - O
domain NOUN - O
( PUNCT - O
Anxiety NNP - B-ORG
, , - I-ORG
Cardiovascular NNP - I-ORG
, PUNCT - O
Testosterone NNP - B-MEDICINE
, PUNCT - O
Insulin NNP - B-ORG
/ SYM - I-ORG
diabetes NN - I-ORG
, PUNCT - O
Obesity NNP - B-ORG
, PUNCT - O
Neurologic NNP - B-ORG
, PUNCT - O
Sleep NNP - B-NORP
apnea NOUN - O
) PUNCT - O
. PUNCT - O

Lower ADJ - O
scores NOUN - O
in ADP - O
Testosterone NNP - B-MEDICINE
( PUNCT - O
p=0.04 PROPN - O
) PUNCT - O
, PUNCT - O
Neurologic NNP - B-ORG
( PUNCT - O
p=0.003 PROPN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
Sleep NNP - B-NORP
apnea NOUN - O
( PUNCT - O
p=0.04 ADJ - O
) PUNCT - O
domains NOUN - O
were VERB - O
significantly ADV - O
associated VERB - O
with ADP - O
medication NOUN - O
discontinuation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
undecanoate ADJ - O
supplementation NOUN - O
together ADV - O
with ADP - O
human ADJ - O
chorionic ADJ - O
gonadotropin NOUN - O
does VERB - O
not ADV - O
impair VERB - O
spermatogenesis NOUN - O
in ADP - O
males NOUN - O
with ADP - O
isolated VERB - O
hypogonadotropic ADJ - O
hypogonadism NOUN - O
: PUNCT - O
a DET - O
retrospective ADJ - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Efficacy PROPN - O
and CCONJ - O
Safety PROPN - O
Profile PROPN - O
of ADP - O
Z-215 PROPN - O
( PUNCT - O
Azeloprazole PROPN - O
Sodium PROPN - O
) PUNCT - O
, PUNCT - O
a DET - O
Proton PROPN - O
Pump PROPN - O
Inhibitor PROPN - O
, PUNCT - O
Compared VERB - O
with ADP - O
Rabeprazole NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
in ADP - O
Patients PROPN - O
with ADP - O
Reflux PROPN - O
Esophagitis PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

Development PROPN - O
and CCONJ - O
Validation PROPN - O
of ADP - O
a DET - O
Stability PROPN - O
- PUNCT - O
Indicating PROPN - O
RP PROPN - O
- PUNCT - O
HPLC PROPN - O
Method PROPN - O
for ADP - O
the DT - B-ORG
Determination NNP - I-ORG
of IN - I-ORG
Process NNP - I-ORG
- HYPH - I-ORG
Related VBN - I-ORG
Impurities NNPS - I-ORG
and CC - I-ORG
Degradation NNP - I-ORG
Products NNPS - I-ORG
of IN - I-ORG
Rabeprazole NNP - I-ORG
Sodium NNP - I-ORG
in ADP - O
Pharmaceutical NNP - B-ORG
Formulation NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Our ADJ - O
efforts NOUN - O
led VERB - O
to ADP - O
the DET - O
discovery NOUN - O
of ADP - O
Rabeprazole NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
as ADP - O
the DET - O
most ADV - O
promising ADJ - O
hit NOUN - O
with ADP - O
an DET - O
IC50 PROPN - O
of ADP - O
4.47±0.44μM. PROPN - O

-DOCSTART- -X- - O

[ PUNCT - O
INSULIN NNP - B-ORG
GLARGINE NNP - I-ORG
300 CD - I-ORG
U PROPN - O
/ SYM - O
mL PROPN - O
( PUNCT - O
TOUJEO NNP - B-MEDICINE
® . - I-ORG

-DOCSTART- -X- - O

Fluconazole NN - B-MEDICINE
is VERB - O
a DET - O
commonly ADV - O
prescribed VERB - O
first JJ - B-ORDINAL
- PUNCT - O
generation NOUN - O
triazole ADJ - O
antifungal NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole JJ - B-MEDICINE
- PUNCT - O
non ADJ - O
- ADJ - O
susceptible ADJ - O
C. PROPN - O
parapsilosis NOUN - O
isolates NOUN - O
carrying VERB - O
the DET - O
novel ADJ - O
K143R NNP - B-PRODUCT
amino NOUN - O
acid NOUN - O
substitution NOUN - O
should VERB - O
be VERB - O
identified VERB - O
in ADP - O
clinical ADJ - O
microbiology NOUN - O
laboratories NOUN - O
to PART - O
prevent VERB - O
further ADJ - O
clonal ADJ - O
transmission NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Fluconazole NNP - B-MEDICINE
Coadministration PROPN - O
and CCONJ - O
CYP2C9 VBD - B-PERSON
Genetic NNP - I-PERSON
Polymorphism PROPN - O
on ADP - O
Siponimod PROPN - O
Pharmacokinetics PROPN - O
in ADP - O
Healthy NNP - B-PERSON
Subjects NNPS - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Evolution NOUN - O
of ADP - O
Fluconazole NNP - B-MEDICINE
- PUNCT - O
Resistant ADJ - O
Candida PROPN - O
albicans NOUN - O
Strains NNP - B-ORG
by IN - I-ORG
Drug NN - I-ORG
- HYPH - I-ORG
Induced NNP - I-ORG
Mating NNP - I-ORG
Competence NNP - I-ORG
and CC - I-ORG
Parasexual NNP - I-ORG
Recombination NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Reflexive PROPN - O
Laboratory PROPN - O
- PUNCT - O
Based VERB - O
Cryptococcal PROPN - O
Antigen PROPN - O
Screening PROPN - O
and CCONJ - O
Preemptive PROPN - O
Fluconazole NNP - B-MEDICINE
Therapy PROPN - O
for ADP - O
Cryptococcal PROPN - O
Antigenemia PROPN - O
in ADP - O
HIV PROPN - O
- PUNCT - O
Infected PROPN - O
Individuals PROPN - O

-DOCSTART- -X- - O

Fluconazole NN - B-MEDICINE
- PUNCT - O
loaded VERB - O
proniosomal ADJ - O
gels NOUN - O
were VERB - O
prepared VERB - O
by ADP - O
the DET - O
coacervation NOUN - O
phase NOUN - O
separation NOUN - O
method NOUN - O
using VERB - O
different ADJ - O
nonionic ADJ - O
surfactants NOUN - O
( PUNCT - O
spans NOUN - O
and CCONJ - O
tweens NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole NN - B-MEDICINE
- PUNCT - O
induced VERB - O
alopecia NOUN - O
is VERB - O
a DET - O
significant ADJ - O
problem NOUN - O
for ADP - O
patients NOUN - O
receiving VERB - O
long ADJ - O
- PUNCT - O
term NOUN - O
therapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Examination NOUN - O
of ADP - O
Fluconazole NNP - B-MEDICINE
- PUNCT - O
Induced VERB - O
Alopecia PROPN - O
in ADP - O
an DET - O
Animal PROPN - O
Model PROPN - O
and CCONJ - O
Human PROPN - O
Cohort PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole JJ - B-MEDICINE
resistance NOUN - O
was VERB - O
shown VERB - O
to PART - O
increase VERB - O
in ADP - O
biofilm NOUN - O
in ADP - O
a DET - O
time NOUN - O
- PUNCT - O
dependent ADJ - O
manner NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
group NOUN - O
of ADP - O
240 CD - B-CARDINAL
pityriasis NOUN - O
versicolor NOUN - O
patients NOUN - O
( PUNCT - O
confirmed VERB - O
with ADP - O
KOH NNP - B-ORG
and CCONJ - O
culture NOUN - O
) PUNCT - O
were VERB - O
classified VERB - O
into ADP - O
3 CD - B-CARDINAL
groups NOUN - O
: PUNCT - O
Fluconazole NNP - B-MEDICINE
300 CD - I-PRODUCT
mg PRP - I-PRODUCT
a DT - I-PRODUCT
week NN - I-PRODUCT
and CCONJ - O
2 CD - B-PERCENT
% NN - I-PERCENT
ketoconazole NOUN - O
foam NOUN - O
twice ADJ - O
a DET - O
week NOUN - O
for ADP - O
2 CD - B-DATE
weeks NNS - I-DATE
( PUNCT - O
Category NOUN - O
I NUM - O
) PUNCT - O
, PUNCT - O
Itraconazole NNP - B-PRODUCT
200 CD - I-PRODUCT
mg NOUN - O
daily ADV - O
for ADP - O
one CD - B-DATE
week NN - I-DATE
( PUNCT - O
category NOUN - O
II NNP - B-PERSON
) PUNCT - O
; PUNCT - O
Ketoconazole NNP - B-ORG
2 CD - I-ORG
% NN - I-ORG
foam NOUN - O
daily RB - B-DATE
for ADP - O
2 CD - B-DATE
weeks NNS - I-DATE
( PUNCT - O
Category NNP - B-PRODUCT
3 CD - I-PRODUCT
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole NNP - B-MEDICINE
was VERB - O
administered VERB - O
intravenously ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Impact NOUN - O
of ADP - O
Farnesol PROPN - O
as ADP - O
a DET - O
Modulator PROPN - O
of ADP - O
Efflux PROPN - O
Pumps PROPN - O
in ADP - O
a DET - O
Fluconazole NNP - B-MEDICINE
- PUNCT - O
Resistant PROPN - O
Strain PROPN - O
of ADP - O
Candida NNP - B-GPE
albicans NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole NNP - B-MEDICINE
, PUNCT - O
an DET - O
inhibitor NOUN - O
of ADP - O
1α CD - B-PERSON
- HYPH - I-PERSON
hydroxylase NN - I-PERSON
, PUNCT - O
was VERB - O
effective ADJ - O
in ADP - O
normalizing ADJ - O
calciuria NOUN - O
without ADP - O
decreasing VERB - O
glomerular ADJ - O
filtration NOUN - O
rate NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole NNP - B-MEDICINE
as ADP - O
a DET - O
New PROPN - O
Therapeutic ADJ - O
Tool NOUN - O
to PART - O
Manage VERB - O
Patients NOUN - O
With ADP - O
NPTIIc PROPN - O
( PUNCT - O
SLC34A3 PROPN - O
) PUNCT - O
Mutation NOUN - O
: PUNCT - O
A DET - O
Case PROPN - O
Report PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole NN - B-MEDICINE
is VERB - O
a DET - O
first JJ - B-ORDINAL
- PUNCT - O
generation NOUN - O
triazole NOUN - O
antifungal NOUN - O
used VERB - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
several ADJ - O
fungal ADJ - O
infections NOUN - O
including VERB - O
coccidioidomycosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Evaluation NOUN - O
of ADP - O
the DT - B-ORG
Long NNP - I-ORG
- HYPH - I-ORG
Term NNP - I-ORG
Tolerability NNP - I-ORG
and CCONJ - O
Efficacy PROPN - O
of ADP - O
Fluconazole NNP - B-MEDICINE
in ADP - O
Patients PROPN - O
With ADP - O
Coccidioidomycosis PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Impact NOUN - O
of ADP - O
Routine NNP - B-ORG
Cryptococcal NNP - I-ORG
Antigen NNP - I-ORG
Screening VBG - I-ORG
and CC - I-ORG
Targeted NNP - I-ORG
Preemptive NNP - I-ORG
Fluconazole NNP - I-MEDICINE
Therapy NNP - I-ORG
in ADP - O
Antiretroviral JJ - B-ORG
- HYPH - I-ORG
naive JJ - I-ORG
Human PROPN - O
Immunodeficiency PROPN - O
Virus PROPN - O
- PUNCT - O
infected VERB - O
Adults PROPN - O
With ADP - O
CD4 PROPN - O
Cell PROPN - O
Counts PROPN - O
< X - O
100/μL NUM - O
: PUNCT - O
A PROPN - O
Systematic PROPN - O
Review PROPN - O
and CCONJ - O
Meta PROPN - O
- PUNCT - O
analysis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole JJ - B-MEDICINE
MICs NOUN - O
were VERB - O
determined VERB - O
for ADP - O
all DET - O
Candida PROPN - O
isolates NOUN - O
. PUNCT - O

Fluconazole JJ - B-MEDICINE
prophylaxis NOUN - O
decreased VERB - O
Candida PROPN - O
albicans NOUN - O
and CCONJ - O
' PUNCT - O
non NOUN - O
- ADJ - O
albicans NOUN - O
' PART - O
Candida PROPN - O
colonization NOUN - O
and CCONJ - O
was VERB - O
associated VERB - O
with ADP - O
a DET - O
slightly ADV - O
higher ADJ - O
fluconazole JJ - B-MEDICINE
MIC NNP - B-ORG
for ADP - O
colonizing VERB - O
Candida PROPN - O
isolates NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole JJ - B-MEDICINE
efficacy NOUN - O
against ADP - O
two CD - B-CARDINAL
weakly ADV - O
( PUNCT - O
≤25 NN - B-PERCENT
% NN - I-PERCENT
growth NOUN - O
) PUNCT - O
, PUNCT - O
two CD - B-CARDINAL
moderately ADV - O
( PUNCT - O
26 CD - B-PERCENT
% NN - I-PERCENT
to TO - I-PERCENT
50 CD - I-PERCENT
% NN - I-PERCENT
growth NOUN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
one CD - B-CARDINAL
heavily ADV - O
( PUNCT - O
> X - O
70 CD - B-PERCENT
% NN - I-PERCENT
growth NOUN - O
) PUNCT - O
trailing VERB - O
resistant ADJ - O
isolate NOUN - O
and CCONJ - O
one CD - B-CARDINAL
resistant ADJ - O
( PUNCT - O
100 CD - B-PERCENT
% NN - I-PERCENT
growth NOUN - O
) PUNCT - O
isolate NOUN - O
were VERB - O
investigated VERB - O
in ADP - O
vitro NOUN - O
and CCONJ - O
in ADP - O
vivo NOUN - O
( PUNCT - O
in ADP - O
a DET - O
Galleria NNP - B-ORG
mellonella NOUN - O
survival NOUN - O
model NOUN - O
and CCONJ - O
two CD - B-CARDINAL
nonlethal ADJ - O
murine NOUN - O
models NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole JJ - B-MEDICINE
MICs NOUN - O
of ADP - O
microcolonies NOUN - O
were VERB - O
then ADV - O
determined VERB - O
over IN - B-CARDINAL
three CD - I-CARDINAL
generations NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Predictive ADJ - O
Model PROPN - O
for ADP - O
Fluconazole NNP - B-MEDICINE
Resistance PROPN - O
in ADP - O
Patient PROPN - O
With ADP - O
Candida PROPN - O
Bloodstream PROPN - O
Infection PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole NNP - B-MEDICINE
is VERB - O
a DET - O
broad ADJ - O
- PUNCT - O
spectrum NOUN - O
triazole ADJ - O
antifungal NOUN - O
that ADJ - O
is VERB - O
well ADV - O
- PUNCT - O
established VERB - O
as ADP - O
the DET - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
treatment NOUN - O
for ADP - O
Candida NNP - B-GPE
albicans NOUN - O
infections NOUN - O
. PUNCT - O

Fluconazole NNP - B-MEDICINE
was VERB - O
used VERB - O
at ADP - O
concentrations NOUN - O
of ADP - O
81.6 CD - B-CARDINAL
, PUNCT - O
163.2 CD - B-CARDINAL
, PUNCT - O
326.5 CD - B-CARDINAL
, PUNCT - O
653 CD - B-CARDINAL
, PUNCT - O
1306 CD - B-DATE
, PUNCT - O
and CCONJ - O
2612.1μM CD - B-CARDINAL
for ADP - O
the DET - O
MTT NNP - B-ORG
assay NOUN - O
and CCONJ - O
81.6 CD - B-CARDINAL
, PUNCT - O
326.5 CD - B-CARDINAL
, PUNCT - O
and CCONJ - O
1306μM NUM - O
for ADP - O
the DET - O
remaining VERB - O
assays NOUN - O
. PUNCT - O

Fluconazole NNP - B-MEDICINE
also ADV - O
induced VERB - O
necrosis NOUN - O
( PUNCT - O
P<0.05 NOUN - O
) PUNCT - O
in ADP - O
Vero NNP - B-PERSON
cell NOUN - O
line NOUN - O
when ADV - O
cells NOUN - O
were VERB - O
exposed VERB - O
to ADP - O
all DET - O
concentrations NOUN - O
( PUNCT - O
81.6 CD - B-CARDINAL
, PUNCT - O
326.5 CD - B-CARDINAL
, PUNCT - O
and CCONJ - O
1306μM NUM - O
) PUNCT - O
for ADP - O
both DET - O
tested VERB - O
harvest NOUN - O
times NOUN - O
( PUNCT - O
24 CD - B-CARDINAL
and CCONJ - O
48 CD - B-CARDINAL
  SPACE - O
h NOUN - O
) PUNCT - O
as ADP - O
compared VERB - O
with ADP - O
the DET - O
negative ADJ - O
control NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Cytotoxic NNP - B-ORG
and CCONJ - O
Genotoxic NNP - B-ORG
Effects NNS - I-ORG
of IN - I-ORG
Fluconazole NNP - I-MEDICINE
on ADP - O
African NNP - B-NORP
Green PROPN - O
Monkey PROPN - O
Kidney PROPN - O
( PUNCT - O
Vero PROPN - O
) PUNCT - O
Cell PROPN - O
Line PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

( PUNCT - O
1 LS - B-CARDINAL
) PUNCT - O
Background NOUN - O
: PUNCT - O
Fluconazole NNP - B-MEDICINE
, PUNCT - O
used VERB - O
orally ADV - O
for ADP - O
vaginal ADJ - O
candidiasis NOUN - O
, PUNCT - O
has VERB - O
reported VERB - O
gastrointestinal ADJ - O
side NOUN - O
effects NOUN - O
. PUNCT - O

Fluconazole JJ - B-MEDICINE
PEC NNP - B-ORG
based VERB - O
vaginal ADJ - O
inserts NOUN - O
were VERB - O
prepared VERB - O
by ADP - O
lyophilization NOUN - O
using VERB - O
mannitol NOUN - O
. PUNCT - O

( PUNCT - O
3 LS - B-CARDINAL
) PUNCT - O
Results NOUN - O
: PUNCT - O
Fluconazole JJ - B-MEDICINE
inserts NOUN - O
showed VERB - O
satisfactory ADJ - O
drug NOUN - O
content NOUN - O
, PUNCT - O
acceptable ADJ - O
friability NOUN - O
percentages NOUN - O
and CCONJ - O
highest ADJ - O
swelling VERB - O
indices NOUN - O
at ADP - O
six CD - B-TIME
hours NNS - I-TIME
. PUNCT - O

-DOCSTART- -X- - O

Optimized VERB - O
Chitosan NNP - B-ORG
/ SYM - I-ORG
Anion NNP - I-ORG
Polyelectrolyte NNP - I-ORG
Complex NNP - I-ORG
Based VBN - I-ORG
Inserts NNP - B-ORG
for IN - I-ORG
Vaginal NNP - I-ORG
Delivery NNP - I-ORG
of IN - I-ORG
Fluconazole NNP - I-MEDICINE
: PUNCT - O

-DOCSTART- -X- - O

Monitoring PROPN - O
of ADP - O
Fluconazole NNP - B-MEDICINE
and CCONJ - O
Caspofungin PROPN - O
Activity PROPN - O
against ADP - O
In ADP - O
Vivo NNS - B-GPE
Candida NNP - I-GPE
glabrata NOUN - O
Biofilms PROPN - O
by ADP - O
Bioluminescence NNP - B-ORG
Imaging NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Gold PROPN - O
Nanoparticles PROPN - O
Conjugation NOUN - O
Enhances NOUN - O
Antiacanthamoebic PROPN - O
Properties PROPN - O
of ADP - O
Nystatin PROPN - O
, PUNCT - O
Fluconazole NNP - B-MEDICINE
and CCONJ - O
Amphotericin PROPN - O
B. PROPN - O

-DOCSTART- -X- - O

curta VERB - O
with ADP - O
Resistance NNP - B-ORG
Reversal NNP - I-ORG
Activity NNP - I-ORG
against ADP - O
Fluconazole NNP - B-MEDICINE
- PUNCT - O
Resistant ADJ - O
Candida PROPN - O
albicans NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole JJ - B-MEDICINE
MICs NOUN - O
were VERB - O
> NUM - O
256 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
L PROPN - O
, PUNCT - O
while ADP - O
> X - O
60 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
voriconazole NOUN - O
MICs NOUN - O
were VERB - O
> X - O
1 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
L NOUN - O
by ADP - O
the DET - O
three CD - B-CARDINAL
methods NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Herpes NNP - B-ORG
Simplex NNP - I-ORG
- HYPH - I-ORG
Like NNP - I-ORG
Fixed VBN - B-ORG
Drug NNP - I-ORG
Eruption NN - I-ORG
Induced VBN - I-ORG
by IN - I-ORG
Fluconazole NNP - B-MEDICINE
Without ADP - O
Cross PROPN - O
- PUNCT - O
reactivity NOUN - O
to ADP - O
Itraconazole NNP - B-LOC
. PUNCT - O

-DOCSTART- -X- - O

CONTEXT NOUN - O
: PUNCT - O
Fluconazole NNP - B-MEDICINE
( PUNCT - O
FNZ NNP - B-ORG
) PUNCT - O
is VERB - O
a DET - O
drug NOUN - O
used VERB - O
in ADP - O
antifungal ADJ - O
therapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole JJ - B-MEDICINE
induces VERB - O
genotoxicity NOUN - O
in ADP - O
cultured VERB - O
human ADJ - O
peripheral ADJ - O
blood NOUN - O
mononuclear NOUN - O
cells NOUN - O
via ADP - O
immunomodulation NOUN - O
of ADP - O
TNF NNP - B-ORG
- HYPH - I-ORG
α NNP - I-ORG
, PUNCT - O
IL-6 PROPN - O
, PUNCT - O
and CCONJ - O
IL-10 PROPN - O
: PUNCT - O
new ADJ - O
challenges NOUN - O
for ADP - O
safe ADJ - O
therapeutic ADJ - O
regimens NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole NN - B-MEDICINE
- PUNCT - O
susceptible ADJ - O
, PUNCT - O
-susceptible ADJ - O
dose NOUN - O
- PUNCT - O
dependent ADJ - O
and CCONJ - O
-resistant ADJ - O
strains NOUN - O
accounted VERB - O
for ADP - O
76.7 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
389/507 PROPN - O
) PUNCT - O
, PUNCT - O
10.5 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
53/507 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O
12.8 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
65/507 NUM - O
) PUNCT - O
of ADP - O
C. NNP - B-ORG
  _SP - I-ORG
tropicalis NOUN - O
isolates VERB - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Transcriptomics PROPN - O
Approach PROPN - O
To ADP - O
Unveiling NNP - B-ORG
the DT - I-ORG
Mechanisms NNPS - I-ORG
of IN - I-ORG
In IN - I-ORG
Vitro NNP - I-ORG
Evolution NNP - I-ORG
towards ADP - O
Fluconazole NNP - B-MEDICINE
Resistance NNP - I-PERSON
of ADP - O
a DET - O
Candida NNP - B-NORP
glabrata NOUN - O
Clinical NNP - B-ORG
Isolate NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Treatment NOUN - O
of ADP - O
Renal JJ - B-ORG
Fungal NNP - I-ORG
Ball NNP - I-ORG
with ADP - O
Fluconazole NNP - B-MEDICINE
Instillation NNP - I-ORG
Through IN - I-ORG
a DT - I-ORG
Nephrostomy NNP - I-ORG
Tube NNP - I-ORG
: : - I-ORG
Case NNP - I-ORG
Report NNP - I-ORG
and CC - I-ORG
Literature NNP - I-ORG
Review NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole JJ - B-MEDICINE
resistance NOUN - O
is VERB - O
not ADV - O
a DET - O
predictor NOUN - O
of ADP - O
poor ADJ - O
outcome NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
cryptococcosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole NN - B-MEDICINE
- PUNCT - O
induced VERB - O
actin NOUN - O
cytoskeleton NOUN - O
remodeling NOUN - O
requires VERB - O
phosphatidylinositol NOUN - O
3-phosphate NUM - O
5-kinase NUM - O
in ADP - O
the DET - O
pathogenic ADJ - O
yeast NOUN - O
Candida PROPN - O
glabrata NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole NNP - B-MEDICINE
exerted VERB - O
better ADJ - O
antifungal ADJ - O
activity NOUN - O
in ADP - O
serum NOUN - O
than ADP - O
traditionally ADV - O
biofilm VERB - O
- PUNCT - O
active ADJ - O
antifungals NOUN - O
against ADP - O
both DET - O
examined VERB - O
biofilms NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole NNP - B-MEDICINE
is VERB - O
not ADV - O
inferior ADJ - O
than ADP - O
caspofungin NOUN - O
, PUNCT - O
micafungin ADJ - O
or CCONJ - O
amphotericin ADJ - O
B NOUN - O
in ADP - O
the DET - O
presence NOUN - O
of ADP - O
50 CD - B-PERCENT
% NN - I-PERCENT
human NOUN - O
serum NOUN - O
against ADP - O
Candida NNP - B-GPE
albicans NOUN - O
and CCONJ - O
Candida NNP - B-NORP
parapsilosis NOUN - O
biofilms NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole NN - B-MEDICINE
is VERB - O
the DET - O
most ADV - O
commonly ADV - O
used VERB - O
antifungal ADJ - O
treatment NOUN - O
for ADP - O
various ADJ - O
forms NOUN - O
of ADP - O
coccidioidomycosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole JJ - B-MEDICINE
- PUNCT - O
Resistant ADJ - O
Candida PROPN - O
parapsilosis NOUN - O
Bloodstream NNP - B-ORG
Isolates NNPS - I-ORG
with ADP - O
Y132F NNP - B-PERSON
Mutation NNP - I-PERSON
in ADP - O
ERG11 PROPN - O

-DOCSTART- -X- - O

Population NNP - B-ORG
Pharmacokinetics NNP - I-ORG
and CCONJ - O
Cerebrospinal NNP - B-ORG
Fluid NNP - I-ORG
Penetration NNP - I-ORG
of IN - I-ORG
Fluconazole NNP - I-MEDICINE
in ADP - O
Adults PROPN - O
with ADP - O
Cryptococcal PROPN - O
Meningitis PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole NN - B-MEDICINE
and CCONJ - O
amphotericin ADJ - O
B NOUN - O
are VERB - O
used VERB - O
as ADP - O
the DET - O
first JJ - B-ORDINAL
choice NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
invasive ADJ - O
fungal ADJ - O
infections NOUN - O
of ADP - O
the DET - O
newborns NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
isolates NOUN - O
made VERB - O
up PART - O
62.3 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
the DET - O
isolates NOUN - O
, PUNCT - O
while ADP - O
echinocanidin- ADJ - O
or CCONJ - O
multidrug NOUN - O
- PUNCT - O
resistant ADJ - O
isolates NOUN - O
were VERB - O
not ADV - O
found VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole NNP - B-MEDICINE
remains VERB - O
an DET - O
important ADJ - O
antifungal ADJ - O
agent NOUN - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
candidemia NOUN - O
, PUNCT - O
and CCONJ - O
data NOUN - O
supporting VERB - O
its ADJ - O
use NOUN - O
based VERB - O
on ADP - O
in ADP - O
vitro NOUN - O
susceptibility NOUN - O
are VERB - O
growing VERB - O
, PUNCT - O
particularly ADV - O
for ADP - O
C. NNP - B-ORG
albicans NOUN - O
and CCONJ - O
C. PROPN - O
glabrata NOUN - O

-DOCSTART- -X- - O

Oral PROPN - O
Coadministration PROPN - O
of ADP - O
Fluconazole NNP - B-MEDICINE
with ADP - O
Tramadol PROPN - O

-DOCSTART- -X- - O

Non JJ - B-ORG
- JJ - I-ORG
Toxic JJ - I-ORG
and CCONJ - O
Ultra NNP - B-ORG
- HYPH - I-ORG
Small JJ - I-ORG
Biosilver PROPN - O
Nanoclusters PROPN - O
Trigger PROPN - O
Apoptotic PROPN - O
Cell PROPN - O
Death PROPN - O
in ADP - O
Fluconazole NNP - B-MEDICINE
- PUNCT - O
Resistant ADJ - O
Candida PROPN - O
albicans NOUN - O
via ADP - O
Ras NNP - B-PERSON
Signaling NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole JJ - B-MEDICINE
susceptibility NOUN - O
testing NOUN - O
indicated VERB - O
that ADP - O
strains NOUN - O
overexpressing VERB - O
ECM22 NNP - B-NORP
could VERB - O
grow VERB - O
at ADP - O
20 CD - B-CARDINAL
  SPACE - O
μg(fluconazole PROPN - O
) PUNCT - O
  SPACE - O
ml-1 NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

, PUNCT - O
" PUNCT - O
Population NNP - B-ORG
Pharmacokinetics NNP - I-ORG
and CCONJ - O
Cerebrospinal NNP - B-ORG
Fluid NNP - I-ORG
Penetration NNP - I-ORG
of IN - I-ORG
Fluconazole NNP - I-MEDICINE
in ADP - O
Adults PROPN - O
with ADP - O
Cryptococcal PROPN - O
Meningitis PROPN - O
" PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole NNP - B-MEDICINE
appeared VERB - O
to PART - O
be VERB - O
the DET - O
best ADJ - O
drug NOUN - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
VVC NNP - B-ORG
according VERB - O
to ADP - O
our ADJ - O
analysis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole JJ - B-MEDICINE
and CCONJ - O
other ADJ - O
triazoles NOUN - O
displayed VERB - O
good ADJ - O
activity NOUN - O
against ADP - O
CNEO NN - B-ORG
whereas ADP - O
echinocandins NOUN - O
, PUNCT - O
including VERB - O
RZF NNP - B-ORG
, PUNCT - O
displayed VERB - O
limited ADJ - O
activity NOUN - O
against ADP - O
CNEO NNP - B-ORG
isolates VERB - O
( PUNCT - O
MIC90 NNP - B-GPE
> X - O
8 CD - B-CARDINAL
µg NOUN - O
/ SYM - O
mL PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole NNP - B-MEDICINE
also ADV - O
caused VERB - O
a DET - O
small ADJ - O
, PUNCT - O
but CCONJ - O
not ADV - O
clinically ADV - O
relevant ADJ - O
, PUNCT - O
decrease NOUN - O
in ADP - O
M1 NNP - B-GPE
and CCONJ - O
M2 NNP - B-ORG
mean VERB - O
Cmax PROPN - O
( PUNCT - O
13 CD - B-PERCENT
% NN - I-PERCENT
and CCONJ - O
14 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
respectively ADV - O
) PUNCT - O
, PUNCT - O
but CCONJ - O
there ADV - O
was VERB - O
minimal ADJ - O
change NOUN - O
in ADP - O
M1 NNP - B-GPE
and CCONJ - O
M2 NNP - B-GPE
mean VERB - O
AUC0-t PROPN - O
( PUNCT - O
3 CD - B-PERCENT
% NN - I-PERCENT
and CCONJ - O
2 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Fluconazole NNP - B-MEDICINE
on ADP - O
the DET - O
Pharmacokinetic PROPN - O
Properties PROPN - O
of ADP - O
Imrecoxib PROPN - O
, PUNCT - O
a DET - O
Novel PROPN - O
NSAID PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

Fluconazole JJ - B-MEDICINE
susceptibility NOUN - O
and CCONJ - O
resistant ADJ - O
rates NOUN - O
were VERB - O
74.1 CD - B-PERCENT
% NN - I-PERCENT
and CCONJ - O
9.7 CD - B-PERCENT
% NN - I-PERCENT
for ADP - O
C. PROPN - O
neoformans NOUN - O
and CCONJ - O
81.0 CD - B-PERCENT
% NN - I-PERCENT
and CCONJ - O
5.2 CD - B-PERCENT
% NN - I-PERCENT
for ADP - O
T. NNP - B-ORG
asahii NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole NNP - B-MEDICINE
is VERB - O
the DET - O
most ADV - O
commonly ADV - O
used VERB - O
agent NOUN - O
for ADP - O
Candida NNP - B-NORP
infections NOUN - O
. PUNCT - O

Fluconazole JJ - B-MEDICINE
- PUNCT - O
resistance NOUN - O
was VERB - O
observed VERB - O
in ADP - O
seven CD - B-CARDINAL
isolates NOUN - O
, PUNCT - O
entailing VERB - O
C. PROPN - O
albicans NOUN - O
( PUNCT - O
n CCONJ - O
  SPACE - O
= SYM - O
  SPACE - O
6 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O
C. NNP - B-PERSON
tropicalis PROPN - O
( PUNCT - O
n CCONJ - O
  SPACE - O
= SYM - O
  SPACE - O
1 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

Fluconazole JJ - B-MEDICINE
MIC NNP - B-ORG
for ADP - O
C. NNP - B-PERSON
lusitaniae NOUN - O
isolates NOUN - O
was VERB - O
above ADP - O
the DET - O
epidemiologic ADJ - O
cut VERB - O
- PUNCT - O
off PART - O
value NOUN - O
( PUNCT - O
4 CD - B-CARDINAL
- SYM - I-CARDINAL
16 CD - I-CARDINAL
  SPACE - O
μg PROPN - O
/ SYM - O
ml PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole JJ - B-MEDICINE
dosages NOUN - O
of ADP - O
100 CD - B-CARDINAL
- SYM - O
200 NUM - O
  SPACE - O
mg NOUN - O
daily RB - B-DATE
may VERB - O
ensure VERB - O
optimal ADJ - O
PTA NNS - B-ORG
against ADP - O
C. NNP - B-PRODUCT
albicans NOUN - O
, PUNCT - O
C. PROPN - O
parapsilosis NOUN - O
, PUNCT - O
and CCONJ - O
C. NNP - B-PERSON
tropicalis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Survival NOUN - O
in ADP - O
Patients PROPN - O
with ADP - O
Candida PROPN - O
glabrata NOUN - O
Bloodstream PROPN - O
Infection PROPN - O
Is VERB - O
Associated VERB - O
with ADP - O
Fluconazole NNP - B-MEDICINE
Dose PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole NNP - B-MEDICINE
remains VERB - O
the DET - O
most ADV - O
frequent ADJ - O
antifungal ADJ - O
prophylactic ADJ - O
agent NOUN - O
given VERB - O
to ADP - O
high ADJ - O
- PUNCT - O
risk NOUN - O
neonates NOUN - O
and CCONJ - O
children NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole JJ - B-MEDICINE
400 CD - B-CARDINAL
mg NOUN - O
daily ADV - O
was VERB - O
later ADV - O
added VERB - O
to PART - O
control VERB - O
the DET - O
persistent ADJ - O
disease NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole NNP - B-MEDICINE
as ADP - O
a DET - O
Safe ADJ - O
and CCONJ - O
Effective ADJ - O
Alternative ADJ - O
to ADP - O
Ketoconazole PROPN - O
in ADP - O
Controlling VERB - O
Hypercortisolism PROPN - O
of ADP - O
Recurrent PROPN - O
Cushing PROPN - O
's PART - O
Disease NOUN - O
: PUNCT - O
A DET - O
Case PROPN - O
Report PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole JJ - B-MEDICINE
prophylaxis NOUN - O
may VERB - O
make VERB - O
no DET - O
clear ADJ - O
difference NOUN - O
to ADP - O
the DET - O
risk NOUN - O
of ADP - O
developing VERB - O
clinically ADV - O
resistant ADJ - O
Candida PROPN - O
disease NOUN - O
( PUNCT - O
RR PROPN - O
0.93 NUM - O
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NOUN - O
0.56 NUM - O
to ADP - O
1.56 CD - B-CARDINAL
; PUNCT - O
3 CD - B-CARDINAL
trials NOUN - O
, PUNCT - O
1198 CD - B-DATE
participants NOUN - O
; PUNCT - O
low ADJ - O
- PUNCT - O
certainty NOUN - O
evidence NOUN - O
) PUNCT - O
; PUNCT - O
however ADV - O
, PUNCT - O
there ADV - O
may VERB - O
be VERB - O
an DET - O
increased VERB - O
detection NOUN - O
of ADP - O
fluconazole NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
Candida PROPN - O
isolates VERB - O
from ADP - O
surveillance NOUN - O
cultures NOUN - O
( PUNCT - O
RR NOUN - O
1.25 CD - B-MONEY
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NOUN - O
1.00 CD - B-CARDINAL
to ADP - O
1.55 CD - B-CARDINAL
; PUNCT - O
3 CD - B-CARDINAL
trials NOUN - O
, PUNCT - O
539 CD - B-CARDINAL
participants NOUN - O
; PUNCT - O
low ADJ - O
- PUNCT - O
certainty NOUN - O
evidence NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole NNP - B-MEDICINE
was VERB - O
the DET - O
choice NOUN - O
prophylaxis NOUN - O
previously ADV - O
, PUNCT - O
but CCONJ - O
recent ADJ - O
strategy NOUN - O
utilization NOUN - O
antifungal ADJ - O
drugs NOUN - O
according VERB - O
to ADP - O
the DET - O
risk NOUN - O

 SPACE - O
of ADP - O
IFI NNP - B-ORG
in ADP - O
patients NOUN - O
undergoing VERB - O
transplantation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-WORK_OF_ART
Role NNP - I-WORK_OF_ART
of IN - I-WORK_OF_ART
Fluconazole NNP - I-MEDICINE
Prophylaxis NNP - I-WORK_OF_ART
Regimen NNP - I-WORK_OF_ART
and CCONJ - O
the DT - B-ORG
Regimes NNPS - I-ORG
Chosen VBN - I-ORG
by ADP - O
the DT - B-ORG
Patient NNP - I-ORG
’s NNP - I-ORG
Risk NN - I-ORG
of IN - I-ORG
Fungal NNP - I-ORG
Infection NNP - I-ORG
in ADP - O
Reducing VBG - B-ORG

 _SP - I-ORG
the DT - I-ORG
Infection NNP - I-ORG
Rate NNP - I-ORG
after ADP - O
Bone PROPN - O
Marrow PROPN - O
Transplantation PROPN - O

-DOCSTART- -X- - O

Fluconazole NN - B-MEDICINE
, PUNCT - O
itraconazole NOUN - O
and CCONJ - O
micafungin NOUN - O
can VERB - O
be VERB - O
used VERB - O
to PART - O
prevent VERB - O
fungal ADJ - O
infections NOUN - O
in ADP - O
patients NOUN - O
undergoing VERB - O
allogeneic ADJ - O
hematopoietic ADJ - O
stem NOUN - O
cell NOUN - O
transplantation NOUN - O
, PUNCT - O
but CCONJ - O
fluconazole NN - B-MEDICINE
is VERB - O
not ADV - O
effective ADJ - O
against ADP - O
Aspergillus NNP - B-ORG
, PUNCT - O
and CCONJ - O
itraconazole NOUN - O
has VERB - O
less ADJ - O
tolerability NOUN - O
from ADP - O
gastrointestinal ADJ - O
toxicity NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole NNP - B-MEDICINE
, PUNCT - O
an DET - O
azole ADJ - O
antifungal ADJ - O
agent NOUN - O
, PUNCT - O
affects VERB - O
blood NOUN - O
concentration NOUN - O
of ADP - O
tacrolimus NOUN - O
by ADP - O
inhibiting VERB - O
the DET - O
cytochromes NOUN - O
P450 PROPN - O
( PUNCT - O
CYP NNP - B-ORG
) PUNCT - O
3A4 NUM - O
and CCONJ - O
3A5 CD - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole NNP - B-MEDICINE
( PUNCT - O
FLC NNP - B-ORG
) PUNCT - O
is VERB - O
a DET - O
fungistatic ADJ - O
drug NOUN - O
commonly ADV - O
administered VERB - O
to PART - O
treat VERB - O
cryptococcosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole JJ - B-MEDICINE
induces VERB - O
ROS PROPN - O
in ADP - O
Cryptococcus NNP - B-ORG
neoformans NOUN - O
and CCONJ - O
contributes VERB - O
to ADP - O
DNA NOUN - O
damage NOUN - O
in ADP - O
vitro NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
statistical ADJ - O
analysis NOUN - O
showed VERB - O
C. PROPN - O
albican PROPN - O
was VERB - O
eradicated VERB - O
in ADP - O
59 CD - B-CARDINAL
participants NOUN - O
( PUNCT - O
78 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
out ADP - O
of ADP - O
75 CD - B-CARDINAL
participants NOUN - O
by ADP - O
the DET - O
use NOUN - O
of ADP - O
Candicure NOUN - O
( PUNCT - O
Test NOUN - O
drug NOUN - O
) PUNCT - O
and CCONJ - O
in ADP - O
56 CD - B-CARDINAL
participants NOUN - O
( PUNCT - O
74 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
out ADP - O
of ADP - O
75 CD - B-CARDINAL
participants NOUN - O
by ADP - O
the DET - O
use NOUN - O
of ADP - O
Fluconazole NNP - B-MEDICINE
therapy NOUN - O
( PUNCT - O
Control PROPN - O
drug NOUN - O
) PUNCT - O
. PUNCT - O

Chi PROPN - O
- PUNCT - O
square ADJ - O
test NOUN - O
was VERB - O
applied VERB - O
and CCONJ - O
p ADJ - O
- PUNCT - O
value NOUN - O
was VERB - O
calculated VERB - O
0.3101 CD - B-PRODUCT
which ADJ - O
is VERB - O
greater JJR - B-CARDINAL
than IN - I-CARDINAL
0.05 CD - I-CARDINAL
showed VERB - O
that ADP - O
Candicure NN - B-NORP
therapy NOUN - O
and CCONJ - O
Fluconazole NNP - B-MEDICINE
therapy NOUN - O
is VERB - O
equally ADV - O
significant ADJ - O
in ADP - O
eradication NOUN - O
of ADP - O
C. PROPN - O
albican PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
retrospective ADJ - O
cohort NOUN - O
study NOUN - O
was VERB - O
conducted VERB - O
among ADP - O
HIV PROPN - O
infected VERB - O
patients NOUN - O
that ADJ - O
had VERB - O
completed VERB - O
10 CD - B-DATE
weeks NNS - I-DATE
of ADP - O
recommended VERB - O
therapy NOUN - O
for ADP - O
CCM NNP - B-ORG
( PUNCT - O
2 CD - B-DATE
weeks NNS - I-DATE
of ADP - O
intravenous ADJ - O
amphotericin NOUN - O
B PROPN - O
1mg NN - B-ORDINAL
/ SYM - O
kg NOUN - O
and CCONJ - O
10 CD - B-DATE
weeks NNS - I-DATE
of ADP - O
oral ADJ - O
Fluconazole NNP - B-MEDICINE
800 NUM - O
mg PART - O
daily ADV - O
) PUNCT - O
in ADP - O
the DET - O
CryptoDex NNP - B-PRODUCT
trial NOUN - O
( PUNCT - O
ISRCTN59144167 PROPN - O
) PUNCT - O
between IN - B-DATE
2013 CD - I-DATE
and CC - I-DATE
2015 CD - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole JJ - B-MEDICINE
resistant ADJ - O
C.albicans PROPN - O
is VERB - O
a DET - O
growing VERB - O
and CCONJ - O
perplexing VERB - O
problem NOUN - O
following VERB - O
years NNS - B-DATE
of ADP - O
indiscriminate ADJ - O
drug NOUN - O
prescription NOUN - O
and CCONJ - O
unnecessary ADJ - O
drug NOUN - O
exposure NOUN - O
and CCONJ - O
for ADP - O
which ADJ - O
there ADV - O
are VERB - O
few ADJ - O
therapeutic ADJ - O
alternatives NOUN - O
. PUNCT - O

Expert PROPN - O
opinion NOUN - O
: PUNCT - O
Fluconazole JJ - B-MEDICINE
resistant ADJ - O
C.albicans PROPN - O
adds VERB - O
to ADP - O
the DET - O
challenge NOUN - O
of ADP - O
azole NOUN - O
resistant ADJ - O
non ADJ - O
- ADJ - O
albicans NOUN - O
Candida NNP - B-GPE
spp NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
isolates NOUN - O
were VERB - O
unrelated ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Candida PROPN - O
catenulata NOUN - O
Candidaemia PROPN - O
and CCONJ - O
Possible PROPN - O
Endocarditis PROPN - O
in ADP - O
a DET - O
Cirrhotic PROPN - O
Patient PROPN - O
Successfully NNP - B-PERSON
De NNP - I-PERSON
- HYPH - I-PERSON
escalated VBD - I-PERSON
to ADP - O
Oral PROPN - O
Fluconazole NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Physiologically RB - B-ORG
Based VBN - I-ORG
Pharmacokinetic JJ - I-ORG
Approach NNP - I-ORG
to ADP - O
Determine VB - B-ORG
Dosing NN - I-ORG
on ADP - O
Extracorporeal PROPN - O
Life PROPN - O
Support PROPN - O
: PUNCT - O
Fluconazole NN - B-MEDICINE
in ADP - O
Children PROPN - O
on ADP - O
ECMO NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Oral PROPN - O
Fluconazole NNP - B-MEDICINE
in ADP - O
Pregnancy PROPN - O
and CCONJ - O
Risk PROPN - O
of ADP - O
Stillbirth PROPN - O
and CCONJ - O
Neonatal PROPN - O
Death PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole JJ - B-MEDICINE
resistance NOUN - O
remained VERB - O
stable ADJ - O
throughout ADP - O
the DET - O
period NOUN - O
and CCONJ - O
was VERB - O
observed VERB - O
in ADP - O
20 CD - B-CARDINAL
( PUNCT - O
10.7 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
of ADP - O
the DET - O
isolates NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Clonal PROPN - O
Spread PROPN - O
of ADP - O
Candida PROPN - O
glabrata NOUN - O
Bloodstream NNP - B-ORG
Isolates NNPS - I-ORG
and CCONJ - O
Fluconazole NNP - B-MEDICINE
Resistance PROPN - O

-DOCSTART- -X- - O

Ibandronate NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
Polymorphs PROPN - O

-DOCSTART- -X- - O

The DET - O
effects NOUN - O
of ADP - O
Ibandronate NNP - B-ORG
Sodium NNP - I-ORG
on ADP - O
the DET - O
cell NOUN - O
cycle NOUN - O
and CCONJ - O
early ADJ - O
apoptosis NOUN - O
of ADP - O
8226 CD - B-CARDINAL
cells NOUN - O
were VERB - O
analyzed VERB - O
by ADP - O
flow NOUN - O
cytometry NOUN - O
, PUNCT - O
  SPACE - O
and CCONJ - O
the DET - O
effect NOUN - O
on ADP - O
its ADJ - O
protein NOUN - O
expression NOUN - O
was VERB - O
analyzed VERB - O
by ADP - O
immunohistochemistry NOUN - O
. PUNCT - O

Ibandronate NNP - B-ORG
Sodium NNP - I-ORG
could VERB - O
inhibit VERB - O
cell NOUN - O
proliferation NOUN - O
by ADP - O
a DET - O
cell NOUN - O
- PUNCT - O
cycle NOUN - O
arrest NOUN - O
in ADP - O
S NOUN - O
- PUNCT - O
phase NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Meanwhile ADV - O
, PUNCT - O
AgNCs@Bacitracin PROPN - O
, PUNCT - O
AuNCs@Bacitracin PROPN - O
, PUNCT - O
and CCONJ - O
CuNCs@Bacitracin NNP - B-ORG
emitted VERB - O
cyan NOUN - O
, PUNCT - O
yellow ADJ - O
, PUNCT - O
and CCONJ - O
red ADJ - O
colors NOUN - O
of ADP - O
fluorescence NOUN - O
, PUNCT - O
respectively ADV - O
, PUNCT - O
and CCONJ - O
different ADJ - O
sizes NOUN - O
and CCONJ - O
nitrogen NOUN - O
contents NOUN - O
of ADP - O
these DET - O
nanoclusters NOUN - O
played VERB - O
a DET - O
critical ADJ - O
role NOUN - O
for ADP - O
their ADJ - O
fluorescence NOUN - O
alterations NOUN - O
. PUNCT - O

Significantly ADV - O
, PUNCT - O
AgNCs@Bacitracin PROPN - O
exhibited VERB - O
robust ADJ - O
bacteria NOUN - O
- PUNCT - O
killing VERB - O
efficiency NOUN - O
than ADP - O
other ADJ - O
nanoclusters NOUN - O
, PUNCT - O
owing VERB - O
to ADP - O
its ADJ - O
marked ADJ - O
damage NOUN - O
on ADP - O
the DET - O
bacterial ADJ - O
membrane NOUN - O
. PUNCT - O

Additionally ADV - O
, PUNCT - O
propidium NOUN - O
iodide NOUN - O
( PUNCT - O
PI PROPN - O
) PUNCT - O
staining NOUN - O
indicated VERB - O
the DET - O
bacterial ADJ - O
membrane ADJ - O
damage NOUN - O
of ADP - O
72.3 CD - B-PERCENT
% NN - I-PERCENT
to ADP - O
the DET - O
bacteria NOUN - O
population NOUN - O
followed VERB - O
by ADP - O
the DET - O
treatment NOUN - O
with ADP - O
AgNCs@Bacitracin PROPN - O
, PUNCT - O
and CCONJ - O
the DET - O
introduction NOUN - O
of ADP - O
AgNCs@Bacitracin PROPN - O
lead NOUN - O
to ADP - O
the DET - O
higher ADJ - O
reactive ADJ - O
oxygen NOUN - O
species NOUN - O
( PUNCT - O
ROS PROPN - O
) PUNCT - O
production NOUN - O
, PUNCT - O
facilitating VERB - O
their ADJ - O
attractive ADJ - O
antibacterial ADJ - O
activity NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Bacitracin NNP - B-MEDICINE
is VERB - O
a DET - O
cell NOUN - O
wall NOUN - O
targeting VERB - O
antimicrobial NOUN - O
with ADP - O
clinical ADJ - O
and CCONJ - O
agricultural ADJ - O
applications NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Bacitracin NNP - B-MEDICINE
has VERB - O
been VERB - O
used VERB - O
in ADP - O
topical ADJ - O
preparations NOUN - O
with ADP - O
polymyxin NOUN - O
B NOUN - O
for ADP - O
bacterial ADJ - O
infections NOUN - O
. PUNCT - O

Bacitracin NNP - B-MEDICINE
had VERB - O
a DET - O
stronger ADJ - O
antibacterial ADJ - O
activity NOUN - O
against ADP - O
S. PROPN - O
aureus PROPN - O
in ADP - O
the DET - O
presence NOUN - O
of ADP - O
colistin NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Colistin NNP - B-PERSON
Induces NNP - I-PERSON
S. NNP - I-PERSON
aureus NNP - I-PERSON
Susceptibility PROPN - O
to ADP - O
Bacitracin NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Bacitracin NNP - B-MEDICINE
, PUNCT - O
a DET - O
new ADJ - O
type NOUN - O
of ADP - O
cyclic ADJ - O
peptide NOUN - O
antibiotic NOUN - O
, PUNCT - O
is VERB - O
widely ADV - O
used VERB - O
as ADP - O
the DET - O
feed NOUN - O
additive ADJ - O
in ADP - O
feed NOUN - O
industry NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Correction NOUN - O
to ADP - O
" PUNCT - O
PEGylated NNP - B-WORK_OF_ART
Self NNP - I-WORK_OF_ART
- HYPH - I-WORK_OF_ART
Assembled NNP - I-WORK_OF_ART
Nano NNP - I-WORK_OF_ART
- HYPH - I-WORK_OF_ART
Bacitracin NN - I-MEDICINE
A NN - I-WORK_OF_ART
: : - I-WORK_OF_ART
Probing VBG - I-WORK_OF_ART
the DT - I-WORK_OF_ART
Antibacterial NNP - I-WORK_OF_ART
Mechanism NNP - I-WORK_OF_ART
and CC - I-WORK_OF_ART
Real NNP - I-WORK_OF_ART
- HYPH - I-WORK_OF_ART
Time NN - I-WORK_OF_ART
Tracing NNP - I-WORK_OF_ART
of IN - I-WORK_OF_ART
Target NNP - I-WORK_OF_ART
Delivery NNP - I-WORK_OF_ART
in IN - I-WORK_OF_ART
Vivo NNP - I-WORK_OF_ART
" PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

MCR-1 NNP - B-ORG
Confers NNP - I-ORG
Cross NNP - I-ORG
- NNP - I-ORG
Resistance NNP - I-ORG
to IN - I-ORG
Bacitracin NNP - I-MEDICINE
, PUNCT - O
a DET - O
Widely ADV - O
Used VERB - O
In PROPN - O
- PUNCT - O
Feed NOUN - O
Antibiotic PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Bacitracin NNP - B-MEDICINE
, PUNCT - O
a DET - O
kind NOUN - O
of ADP - O
cyclic ADJ - O
peptide NOUN - O
antibiotic NOUN - O
mainly ADV - O
produced VERB - O
by ADP - O
Bacillus PROPN - O
, PUNCT - O
has VERB - O
wide ADJ - O
ranges NOUN - O
of ADP - O
applications NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Enhancement NOUN - O
of ADP - O
Bacitracin NNP - B-MEDICINE
Production PROPN - O
by ADP - O
NADPH NNP - B-ORG
Generation NNP - I-ORG
via ADP - O
Overexpressing PROPN - O
Glucose-6-Phosphate PROPN - O
Dehydrogenase NNP - B-PERSON
Zwf NNP - I-PERSON
in ADP - O
Bacillus PROPN - O
licheniformis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Loss PROPN - O
of ADP - O
Bacitracin NNP - B-MEDICINE
Resistance NNP - I-ORG

-DOCSTART- -X- - O

Bacitracin NNP - B-MEDICINE
is VERB - O
a DET - O
broad ADJ - O
- PUNCT - O
spectrum NOUN - O
polypeptide NOUN - O
antibiotic NOUN - O
, PUNCT - O
which ADJ - O
is VERB - O
formed VERB - O
by ADP - O
11 CD - B-CARDINAL
amino NOUN - O
acids NOUN - O
residues NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Bacitracin NNP - B-MEDICINE
, PUNCT - O
a DET - O
widely ADV - O
used VERB - O
metallopeptide NOUN - O
antibiotic NOUN - O
, PUNCT - O
has VERB - O
been VERB - O
reported VERB - O
to PART - O
be VERB - O
locally ADV - O
used VERB - O
in ADP - O
treating VERB - O
wounds NOUN - O
without ADP - O
systemic ADJ - O
adverse ADJ - O
reactions NOUN - O
. PUNCT - O

Bacitracin NN - B-MEDICINE
treatment NOUN - O
increased VERB - O
osteogenic ADJ - O
differentiation NOUN - O
of ADP - O
HBMSCs PROPN - O
without ADP - O
cytotoxicity NOUN - O
and CCONJ - O
did VERB - O
not ADV - O
adversely ADV - O
affect VERB - O
cell NOUN - O
cycle NOUN - O
progression NOUN - O
or CCONJ - O
apoptosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Bacitracin NNP - B-MEDICINE
promotes VERB - O
osteogenic ADJ - O
differentiation NOUN - O
of ADP - O
human ADJ - O
bone NOUN - O
marrow NOUN - O
mesenchymal ADJ - O
stem NOUN - O
cells NOUN - O
by ADP - O
stimulating VERB - O
the DET - O
bone NOUN - O
morphogenetic ADJ - O
protein-2/Smad PROPN - O
axis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

PEGylated PROPN - O
Self PROPN - O
- PUNCT - O
Assembled PROPN - O
Nano PROPN - O
- PUNCT - O
Bacitracin NN - B-MEDICINE
A NOUN - O
: PUNCT - O
Probing VERB - O
the DET - O
Antibacterial PROPN - O
Mechanism PROPN - O
and CCONJ - O
Real PROPN - O
- PUNCT - O
Time NOUN - O
Tracing PROPN - O
of ADP - O
Target PROPN - O
Delivery PROPN - O
in ADP - O
Vivo PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Analysis NOUN - O
of ADP - O
Major PROPN - O
Components PROPN - O
of ADP - O
Bacitracin NNP - B-MEDICINE
, PUNCT - O
Colistin NNP - B-PERSON
and CCONJ - O
Virginiamycin PROPN - O
in ADP - O
Feed PROPN - O
Using VERB - O
Matrix NNP - B-PERSON
Solid NNP - I-PERSON
- HYPH - I-PERSON
phase NN - I-PERSON
Dispersion NNP - B-ORG
Extraction NNP - I-ORG
by ADP - O
Liquid NNP - B-PERSON
Chromatography NNP - I-PERSON
- HYPH - I-PERSON
electrospray NN - I-PERSON
Ionization NNP - B-ORG
Tandem PROPN - O
Mass PROPN - O
Spectrometry PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Bacitracin NNP - B-MEDICINE
consistently ADV - O
decreased VERB - O
Bifidobacterium NNP - B-ORG
while ADP - O
other ADJ - O
bacterial ADJ - O
groups NOUN - O
were VERB - O
affected VERB - O
only ADV - O
at ADP - O
certain ADJ - O
times NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Tannins PROPN - O
and CCONJ - O
Bacitracin NNP - B-MEDICINE
Differentially ADV - O
Modulate PROPN - O
Gut PROPN - O
Microbiota PROPN - O
of ADP - O
Broiler PROPN - O
Chickens PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Vitamin NOUN - O
D NOUN - O
Compounds NOUN - O
Are VERB - O
Bactericidal PROPN - O
against ADP - O
Streptococcus NNP - B-ORG
mutans NOUN - O
and CCONJ - O
Target NNP - B-ORG
the DT - I-ORG
Bacitracin NNP - I-MEDICINE
- HYPH - I-ORG
Associated NNP - I-ORG
Efflux NNP - I-ORG
System NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Bacitracin NN - B-MEDICINE
or CCONJ - O
β PROPN - O
- PUNCT - O
defensin-3 NOUN - O
at ADP - O
a DET - O
sub NOUN - O
- PUNCT - O
inhibitory NOUN - O
concentration NOUN - O
induced VERB - O
biofilm ADJ - O
formation NOUN - O
in ADP - O
the DET - O
parent NOUN - O
, PUNCT - O
but CCONJ - O
not ADV - O
in ADP - O
any DET - O
of ADP - O
the DET - O
BceABRS NN - B-ORG
mutants NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Bacitracin NN - B-MEDICINE
irrigation NOUN - O
leading VERB - O
to ADP - O
anaphylaxis VERB - O
and CCONJ - O
cardiovascular ADJ - O
collapse NOUN - O
in ADP - O
the DET - O
ambulatory ADJ - O
surgery NOUN - O
center NOUN - O
setting NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Bacitracin NN - B-MEDICINE
and CCONJ - O
multidrug NOUN - O
were VERB - O
predominant ADJ - O
ARG PROPN - O
types NOUN - O
in ADP - O
water NOUN - O
and CCONJ - O
sediment ADJ - O
samples NOUN - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Stimulated ADJ - O
saliva NOUN - O
samples NOUN - O
from ADP - O
volunteers NOUN - O
were VERB - O
collected VERB - O
and CCONJ - O
cultured VERB - O
in ADP - O
Mitis NNP - B-ORG
Salivarius NNP - I-ORG
Bacitracin NNP - I-MEDICINE
( PUNCT - O
MSB NNP - B-ORG
) PUNCT - O
agar VERB - O
for ADP - O
estimation NOUN - O
of ADP - O
Streptococcus NNP - B-ORG
mutans NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Total ADJ - O
192 CD - B-CARDINAL
broiler NOUN - O
chicks NOUN - O
were VERB - O
grouped VERB - O
randomly ADV - O
into ADP - O
six CD - B-CARDINAL
treatments NOUN - O
and CCONJ - O
fed VERB - O
with ADP - O
basal ADJ - O
diet NOUN - O
( PUNCT - O
BD PROPN - O
) PUNCT - O
along ADP - O
with ADP - O
different ADJ - O
levels NOUN - O
of ADP - O
seeds NOUN - O
, PUNCT - O
viz NOUN - O
. PUNCT - O
, PUNCT - O
T1 PROPN - O
( PUNCT - O
BD PROPN - O
) PUNCT - O
, PUNCT - O
T2 NNP - B-PERSON
( PUNCT - O
BD PROPN - O
  SPACE - O
+ CCONJ - O
  SPACE - O
0.2 CD - B-PERCENT
% NN - I-PERCENT
HS PROPN - O
) PUNCT - O
, PUNCT - O
T3 NNP - B-PERSON
( PUNCT - O
BD PROPN - O
  SPACE - O
+ CCONJ - O
  SPACE - O
0.2 CD - B-PERCENT
% NN - I-PERCENT
HS NOUN - O
  SPACE - O
+ CCONJ - O
  SPACE - O
0.3 NUM - O
DS PROPN - O
) PUNCT - O
, PUNCT - O
T4 PROPN - O
( PUNCT - O
BD PROPN - O
  SPACE - O
+ CCONJ - O
  SPACE - O
0.3 CD - B-PERCENT
% NN - I-PERCENT
HS PROPN - O
) PUNCT - O
and CCONJ - O
T5 NNP - B-PERSON
( PUNCT - O
BD PROPN - O
  SPACE - O
+ CCONJ - O
  SPACE - O
0.3 CD - B-PERCENT
% NN - I-PERCENT
HS NOUN - O
  SPACE - O
+ CCONJ - O
  SPACE - O
0.3 NUM - O
DS PROPN - O
) PUNCT - O
and CCONJ - O
T6 NNP - B-PERSON
( PUNCT - O
BD PROPN - O
  SPACE - O
+ CCONJ - O
  SPACE - O
0.025 CD - B-PERCENT
% NN - I-PERCENT
Bacitracin NNP - B-MEDICINE
Methylene NNP - I-ORG
Disalicylate NNP - I-ORG
- HYPH - I-ORG
BMD NNP - I-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Bacitracin NNP - B-MEDICINE
was VERB - O
inferior ADJ - O
to PART - O
teicoplanin VERB - O
( PUNCT - O
0·22 NUM - O
, PUNCT - O
0·06 NUM - O
- PUNCT - O
0·77 NUM - O
) PUNCT - O
and CCONJ - O
fidaxomicin PROPN - O
( PUNCT - O
0·40 PROPN - O
, PUNCT - O
0·17 CD - B-CARDINAL
- PUNCT - O
0·94 PROPN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
tolevamer NOUN - O
was VERB - O
inferior ADJ - O
to ADP - O
all DET - O
drugs NOUN - O
except ADP - O
for ADP - O
LFF571 NNP - B-PERSON
( PUNCT - O
0·50 NUM - O
, PUNCT - O
0·18 CD - B-PRODUCT
- SYM - I-PRODUCT
1·39 CD - I-PRODUCT
) PUNCT - O
and CCONJ - O
bacitracin NN - B-MEDICINE
( PUNCT - O
0·67 NN - B-ORG
, PUNCT - O
0·28 CD - B-CARDINAL
- SYM - I-CARDINAL
1·58 CD - I-CARDINAL
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Bacitracin NNP - B-MEDICINE
, PUNCT - O
penicillin NOUN - O
V NOUN - O
, PUNCT - O
and CCONJ - O
neomycin NOUN - O
, PUNCT - O
all DET - O
produced VERB - O
dose NOUN - O
- PUNCT - O
dependent ADJ - O
alterations NOUN - O
to ADP - O
the DET - O
velocity NOUN - O
, PUNCT - O
frequency NOUN - O
, PUNCT - O
and CCONJ - O
amplitude NOUN - O
of ADP - O
PCC NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Antibacterial ADJ - O
activity NOUN - O
was VERB - O
assessed VERB - O
by ADP - O
measuring VERB - O
inhibition NOUN - O
zones NOUN - O
on ADP - O
Mitis NNP - B-WORK_OF_ART
Salivarius NNP - I-WORK_OF_ART
Bacitracin NNP - I-MEDICINE
( PUNCT - O
MSB NNP - B-ORG
) PUNCT - O
agar NOUN - O
inoculated VERB - O
with ADP - O
pure ADJ - O
strain NOUN - O
of ADP - O
Streptococcus NN - B-ORG
mutans NOUN - O
( PUNCT - O
S. PROPN - O
mutans NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Bacitracin NNP - B-MEDICINE
is VERB - O
a DET - O
broad ADJ - O
- PUNCT - O
spectrum NOUN - O
antibiotic NOUN - O
used VERB - O
extensively ADV - O
as ADP - O
a DET - O
feed NOUN - O
additive ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Optimization NOUN - O
of ADP - O
Inexpensive PROPN - O
Agricultural PROPN - O
By PROPN - O
- PUNCT - O
Products PROPN - O
as ADP - O
Raw PROPN - O
Materials PROPN - O
for ADP - O
Bacitracin NNP - B-MEDICINE
Production PROPN - O
in ADP - O
Bacillus PROPN - O
licheniformis NOUN - O
DW2 PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Bacitracin VB - B-MEDICINE
topical ADJ - O
antibiotic ADJ - O
ointment NOUN - O
was VERB - O
routinely ADV - O
applied VERB - O
to ADP - O
the DET - O
sternal ADJ - O
surgical ADJ - O
incision NOUN - O
after ADP - O
skin NOUN - O
closure NOUN - O
for ADP - O
all DET - O
patients NOUN - O
during ADP - O
this DET - O
period NOUN - O
. PUNCT - O

Bacitracin NNP - B-MEDICINE
ointment NOUN - O
was VERB - O
well ADV - O
tolerated VERB - O
by ADP - O
patients NOUN - O
, PUNCT - O
with ADP - O
no DET - O
serious ADJ - O
adverse ADJ - O
effects NOUN - O
reported VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Routine JJ - B-ORG
Use NNP - I-ORG
of IN - I-ORG
Topical NNP - I-ORG
Bacitracin NNP - I-MEDICINE
to IN - I-ORG
Prevent NNP - I-ORG
Sternal PROPN - O
Wound PROPN - O
Infections PROPN - O

-DOCSTART- -X- - O

Bacitracin NN - B-MEDICINE
, PUNCT - O
neomycin NOUN - O
, PUNCT - O
and CCONJ - O
methicillin NOUN - O
were VERB - O
found VERB - O
to PART - O
be VERB - O
100 CD - B-PERCENT
% NN - I-PERCENT
resistant ADJ - O
to ADP - O
S. PROPN - O
aureus NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Bacitracin NNP - B-MEDICINE
( PUNCT - O
48 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
vancomycin PROPN - O
( PUNCT - O
39 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
and CCONJ - O
a DET - O
cephalosporin ADJ - O
( PUNCT - O
29 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
are VERB - O
the DET - O
most ADV - O
commonly ADV - O
chosen VERB - O
antibiotics NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Bacitracin NNP - B-MEDICINE
was VERB - O
discovered VERB - O
and CCONJ - O
named VERB - O
after ADP - O
a DET - O
7 CD - B-DATE
year NN - I-DATE
old JJ - I-DATE
American JJ - B-NORP
girl NOUN - O
, PUNCT - O
Margaret NNP - B-PERSON
Tracey NNP - I-PERSON
in ADP - O
1943 CD - B-DATE
as ADP - O
Bacillus PROPN - O
was VERB - O
isolated VERB - O
from ADP - O
her ADJ - O
wounds NOUN - O
. PUNCT - O

There ADV - O
are VERB - O
different ADJ - O
types NOUN - O
of ADP - O
bacitracin NN - B-MEDICINE
but CCONJ - O
the DET - O
one CD - B-CARDINAL
most ADV - O
potent ADJ - O
is VERB - O
Bacitracin NNP - B-MEDICINE
A. NNP - I-ORG
Bacitracin NNP - I-MEDICINE
induced VERB - O
proteins NOUN - O
are VERB - O
localized VERB - O
in ADP - O
bacterial ADJ - O
membrane NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Up PROPN - O
Scaling PROPN - O
Strategies PROPN - O
to PART - O
Improve VERB - O
the DET - O
Industrial PROPN - O
Production PROPN - O
of ADP - O
Bacitracin NNP - B-MEDICINE
at ADP - O
Largescale NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Bacitracin NN - B-MEDICINE
, PUNCT - O
multidrug NOUN - O
, PUNCT - O
aminoglycoside NOUN - O
, PUNCT - O
sulfonamide NOUN - O
, PUNCT - O
and CCONJ - O
beta NOUN - O
- PUNCT - O
lactam NOUN - O
resistance NOUN - O
genes NOUN - O
were VERB - O
dominant ADJ - O
in ADP - O
drinking NOUN - O
water NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Bacitracin NNP - B-MEDICINE
immobilized VERB - O
on ADP - O
the DET - O
titanium NOUN - O
( PUNCT - O
Ti PROPN - O
) PUNCT - O
surface NOUN - O
significantly ADV - O
improves VERB - O
anti ADJ - O
- ADJ - O
bacterial ADJ - O
activity NOUN - O
and CCONJ - O
biocompatibility NOUN - O
in ADP - O
vitro NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Bacitracin NNP - B-MEDICINE
showed VERB - O
a DET - O
cytotoxicity NOUN - O
in ADP - O
3rd JJ - B-ORDINAL
( PUNCT - O
p<0.05 NOUN - O
) PUNCT - O
and CCONJ - O
4th NNP - B-ORDINAL
( PUNCT - O
p<0.001 NOUN - O
) PUNCT - O
days NOUN - O
, PUNCT - O
in ADP - O
5.0 CD - B-CARDINAL
Mm NOUN - O
concentration NOUN - O
. PUNCT - O

Bacitracin NN - B-MEDICINE
, PUNCT - O
as ADP - O
a DET - O
functional ADJ - O
inhibitor NOUN - O
of ADP - O
PDI NNP - B-ORG
, PUNCT - O
decreased VERB - O
the DET - O
phosphorylated VERB - O
FAK NN - B-ORG
and CCONJ - O
the DET - O
secreted ADJ - O
MMP-2 NNP - B-ORG
, PUNCT - O
which ADJ - O
are VERB - O
the DET - O
downstream NOUN - O
of ADP - O
integrin NOUN - O
and CCONJ - O
play VERB - O
a DET - O
major ADJ - O
role NOUN - O
in ADP - O
cell NOUN - O
migration NOUN - O
and CCONJ - O
invasion NOUN - O
, PUNCT - O
might VERB - O
become VERB - O
one NUM - O
of ADP - O
the DET - O
feasible ADJ - O
therapeutic ADJ - O
strategies NOUN - O
for ADP - O
glioblastoma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

P08.56 PROPN - O
  SPACE - O
Bacitracin NNP - B-MEDICINE
inhibits VERB - O
the DET - O
migration NOUN - O
of ADP - O
U87-MG NNP - B-GPE
glioma NOUN - O
cells NOUN - O
via ADP - O
interferences NOUN - O
of ADP - O
the DET - O
integrin ADJ - O
outside ADV - O
- PUNCT - O
in NOUN - O
signaling VERB - O
pathway NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Bacitracin NN - B-MEDICINE
and CCONJ - O
its ADJ - O
complex NOUN - O
with ADP - O
zinc NOUN - O
were VERB - O
exposed VERB - O
to ADP - O
temperature NOUN - O
and CCONJ - O
relative ADJ - O
humidity NOUN - O
conditions NOUN - O
from ADP - O
50 CD - B-CARDINAL
to PART - O
80 CD - B-CARDINAL
° NOUN - O
C NOUN - O
and CCONJ - O
from ADP - O
0 CD - B-PERCENT
to IN - I-PERCENT
63 CD - I-PERCENT
% NN - I-PERCENT
for ADP - O
up ADP - O
to PART - O
21 CD - B-CARDINAL
  SPACE - O
days NNS - B-DATE
. PUNCT - O

-DOCSTART- -X- - O

Accelerated ADJ - O
Stability PROPN - O
Modeling PROPN - O
for ADP - O
Peptides PROPN - O
: PUNCT - O
a DET - O
Case PROPN - O
Study PROPN - O
with ADP - O
Bacitracin NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Bacitracin NNP - B-MEDICINE
is VERB - O
a DET - O
mixture NOUN - O
of ADP - O
nonribosomal ADJ - O
peptides NOUN - O
( PUNCT - O
NRPs NOUN - O
) PUNCT - O
that ADJ - O
is VERB - O
extensively ADV - O
used VERB - O
as ADP - O
an DET - O
antibiotic NOUN - O
in ADP - O
both CCONJ - O
human ADJ - O
and CCONJ - O
veterinary ADJ - O
medicine NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Photooxidation NOUN - O
of ADP - O
the DET - O
Antimicrobial PROPN - O
, PUNCT - O
Nonribosomal VERB - O
Peptide NOUN - O
Bacitracin NN - B-MEDICINE
A NOUN - O
by ADP - O
Singlet NNP - B-PERSON
Oxygen NNP - I-PERSON
under ADP - O
Environmentally PROPN - O
Relevant PROPN - O
Conditions PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Mosquito RB - B-MEDICINE
- PUNCT - O
borne VERB - O
viral ADJ - O
diseases NOUN - O
increase VERB - O
globally ADV - O
incidence NOUN - O
, PUNCT - O
including VERB - O
the DET - O
Sudan NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Dengue PROPN - O
Virus PROPN - O
Nonstructural PROPN - O
Protein PROPN - O
1 NUM - O
( PUNCT - O
NS1 NOUN - O
) PUNCT - O
Is VERB - O
Secreted VERB - O
from ADP - O
Mosquito NNP - B-MEDICINE
Cells NNP - I-ORG
in IN - I-ORG
Association NNP - I-ORG
with ADP - O
the DT - B-ORG
Intracellular NNP - I-ORG
Cholesterol NNP - I-ORG
Transporter NNP - I-ORG
Chaperone NN - I-ORG
Caveolin NNP - I-ORG
Complex NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Insights NOUN - O
Into ADP - O
an DET - O
Unexplored PROPN - O
Component PROPN - O
of ADP - O
the DET - O
Mosquito NNP - B-MEDICINE
Repeatome PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

A DET - O
Microsatellite NNP - B-NORP
Multiplex PROPN - O
Assay PROPN - O
for ADP - O
Profiling PROPN - O
Pig PROPN - O
DNA PROPN - O
in ADP - O
Mosquito NNP - B-MEDICINE
Bloodmeals PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Mosquito JJ - B-MEDICINE
species NOUN - O
from ADP - O
the DET - O
genus ADJ - O
Culex NNP - B-ORG
, PUNCT - O
Aedes NNP - B-ORG
and CCONJ - O
Ochlerotatus NNP - B-ORG
display VERB - O
variable ADJ - O
host NOUN - O
preferences NOUN - O
, PUNCT - O
ranging VERB - O
between ADP - O
birds NOUN - O
and CCONJ - O
mammals NOUN - O
, PUNCT - O
including VERB - O
humans NOUN - O
, PUNCT - O
and CCONJ - O
may VERB - O
bridge VERB - O
transmission NOUN - O
among ADP - O
avian ADJ - O
hosts NOUN - O
and CCONJ - O
contribute VERB - O
to ADP - O
spill NOUN - O
- PUNCT - O
over PART - O
transmission NOUN - O
to ADP - O
humans NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Linking NNP - B-ORG
Bird NNP - I-ORG
and CCONJ - O
Mosquito NNP - B-MEDICINE
Data NNPS - I-ORG
to ADP - O
Assess NNP - B-ORG
Spatiotemporal NNP - I-ORG
West NNP - I-ORG
Nile NNP - I-ORG
Virus NNP - I-ORG
Risk NN - I-ORG
in ADP - O
Humans NNPS - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Novel ADJ - O
Assay PROPN - O
for ADP - O
Simultaneous PROPN - O
Assessment PROPN - O
of ADP - O
Mammalian NNP - B-ORG
Host NNP - I-ORG
Blood NNP - I-ORG
, PUNCT - O
Mosquito NNP - B-MEDICINE
Species NNPS - I-ORG
, PUNCT - O
and CCONJ - O
Plasmodium NNP - B-GPE
spp NOUN - O
. PUNCT - O

in ADP - O
the DT - B-ORG
Medically RB - I-ORG
Important JJ - I-ORG
Anopheles NNP - B-PERSON
Mosquitoes NNP - I-PERSON
of ADP - O
Madagascar NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Mosquito NNP - B-MEDICINE
( PUNCT - O
Diptera NOUN - O
: PUNCT - O
Culicidae PROPN - O
) PUNCT - O
Species VERB - O
Composition PROPN - O
in ADP - O
Ovitraps PROPN - O
From ADP - O
a DET - O
Mesoamerican PROPN - O
Tropical PROPN - O
Montane PROPN - O
Cloud PROPN - O
Forest PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Mosquito NN - B-MEDICINE
- PUNCT - O
bornediseases NOUN - O
can VERB - O
have VERB - O
disastrous ADJ - O
effects NOUN - O
on ADP - O
avian ADJ - O
populations NOUN - O
; PUNCT - O
therefore ADV - O
, PUNCT - O
most ADJ - O
studies NOUN - O
of ADP - O
bird NOUN - O
and CCONJ - O
mosquito NN - B-MEDICINE
interactions NOUN - O
have VERB - O
focused VERB - O
on ADP - O
the DET - O
mortality NOUN - O
and CCONJ - O
morbidity NOUN - O
associated VERB - O
with ADP - O
the DET - O
diseases NOUN - O
. PUNCT - O

Mosquito JJ - B-MEDICINE
suction NOUN - O
traps NOUN - O
were VERB - O
fixed VERB - O
to ADP - O
the DET - O
outside NOUN - O
of ADP - O
eight CD - B-CARDINAL
nest NOUN - O
boxes NOUN - O
( PUNCT - O
four CD - B-CARDINAL
treated VERB - O
and CCONJ - O
four CD - B-CARDINAL
untreated ADJ - O
) PUNCT - O
to PART - O
collect VERB - O
mosquitoes NOUN - O
over ADP - O
a DET - O
24-h CD - B-GPE
period NOUN - O
( PUNCT - O
one CD - B-TIME
trap NN - I-TIME
night NN - I-TIME
) PUNCT - O
once ADV - O
weekly RB - B-DATE
, PUNCT - O
from ADP - O
incubation NOUN - O
until ADP - O
all DET - O
nestlings NOUN - O
fledged VERB - O
. PUNCT - O

Mosquitoes NOUN - O
can VERB - O
impose VERB - O
energetic ADJ - O
costs NOUN - O
on ADP - O
nestlings NOUN - O
by ADP - O
causing VERB - O
stress NOUN - O
from ADP - O
irritation NOUN - O
, PUNCT - O
dehydration NOUN - O
, PUNCT - O
and CCONJ - O
the DET - O
constant ADJ - O
regeneration NOUN - O
of ADP - O
blood NOUN - O
cells NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
finding NOUN - O
was VERB - O
triggered VERB - O
by ADP - O
the DET - O
citizen NOUN - O
science NOUN - O
platform NOUN - O
Mosquito NNP - B-MEDICINE
Alert NNP - I-PERSON
. PUNCT - O

In ADP - O
June NNP - B-DATE
2018 CD - I-DATE
, PUNCT - O
a DET - O
citizen NOUN - O
sent VERB - O
a DET - O
report NOUN - O
via ADP - O
the DT - B-ORG
Mosquito NNP - I-MEDICINE
Alert NNP - I-ORG
app NOUN - O
from ADP - O
the DET - O
municipality NOUN - O
of ADP - O
Siero NNP - B-GPE
in ADP - O
the DET - O
Asturias NNP - B-NORP
region NOUN - O
( PUNCT - O
NW NNP - B-ORG
Spain NNP - I-ORG
) PUNCT - O
containing VERB - O
pictures NOUN - O
of ADP - O
a DET - O
female ADJ - O
mosquito NN - B-MEDICINE
compatible ADJ - O
with ADP - O
Ae NNP - B-ORG
. PUNCT - O

The DET - O
strong ADJ - O
media NOUN - O
impact NOUN - O
in ADP - O
Asturias NNP - B-GPE
derived VERB - O
from ADP - O
the DET - O
discovery NOUN - O
raised VERB - O
local ADJ - O
participation NOUN - O
in ADP - O
the DET - O
Mosquito NNP - B-MEDICINE
Alert NNP - I-ORG
project NOUN - O
, PUNCT - O
resulting VERB - O
in ADP - O
further ADJ - O
evidence NOUN - O
from ADP - O
surrounding VERB - O
areas NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Overall PROPN - O
considered VERB - O
, PUNCT - O
the DT - B-ORG
Mean NNP - I-ORG
Mosquito NNP - I-MEDICINE
Density NNP - I-ORG
( PUNCT - O
MMD NNP - B-ORG
) PUNCT - O
was VERB - O
36.2 CD - B-CARDINAL
/ SYM - O
mosquito NN - B-MEDICINE
per ADP - O
room NOUN - O
( PUNCT - O
6.9 CD - B-CARDINAL
Anopheles PROPN - O
/ SYM - O
room NOUN - O
, PUNCT - O
29.1 CD - B-CARDINAL
Culex NNP - B-ORG
/ SYM - O
room NOUN - O
and CCONJ - O
2.1 CD - B-CARDINAL
Aedes PROPN - O
/ SYM - O
room NOUN - O
with ADP - O
an DET - O
extreme NOUN - O
between ADP - O
0 CD - B-CARDINAL
and CCONJ - O
144 CD - B-QUANTITY
mosquitoes NNS - I-QUANTITY
/ SYM - O
room NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Semi ADJ - O
- ADJ - O
synthetic ADJ - O
Cinnamodial PROPN - O
Analogues PROPN - O
: PUNCT - O
Structural ADJ - O
Insights PROPN - O
into ADP - O
the DET - O
Insecticidal NNP - B-ORG
and CCONJ - O
Antifeedant NNP - B-ORG
Activities NNPS - I-ORG
of IN - I-ORG
Drimane NNP - I-ORG
Sesquiterpenes NNPS - I-ORG
Against ADP - O
the DET - O
Mosquito NNP - B-MEDICINE
Aedes PROPN - O

-DOCSTART- -X- - O

Mosquitoes NNS - B-GPE
were VERB - O
generally ADV - O
collected VERB - O
with ADP - O
either CCONJ - O
a DET - O
Biogents NNP - B-ORG
Sentinel NNP - I-ORG
trap NOUN - O
or CCONJ - O
a DET - O
Heavy JJ - B-ORG
Duty NNP - I-ORG
Encephalitis NNP - I-ORG
Vector NNP - I-ORG
Survey NNP - I-ORG
trap NOUN - O
installed VERB - O
outside ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Mosquito VBN - B-MEDICINE
- PUNCT - O
borne VERB - O
pathogens NOUN - O
contribute VERB - O
significantly ADV - O
to ADP - O
the DET - O
global ADJ - O
burden NOUN - O
of ADP - O
disease NOUN - O
, PUNCT - O
infecting VERB - O
millions NNS - B-CARDINAL
of ADP - O
people NOUN - O
each DT - B-DATE
year NN - I-DATE
. PUNCT - O

Mosquito JJ - B-MEDICINE
feeding NOUN - O
is VERB - O
critical ADJ - O
to ADP - O
the DET - O
transmission NOUN - O
dynamics NOUN - O
of ADP - O
pathogens NOUN - O
, PUNCT - O
and CCONJ - O
thus ADV - O
it PRON - O
is VERB - O
important ADJ - O
to ADP - O
understanding NOUN - O
and CCONJ - O
interpreting VERB - O
mosquito VBN - B-MEDICINE
feeding NOUN - O
patterns NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Neuropeptide PROPN - O
Y PROPN - O
Receptor PROPN - O
Block NNP - B-PERSON
Mosquito NNP - I-MEDICINE
Biting PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Mosquito NN - B-MEDICINE
- PUNCT - O
borne VERB - O
infections NOUN - O
are VERB - O
a DET - O
constant ADJ - O
problem NOUN - O
in ADP - O
Vietnam NNP - B-GPE
, PUNCT - O
and CCONJ - O
mosquito NN - B-MEDICINE
vector NOUN - O
control NOUN - O
is VERB - O
a DET - O
primary ADJ - O
approach NOUN - O
to PART - O
control VERB - O
these DET - O
infections NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mosquito NNP - B-MEDICINE
Larvicidal NNP - I-ORG
Activity NNP - I-ORG
of ADP - O
the DET - O
Essential PROPN - O
Oils PROPN - O
of ADP - O
Erechtites PROPN - O
Species PROPN - O
Growing VERB - O
Wild PROPN - O
in ADP - O
Vietnam NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Mosquitoes NOUN - O
from ADP - O
Vero NNP - B-GPE
Beach NNP - I-GPE
( PUNCT - O
east ADJ - O
coast NOUN - O
Florida NNP - B-GPE
) PUNCT - O
were VERB - O
dominated VERB - O
by ADP - O
uncultivated ADJ - O
Asaia NNP - B-ORG
sp ADP - O
. PUNCT - O

-DOCSTART- -X- - O

Homologs NOUN - O
of ADP - O
Human PROPN - O
Dengue PROPN - O
- PUNCT - O
Resistance PROPN - O
Genes PROPN - O
, PUNCT - O
FKBP1B NNP - B-GPE
and CCONJ - O
ATCAY NNP - B-ORG
, PUNCT - O
Confer PROPN - O
Antiviral PROPN - O
Resistance PROPN - O
in ADP - O
Aedes NNP - B-GPE
aegypti NOUN - O
Mosquitoes NNS - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Factors NOUN - O
Affecting VERB - O
Short ADJ - O
- PUNCT - O
Range NOUN - O
Host NOUN - O
- PUNCT - O
Seeking NOUN - O
for ADP - O
the DET - O
Yellow PROPN - O
Fever PROPN - O
Mosquito NNP - B-MEDICINE
( PUNCT - O
Diptera NOUN - O
: PUNCT - O
Culicidae PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Differential ADJ - O
Metabolic PROPN - O
Reprogramming PROPN - O
by ADP - O
Zika NNP - B-PERSON
Virus NNP - I-PERSON
Promotes PROPN - O
Cell PROPN - O
Death NOUN - O
in ADP - O
Human PROPN - O
versus ADP - O
Mosquito NNP - B-MEDICINE
Cells NNPS - I-GPE
. PUNCT - O

-DOCSTART- -X- - O

Infectious ADJ - O
Disease PROPN - O
: PUNCT - O
Mosquito NNP - B-MEDICINE
- PUNCT - O
Borne PROPN - O
Viral PROPN - O
Illnesses PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Mosquitoes NOUN - O
from ADP - O
treatment NOUN - O
Z NOUN - O
survived VERB - O
significantly ADV - O
longer ADV - O
than ADP - O
treatments VERB - O
M.Z NNP - B-ORG
and CCONJ - O
S.Z NNP - B-PERSON
, PUNCT - O
though ADP - O
this DET - O
difference NOUN - O
was VERB - O
modest ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Mosquito JJ - B-MEDICINE
species NOUN - O
distribution NOUN - O
and CCONJ - O
D NOUN - O
immitis NOUN - O
infection NOUN - O
rates NOUN - O
were VERB - O
determined VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Preparation NOUN - O
and CCONJ - O
Use PROPN - O
of ADP - O
a DET - O
Yeast PROPN - O
shRNA NOUN - O
Delivery PROPN - O
System PROPN - O
for ADP - O
Gene PROPN - O
Silencing PROPN - O
in ADP - O
Mosquito NNP - B-MEDICINE
Larvae PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

albopictus NOUN - O
Mosquitoes NNP - B-GPE
for ADP - O
Zika NNP - B-GPE
Virus NNP - I-GPE
, PUNCT - O
Spain NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Mosquito VBN - B-MEDICINE
- PUNCT - O
borne VERB - O
diseases NOUN - O
are VERB - O
responsible ADJ - O
for ADP - O
several JJ - B-CARDINAL
million CD - I-CARDINAL
human ADJ - O
deaths NOUN - O
annually ADV - O
around ADP - O
the DET - O
world NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Green PROPN - O
, PUNCT - O
Yellow NNP - B-PERSON
, PUNCT - O
and CCONJ - O
Red NNP - B-ORG
Fluorescent NNP - I-ORG
Proteins NNPS - I-ORG
as IN - I-ORG
Markers NNPS - I-ORG
for IN - I-ORG
Bacterial NNP - I-ORG
Isolates NNPS - I-ORG
from ADP - O
Mosquito NNP - B-MEDICINE
Midguts NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Mosquito JJ - B-MEDICINE
vectors NOUN - O
that ADJ - O
belong VERB - O
to ADP - O
several ADJ - O
genera NOUN - O
such ADJ - O
as ADP - O
Anopheles NNP - B-ORG
, PUNCT - O
Aedes NNPS - B-PERSON
, PUNCT - O
and CCONJ - O
Culex NNP - B-ORG
play VERB - O
a DET - O
crucial ADJ - O
role NOUN - O
in ADP - O
the DET - O
transmission NOUN - O
of ADP - O
malaria NOUN - O
, PUNCT - O
dengue NOUN - O
, PUNCT - O
chikungunya NOUN - O
, PUNCT - O
Zika PROPN - O
, PUNCT - O
and CCONJ - O
elephantiasis NOUN - O
diseases NOUN - O
worldwide ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Mosquito JJ - B-MEDICINE
species NOUN - O
which ADJ - O
belong VERB - O
to ADP - O
genus ADJ - O
Anopheles NNS - B-NORP
are VERB - O
considered VERB - O
to PART - O
be VERB - O
of ADP - O
public ADJ - O
health NOUN - O
and CCONJ - O
medical ADJ - O
importance NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Environmental PROPN - O
Factors NOUN - O
Associated VERB - O
with ADP - O
Mosquito NNP - B-MEDICINE
Vector PROPN - O
Larvae PROPN - O
in ADP - O
a DET - O
Malaria PROPN - O
- PUNCT - O
Endemic PROPN - O
Area PROPN - O
in ADP - O
Ratchaburi NNP - B-GPE
Province NNP - I-GPE
, PUNCT - O
Thailand NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Mosquito VBN - B-MEDICINE
- PUNCT - O
borne VERB - O
diseases NOUN - O
constitute VERB - O
a DET - O
large ADJ - O
portion NOUN - O
of ADP - O
infectious ADJ - O
diseases NOUN - O
, PUNCT - O
causing VERB - O
more JJR - B-CARDINAL
than IN - I-CARDINAL
700,000 CD - I-CARDINAL
deaths NOUN - O
annually RB - B-DATE
. PUNCT - O

Mosquito NNS - B-MEDICINE
- PUNCT - O
transmitted VERB - O
viruses NOUN - O
, PUNCT - O
such ADJ - O
as ADP - O
yellow ADJ - O
fever NOUN - O
, PUNCT - O
dengue NOUN - O
, PUNCT - O
West NNP - B-LOC
Nile NNP - I-LOC
, PUNCT - O
chikungunya NOUN - O
, PUNCT - O
and CCONJ - O
Zika NNP - B-PERSON
viruses NOUN - O
, PUNCT - O
have VERB - O
re VERB - O
- VERB - O
emerged VERB - O
recently ADV - O
and CCONJ - O
remain VERB - O
a DET - O
public ADJ - O
health NOUN - O
threat NOUN - O
worldwide ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Mosquitoes NNS - B-GPE
rely VERB - O
on ADP - O
the DET - O
integration NOUN - O
of ADP - O
multiple ADJ - O
sensory ADJ - O
cues NOUN - O
, PUNCT - O
including VERB - O
olfactory NOUN - O
, PUNCT - O
visual ADJ - O
, PUNCT - O
and CCONJ - O
thermal ADJ - O
stimuli NOUN - O
, PUNCT - O
to PART - O
detect VERB - O
, PUNCT - O
identify VERB - O
and CCONJ - O
locate VERB - O
their ADJ - O
hosts NOUN - O
[ PUNCT - O
1 NUM - O
- SYM - O
4]. NUM - O

-DOCSTART- -X- - O

Mosquito JJ - B-MEDICINE
saliva NOUN - O
contains VERB - O
potent ADJ - O
immunogens NOUN - O
capable ADJ - O
of ADP - O
inducing VERB - O
antibody NOUN - O
production NOUN - O
directly ADV - O
related VERB - O
to ADP - O
mosquito JJ - B-MEDICINE
bite NOUN - O
exposure NOUN - O
intensity NOUN - O
and CCONJ - O
disease NOUN - O
risk NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Argemone NUM - O
mexicana NOUN - O
( PUNCT - O
Papaverales NOUN - O
: PUNCT - O
Papavaraceae PROPN - O
) PUNCT - O
as ADP - O
an DET - O
Alternative NNP - B-ORG
for IN - I-ORG
Mosquito NNP - I-MEDICINE
Control NNP - I-ORG
: : - I-ORG

-DOCSTART- -X- - O

Mosquitoes NNS - B-GPE
transmit VERB - O
many ADJ - O
harmful ADJ - O
diseases NOUN - O
that ADJ - O
seriously ADV - O
threaten VERB - O
public ADJ - O
health NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Long PROPN - O
and CCONJ - O
Short PROPN - O
of ADP - O
Hearing VERB - O
in ADP - O
the DET - O
Mosquito NNP - B-MEDICINE
Aedes PROPN - O
aegypti NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

At ADP - O
the DT - B-ORG
European NNP - I-ORG
Mosquito NNP - I-MEDICINE
Control NNP - I-ORG
Association NNP - I-ORG
( PUNCT - O
EMCA PROPN - O
) PUNCT - O
conference NOUN - O
in ADP - O
Montenegro NNP - B-GPE
in ADP - O
March NNP - B-DATE
2017 CD - I-DATE
, PUNCT - O
a DET - O
questionnaire NOUN - O
was VERB - O
distributed VERB - O
among ADP - O
meeting VERB - O
participants NOUN - O
to PART - O
collect VERB - O
expert ADJ - O
data NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mosquito JJ - B-MEDICINE
breeding NOUN - O
depends VERB - O
on ADP - O
the DET - O
supply NOUN - O
of ADP - O
fresh ADJ - O
vertebrate NOUN - O
blood NOUN - O
, PUNCT - O
a DET - O
major ADJ - O
bottleneck NOUN - O
for ADP - O
large ADJ - O
- PUNCT - O
scale NOUN - O
production NOUN - O
of ADP - O
Anopheles NNP - B-ORG
spp NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mosquito JJ - B-MEDICINE
trap NOUN - O
counts NOUN - O
are VERB - O
heavily ADV - O
influenced VERB - O
by ADP - O
environmental ADJ - O
factors NOUN - O
such ADJ - O
as ADP - O
temperature NOUN - O
and CCONJ - O
precipitation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Modeling NNP - B-ORG
Spatiotemporal NNP - I-ORG
Distribution NNP - I-ORG
of IN - I-ORG
Mosquitoes NNP - I-ORG
Abundance NNP - I-ORG
With IN - I-ORG
Unobservable NNP - I-ORG
Environmental NNP - I-ORG
Factors NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Landscape PROPN - O
and CCONJ - O
Environmental PROPN - O
Factors PROPN - O
Influencing PROPN - O
Stage PROPN - O
Persistence PROPN - O
and CCONJ - O
Abundance PROPN - O
of ADP - O
the DET - O
Bamboo PROPN - O
Mosquito NNP - B-MEDICINE
, PUNCT - O
Tripteroides PROPN - O
bambusa NOUN - O
( PUNCT - O
Diptera NOUN - O
: PUNCT - O
Culicidae PROPN - O
) PUNCT - O
, PUNCT - O
across ADP - O
an DET - O
Altitudinal PROPN - O
Gradient PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

A DT - B-LAW
Comparative NNP - I-LAW
Study NNP - I-LAW
of IN - I-LAW
Mosquito NNP - I-MEDICINE
and CCONJ - O
Sand PROPN - O
Fly PROPN - O

-DOCSTART- -X- - O

Mosquito NN - B-MEDICINE
- PUNCT - O
borne VERB - O
viruses NOUN - O
- PUNCT - O
such ADJ - O
as ADP - O
Zika NNP - B-PRODUCT
, PUNCT - O
chikungunya NOUN - O
, PUNCT - O
dengue NOUN - O
fever NOUN - O
, PUNCT - O
and CCONJ - O
yellow ADJ - O
fever NOUN - O
, PUNCT - O
among ADP - O
others NOUN - O
- PUNCT - O
are VERB - O
of ADP - O
global ADJ - O
importance NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mosquito JJ - B-MEDICINE
bloodmeal NOUN - O
preferences NOUN - O
in ADP - O
two CD - B-CARDINAL
zoological ADJ - O
gardens NOUN - O
in ADP - O
Germany NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Mosquito JJ - B-MEDICINE
sampling NOUN - O
was VERB - O
done VERB - O
over ADP - O
a DET - O
13-month CD - B-CARDINAL
period NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mosquito JJ - B-MEDICINE
samples NOUN - O
from ADP - O
10 CD - B-CARDINAL
locations NOUN - O
within ADP - O
Akure JJ - B-PRODUCT
metropolis NOUN - O
in ADP - O
Southwest NNP - B-LOC
Nigeria NNP - I-LOC
were VERB - O
tested VERB - O
for ADP - O
variation NOUN - O
in ADP - O
susceptibility NOUN - O
to ADP - O
the DET - O
toxic ADJ - O
effect NOUN - O
of ADP - O
botanical ADJ - O
extracts NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mosquitoes NOUN - O
are VERB - O
hematophagous ADJ - O
insects NOUN - O
of ADP - O
major ADJ - O
public ADJ - O
health NOUN - O
concern NOUN - O
, PUNCT - O
serving VERB - O
as ADP - O
vectors NOUN - O
of ADP - O
many ADJ - O
diseases NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mosquitoes NOUN - O
are VERB - O
ubiquitous ADJ - O
insects NOUN - O
, PUNCT - O
responsible ADJ - O
for ADP - O
transmitting VERB - O
many ADJ - O
deadly ADJ - O
arboviruses NOUN - O
causing VERB - O
millions NNS - B-CARDINAL
of ADP - O
human ADJ - O
deaths NOUN - O
every DET - O
year NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mosquitoes NNS - B-GPE
exhibited VERB - O
multiple ADJ - O
blood NOUN - O
feeding NOUN - O
behavior NOUN - O
within ADP - O
a DET - O
gonotrophic ADJ - O
cycle NOUN - O
, PUNCT - O
with ADP - O
predominantly ADV - O
non ADJ - O
- ADJ - O
human ADJ - O
hosts NOUN - O
in ADP - O
the DET - O
bloodmeal NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Integrated NNP - B-ORG
Mosquito NNP - I-MEDICINE
Management NNP - I-ORG
: : - I-ORG
Is VBZ - I-ORG
Precision NNP - I-ORG
Control NNP - I-ORG
a DET - O
Luxury NNP - B-ORG
or CCONJ - O
Necessity NOUN - O
? PUNCT - O

-DOCSTART- -X- - O

Relationships NOUN - O
Among ADP - O
Immature NNP - B-ORG
- HYPH - I-ORG
Stage NNP - I-ORG
Metrics NNPS - I-ORG
and CCONJ - O
Adult NNP - B-ORG
Abundances NNPS - I-ORG
of ADP - O
Mosquito NNP - B-MEDICINE
Populations NNPS - I-ORG
in ADP - O
Baltimore NNP - B-GPE
, PUNCT - O
MD NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
C PROPN - O
- PUNCT - O
Terminal PROPN - O
Domain PROPN - O
of ADP - O
the DET - O
Bacillus NOUN - O
thuringiensis NOUN - O
Cry4Ba NNP - B-ORG
Mosquito NNP - I-MEDICINE
- HYPH - I-ORG
Specific NNP - I-ORG
Toxin NNP - I-ORG
Serves VBZ - I-ORG
as ADP - O
a DET - O
Potential PROPN - O
Membrane PROPN - O
Anchor PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Mosquito RB - B-MEDICINE
- PUNCT - O
borne ADJ - O
epornitic ADJ - O
flaviviruses NOUN - O
: PUNCT - O
an DET - O
update NOUN - O
and CCONJ - O
review NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mosquito NN - B-MEDICINE
- PUNCT - O
borne VERB - O
arboviruses NOUN - O
, PUNCT - O
like ADP - O
dengue NOUN - O
virus NOUN - O
, PUNCT - O
continue VERB - O
to PART - O
cause VERB - O
significant ADJ - O
global ADJ - O
morbidity NOUN - O
and CCONJ - O
mortality NOUN - O
, PUNCT - O
particularly ADV - O
in ADP - O
Southeast NNP - B-LOC
Asia NNP - I-LOC
. PUNCT - O

-DOCSTART- -X- - O

Mosquito NNP - B-MEDICINE
biting NOUN - O
or CCONJ - O
exposure NOUN - O
is VERB - O
a DET - O
risk NOUN - O
factor NOUN - O
for ADP - O
malaria NOUN - O
transmission NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mosquito JJ - B-MEDICINE
genetic ADJ - O
control NOUN - O
strategies NOUN - O
( PUNCT - O
GCSs NOUN - O
) PUNCT - O
have VERB - O
become VERB - O
an DET - O
increasingly ADV - O
important ADJ - O
area NOUN - O
of ADP - O
research NOUN - O
on ADP - O
account NOUN - O
of ADP - O
their ADJ - O
species NOUN - O
- PUNCT - O
specificity NOUN - O
, PUNCT - O
track NOUN - O
record NOUN - O
in ADP - O
targeting VERB - O
agricultural ADJ - O
insect NOUN - O
pests NOUN - O
, PUNCT - O
and CCONJ - O
their ADJ - O
environmentally ADV - O
non ADJ - O
- ADJ - O
polluting ADJ - O
nature NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mosquitoes NOUN - O
were VERB - O
collected VERB - O
at ADP - O
14 CD - B-CARDINAL
sites NOUN - O
in ADP - O
northern ADJ - O
regions NOUN - O
of ADP - O
Iran NNP - B-GPE
in ADP - O
2015 CD - B-DATE
and CCONJ - O
2016 CD - B-DATE
. PUNCT - O

-DOCSTART- -X- - O

Mosquito JJ - B-MEDICINE
and CCONJ - O
primate NOUN - O
ecology NOUN - O
predict VERB - O
human ADJ - O
risk NOUN - O
of ADP - O
yellow ADJ - O
fever NOUN - O
virus NOUN - O
spillover NOUN - O
in ADP - O
Brazil NNP - B-GPE
: PUNCT - O

-DOCSTART- -X- - O

Mosquito JJ - B-MEDICINE
legs NOUN - O
were VERB - O
the DET - O
body NOUN - O
part NOUN - O
most ADV - O
frequently ADV - O
used VERB - O
to PART - O
create VERB - O
identification NOUN - O
DB NN - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Mosquito JJ - B-MEDICINE
density NOUN - O
significantly ADV - O
changed VERB - O
( PUNCT - O
generalized VERB - O
linear ADJ - O
mixed VERB - O
model NOUN - O
; PUNCT - O
F8 PROPN - O
, PUNCT - O
14,588 CD - B-CARDINAL
= SYM - O
296 CD - B-CARDINAL
; PUNCT - O
P NOUN - O
< X - O
0.001 CD - B-CARDINAL
) PUNCT - O
from ADP - O
8.0 CD - B-CARDINAL
± NUM - O
0.1 CD - B-CARDINAL
females NOUN - O
per ADP - O
trap NOUN - O
per ADP - O
week NN - B-DATE
before ADP - O
the DET - O
intervention NOUN - O
to ADP - O
2.1 CD - B-CARDINAL
± NUM - O
0.04 CD - B-CARDINAL
after ADP - O
the DET - O
percentage NOUN - O
of ADP - O
buildings NOUN - O
treated VERB - O
with ADP - O
traps NOUN - O
was VERB - O
60 CD - B-PERCENT
% NN - I-PERCENT
and CCONJ - O
to ADP - O
1.4 CD - B-CARDINAL
± NUM - O
0.04 CD - B-CARDINAL
when ADV - O
coverage NOUN - O
was VERB - O
above ADP - O
80 CD - B-PERCENT
% NN - I-PERCENT
. PUNCT - O

-DOCSTART- -X- - O

( PUNCT - O
Diptera NOUN - O
: PUNCT - O
Culicidae PROPN - O
) PUNCT - O
during ADP - O
the DET - O
2016 CD - B-DATE
Zika PROPN - O
Epidemic PROPN - O
by ADP - O
Integrating PROPN - O
Community PROPN - O
Awareness PROPN - O
, PUNCT - O
Education PROPN - O
, PUNCT - O
Source PROPN - O
Reduction PROPN - O
, PUNCT - O
Larvicides PROPN - O
, PUNCT - O
and CCONJ - O
Mass NNP - B-ORG
Mosquito NNP - I-MEDICINE
Trapping NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Mosquitoes NOUN - O
are VERB - O
hematophagous ADJ - O
vectors NOUN - O
that ADJ - O
can VERB - O
acquire VERB - O
human ADJ - O
viruses NOUN - O
in ADP - O
their ADJ - O
intestinal ADJ - O
tract NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Gut PROPN - O
Commensal PROPN - O
Bacterium PROPN - O
Promotes PROPN - O
Mosquito NNP - B-MEDICINE
Permissiveness PROPN - O
to ADP - O
Arboviruses PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Mosquitoes NNS - B-GPE
may VERB - O
develop VERB - O
resistance NOUN - O
to PART - O
insecticide VERB - O
active ADJ - O
ingredients NOUN - O
( PUNCT - O
AIs NOUN - O
) PUNCT - O
found VERB - O
in ADP - O
formulated VERB - O
products NOUN - O
( PUNCT - O
FPs NOUN - O
) PUNCT - O
due ADP - O
to ADP - O
environmental ADJ - O
exposure NOUN - O
from ADP - O
insecticides NOUN - O
in ADP - O
mosquito JJ - B-MEDICINE
control NOUN - O
and/or CCONJ - O
unrelated ADJ - O
to ADP - O
mosquito JJ - B-MEDICINE
control NOUN - O
, PUNCT - O
e.g. ADJ - O
, PUNCT - O
agricultural ADJ - O
, PUNCT - O
household NOUN - O
pest NOUN - O
control NOUN - O
. PUNCT - O

Mosquito JJ - B-MEDICINE
control NOUN - O
programs NOUN - O
should VERB - O
implement VERB - O
resistance NOUN - O
management NOUN - O
strategies NOUN - O
by ADP - O
assessing VERB - O
resistance NOUN - O
in ADP - O
targeted ADJ - O
populations NOUN - O
, PUNCT - O
rotating VERB - O
different ADJ - O
classes NOUN - O
of ADP - O
insecticides NOUN - O
based VERB - O
on ADP - O
resistance NOUN - O
testing NOUN - O
, PUNCT - O
and/or CCONJ - O
increasing VERB - O
insecticide ADJ - O
concentration NOUN - O
( PUNCT - O
i.e. X - O
, PUNCT - O
saturation NOUN - O
, PUNCT - O
using VERB - O
maximum ADJ - O
labeled VERB - O
rate NOUN - O
) PUNCT - O
to PART - O
overcome VERB - O
emerging VERB - O
resistance NOUN - O
. PUNCT - O

Centers NNS - B-ORG
for IN - I-ORG
Disease NNP - I-ORG
Control NNP - I-ORG
and CC - I-ORG
Prevention NNP - I-ORG
( PUNCT - O
CDC NNP - B-ORG
) PUNCT - O
bottle NOUN - O
bioassays NOUN - O
were VERB - O
used VERB - O
to PART - O
assess VERB - O
resistance NOUN - O
/ SYM - O
susceptibility NOUN - O
status NOUN - O
for ADP - O
eight CD - B-CARDINAL
AIs NOUN - O
( PUNCT - O
i.e. X - O
, PUNCT - O
bifenthrin NOUN - O
, PUNCT - O
permethrin NOUN - O
, PUNCT - O
sumethrin VERB - O
/ SYM - O
prallethrin NOUN - O
, PUNCT - O
deltamethrin NOUN - O
, PUNCT - O
tau NOUN - O
- PUNCT - O
fluvalinate NOUN - O
, PUNCT - O
chlorpyrifos NOUN - O
, PUNCT - O
malathion NOUN - O
, PUNCT - O
and CCONJ - O
naled VERB - O
) PUNCT - O
and CCONJ - O
eight CD - B-CARDINAL
FPs NOUN - O
( PUNCT - O
TalStar NNP - B-ORG
, PUNCT - O
Biomist PROPN - O
3 CD - B-CARDINAL
+ SYM - O
15 NUM - O
, PUNCT - O
Duet PROPN - O
, PUNCT - O
Suspend NNP - B-PERSON
Polyzone NNP - I-PERSON
, PUNCT - O
Mavrik NNP - B-PERSON
, PUNCT - O
MosquitoMist NNP - B-ORG
, PUNCT - O
Fyfanon NNP - B-ORG
, PUNCT - O
and CCONJ - O
Dibrom NNP - B-PERSON
) PUNCT - O
that ADJ - O
respectively ADV - O
contain VERB - O
the DET - O
AIs NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mosquitoes NNS - B-GPE
were VERB - O
screened VERB - O
for ADP - O
major ADJ - O
arboviruses NOUN - O
to PART - O
investigate VERB - O
if ADP - O
any DET - O
evidence NOUN - O
could VERB - O
be VERB - O
provided VERB - O
for ADP - O
their ADJ - O
potential ADJ - O
role NOUN - O
in ADP - O
transmission NOUN - O
and CCONJ - O
we PRON - O
report VERB - O
the DET - O
presence NOUN - O
of ADP - O
Rift NNP - B-LOC
Valley NNP - I-LOC
fever NOUN - O
virus NOUN - O
in ADP - O
three CD - B-CARDINAL
Culex NNP - B-NORP
species NOUN - O
: PUNCT - O
Culex JJ - B-ORG
tritaeniorhynchus NOUN - O
, PUNCT - O
Culex NNP - B-ORG
antennatus NOUN - O
and CCONJ - O
Culex NNP - B-ORG
decens NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mosquitoes NOUN - O
are VERB - O
widely ADV - O
despised VERB - O
for ADP - O
their ADJ - O
exasperating VERB - O
buzzing VERB - O
and CCONJ - O
irritating VERB - O
bites NOUN - O
, PUNCT - O
and CCONJ - O
more ADV - O
poignantly ADV - O
because ADP - O
, PUNCT - O
during ADP - O
blood NOUN - O
- PUNCT - O
feeding NOUN - O
, PUNCT - O
females NOUN - O
may VERB - O
transmit VERB - O
pathogens NOUN - O
that ADJ - O
cause VERB - O
devastating ADJ - O
diseases NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Of ADP - O
Genes PROPN - O
and CCONJ - O
Genomes PROPN - O
: PUNCT - O
Mosquito NNP - B-MEDICINE
Evolution PROPN - O
and CCONJ - O
Diversity PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Mosquito VBN - B-MEDICINE
- PUNCT - O
borne VERB - O
viruses NOUN - O
are VERB - O
the DET - O
cause NOUN - O
of ADP - O
some DET - O
of ADP - O
the DET - O
greatest ADJ - O
burdens NOUN - O
to ADP - O
human ADJ - O
health NOUN - O
worldwide ADV - O
, PUNCT - O
particularly ADV - O
in ADP - O
tropical ADJ - O
regions NOUN - O
where ADV - O
both CCONJ - O
human ADJ - O
populations NOUN - O
and CCONJ - O
mosquito NN - B-MEDICINE
numbers NOUN - O
are VERB - O
abundant ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Emerging PROPN - O
Mosquito NNP - B-MEDICINE
- PUNCT - O
Borne PROPN - O
Threats PROPN - O
and CCONJ - O
the DET - O
Response NNP - B-ORG
from ADP - O
European JJ - B-NORP
and CCONJ - O
Eastern NNP - B-LOC
Mediterranean NNP - I-LOC
Countries NNP - I-LOC
. PUNCT - O

-DOCSTART- -X- - O

Mosquito JJ - B-MEDICINE
coils NOUN - O
in ADP - O
a DET - O
metal NOUN - O
casing VERB - O
worn VERB - O
on ADP - O
a DET - O
belt NOUN - O
resulted VERB - O
in ADP - O
92.3 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
confidence NOUN - O
interval NOUN - O
, PUNCT - O
CI NNP - B-ORG
: PUNCT - O
88.9 CD - B-PERCENT
- SYM - I-PERCENT
94.6 CD - I-PERCENT
% NN - I-PERCENT
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Mosquito VBN - B-MEDICINE
- PUNCT - O
borne VERB - O
viruses NOUN - O
encompass VERB - O
a DET - O
wide ADJ - O
range NOUN - O
of ADP - O
pathogens NOUN - O
, PUNCT - O
such ADJ - O
as ADP - O
dengue NOUN - O
and CCONJ - O
Zika PROPN - O
viruses NOUN - O
, PUNCT - O
that ADJ - O
often ADV - O
cocirculate VERB - O
geographically ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Targeting VERB - O
the DT - B-WORK_OF_ART
Achilles NNP - I-WORK_OF_ART
Heel NNP - I-WORK_OF_ART
of IN - I-WORK_OF_ART
Mosquito NNP - I-MEDICINE
- HYPH - I-WORK_OF_ART
Borne NNP - I-WORK_OF_ART
Viruses NNP - I-WORK_OF_ART
for IN - I-WORK_OF_ART
Antiviral NNP - I-WORK_OF_ART
Therapy NNP - I-WORK_OF_ART
. PUNCT - O

-DOCSTART- -X- - O

( PUNCT - O
Diptera NOUN - O
: PUNCT - O
Culicidae PROPN - O
) PUNCT - O
Mosquitoes PROPN - O
Is VERB - O
Lower ADJ - O
Than ADP - O
Would VERB - O
Be VERB - O
Expected VERB - O
by ADP - O
a DET - O
Randomized PROPN - O
Search PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Mosquito JJ - B-MEDICINE
immature ADJ - O
stages NOUN - O
were VERB - O
present ADJ - O
in ADP - O
all ADJ - O
the DET - O
occasions NOUN - O
in ADP - O
which ADJ - O
water NOUN - O
bodies NOUN - O
were VERB - O
recorded VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Seasonal ADJ - O
and CCONJ - O
Environmental NNP - B-ORG
Variables NNS - I-ORG
Related VBN - I-ORG
to ADP - O
the DET - O
Abundance PROPN - O
of ADP - O
Immature PROPN - O
Mosquitoes PROPN - O
in ADP - O
Rain NNP - B-GPE
Pools PROPN - O
of ADP - O
a DET - O
Peri PROPN - O
- PUNCT - O
Urban PROPN - O
Park PROPN - O
of ADP - O
Buenos NNP - B-PERSON
Aires NNP - I-PERSON
( PUNCT - O
Argentina NNP - B-GPE
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

DEET PROPN - O
Efficacy NOUN - O
Increases VERB - O
With ADP - O
Age PROPN - O
in ADP - O
the DET - O
Vector PROPN - O
Mosquitoes PROPN - O
Anopheles PROPN - O
gambiae PROPN - O
s.s PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Base NOUN - O
Distribution NOUN - O
in ADP - O
Dengue PROPN - O
Nucleotide PROPN - O
Sequences PROPN - O
Differs VERB - O
Significantly ADV - O
from ADP - O
Other PROPN - O
Mosquito NNP - B-MEDICINE
- PUNCT - O
Borne PROPN - O
Human PROPN - O
- PUNCT - O
Infecting PROPN - O
Flavivirus PROPN - O
Members PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Role NOUN - O
for ADP - O
the DET - O
Insulin PROPN - O
Receptor PROPN - O
in ADP - O
the DT - B-ORG
Suppression NNP - I-ORG
of IN - I-ORG
Dengue NNP - I-ORG
Virus NNP - I-ORG
and CC - I-ORG
Zika NNP - B-PERSON
Virus NNP - I-PERSON
in ADP - O
Wolbachia NNP - B-ORG
- HYPH - I-ORG
Infected NNP - I-ORG
Mosquito NNP - I-MEDICINE
Cells NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Comparison NNP - B-ORG
of IN - I-ORG
Landmark- NNP - I-ORG
and CCONJ - O
Outline PROPN - O
- PUNCT - O
Based VERB - O
Geometric PROPN - O
Morphometrics PROPN - O
for ADP - O
Discriminating PROPN - O
Mosquito NNP - B-MEDICINE
Vectors PROPN - O
in ADP - O
Ratchaburi NNP - B-GPE
Province NNP - I-GPE
, PUNCT - O
Thailand NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Zika PROPN - O
Virus PROPN - O
Infection PROPN - O
Produces VERB - O
a DET - O
Reduction NOUN - O
on ADP - O
Aedes PROPN - O
aegypti NOUN - O
Lifespan NNP - B-GPE
but CCONJ - O
No DET - O
Effects PROPN - O
on ADP - O
Mosquito NNP - B-MEDICINE
Fecundity NNP - I-ORG
and CC - I-ORG
Oviposition NNP - I-ORG
Success NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Biological NNP - B-ORG
Control NNP - I-ORG
of IN - I-ORG
Mosquito NNP - I-MEDICINE
- HYPH - I-ORG
Borne NNP - I-ORG
Diseases NNPS - I-ORG
: PUNCT - O
The DET - O
Potential PROPN - O
of ADP - O
Wolbachia PROPN - O
- PUNCT - O
Based VERB - O
Interventions PROPN - O
in ADP - O
an DET - O
IVM NNP - B-ORG
Framework NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Simple PROPN - O
Model PROPN - O
to PART - O
Predict VB - B-GPE
the DET - O
Potential PROPN - O
Abundance PROPN - O
of ADP - O
Aedes PROPN - O
aegypti NOUN - O
Mosquitoes NNP - B-GPE

-DOCSTART- -X- - O

Correction NOUN - O
to PART - O
: PUNCT - O
Mosquito NN - B-MEDICINE
- PUNCT - O
borne VERB - O
heartworm NOUN - O
Dirofilaria NNP - B-NORP
immitis NOUN - O
in ADP - O
dogs NOUN - O
from ADP - O
Australia NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Efficacy NOUN - O
of ADP - O
Mosquito NNP - B-MEDICINE
Coils NNPS - I-ORG
: PUNCT - O
Cross NOUN - O
- PUNCT - O
resistance NOUN - O
to ADP - O
Pyrethroids NNP - B-GPE
in ADP - O

-DOCSTART- -X- - O

Arbovirus PROPN - O
- PUNCT - O
Mosquito NNP - B-MEDICINE
Vector PROPN - O
- PUNCT - O
Host PROPN - O
Interactions NOUN - O
and CCONJ - O
the DET - O
Impact NOUN - O
on ADP - O
Transmission PROPN - O
and CCONJ - O
Disease PROPN - O
Pathogenesis PROPN - O
of ADP - O
Arboviruses PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Mosquito VBN - B-MEDICINE
- PUNCT - O
borne VERB - O
infectious ADJ - O
disease NOUN - O
, PUNCT - O
risk NOUN - O
- PUNCT - O
perceptions NOUN - O
, PUNCT - O
and CCONJ - O
personal ADJ - O
protective ADJ - O
behavior NOUN - O
among ADP - O
U.S. NNP - B-GPE
international ADJ - O
travelers NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Essential PROPN - O
Oil PROPN - O
Against PROPN - O
Mosquito NNP - B-MEDICINE
Larvae NNP - B-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Mosquito JJ - B-MEDICINE
dynamics NOUN - O
are VERB - O
coupled VERB - O
to PART - O
infection VERB - O
among ADP - O
a DET - O
human ADJ - O
population NOUN - O
with ADP - O
symptomatic ADJ - O
and CCONJ - O
asymptomatic ADJ - O
disease NOUN - O
carriers NOUN - O
, PUNCT - O
as ADV - O
well ADV - O
as ADP - O
temporary ADJ - O
immunity NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Protocols NNS - B-ORG
for IN - I-ORG
Testing VBG - I-ORG
the DT - I-ORG
Toxicity NNP - I-ORG
of IN - I-ORG
Novel NNP - I-ORG
Insecticidal NNP - I-ORG
Chemistries VBZ - I-ORG
to ADP - O
Mosquitoes NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Mosquito NNP - B-MEDICINE
Bite NNP - I-ORG
with IN - I-ORG
Devastating NNP - I-ORG
Complications NNPS - I-ORG
in ADP - O
an DT - B-ORG
Immunocompromised NNP - I-ORG
Patient NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
addition NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
to PART - O
radiotherapy VERB - O
( PUNCT - O
RT PROPN - O
) PUNCT - O
improves VERB - O
survival NOUN - O
of ADP - O
patients NOUN - O
with ADP - O
glioblastoma NOUN - O
( PUNCT - O
GBM NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Data NOUN - O
from ADP - O
a DET - O
previous ADJ - O
unrandomised ADJ - O
phase NOUN - O
2 CD - B-CARDINAL
trial NOUN - O
suggested VERB - O
that ADP - O
lomustine NOUN - O
- PUNCT - O
temozolomide NN - B-MEDICINE
plus CCONJ - O
radiotherapy NOUN - O
might VERB - O
be VERB - O
superior ADJ - O
to PART - O
temozolomide NN - B-MEDICINE
chemoradiotherapy NOUN - O
in ADP - O
newly ADV - O
diagnosed VERB - O
glioblastoma NOUN - O
with ADP - O
methylation NOUN - O
of ADP - O
the DET - O
MGMT NNP - B-ORG
promoter NOUN - O
. PUNCT - O

In ADP - O
the DET - O
CeTeG PROPN - O
/ SYM - O
NOA-09 PROPN - O
trial NOUN - O
, PUNCT - O
we PRON - O
aimed VERB - O
to PART - O
further ADV - O
investigate VERB - O
the DET - O
effect NOUN - O
of ADP - O
lomustine NOUN - O
- PUNCT - O
temozolomide NN - B-MEDICINE
therapy NOUN - O
in ADP - O
the DET - O
setting NOUN - O
of ADP - O
a DET - O
randomised VERB - O
phase NOUN - O
3 CD - B-CARDINAL
trial NOUN - O
. PUNCT - O

Patients NOUN - O
were VERB - O
randomly ADV - O
assigned VERB - O
( PUNCT - O
1:1 CD - B-CARDINAL
) PUNCT - O
with ADP - O
a DET - O
predefined VERB - O
SAS NNP - B-ORG
- PUNCT - O
generated VERB - O
randomisation NOUN - O
list NOUN - O
to ADP - O
standard ADJ - O
temozolomide NN - B-MEDICINE
chemoradiotherapy NOUN - O
( PUNCT - O
75 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
m2 NOUN - O
per ADP - O
day NOUN - O
concomitant NOUN - O
to PART - O
radiotherapy VERB - O
[ PUNCT - O
59 CD - B-CARDINAL
- SYM - I-CARDINAL
60 CD - I-CARDINAL
Gy PROPN - O
] PUNCT - O
followed VERB - O
by ADP - O
six CD - B-CARDINAL
courses NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
150 CD - B-CARDINAL
- SYM - I-CARDINAL
200 CD - I-CARDINAL
mg NOUN - O
/ SYM - O
m2 NOUN - O
per ADP - O
day NOUN - O
on ADP - O
the DT - B-DATE
first JJ - I-DATE
5 CD - I-DATE
days NNS - I-DATE
of ADP - O
the DET - O
4-week CD - B-DATE
course NOUN - O
) PUNCT - O
or CCONJ - O
to PART - O
up ADP - O
to PART - O
six CD - B-CARDINAL
courses NOUN - O
of ADP - O
lomustine NOUN - O
( PUNCT - O
100 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
m2 NOUN - O
on ADP - O
day NN - B-DATE
1 CD - I-DATE
) PUNCT - O
plus CCONJ - O
temozolomide NN - B-MEDICINE
( PUNCT - O
100 CD - B-CARDINAL
- SYM - I-CARDINAL
200 CD - I-CARDINAL
mg NOUN - O
/ SYM - O
m2 NOUN - O
per ADP - O
day NOUN - O
on ADP - O
days NNS - B-DATE
2 CD - I-DATE
- SYM - I-DATE
6 CD - I-DATE
of ADP - O
the DET - O
6-week CD - B-ORDINAL
course NOUN - O
) PUNCT - O
in ADP - O
addition NOUN - O
to ADP - O
radiotherapy PROPN - O
( PUNCT - O
59 CD - B-CARDINAL
- SYM - I-CARDINAL
60 CD - I-CARDINAL
Gy PROPN - O
) PUNCT - O
. PUNCT - O

Between IN - B-DATE
June NNP - I-DATE
17 CD - I-DATE
, , - I-DATE
2011 CD - I-DATE
, PUNCT - O
and CCONJ - O
April NNP - B-DATE
8 CD - I-DATE
, , - I-DATE
2014 CD - I-DATE
, PUNCT - O
141 CD - B-CARDINAL
patients NOUN - O
were VERB - O
randomly ADV - O
assigned VERB - O
to ADP - O
the DET - O
treatment NOUN - O
groups NOUN - O
; PUNCT - O
129 CD - B-CARDINAL
patients NOUN - O
( PUNCT - O
63 CD - B-CARDINAL
in ADP - O
the DET - O
temozolomide NN - B-MEDICINE
and CCONJ - O
66 CD - B-CARDINAL
in ADP - O
the DET - O
lomustine NOUN - O
- PUNCT - O
temozolomide NN - B-MEDICINE
group NOUN - O
) PUNCT - O
constituted VERB - O
the DET - O
modified VERB - O
intention NOUN - O
- PUNCT - O
to ADP - O
- PUNCT - O
treat VERB - O
population NOUN - O
. PUNCT - O

Median ADJ - O
overall ADJ - O
survival NOUN - O
was VERB - O
improved VERB - O
from ADP - O
31·4 CD - B-DATE
months NNS - I-DATE
( PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
27·7 PROPN - O
- SYM - O
47·1 NUM - O
) PUNCT - O
with ADP - O
temozolomide NN - B-MEDICINE
to ADP - O
48·1 CD - B-DATE
months NNS - I-DATE
( PUNCT - O
32·6 NUM - O
months NOUN - O
- PUNCT - O
not ADV - O
assessable ADJ - O
) PUNCT - O
with ADP - O
lomustine NOUN - O
- PUNCT - O
temozolomide NN - B-MEDICINE
( PUNCT - O
hazard NOUN - O
ratio NOUN - O
[ PUNCT - O
HR PROPN - O
] PUNCT - O
0·60 PROPN - O
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
0·35 PROPN - O
- PUNCT - O
1·03 NOUN - O
; PUNCT - O
p=0·0492 NOUN - O
for ADP - O
log NOUN - O
- PUNCT - O
rank NOUN - O
analysis NOUN - O
) PUNCT - O
. PUNCT - O

Adverse JJ - B-ORG
events NOUN - O
of ADP - O
grade NOUN - O
3 CD - B-CARDINAL
or CCONJ - O
higher ADJ - O
were VERB - O
observed VERB - O
in ADP - O
32 CD - B-CARDINAL
( PUNCT - O
51 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
of ADP - O
63 CD - B-CARDINAL
patients NOUN - O
in ADP - O
the DET - O
temozolomide NN - B-MEDICINE
group NOUN - O
and CCONJ - O
39 CD - B-CARDINAL
( PUNCT - O
59 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
of ADP - O
66 CD - B-CARDINAL
patients NOUN - O
in ADP - O
the DET - O
lomustine NOUN - O
- PUNCT - O
temozolomide NN - B-MEDICINE
group NOUN - O
. PUNCT - O

Our ADJ - O
results NOUN - O
suggest VERB - O
that ADP - O
lomustine NOUN - O
- PUNCT - O
temozolomide NN - B-MEDICINE
chemotherapy NOUN - O
might VERB - O
improve VERB - O
survival NOUN - O
compared VERB - O
with ADP - O
temozolomide NN - B-MEDICINE
standard ADJ - O
therapy NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
newly ADV - O
diagnosed VERB - O
glioblastoma NOUN - O
with ADP - O
methylated VERB - O
MGMT NNP - B-ORG
promoter NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Lomustine NOUN - O
- PUNCT - O
temozolomide NN - B-MEDICINE
combination NOUN - O
therapy NOUN - O
versus ADP - O
standard ADJ - O
temozolomide NN - B-MEDICINE
therapy NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
newly ADV - O
diagnosed VERB - O
glioblastoma NOUN - O
with ADP - O
methylated VERB - O
MGMT NNP - B-ORG
promoter NOUN - O
( PUNCT - O
CeTeG NNP - B-WORK_OF_ART
/ SYM - I-WORK_OF_ART
NOA-09 NNP - I-WORK_OF_ART
) PUNCT - O
: PUNCT - O
a DET - O
randomised ADJ - O
, PUNCT - O
open ADJ - O
- PUNCT - O
label NOUN - O
, PUNCT - O
phase NOUN - O
3 CD - B-CARDINAL
trial NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Here ADV - O
we PRON - O
provide VERB - O
evidence NOUN - O
that ADP - O
the DET - O
DNA NOUN - O
damage NOUN - O
kinase NOUN - O
HIPK2 NNP - B-ORG
and CCONJ - O
its ADJ - O
negative ADJ - O
regulatory ADJ - O
E3-ubiquitin NNP - B-GPE
ligase NOUN - O
SIAH1 NOUN - O
are VERB - O
critical ADJ - O
factors NOUN - O
controlling VERB - O
temozolomide NN - B-MEDICINE
- PUNCT - O
induced VERB - O
cell NOUN - O
death NOUN - O
. PUNCT - O

Upon ADP - O
temozolomide NN - B-MEDICINE
treatment NOUN - O
, PUNCT - O
p53 NOUN - O
becomes VERB - O
phosphorylated VERB - O
whereby ADP - O
HIPK2kd NNP - B-GPE
had VERB - O
impact NOUN - O
exclusively ADV - O
on ADP - O
ser46 NOUN - O
, PUNCT - O
but CCONJ - O
not ADV - O
ser15 VERB - O
. PUNCT - O

Thus ADV - O
, PUNCT - O
the DET - O
expression NOUN - O
of ADP - O
FAS NNP - B-ORG
was VERB - O
attenuated VERB - O
following VERB - O
HIPK2kd NNP - B-GPE
, PUNCT - O
supporting VERB - O
the DET - O
conclusion NOUN - O
that ADP - O
HIPK2 NNP - B-PERSON
regulates VERB - O
temozolomide NN - B-MEDICINE
- PUNCT - O
induced VERB - O
apoptosis NOUN - O
via ADP - O
p NOUN - O
- PUNCT - O
p53ser46 NOUN - O
driven VERB - O
FAS PROPN - O
expression NOUN - O
. PUNCT - O

Other ADJ - O
pro ADJ - O
- ADJ - O
apoptotic ADJ - O
proteins NOUN - O
like ADP - O
PUMA NNP - B-ORG
, PUNCT - O
NOXA NNP - B-ORG
, PUNCT - O
BAX NNP - B-ORG
and CCONJ - O
PTEN NNP - B-ORG
were VERB - O
not ADV - O
affected VERB - O
in ADP - O
HIPK2kd NNP - B-GPE
, PUNCT - O
and CCONJ - O
also ADV - O
double ADJ - O
- PUNCT - O
strand NOUN - O
breaks NOUN - O
following VERB - O
temozolomide NN - B-MEDICINE
remained VERB - O
unaffected ADJ - O
. PUNCT - O

We PRON - O
further ADV - O
show VERB - O
that ADP - O
downregulation NOUN - O
of ADP - O
the DET - O
HIPK2 NNP - B-PERSON
inactivator NOUN - O
SIAH1 PROPN - O
significantly ADV - O
ameliorates VERB - O
temozolomide NN - B-MEDICINE
- PUNCT - O
induced VERB - O
apoptosis NOUN - O
, PUNCT - O
suggesting VERB - O
that ADP - O
the DET - O
ATM NNP - B-ORG
/ SYM - I-ORG
ATR NNP - I-ORG
target NOUN - O
SIAH1 VERB - O
together ADV - O
with ADP - O
HIPK2 NNP - B-PERSON
plays VERB - O
a DET - O
proapoptotic ADJ - O
role NOUN - O
in ADP - O
glioma NOUN - O
cells NOUN - O
exhibiting VERB - O
p53wt NOUN - O
status NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
SIAH1-HIPK2-p53ser46 JJ - B-ORG
damage NOUN - O
response NOUN - O
pathway NOUN - O
is VERB - O
involved VERB - O
in ADP - O
temozolomide NN - B-MEDICINE
- PUNCT - O
induced VERB - O
glioblastoma NOUN - O
cell NOUN - O
death NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Therefore ADV - O
, PUNCT - O
we PRON - O
aimed VERB - O
to PART - O
determine VERB - O
the DET - O
immune ADJ - O
modulatory ADJ - O
effects NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
that ADJ - O
would VERB - O
impact VERB - O
response NOUN - O
to ADP - O
immune ADJ - O
checkpoint NOUN - O
inhibition NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
experimental ADJ - O
GBM NNS - B-ORG
. PUNCT - O

Immune ADJ - O
function NOUN - O
and CCONJ - O
anti ADJ - O
- ADJ - O
tumor ADJ - O
efficacy NOUN - O
of ADP - O
immune ADJ - O
checkpoint NOUN - O
inhibition NOUN - O
were VERB - O
tested VERB - O
after ADP - O
treatment NOUN - O
with ADP - O
metronomic ADJ - O
dose NOUN - O
( PUNCT - O
MD NNP - B-ORG
) PUNCT - O
temozolomide NN - B-MEDICINE
( PUNCT - O
25mg NNP - B-ORDINAL
/ SYM - O
kg NOUN - O
x SYM - O
10 CD - B-DATE
days NNS - I-DATE
) PUNCT - O
or CCONJ - O
standard NOUN - O
dose NOUN - O
( PUNCT - O
SD NNP - B-ORG
) PUNCT - O
temozolomide NN - B-MEDICINE
( PUNCT - O
50 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
kg NOUN - O
x SYM - O
5 CD - B-DATE
days NNS - I-DATE
) PUNCT - O
in ADP - O
the DET - O
GL261 NN - B-PRODUCT
and CCONJ - O
KR158 NNP - B-PRODUCT
murine VERB - O
glioma NOUN - O
models NOUN - O
. PUNCT - O

Results NOUN - O
: PUNCT - O
SD NOUN - O
temozolomide NN - B-MEDICINE
treatment NOUN - O
resulted VERB - O
in ADP - O
an DET - O
upregulation NOUN - O
of ADP - O
markers NOUN - O
of ADP - O
T NOUN - O
cell NOUN - O
exhaustion NOUN - O
such ADJ - O
as ADP - O
LAG-3 PROPN - O
and CCONJ - O
TIM-3 PROPN - O
in ADP - O
lymphocytes NOUN - O
which ADJ - O
was VERB - O
not ADV - O
seen VERB - O
with ADP - O
MD NNP - B-ORG
temozolomide NN - B-MEDICINE
. PUNCT - O

When ADV - O
temozolomide NN - B-MEDICINE
treatment NOUN - O
was VERB - O
combined VERB - O
with ADP - O
PD-1 NNP - B-CARDINAL
antibody NOUN - O
therapy NOUN - O
, PUNCT - O
MD NNP - B-ORG
temozolomide NN - B-MEDICINE
/ SYM - O
PD-1 PROPN - O
antibody NOUN - O
group NOUN - O
demonstrated VERB - O
a DET - O
decrease NOUN - O
in ADP - O
exhaustion NOUN - O
markers NOUN - O
in ADP - O
tumor NOUN - O
infiltrating VERB - O
lymphocytes NOUN - O
( PUNCT - O
TILs PROPN - O
) PUNCT - O
that ADJ - O
were VERB - O
not ADV - O
observed VERB - O
in ADP - O
the DET - O
SD NN - B-ORG
temozolomide NN - B-MEDICINE
/PD-1 SYM - O
antibody NOUN - O
group NOUN - O
. PUNCT - O

Also ADV - O
, PUNCT - O
the DET - O
survival NOUN - O
advantage NOUN - O
of ADP - O
PD-1 NNP - B-CARDINAL
antibody NOUN - O
therapy NOUN - O
in ADP - O
a DET - O
murine ADJ - O
syngeneic ADJ - O
intracranial ADJ - O
glioma NOUN - O
model NOUN - O
was VERB - O
abrogated VERB - O
by ADP - O
adding VERB - O
SD NN - B-ORG
temozolomide NN - B-MEDICINE
to ADP - O
treatment NOUN - O
. PUNCT - O

However ADV - O
, PUNCT - O
when ADV - O
MD NNP - B-ORG
temozolomide NN - B-MEDICINE
was VERB - O
added VERB - O
to ADP - O
PD-1 PROPN - O
inhibition NOUN - O
, PUNCT - O
it PRON - O
preserved VERB - O
the DET - O
survival NOUN - O
benefit NOUN - O
that ADJ - O
was VERB - O
seen VERB - O
by ADP - O
PD-1 NNP - B-CARDINAL
antibody NOUN - O
therapy NOUN - O
alone ADV - O
. PUNCT - O

Conclusion NOUN - O
: PUNCT - O
The DET - O
peripheral ADJ - O
and CCONJ - O
intratumoral ADJ - O
immune ADJ - O
microenvironments NOUN - O
are VERB - O
distinctively ADV - O
affected VERB - O
by ADP - O
dose NOUN - O
modulation NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Modulation NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
dose NOUN - O
differentially ADV - O
affects VERB - O
T PROPN - O
cell NOUN - O
response NOUN - O
to ADP - O
immune ADJ - O
checkpoint NOUN - O
inhibition NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Continuous ADJ - O
low ADV - O
- PUNCT - O
dose NOUN - O
temozolomide NN - B-MEDICINE
has VERB - O
shown VERB - O
to PART - O
cause VERB - O
immunomodulatory ADJ - O
effects NOUN - O
resulting VERB - O
in ADP - O
CD4 PROPN - O
+ CCONJ - O
lymphopenia NOUN - O
due ADP - O
to ADP - O
which ADJ - O
Treg NNP - B-GPE
population NOUN - O
can VERB - O
also ADV - O
decrease VERB - O
significantly ADV - O
. PUNCT - O

Herein NNP - B-PERSON
, PUNCT - O
we PRON - O
present VERB - O
a DET - O
case NOUN - O
series NOUN - O
of ADP - O
three CD - B-CARDINAL
patients NOUN - O
with ADP - O
metastatic ADJ - O
melanoma NOUN - O
who NOUN - O
after ADP - O
progression NOUN - O
on ADP - O
pembrolizumab NOUN - O
showed VERB - O
a DET - O
radiological ADJ - O
response NOUN - O
after ADP - O
just ADV - O
one CD - B-CARDINAL
cycle NOUN - O
of ADP - O
metronomic ADJ - O
temozolomide NN - B-MEDICINE
( PUNCT - O
75 CD - B-CARDINAL
  SPACE - O
mg PROPN - O
/ SYM - O
m PROPN - O
daily ADV - O
for ADP - O
6 CD - B-DATE
weeks NNS - I-DATE
on ADP - O
8-week CD - B-CARDINAL
cycle NOUN - O
) PUNCT - O
. PUNCT - O

This DET - O
suggests VERB - O
that ADP - O
temozolomide NN - B-MEDICINE
may VERB - O
be VERB - O
a DET - O
useful ADJ - O
alternative NOUN - O
for ADP - O
patients NOUN - O
with ADP - O
metastatic ADJ - O
melanoma NOUN - O
after ADP - O
disease NOUN - O
progression NOUN - O
on ADP - O
pembrolizumab NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Exceptional ADJ - O
responses NOUN - O
with ADP - O
sequential ADJ - O
metronomic ADJ - O
temozolomide NN - B-MEDICINE
after ADP - O
pembrolizumab NOUN - O
failure NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
metastatic ADJ - O
melanoma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Using VERB - O
three CD - B-CARDINAL
GBM NNP - B-ORG
cell NOUN - O
- PUNCT - O
lines NOUN - O
( PUNCT - O
U87 VERB - O
, PUNCT - O
U251 PROPN - O
, PUNCT - O
and CCONJ - O
SNB19 NNP - B-ORG
) PUNCT - O
, PUNCT - O
the DET - O
effect NOUN - O
of ADP - O
culturing VERB - O
cells NOUN - O
in ADP - O
a DET - O
Cultrex NNP - B-ORG
- PUNCT - O
based VERB - O
basement NOUN - O
membrane NOUN - O
extract NOUN - O
( PUNCT - O
BME NNP - B-ORG
) PUNCT - O
[ PUNCT - O
3D PROPN - O
Tumour NOUN - O
Growth NOUN - O
Assay PROPN - O
( PUNCT - O
TGA NNP - B-ORG
) PUNCT - O
] PUNCT - O
on ADP - O
morphology NOUN - O
, PUNCT - O
gene NOUN - O
expression NOUN - O
, PUNCT - O
metabolism NOUN - O
, PUNCT - O
and CCONJ - O
temozolomide NN - B-MEDICINE
chemoresistance NOUN - O
was VERB - O
investigated VERB - O
. PUNCT - O

Compared VERB - O
with ADP - O
cells NOUN - O
cultured VERB - O
in ADP - O
the DET - O
2D NN - B-PRODUCT
model NOUN - O
, PUNCT - O
cells NOUN - O
were VERB - O
more ADV - O
resistant ADJ - O
to PART - O
temozolomide VB - B-MEDICINE
in ADP - O
the DET - O
3D JJ - B-PERSON
model NOUN - O
and CCONJ - O
this DET - O
resistance NOUN - O
was VERB - O
potentiated VERB - O
by ADP - O
hypoxia NOUN - O
. PUNCT - O

Taken VERB - O
together ADV - O
, PUNCT - O
these DET - O
results NOUN - O
suggest VERB - O
that ADP - O
micro ADJ - O
- ADJ - O
environmental ADJ - O
factors NOUN - O
influence NOUN - O
GBM NNP - B-ORG
sensitivity NOUN - O
to PART - O
temozolomide VB - B-MEDICINE
. PUNCT - O

Knowledge PROPN - O
of ADP - O
the DET - O
mechanisms NOUN - O
involved VERB - O
in ADP - O
temozolomide NN - B-MEDICINE
resistance NOUN - O
in ADP - O
this DET - O
3D JJ - B-PERSON
model NOUN - O
might VERB - O
lead VERB - O
to ADP - O
the DET - O
identification NOUN - O
of ADP - O
new ADJ - O
strategies NOUN - O
that ADJ - O
enable VERB - O
the DET - O
more ADV - O
effective ADJ - O
use NOUN - O
of ADP - O
the DET - O
current ADJ - O
standard NOUN - O
of ADP - O
care NOUN - O
agents NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
novel ADJ - O
3D NN - B-NORP
in ADP - O
vitro NOUN - O
model NOUN - O
of ADP - O
glioblastoma NOUN - O
reveals VERB - O
resistance NOUN - O
to ADP - O
temozolomide NN - B-MEDICINE
which ADJ - O
was VERB - O
potentiated VERB - O
by ADP - O
hypoxia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

He PRON - O
received VERB - O
3 CD - B-CARDINAL
cycles NOUN - O
of ADP - O
radiopeptide NOUN - O
therapy NOUN - O
using VERB - O
[ PUNCT - O
Lu]Lutetium PROPN - O
- PUNCT - O
DOTATATE PROPN - O
combined VERB - O
with ADP - O
temozolomide NN - B-MEDICINE
. PUNCT - O

After ADP - O
combined VERB - O
treatment NOUN - O
with ADP - O
radiopeptide NOUN - O
therapy NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
, PUNCT - O
the DET - O
patient NOUN - O
showed VERB - O
a DET - O
very ADV - O
good ADJ - O
response NOUN - O
in ADP - O
all DET - O
tumor NOUN - O
lesions NOUN - O
, PUNCT - O
including VERB - O
the DET - O
FDG NNP - B-ORG
- PUNCT - O
positive ADJ - O
ones NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Here ADV - O
, PUNCT - O
we PRON - O
established VERB - O
that DET - O
LNT-229 JJ - B-GPE
glioma NOUN - O
cell NOUN - O
lines NOUN - O
stably ADV - O
expressed VERB - O
shRNA NN - B-CARDINAL
constructs NOUN - O
targeting VERB - O
TIGAR NNP - B-ORG
, PUNCT - O
and CCONJ - O
exposed VERB - O
them PRON - O
to PART - O
hypoxia VERB - O
, PUNCT - O
irradiation NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
. PUNCT - O

The DET - O
disruption NOUN - O
of ADP - O
TIGAR NNP - B-ORG
enhanced VERB - O
levels NOUN - O
of ADP - O
reactive ADJ - O
oxygen NOUN - O
species NOUN - O
and CCONJ - O
cell NOUN - O
death NOUN - O
under ADP - O
hypoxic NOUN - O
conditions NOUN - O
, PUNCT - O
as ADV - O
well ADV - O
as ADP - O
the DET - O
effectiveness NOUN - O
of ADP - O
irradiation NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
aim NOUN - O
of ADP - O
the DET - O
present ADJ - O
study NOUN - O
was VERB - O
to PART - O
evaluate VERB - O
whether ADP - O
mifepristone NOUN - O
, PUNCT - O
an DET - O
antihormonal ADJ - O
agent NOUN - O
, PUNCT - O
has VERB - O
a DET - O
synergistic ADJ - O
effect NOUN - O
with ADP - O
temozolomide NN - B-MEDICINE
( PUNCT - O
used VERB - O
in ADP - O
standard ADJ - O
therapy NOUN - O
for ADP - O
gliomas NOUN - O
) PUNCT - O
. PUNCT - O

Whereas ADP - O
the DET - O
mechanism NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
involves VERB - O
damage NOUN - O
to ADP - O
tumor NOUN - O
DNA NOUN - O
leading VERB - O
to ADP - O
apoptosis NOUN - O
, PUNCT - O
tumor NOUN - O
resistance NOUN - O
is VERB - O
associated VERB - O
with ADP - O
DNA NOUN - O
damage NOUN - O
repair NOUN - O
through ADP - O
the DET - O
O⁶-methylguanine JJ - B-PERSON
- PUNCT - O
DNA NOUN - O
- PUNCT - O
methyltransferase NOUN - O
( PUNCT - O
MGMT NNP - B-ORG
) PUNCT - O
enzyme ADJ - O
. PUNCT - O

Thus ADV - O
, PUNCT - O
greater ADJ - O
apoptosis NOUN - O
of ADP - O
tumor NOUN - O
cells NOUN - O
caused VERB - O
by ADP - O
their ADJ - O
diminished VERB - O
capacity NOUN - O
to PART - O
repair VERB - O
DNA NOUN - O
probably ADV - O
contributed VERB - O
significantly ADV - O
to ADP - O
the DET - O
enhanced ADJ - O
activity NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
. PUNCT - O

The DET - O
results NOUN - O
suggest VERB - O
that ADP - O
mifepristone NOUN - O
could VERB - O
possibly ADV - O
act VERB - O
as ADP - O
a DET - O
chemo NOUN - O
- PUNCT - O
sensitizing VERB - O
agent NOUN - O
for ADP - O
temozolomide NN - B-MEDICINE
during ADP - O
chemotherapy NOUN - O
for ADP - O
GBM NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Tibolone NNP - B-ORG
's PART - O
pro ADJ - O
- ADJ - O
estrogenic ADJ - O
effects NOUN - O
occur VERB - O
particularly ADV - O
in ADP - O
bone NOUN - O
and CCONJ - O
brain NOUN - O
and CCONJ - O
both CCONJ - O
MPA NNP - B-ORG
and CCONJ - O
tibolone NOUN - O
inhibit VERB - O
AKR1C NNP - B-ORG
enzymes VERB - O
, PUNCT - O
which ADJ - O
involve VERB - O
in ADP - O
temozolomide JJ - B-MEDICINE
chemoresistance NOUN - O
. PUNCT - O

Hence ADV - O
, PUNCT - O
we PRON - O
aimed VERB - O
to PART - O
investigate VERB - O
interactions NOUN - O
between ADP - O
MPA NNP - B-ORG
, PUNCT - O
tibolone NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
in ADP - O
modification NOUN - O
of ADP - O
glioma NOUN - O
cell NOUN - O
growth NOUN - O
and CCONJ - O
fine ADJ - O
structure NOUN - O
. PUNCT - O

We PRON - O
previously ADV - O
showed VERB - O
that ADP - O
MPA NNP - B-ORG
reduced VERB - O
growth NOUN - O
and CCONJ - O
induced VERB - O
procarbazine NOUN - O
- PUNCT - O
sensitization NOUN - O
in ADP - O
C6 NNP - B-ORG
cells NOUN - O
; PUNCT - O
ii PUNCT - O
) PUNCT - O
temozolomide NN - B-MEDICINE
has VERB - O
a DET - O
triazene NOUN - O
- PUNCT - O
type NOUN - O
molecular ADJ - O
structure NOUN - O
like ADP - O
procarbazine NOUN - O
; PUNCT - O
iii PUNCT - O
) PUNCT - O
other ADJ - O
groups NOUN - O
previously ADV - O
showed VERB - O
that ADP - O
C6 NNP - B-ORG
glioma NOUN - O
cell NOUN - O
line NOUN - O
is VERB - O
more ADV - O
resistant ADJ - O
to PART - O
temozolomide VB - B-MEDICINE
than ADP - O
human ADJ - O
glioma NOUN - O
cells NOUN - O
; PUNCT - O
hence ADV - O
it PRON - O
may VERB - O
provide VERB - O
a DET - O
native ADJ - O
model NOUN - O
of ADP - O
chemoresistance NOUN - O
. PUNCT - O

Monolayer NOUN - O
plating VERB - O
efficacy NOUN - O
, PUNCT - O
soft ADJ - O
agar ADJ - O
colony NOUN - O
growth NOUN - O
, PUNCT - O
3D NOUN - O
- PUNCT - O
spheroid ADJ - O
S NOUN - O
- PUNCT - O
phase PROPN - O
( PUNCT - O
as ADP - O
determined VERB - O
by ADP - O
BrdU PROPN - O
- PUNCT - O
labeling PROPN - O
) PUNCT - O
and CCONJ - O
electron ADJ - O
microscopical ADJ - O
analyses NOUN - O
were VERB - O
performed VERB - O
to PART - O
assess VERB - O
mutual ADJ - O
interactions NOUN - O
between ADP - O
MPA NNP - B-ORG
, PUNCT - O
tibolone NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
. PUNCT - O

MPA NNP - B-ORG
inhibited VERB - O
clonogenic ADJ - O
growth NOUN - O
of ADP - O
C6 NNP - B-ORG
glioma NOUN - O
and CCONJ - O
this DET - O
effect NOUN - O
is VERB - O
augmented VERB - O
by ADP - O
both DET - O
tibolone NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
. PUNCT - O

MPA NNP - B-ORG
and CCONJ - O
tibolone NOUN - O
inhibited ADJ - O
DNA NOUN - O
synthesis NOUN - O
in ADP - O
C6 NNP - B-ORG
glioma NOUN - O
spheroids NOUN - O
to ADP - O
similar ADJ - O
levels NOUN - O
which ADJ - O
can VERB - O
be VERB - O
achieved VERB - O
with ADP - O
temozolomide NN - B-MEDICINE
. PUNCT - O

Electron NNP - B-ORG
microscopical NOUN - O
analyses VERB - O
revealed VERB - O
synergisms NOUN - O
between ADP - O
MPA NNP - B-ORG
, PUNCT - O
tibolone NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
involved VERB - O
mitochondrial ADJ - O
proliferation NOUN - O
, PUNCT - O
condensation NOUN - O
, PUNCT - O
mitophagy NOUN - O
and CCONJ - O
autophagy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Medroxyprogesterone JJ - B-ORG
effects NOUN - O
on ADP - O
colony NOUN - O
growth NOUN - O
, PUNCT - O
autophagy NOUN - O
and CCONJ - O
mitochondria NOUN - O
of ADP - O
C6 NNP - B-ORG
glioma NOUN - O
cells NOUN - O
are VERB - O
augmented VERB - O
with ADP - O
tibolone NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
: PUNCT - O
Cell NOUN - O
kinetic NOUN - O
and CCONJ - O
electron ADJ - O
microscopical ADJ - O
studies NOUN - O
with ADP - O
a DET - O
broad ADJ - O
review NOUN - O
of ADP - O
the DET - O
literature NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
mathematical ADJ - O
modelling NOUN - O
is VERB - O
applied VERB - O
to PART - O
simulate VERB - O
the DET - O
liposome ADV - O
- PUNCT - O
mediated VERB - O
delivery NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
under ADP - O
different ADJ - O
conditions NOUN - O
in ADP - O
a DET - O
3-D ADJ - O
realistic ADJ - O
brain NOUN - O
tumour NOUN - O
model NOUN - O
reconstructed VERB - O
from ADP - O
MR NNP - B-ORG
images NOUN - O
. PUNCT - O

Delivery NOUN - O
outcomes NOUN - O
are VERB - O
evaluated VERB - O
by ADP - O
the DET - O
bioavailability NOUN - O
of ADP - O
free ADJ - O
temozolomide NN - B-MEDICINE
across ADP - O
time NOUN - O
. PUNCT - O

As ADP - O
compared VERB - O
to ADP - O
the DET - O
oral ADJ - O
and CCONJ - O
intravenous ADJ - O
administration NOUN - O
of ADP - O
free ADJ - O
temozolomide NN - B-MEDICINE
, PUNCT - O
liposome PROPN - O
- PUNCT - O
mediated VERB - O
delivery NOUN - O
can VERB - O
successfully ADV - O
improve VERB - O
the DET - O
drug NOUN - O
accumulation NOUN - O
in ADP - O
tumour NOUN - O
while ADP - O
reducing VERB - O
the DET - O
drug NOUN - O
exposure NOUN - O
in ADP - O
blood NOUN - O
and CCONJ - O
normal ADJ - O
tissue NOUN - O
. PUNCT - O

Results NOUN - O
obtained VERB - O
in ADP - O
this DET - O
study NOUN - O
could VERB - O
be VERB - O
applied VERB - O
for ADP - O
optimising VERB - O
the DET - O
treatment NOUN - O
using VERB - O
liposome ADJ - O
encapsulated VERB - O
temozolomide NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Delivery NOUN - O
of ADP - O
liposome ADJ - O
encapsulated VERB - O
temozolomide NN - B-MEDICINE
to ADP - O
brain NOUN - O
tumour NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

Forced VERB - O
inhibition NOUN - O
of ADP - O
CCND1 NNP - B-PERSON
increased VERB - O
temozolomide NN - B-MEDICINE
efficacy NOUN - O
in ADP - O
U251 PROPN - O
and CCONJ - O
SHG-44 PROPN - O
cells NOUN - O
. PUNCT - O

After ADP - O
CCND1 NNP - B-PERSON
overexpression NOUN - O
, PUNCT - O
the DET - O
temozolomide NN - B-MEDICINE
efficacy NOUN - O
decreased VERB - O
in ADP - O
U251 PROPN - O
and CCONJ - O
SHG-44 PROPN - O
cells NOUN - O
. PUNCT - O

Colony NOUN - O
survival NOUN - O
assay NOUN - O
and CCONJ - O
apoptosis NOUN - O
analysis NOUN - O
confirmed VERB - O
that ADP - O
CCND1 NNP - B-PERSON
inhibition NOUN - O
renders VERB - O
cells NOUN - O
more ADV - O
sensitive ADJ - O
to ADP - O
temozolomide NN - B-MEDICINE
treatment NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
- PUNCT - O
induced VERB - O
apoptosis NOUN - O
in ADP - O
U251 PROPN - O
and CCONJ - O
SHG-44 PROPN - O
cells NOUN - O
. PUNCT - O

Inhibition NOUN - O
of ADP - O
P PROPN - O
- PUNCT - O
gp PROPN - O
( PUNCT - O
MDR1 PROPN - O
) PUNCT - O
by ADP - O
Tariquidar NNP - B-ORG
overcomes VERB - O
the DET - O
effects NOUN - O
of ADP - O
CCND1 NNP - B-PERSON
overexpression NOUN - O
on ADP - O
inhibiting VERB - O
temozolomide NN - B-MEDICINE
- PUNCT - O
induced VERB - O
apoptosis NOUN - O
. PUNCT - O

Inhibition NOUN - O
of ADP - O
CCND1 NNP - B-PERSON
inhibited VERB - O
cell NOUN - O
growth NOUN - O
in ADP - O
vitro NOUN - O
and CCONJ - O
in ADP - O
vivo NOUN - O
significantly ADV - O
more ADV - O
effectively ADV - O
after ADP - O
temozolomide NN - B-MEDICINE
treatments NOUN - O
than ADP - O
single ADJ - O
temozolomide NN - B-MEDICINE
treatments NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

PURPOSE PROPN - O
: PUNCT - O
Preclinical ADJ - O
studies NOUN - O
have VERB - O
suggested VERB - O
promising ADJ - O
activity NOUN - O
for ADP - O
the DET - O
combination NOUN - O
of ADP - O
disulfiram NOUN - O
and CCONJ - O
copper NOUN - O
( PUNCT - O
DSF PROPN - O
/ SYM - O
Cu PROPN - O
) PUNCT - O
against ADP - O
glioblastoma NOUN - O
( PUNCT - O
GBM NNP - B-ORG
) PUNCT - O
including VERB - O
re NOUN - O
- NOUN - O
sensitization NOUN - O
to PART - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
multicenter ADJ - O
phase NOUN - O
II NNP - B-ORG
study NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
plus CCONJ - O
disulfiram NOUN - O
and CCONJ - O
copper NOUN - O
for ADP - O
recurrent NOUN - O
temozolomide NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
glioblastoma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Lomustine NOUN - O
- PUNCT - O
temozolomide NN - B-MEDICINE
combination NOUN - O
efficacious ADJ - O
in ADP - O
newly ADV - O
diagnosed VERB - O
glioblastoma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
investigated VERB - O
the DET - O
anticancer NOUN - O
potential NOUN - O
of ADP - O
combination NOUN - O
of ADP - O
biochanin NOUN - O
A NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
against ADP - O
U-87 NNP - B-ORG
MG NNP - I-ORG
and CCONJ - O
T98 NNP - B-ORG
G NNP - I-ORG

We PRON - O
evaluated VERB - O
the DET - O
effect NOUN - O
of ADP - O
biochanin NOUN - O
A NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
treatment NOUN - O
on ADP - O
cell NOUN - O
viability NOUN - O
, PUNCT - O
expression NOUN - O
of ADP - O
survival NOUN - O
proteins NOUN - O
, PUNCT - O
cell NOUN - O
cycle NOUN - O
, PUNCT - O
cell NOUN - O
metabolism NOUN - O
and CCONJ - O
mitochondrial ADJ - O
function NOUN - O
. PUNCT - O

Biochanin PROPN - O
A PROPN - O
significantly ADV - O
enhanced VERB - O
the DET - O
anticancer NOUN - O
efficacy NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
in ADP - O
GBM NNP - B-ORG
cells NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Temozolomide NN - B-MEDICINE
was VERB - O
recognized VERB - O
as ADP - O
the DET - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
therapy NOUN - O
for ADP - O
glioblastoma NOUN - O
to PART - O
prolong VERB - O
the DET - O
survival NOUN - O
of ADP - O
patients NOUN - O
noticeably ADV - O
, PUNCT - O
while ADP - O
recent ADJ - O
clinical ADJ - O
studies NOUN - O
found VERB - O
that ADP - O
some DET - O
patients NOUN - O
were VERB - O
not ADV - O
sensitive ADJ - O
to PART - O
temozolomide NN - B-MEDICINE
treatment NOUN - O
. PUNCT - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
we PRON - O
provide VERB - O
evidence NOUN - O
that ADP - O
Fstl1 PROPN - O
plays VERB - O
a DET - O
vital ADJ - O
role NOUN - O
in ADP - O
temozolomide NN - B-MEDICINE
resistance NOUN - O
by ADP - O
sequentially ADV - O
regulating VERB - O
DIP2A NNP - B-PERSON
protein NOUN - O
distribution NOUN - O
, PUNCT - O
H3K9 NOUN - O
acetylation NOUN - O
( PUNCT - O
H3K9Ac PROPN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
MGMT NNP - B-ORG
transcription NOUN - O
. PUNCT - O

As ADP - O
a DET - O
multifunctional ADJ - O
protein NOUN - O
widely ADV - O
distributed VERB - O
in ADP - O
cells NOUN - O
, PUNCT - O
DIP2A NNP - B-PERSON
cooperates VERB - O
with ADP - O
the DET - O
HDAC2-DMAP1 NNP - B-GPE
complex NOUN - O
to PART - O
enhance VERB - O
H3K9Ac PROPN - O
deacetylation NOUN - O
, PUNCT - O
prevent VERB - O
MGMT NNP - B-ORG
transcription NOUN - O
, PUNCT - O
and CCONJ - O
increase VERB - O
temozolomide NN - B-MEDICINE
sensitivity NOUN - O
. PUNCT - O

Upregulation NOUN - O
of ADP - O
Fstl1 PROPN - O
enhanced VERB - O
temozolomide NN - B-MEDICINE
resistance NOUN - O
, PUNCT - O
whereas ADP - O
Fstl1 NOUN - O
silencing VERB - O
obviously ADV - O
sensitized VERB - O
GBM NNP - B-ORG
cells NOUN - O
to PART - O
temozolomide VB - B-MEDICINE
both DET - O
in ADP - O
vivo NOUN - O
and CCONJ - O
in ADP - O
vitro NOUN - O
. PUNCT - O

Moreover ADV - O
, PUNCT - O
DIP2A NNP - B-PERSON
depletion NOUN - O
abolished VERB - O
the DET - O
effects NOUN - O
of ADP - O
Fstl1 PROPN - O
on ADP - O
MGMT NNP - B-ORG
expression NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
resistance NOUN - O
. PUNCT - O

These DET - O
findings NOUN - O
highlight VERB - O
an DET - O
important ADJ - O
role NOUN - O
of ADP - O
Fstl1 PROPN - O
in ADP - O
the DET - O
regulation NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
resistance NOUN - O
by ADP - O
modulation NOUN - O
of ADP - O
DIP2A NNP - B-ORG
/ SYM - I-ORG
MGMT NNP - I-ORG
signaling VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Fstl1/DIP2A NNP - B-ORG
/ SYM - I-ORG
MGMT NNP - I-ORG
signaling VERB - O
pathway NOUN - O
plays VERB - O
important ADJ - O
roles NOUN - O
in ADP - O
temozolomide NN - B-MEDICINE
resistance NOUN - O
in ADP - O
glioblastoma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
purpose NOUN - O
of ADP - O
this DET - O
retrospective ADJ - O
study NOUN - O
was VERB - O
to PART - O
compare VERB - O
the DET - O
efficacy NOUN - O
and CCONJ - O
toxicity NOUN - O
of ADP - O
high ADJ - O
- PUNCT - O
dose NOUN - O
methotrexate NOUN - O
plus CCONJ - O
temozolomide NN - B-MEDICINE
( PUNCT - O
MT NNP - B-NORP
regimen NOUN - O
) PUNCT - O
and CCONJ - O
rituximab NOUN - O
plus CCONJ - O
MT NNP - B-GPE
( PUNCT - O
RMT PROPN - O
regimen VERB - O
) PUNCT - O
in ADP - O
patients NOUN - O
with ADP - O
untreated ADJ - O
primary ADJ - O
central ADJ - O
nervous ADJ - O
system NOUN - O
lymphoma NOUN - O
( PUNCT - O
PCNSL NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

High ADV - O
- PUNCT - O
dose NOUN - O
Methotrexate NOUN - O
plus CCONJ - O
temozolomide NN - B-MEDICINE
with ADP - O
or CCONJ - O
without ADP - O
rituximab NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
untreated ADJ - O
primary ADJ - O
central ADJ - O
nervous ADJ - O
system NOUN - O
lymphoma NOUN - O
: PUNCT - O
A DET - O
retrospective ADJ - O
study NOUN - O
from ADP - O
China NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
determine VERB - O
whether ADP - O
MI NNP - B-ORG
correlates VERB - O
with ADP - O
prognosis NOUN - O
in ADP - O
GBM NNP - B-ORG
patients NOUN - O
who NOUN - O
underwent VERB - O
the DET - O
standard ADJ - O
treatment NOUN - O
protocol NOUN - O
of ADP - O
radiotherapy NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
administration NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Chemotherapy NOUN - O
with ADP - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
is VERB - O
the DET - O
traditional ADJ - O
treatment NOUN - O
for ADP - O
glioblastoma NOUN - O
( PUNCT - O
GBM NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

MCCK1 PROPN - O
enhances VERB - O
the DET - O
anticancer ADJ - O
effect NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
in ADP - O
attenuating VERB - O
the DET - O
invasion NOUN - O
, PUNCT - O
migration NOUN - O
and CCONJ - O
epithelial ADJ - O
- PUNCT - O
mesenchymal ADJ - O
transition NOUN - O
of ADP - O
glioblastoma NOUN - O
cells NOUN - O
in ADP - O
vitro NOUN - O
and CCONJ - O
in ADP - O
vivo NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
solvent NOUN - O
used VERB - O
for ADP - O
fabrication NOUN - O
on ADP - O
drug NOUN - O
loading NOUN - O
and CCONJ - O
release NOUN - O
kinetics NOUN - O
of ADP - O
electrosprayed VERB - O
temozolomide NN - B-MEDICINE
- PUNCT - O
loaded VERB - O
PLGA NOUN - O
microparticles NOUN - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
glioblastoma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Radiation NOUN - O
therapy NOUN - O
and CCONJ - O
concomitant ADJ - O
temozolomide NN - B-MEDICINE
chemotherapy NOUN - O
are VERB - O
commonly ADV - O
used VERB - O
in ADP - O
treatment NOUN - O
of ADP - O
brain NOUN - O
tumors NOUN - O
, PUNCT - O
but CCONJ - O
they PRON - O
may VERB - O
also ADV - O
result VERB - O
in ADP - O
behavioral ADJ - O
impairments NOUN - O
such ADJ - O
as ADP - O
anxiety NOUN - O
and CCONJ - O
cognitive ADJ - O
deficit NOUN - O
. PUNCT - O

The DET - O
present ADJ - O
study NOUN - O
sought VERB - O
to PART - O
investigate VERB - O
the DET - O
effect NOUN - O
of ADP - O
fluoxetine NOUN - O
on ADP - O
the DET - O
behavioral ADJ - O
impairments NOUN - O
caused VERB - O
by ADP - O
radiation NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
treatment NOUN - O
. PUNCT - O

C57BL/6J NOUN - O
mice NOUN - O
were VERB - O
subjected VERB - O
to ADP - O
a DET - O
single ADJ - O
cranial ADJ - O
radiation NOUN - O
followed VERB - O
by ADP - O
6-wk CD - B-CARDINAL
cyclic ADJ - O
temozolomide NN - B-MEDICINE
administration NOUN - O
and CCONJ - O
were VERB - O
then ADV - O
treated VERB - O
with ADP - O
chronic ADJ - O
administration NOUN - O
of ADP - O
fluoxetine NOUN - O
. PUNCT - O

Mice NOUN - O
treated VERB - O
with ADP - O
radiation NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
showed VERB - O
increased VERB - O
anxiety NOUN - O
- PUNCT - O
like ADJ - O
behavior NOUN - O
and CCONJ - O
cognitive ADJ - O
impairment NOUN - O
, PUNCT - O
along ADP - O
with ADP - O
LTP NNP - B-ORG
impairment NOUN - O
and CCONJ - O
neurogenesis NOUN - O
deficit NOUN - O
. PUNCT - O

NEW NNP - B-ORG
& CC - I-ORG
NOTEWORTHY NNP - I-ORG
Mice NNS - I-ORG
treated VERB - O
with ADP - O
radiation NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
showed VERB - O
increased VERB - O
anxiety NOUN - O
- PUNCT - O
like ADJ - O
behavior NOUN - O
and CCONJ - O
cognitive ADJ - O
impairment NOUN - O
. PUNCT - O

The DET - O
effect NOUN - O
of ADP - O
fluoxetine NOUN - O
might VERB - O
be VERB - O
via ADP - O
rescuing VERB - O
the DET - O
neurogenesis NOUN - O
deficit NOUN - O
caused VERB - O
by ADP - O
radiation NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
treatment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluoxetine NOUN - O
reverses VERB - O
brain NOUN - O
radiation NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
- PUNCT - O
induced VERB - O
anxiety NOUN - O
and CCONJ - O
spatial ADJ - O
learning NOUN - O
and CCONJ - O
memory NOUN - O
defect NOUN - O
in ADP - O
mice NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Despite ADP - O
advances NOUN - O
in ADP - O
cancer NOUN - O
therapies NOUN - O
, PUNCT - O
glioblastoma NOUN - O
multiforme NOUN - O
treatment NOUN - O
remains VERB - O
inefficient ADJ - O
due ADP - O
to ADP - O
the DET - O
brain NOUN - O
- PUNCT - O
blood NOUN - O
barrier NOUN - O
( PUNCT - O
BBB NNP - B-ORG
) PUNCT - O
inhibitory NOUN - O
activity NOUN - O
and CCONJ - O
to ADP - O
the DET - O
low ADJ - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
chemotherapeutic ADJ - O
selectivity NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
cell NOUN - O
culture NOUN - O
platform NOUN - O
that ADJ - O
enables VERB - O
ex PROPN - O
vivo NOUN - O
tissue VERB - O
growth NOUN - O
from ADP - O
patients NOUN - O
or CCONJ - O
patient NOUN - O
- PUNCT - O
derived VERB - O
xenograft NOUN - O
( PUNCT - O
PDX NNP - B-ORG
) PUNCT - O
models NOUN - O
and CCONJ - O
assesses VERB - O
sensitivity NOUN - O
to ADP - O
approved VERB - O
therapies NOUN - O
( PUNCT - O
e.g. ADV - O
, PUNCT - O
temozolomide NN - B-MEDICINE
) PUNCT - O
in ADP - O
a DET - O
clinically ADV - O
relevant ADJ - O
time NOUN - O
frame NOUN - O
would VERB - O
be VERB - O
very ADV - O
useful ADJ - O
in ADP - O
translational ADJ - O
research NOUN - O
and CCONJ - O
personalized VERB - O
medicine NOUN - O
. PUNCT - O

Specifically ADV - O
, PUNCT - O
multicellular ADJ - O
spheroids NOUN - O
deriving VERB - O
from ADP - O
either CCONJ - O
5 CD - B-CARDINAL
patients NOUN - O
with ADP - O
glioblastoma NOUN - O
( PUNCT - O
GBM NNP - B-ORG
) PUNCT - O
or CCONJ - O
a DET - O
renal ADJ - O
cell NOUN - O
carcinoma NOUN - O
( PUNCT - O
RCC NNP - B-ORG
) PUNCT - O
PDX PROPN - O
model NOUN - O
were VERB - O
incorporated VERB - O
into ADP - O
VersaGel NNP - B-ORG
and CCONJ - O
treated VERB - O
with ADP - O
temozolomide NN - B-MEDICINE
and CCONJ - O
several ADJ - O
other ADJ - O
therapies NOUN - O
, PUNCT - O
guided VERB - O
by ADP - O
the DET - O
most ADV - O
recent ADJ - O
advances NOUN - O
in ADP - O
GBM NNP - B-ORG
treatment NOUN - O
. PUNCT - O

For ADP - O
the DET - O
GBM NNP - B-ORG
patient NOUN - O
tumor NOUN - O
testing NOUN - O
, PUNCT - O
all DET - O
five CD - B-CARDINAL
clinical ADJ - O
responses NOUN - O
were VERB - O
predicted VERB - O
by ADP - O
the DET - O
results NOUN - O
of ADP - O
our ADJ - O
3D JJ - B-QUANTITY
- HYPH - I-QUANTITY
temozolomide NN - I-MEDICINE
assay NOUN - O
. PUNCT - O

In ADP - O
contrast NOUN - O
, PUNCT - O
the DET - O
MTT NNP - B-ORG
assay NOUN - O
found VERB - O
no DET - O
response NOUN - O
to PART - O
temozolomide VB - B-MEDICINE
regardless ADV - O
of ADP - O
the DET - O
clinical ADJ - O
outcome NOUN - O
, PUNCT - O
and CCONJ - O
moreover ADV - O
, PUNCT - O
basement NOUN - O
membrane NOUN - O
extract NOUN - O
failed VERB - O
to PART - O
predict VERB - O
the DET - O
2 CD - B-CARDINAL
patient NOUN - O
responders NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
addition NOUN - O
of ADP - O
combination NOUN - O
chemotherapy NOUN - O
with ADP - O
procarbazine NOUN - O
, PUNCT - O
lomustine NOUN - O
, PUNCT - O
and CCONJ - O
vincristine ADJ - O
confers NOUN - O
survival NOUN - O
advantage NOUN - O
, PUNCT - O
as ADV - O
likely ADV - O
does VERB - O
temozolomide NN - B-MEDICINE
, PUNCT - O
but CCONJ - O
radiochemotherapy NOUN - O
may VERB - O
not ADV - O
be VERB - O
appropriate ADJ - O
for ADP - O
all DET - O
patients NOUN - O
owing VERB - O
to ADP - O
its ADJ - O
toxicity NOUN - O
profile NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
describe VERB - O
oncological ADJ - O
patterns NOUN - O
of ADP - O
care NOUN - O
, PUNCT - O
prognostic ADJ - O
factors NOUN - O
, PUNCT - O
and CCONJ - O
survival NOUN - O
for ADP - O
all DET - O
patients NOUN - O
in ADP - O
France NNP - B-GPE
with ADP - O
newly ADV - O
- PUNCT - O
diagnosed VERB - O
and CCONJ - O
histologically ADV - O
confirmed VERB - O
glioblastoma NOUN - O
, PUNCT - O
and CCONJ - O
evaluate VERB - O
the DET - O
impact NOUN - O
of ADP - O
extended VERB - O
temozolomide NN - B-MEDICINE
use NOUN - O
at ADP - O
the DET - O
population NOUN - O
level NOUN - O
. PUNCT - O

( PUNCT - O
MS PROPN - O
  SPACE - O
= SYM - O
  SPACE - O
1.8 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NNP - B-ORG
1.6 NUM - O
- SYM - O
2.1 NUM - O
) PUNCT - O
, PUNCT - O
27 CD - B-PERCENT
% NN - I-PERCENT
received VERB - O
treatment NOUN - O
without ADP - O
the DET - O
combination NOUN - O
of ADP - O
radiotherapy NOUN - O
( PUNCT - O
RT)-temozolomide PROPN - O
( PUNCT - O
MS NNP - B-ORG
  SPACE - O
= PUNCT - O
  SPACE - O
5.9 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NNP - B-ORG
5.5 NUM - O
- SYM - O
6.6 NUM - O
) PUNCT - O
, PUNCT - O
60 CD - B-PERCENT
% NN - I-PERCENT
received VERB - O
treatment NOUN - O
including VERB - O
the DET - O
initiation NOUN - O
of ADP - O
the DET - O
concomitant ADJ - O
phase NOUN - O
of ADP - O
RT NOUN - O
- PUNCT - O
temozolomide NNP - B-MEDICINE
( PUNCT - O
MS PROPN - O
  SPACE - O
= SYM - O
  SPACE - O
16.4 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
15.2 CD - B-CARDINAL
- PUNCT - O
17.4 NUM - O
) PUNCT - O
whom NOUN - O
44 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
patients NOUN - O
initiated VERB - O
the DET - O
temozolomide NN - B-MEDICINE
adjuvant ADJ - O
phase NOUN - O
( PUNCT - O
MS PROPN - O
  SPACE - O
= SYM - O
  SPACE - O

Only RB - B-PERCENT
22 CD - I-PERCENT
% NN - I-PERCENT
patients NOUN - O
received VERB - O
6 CD - B-CARDINAL
cycles NOUN - O
or CCONJ - O
more ADJ - O
of ADP - O
adjuvant ADJ - O
temozolomide NN - B-MEDICINE
( PUNCT - O
MS PROPN - O
  SPACE - O
= SYM - O
  SPACE - O
25.5 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
24.0 NUM - O
- SYM - O
28.3 NUM - O
) PUNCT - O
. PUNCT - O

In ADP - O
non ADJ - O
- ADJ - O
progressive ADJ - O
patients NOUN - O
, PUNCT - O
prolonging VERB - O
the DET - O
adjuvant ADJ - O
temozolomide NN - B-MEDICINE
beyond ADP - O
6 CD - B-CARDINAL
cycles NOUN - O
may VERB - O
improve VERB - O
OS NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Association PROPN - O
of ADP - O
patterns NOUN - O
of ADP - O
care NOUN - O
, PUNCT - O
prognostic ADJ - O
factors NOUN - O
, PUNCT - O
and CCONJ - O
use NOUN - O
of ADP - O
radiotherapy NOUN - O
- PUNCT - O
temozolomide NN - B-MEDICINE
therapy NOUN - O
with ADP - O
survival NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
newly ADV - O
diagnosed VERB - O
glioblastoma NOUN - O
: PUNCT - O
a DET - O
French JJ - B-NORP
national ADJ - O
population NOUN - O
- PUNCT - O
based VERB - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Standard ADJ - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
therapy NOUN - O
for ADP - O
glioma NOUN - O
includes VERB - O
surgery NOUN - O
, PUNCT - O
radiotherapy NOUN - O
and CCONJ - O
systemic ADJ - O
administration NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
. PUNCT - O

However ADV - O
, PUNCT - O
temozolomide NN - B-MEDICINE
does VERB - O
not ADV - O
reach VERB - O
the DET - O
brain NOUN - O
in ADP - O
sufficient ADJ - O
doses NOUN - O
when ADV - O
administered VERB - O
orally ADV - O
and CCONJ - O
has VERB - O
poor ADJ - O
efficiency NOUN - O
in ADP - O
more JJR - B-CARDINAL
than IN - I-CARDINAL
half NN - I-CARDINAL
of ADP - O
the DET - O
patients NOUN - O
. PUNCT - O

We PRON - O
have VERB - O
recently ADV - O
developed VERB - O
a DET - O
system NOUN - O
( PUNCT - O
Temodex NNP - B-ORG
) PUNCT - O
for ADP - O
local ADJ - O
administration NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
by ADP - O
encapsulating VERB - O
the DET - O
drug NOUN - O
in ADP - O
a DET - O
biologically ADV - O
inert ADJ - O
matrix NOUN - O
. PUNCT - O

Since ADP - O
the DET - O
efficacy NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
therapy NOUN - O
is VERB - O
known VERB - O
to PART - O
depend VERB - O
on ADP - O
the DET - O
methylation NOUN - O
status NOUN - O
of ADP - O
the DET - O
O6-methylguanine JJ - B-CARDINAL
- PUNCT - O
DNA NOUN - O
methyltransferase NOUN - O
gene NOUN - O
( PUNCT - O
MGMT NNP - B-ORG
) PUNCT - O
promoter NOUN - O
, PUNCT - O
we PRON - O
also ADV - O
analyzed VERB - O
whether ADP - O
the DET - O
effect NOUN - O
of ADP - O
Temodex NNP - B-GPE
was VERB - O
influenced VERB - O
by ADP - O
the DET - O
methylation NOUN - O
status NOUN - O
of ADP - O
MGMT NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Local ADJ - O
delivery NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
via ADP - O
a DET - O
biologically ADV - O
inert ADJ - O
carrier NOUN - O
( PUNCT - O
Temodex NNP - B-ORG
) PUNCT - O
prolongs NOUN - O
survival NOUN - O
of ADP - O
glioma NOUN - O
patients NOUN - O
irrespectively ADV - O
of ADP - O
the DET - O
MGMT NNP - B-ORG
methylation NOUN - O
status NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Two CD - B-DATE
months NNS - I-DATE
after ADP - O
the DET - O
fourth JJ - B-ORDINAL
operation NOUN - O
, PUNCT - O
she PRON - O
started VERB - O
treatment NOUN - O
with ADP - O
temozolomide NN - B-MEDICINE
( PUNCT - O
200mg PROPN - O
/ SYM - O
m2 NOUN - O
, PUNCT - O
d1 NOUN - O
- PUNCT - O
5 NUM - O
, PUNCT - O
28d NNS - B-DATE
, PUNCT - O
orally ADV - O
) PUNCT - O
and CCONJ - O
apatinib NOUN - O
( PUNCT - O
0.425 CD - B-CARDINAL
g NOUN - O
, PUNCT - O
daily ADV - O
, PUNCT - O
orally ADV - O
) PUNCT - O
. PUNCT - O

CONCLUSION NOUN - O
: PUNCT - O
we PRON - O
successfully ADV - O
treated VERB - O
this DET - O
patient NOUN - O
with ADP - O
recurrent ADJ - O
invasive ADJ - O
pituitary ADJ - O
adenoma NOUN - O
with ADP - O
temozolomide NN - B-MEDICINE
and CCONJ - O
apatinib NOUN - O
for ADP - O
31.5 CD - B-DATE
months NNS - I-DATE
without ADP - O
recurrence NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Apatinib PROPN - O
( PUNCT - O
YN968D1 NN - B-ORG
) PUNCT - O
and CCONJ - O
temozolomide NN - B-MEDICINE
in ADP - O
recurrent ADJ - O
invasive ADJ - O
pituitary ADJ - O
adenoma NOUN - O
: PUNCT - O
case NOUN - O
report NOUN - O
and CCONJ - O
literature NOUN - O
review NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Second RB - B-ORDINAL
, PUNCT - O
genes NOUN - O
are VERB - O
expressed VERB - O
from ADP - O
a DET - O
tumor NOUN - O
- PUNCT - O
activated VERB - O
and CCONJ - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ)-induced X - O
promoter NOUN - O
of ADP - O
the DET - O
glucose NOUN - O
- PUNCT - O
regulated VERB - O
protein NOUN - O
, PUNCT - O
Grp78 NNP - B-PERSON
Here RB - I-PERSON
, PUNCT - O
we PRON - O
investigated VERB - O
systemic ADJ - O
combination NOUN - O
therapy NOUN - O
using VERB - O
TMZ NNP - B-ORG
and CCONJ - O
targeted VERB - O
suicide NOUN - O
gene NOUN - O
therapy NOUN - O
by ADP - O
the DET - O
RGD4C NNP - B-ORG
/ SYM - I-ORG
AAVP NNP - I-ORG
- HYPH - I-ORG
Grp78 NNP - I-ORG
Firstly ADV - O
, PUNCT - O
in ADP - O
  SPACE - O
vitro NOUN - O
we PRON - O
showed VERB - O
that ADP - O
TMZ NNP - B-ORG
increases VERB - O
endogenous ADJ - O
Grp78 PROPN - O
gene NOUN - O
expression NOUN - O
and CCONJ - O
boosts VERB - O
transgene NOUN - O
expression NOUN - O
from ADP - O
the DET - O
RGD4C NNP - B-EVENT
/ SYM - I-EVENT
AAVP NNP - I-EVENT
- HYPH - I-EVENT
Grp78 NNP - I-EVENT
in ADP - O
human ADJ - O
GBM NNP - B-ORG
cells NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Efficacy NOUN - O
of ADP - O
systemic ADJ - O
temozolomide NN - B-MEDICINE
- PUNCT - O
activated VERB - O
phage NOUN - O
- PUNCT - O
targeted VERB - O
gene NOUN - O
therapy NOUN - O
in ADP - O
human ADJ - O
glioblastoma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

: PUNCT - O
The DET - O
DNA NOUN - O
- PUNCT - O
methylating VERB - O
drug NOUN - O
temozolomide NN - B-MEDICINE
, PUNCT - O
which ADJ - O
induces VERB - O
cell NOUN - O
death NOUN - O
through ADP - O
apoptosis NOUN - O
, PUNCT - O
is VERB - O
used VERB - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
malignant ADJ - O
glioma NOUN - O
. PUNCT - O

Here ADV - O
, PUNCT - O
we PRON - O
investigate VERB - O
the DET - O
mechanisms NOUN - O
underlying VERB - O
the DET - O
ability NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
to PART - O
induce VERB - O
senescence NOUN - O
in ADP - O
glioblastoma NOUN - O
cells NOUN - O
. PUNCT - O

Inhibitor NOUN - O
experiments NOUN - O
revealed VERB - O
that ADP - O
temozolomide NN - B-MEDICINE
- PUNCT - O
induced VERB - O
senescence NOUN - O
was VERB - O
initiated VERB - O
by ADP - O
damage NOUN - O
recognition NOUN - O
through ADP - O
the DET - O
MRN NNP - B-ORG
complex NOUN - O
, PUNCT - O
activation NOUN - O
of ADP - O
the DET - O
ATR NNP - B-ORG
/ SYM - I-ORG
CHK1 NNP - I-ORG
axis NOUN - O
of ADP - O
the DET - O
DNA NOUN - O
damage NOUN - O
response NOUN - O
pathway NOUN - O
, PUNCT - O
and CCONJ - O
mediated VERB - O
by ADP - O
degradation NOUN - O
of ADP - O
CDC25c PROPN - O
. PUNCT - O

p14 NOUN - O
and CCONJ - O
p16 ADJ - O
, PUNCT - O
targets NOUN - O
of ADP - O
p53 NOUN - O
, PUNCT - O
were VERB - O
silenced VERB - O
in ADP - O
our ADJ - O
cell NOUN - O
system NOUN - O
and CCONJ - O
did VERB - O
not ADV - O
seem VERB - O
to PART - O
play VERB - O
a DET - O
role NOUN - O
in ADP - O
temozolomide NN - B-MEDICINE
- PUNCT - O
induced VERB - O
senescence NOUN - O
. PUNCT - O

Upon ADP - O
temozolomide NN - B-MEDICINE
exposure NOUN - O
, PUNCT - O
we PRON - O
found VERB - O
a DET - O
strong ADJ - O
repression NOUN - O
of ADP - O
the DET - O
mismatch NOUN - O
repair NOUN - O
proteins NOUN - O
MSH2 PROPN - O
, PUNCT - O
MSH6 NNP - B-GPE
, PUNCT - O
and CCONJ - O
EXO1 NNP - B-GPE
as ADV - O
well ADV - O
as ADP - O
the DET - O
homologous ADJ - O
recombination NOUN - O
protein NOUN - O
RAD51 NNP - B-ORG
, PUNCT - O
which ADJ - O
was VERB - O
downregulated VERB - O
by ADP - O
disruption NOUN - O
of ADP - O
the DET - O
E2F1/DP1 PROPN - O
complex NOUN - O
. PUNCT - O

Repression NOUN - O
of ADP - O
these DET - O
repair NOUN - O
factors NOUN - O
was VERB - O
not ADV - O
observed VERB - O
in ADP - O
G2-M NNP - B-PERSON
arrested VERB - O
p53-deficient NOUN - O
cells NOUN - O
and CCONJ - O
, PUNCT - O
therefore ADV - O
, PUNCT - O
it PRON - O
seems VERB - O
to PART - O
represent VERB - O
a DET - O
specific ADJ - O
trait NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
- PUNCT - O
induced VERB - O
senescence NOUN - O
. PUNCT - O

These DET - O
findings NOUN - O
reveal VERB - O
a DET - O
mechanism NOUN - O
by ADP - O
which ADJ - O
the DET - O
anticancer NOUN - O
drug NOUN - O
temozolomide NN - B-MEDICINE
induces NOUN - O
senescence NOUN - O
and CCONJ - O
downregulation NOUN - O
of ADP - O
DNA NOUN - O
repair NOUN - O
pathways NOUN - O
in ADP - O
glioma NOUN - O
cells NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Momelotinib NOUN - O
sensitizes VERB - O
glioblastoma NOUN - O
cells NOUN - O
to PART - O
temozolomide VB - B-MEDICINE
by ADP - O
enhancement NOUN - O
of ADP - O
autophagy NOUN - O
via ADP - O
JAK2/STAT3 PROPN - O
inhibition NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Other ADJ - O
pathways NOUN - O
must VERB - O
be VERB - O
activated VERB - O
to PART - O
escape VERB - O
from ADP - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
treatment NOUN - O
, PUNCT - O
however ADV - O
acquired VERB - O
resistance NOUN - O
mechanisms NOUN - O
to ADP - O
TMZ NNP - B-ORG
are VERB - O
not ADV - O
well ADV - O
understood VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Ibudilast PROPN - O
sensitizes VERB - O
glioblastoma NOUN - O
to PART - O
temozolomide VB - B-MEDICINE
by ADP - O
targeting VERB - O
Macrophage NNP - B-ORG
Migration NNP - I-ORG
Inhibitory NNP - I-ORG
Factor NNP - I-ORG
( PUNCT - O
MIF NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Viability NOUN - O
of ADP - O
U87 VERB - O
MG PROPN - O
and CCONJ - O
11ST NUM - O
patient NOUN - O
- PUNCT - O
derived VERB - O
GMB NNP - B-ORG
cell NOUN - O
lines NOUN - O
, PUNCT - O
after ADP - O
valproic ADJ - O
acid NOUN - O
, PUNCT - O
tranylcypromine NOUN - O
or CCONJ - O
riluzole ADJ - O
alone ADV - O
, PUNCT - O
in ADP - O
different ADJ - O
combinations NOUN - O
, PUNCT - O
as ADV - O
well ADV - O
as ADP - O
combined VERB - O
with ADP - O
standard ADJ - O
temozolomide NN - B-MEDICINE
chemotherapy NOUN - O
was VERB - O
examined VERB - O
using VERB - O
the DET - O
MTT NNP - B-ORG
assay NOUN - O
. PUNCT - O

Tranylcypromine NOUN - O
significantly ADV - O
enhanced VERB - O
the DET - O
effect NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
when ADV - O
used VERB - O
in ADP - O
combination NOUN - O
, PUNCT - O
as ADP - O
did VERB - O
valproic ADJ - O
acid NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
significant ADJ - O
roadblock NOUN - O
in ADP - O
treatment NOUN - O
of ADP - O
GBM NNP - B-ORG
multiforme NOUN - O
( PUNCT - O
GBM NNP - B-ORG
) PUNCT - O
is VERB - O
resistance NOUN - O
to PART - O
temozolomide VB - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

BET PROPN - O
inhibitor NOUN - O
I PROPN - O
- PUNCT - O
BET151 PROPN - O
sensitizes VERB - O
GBM NNP - B-ORG
cells NOUN - O
to PART - O
temozolomide VB - B-MEDICINE
via ADP - O
PUMA PROPN - O
induction NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Circular PROPN - O
RNA-0007874 PROPN - O
( PUNCT - O
circMTO1 NOUN - O
) PUNCT - O
reverses VERB - O
chemoresistance NOUN - O
to PART - O
temozolomide VB - B-MEDICINE
by ADP - O
acting VERB - O
as ADP - O
a DET - O
sponge NOUN - O
of ADP - O
microRNA-630 ADV - O
in ADP - O
glioblastoma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Tri NOUN - O
- PUNCT - O
block NOUN - O
copolymer NOUN - O
nanoparticles NOUN - O
modified VERB - O
with ADP - O
folic ADJ - O
acid NOUN - O
for ADP - O
temozolomide NN - B-MEDICINE
delivery NOUN - O
in ADP - O
glioblastoma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Purpose NOUN - O
: PUNCT - O
The DET - O
methylation NOUN - O
status NOUN - O
of ADP - O
the DET - O
O6-methylguanine JJ - B-LAW
DNA NN - I-LAW
methyltransferase NOUN - O
( PUNCT - O
MGMT NNP - B-ORG
) PUNCT - O
gene NOUN - O
promoter NOUN - O
is VERB - O
predictive ADJ - O
for ADP - O
benefit NOUN - O
from ADP - O
temozolomide NN - B-MEDICINE
in ADP - O
glioblastoma NOUN - O
( PUNCT - O
GBM NNP - B-ORG
) PUNCT - O
. PUNCT - O

A DET - O
clinically ADV - O
optimized VERB - O
cutoff NOUN - O
was VERB - O
sought VERB - O
allowing VERB - O
patient ADJ - O
selection NOUN - O
for ADP - O
therapy NOUN - O
without ADP - O
temozolomide NN - B-MEDICINE
, PUNCT - O
while ADP - O
avoiding VERB - O
to PART - O
withhold VERB - O
it PRON - O
from ADP - O
patients NOUN - O
who NOUN - O
may VERB - O
potentially ADV - O
benefit VERB - O
. PUNCT - O

Quantitative ADJ - O
MGMT PROPN - O
methylation NOUN - O
- PUNCT - O
specific ADJ - O
PCR NNP - B-ORG
data NOUN - O
were VERB - O
obtained VERB - O
for ADP - O
newly ADV - O
diagnosed VERB - O
patients NOUN - O
with ADP - O
GBM NNP - B-ORG
screened VERB - O
or CCONJ - O
treated VERB - O
with ADP - O
standard ADJ - O
radiotherapy NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
in ADP - O
four CD - B-CARDINAL
randomized VERB - O
trials NOUN - O
. PUNCT - O

The DET - O
MGMT NNP - B-ORG
assay NOUN - O
was VERB - O
highly ADV - O
reproducible ADJ - O
upon ADP - O
retesting NOUN - O
of ADP - O
218 CD - B-CARDINAL
paired VERB - O
samples NOUN - O
( PUNCT - O
R NOUN - O
2 CD - B-CARDINAL
= SYM - O
0.94).Conclusions NUM - O
: PUNCT - O
Low ADJ - O
MGMT PROPN - O
methylation NOUN - O
( PUNCT - O
gray ADJ - O
zone NOUN - O
) PUNCT - O
may VERB - O
confer VERB - O
some DET - O
sensitivity NOUN - O
to PART - O
temozolomide VB - B-MEDICINE
treatment NOUN - O
, PUNCT - O
hence ADV - O
the DET - O
lower ADJ - O
safety NOUN - O
margin NOUN - O
should VERB - O
be VERB - O
considered VERB - O
for ADP - O
selecting VERB - O
patients NOUN - O
with ADP - O
unmethylated ADJ - O
GBM NNS - B-ORG
into ADP - O
trials NOUN - O
omitting VERB - O
temozolomide NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

RO6839921 NNP - B-PERSON
( PUNCT - O
RG7775 NOUN - O
) PUNCT - O
, PUNCT - O
both CCONJ - O
alone ADJ - O
and CCONJ - O
in ADP - O
combination NOUN - O
with ADP - O
temozolomide NN - B-MEDICINE
in ADP - O
TP53 PROPN - O
wt PART - O
orthotopic ADJ - O
neuroblastoma NOUN - O
models NOUN - O
. PUNCT - O

RO6839921 NOUN - O
and CCONJ - O
temozolomide RB - B-MEDICINE
, PUNCT - O
alone ADV - O
or CCONJ - O
in ADP - O
combination NOUN - O
in ADP - O
mice NOUN - O
implanted VERB - O
with ADP - O
TP53 PROPN - O
wt ADP - O
SHSY5Y NNP - B-PERSON
- HYPH - I-PERSON
Luc NNP - I-PERSON
and CCONJ - O
NB1691-Luc NNP - B-PERSON
cells NOUN - O
showed VERB - O
that ADP - O
combined VERB - O
RO6839921 NN - B-PRODUCT
and CCONJ - O
temozolomide NN - B-MEDICINE
led VERB - O
to ADP - O
greater ADJ - O
tumour NOUN - O
growth NOUN - O
inhibition NOUN - O
and CCONJ - O
increase NOUN - O
in ADP - O
survival NOUN - O
compared VERB - O
to ADP - O
vehicle NOUN - O
control NOUN - O
. PUNCT - O

These DET - O
preclinical ADJ - O
studies NOUN - O
support VERB - O
the DET - O
further ADJ - O
development NOUN - O
of ADP - O
idasanutlin NOUN - O
in ADP - O
combination NOUN - O
with ADP - O
temozolomide NN - B-MEDICINE
in ADP - O
neuroblastoma NOUN - O
in ADP - O
early ADJ - O
phase NOUN - O
clinical ADJ - O
trials NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Preclinical ADJ - O
evaluation NOUN - O
of ADP - O
the DET - O
first JJ - B-ORDINAL
intravenous ADJ - O
small ADJ - O
molecule NOUN - O
MDM2 PROPN - O
antagonist VERB - O
alone ADV - O
and CCONJ - O
in ADP - O
combination NOUN - O
with ADP - O
temozolomide NN - B-MEDICINE
in ADP - O
neuroblastoma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Given VERB - O
its ADJ - O
ability NOUN - O
to PART - O
traverse VERB - O
the DET - O
blood NOUN - O
- PUNCT - O
brain NOUN - O
barrier NOUN - O
, PUNCT - O
temozolomide NN - B-MEDICINE
has VERB - O
also ADV - O
been VERB - O
evaluated VERB - O
in ADP - O
other ADJ - O
cancers NOUN - O
that ADJ - O
involve VERB - O
the DET - O
central ADJ - O
nervous ADJ - O
system NOUN - O
( PUNCT - O
CNS NNP - B-ORG
) PUNCT - O
. PUNCT - O

There ADV - O
is VERB - O
strong ADJ - O
evidence NOUN - O
that ADP - O
temozolomide NN - B-MEDICINE
is VERB - O
effective ADJ - O
in ADP - O
patients NOUN - O
with ADP - O
high ADJ - O
- PUNCT - O
grade NOUN - O
astrocytomas NOUN - O
and CCONJ - O
oligodendrogliomas NOUN - O
. PUNCT - O

Given VERB - O
that ADP - O
concentrations NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
in ADP - O
the DET - O
CNS NNP - B-ORG
are VERB - O
only RB - B-PERCENT
20 CD - I-PERCENT
% NN - I-PERCENT
of ADP - O
those DET - O
in ADP - O
the DET - O
blood NOUN - O
, PUNCT - O
it PRON - O
is VERB - O
not ADV - O
surprising ADJ - O
that ADP - O
it PRON - O
is VERB - O
generally ADV - O
inactive ADJ - O
in ADP - O
patients NOUN - O
with ADP - O
CNS NNP - B-ORG
metastases NOUN - O
from ADP - O
solid ADJ - O
tumors NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Temozolomide NN - B-MEDICINE
is VERB - O
the DET - O
most ADV - O
widely ADV - O
used VERB - O
chemotherapy NOUN - O
for ADP - O
patients NOUN - O
with ADP - O
glioblastoma NOUN - O
( PUNCT - O
GBM NNP - B-ORG
) PUNCT - O
despite ADP - O
the DET - O
fact NOUN - O
that ADP - O
approximately RB - B-CARDINAL
half NN - I-CARDINAL
of ADP - O
treated VERB - O
patients NOUN - O
have VERB - O
temozolomide NN - B-MEDICINE
resistance NOUN - O
and CCONJ - O
all DET - O
patients NOUN - O
eventually ADV - O
fail VERB - O
therapy NOUN - O
. PUNCT - O

Here ADV - O
we PRON - O
summarize VERB - O
the DET - O
immune ADJ - O
modulating VERB - O
role NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
alone ADV - O
and CCONJ - O
in ADP - O
combination NOUN - O
with ADP - O
immunotherapies NOUN - O
such ADJ - O
as ADP - O
dendritic ADJ - O
cell NOUN - O
vaccines NOUN - O
, PUNCT - O
T PROPN - O
- PUNCT - O
cell NOUN - O
therapy NOUN - O
, PUNCT - O
and CCONJ - O
immune ADJ - O
checkpoint NOUN - O
inhibitors NOUN - O
for ADP - O
patients NOUN - O
with ADP - O
GBM NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Additionally ADV - O
, PUNCT - O
in ADP - O
clonogenic ADJ - O
survival NOUN - O
analyses NOUN - O
, PUNCT - O
DDIT4 NNP - B-PERSON
induction NOUN - O
conferred ADJ - O
protection NOUN - O
from ADP - O
radiotherapy NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
, PUNCT - O
while ADP - O
DDIT4 NNP - B-GPE
gene NOUN - O
suppression NOUN - O
sensitised VERB - O
cells NOUN - O
. PUNCT - O

We PRON - O
identified VERB - O
DDIT4 NNP - B-PERSON
as ADP - O
a DET - O
cell NOUN - O
- PUNCT - O
intrinsic ADJ - O
regulator NOUN - O
for ADP - O
adaptive ADJ - O
responses NOUN - O
and CCONJ - O
therapy NOUN - O
resistance NOUN - O
in ADP - O
glioblastoma NOUN - O
cells NOUN - O
which ADJ - O
may VERB - O
interfere VERB - O
with ADP - O
cell NOUN - O
death NOUN - O
induction NOUN - O
by ADP - O
temozolomide NN - B-MEDICINE
, PUNCT - O
radiotherapy NOUN - O
or CCONJ - O
hypoxia NOUN - O
by ADP - O
inhibiting VERB - O
mTORC1 NOUN - O
activity NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
glioblastoma NOUN - O
, PUNCT - O
the DET - O
benefit NOUN - O
from ADP - O
temozolomide NN - B-MEDICINE
chemotherapy NOUN - O
is VERB - O
largely ADV - O
limited ADJ - O
to ADP - O
a DET - O
subgroup NOUN - O
of ADP - O
patients NOUN - O
( PUNCT - O
30 CD - B-PERCENT
- SYM - I-PERCENT
35 CD - I-PERCENT
% NN - I-PERCENT
) PUNCT - O
with ADP - O
tumors NOUN - O
exhibiting VERB - O
methylation NOUN - O
of ADP - O
the DET - O
promoter NOUN - O
region NOUN - O
of ADP - O
the DET - O
O6-methylguanine JJ - B-PERSON
- PUNCT - O
DNA NOUN - O
methyltransferase NOUN - O
( PUNCT - O
MGMT NNP - B-ORG
) PUNCT - O
gene NOUN - O
. PUNCT - O

In ADP - O
order NOUN - O
to PART - O
allow VERB - O
more ADJ - O
patients NOUN - O
to PART - O
benefit VERB - O
from ADP - O
this DET - O
treatment NOUN - O
, PUNCT - O
we PRON - O
explored VERB - O
magnetic ADJ - O
resonance NOUN - O
image NOUN - O
- PUNCT - O
guided VERB - O
microbubble NOUN - O
- PUNCT - O
enhanced VERB - O
low ADJ - O
- PUNCT - O
intensity NOUN - O
pulsed VERB - O
focused VERB - O
ultrasound NOUN - O
( PUNCT - O
LIFU NNP - B-ORG
) PUNCT - O
to PART - O
transiently ADV - O
open VERB - O
the DET - O
blood NOUN - O
- PUNCT - O
brain NOUN - O
barrier NOUN - O
and CCONJ - O
deliver VERB - O
a DET - O
first JJ - B-ORDINAL
- PUNCT - O
in ADP - O
- PUNCT - O
class NOUN - O
liposome NOUN - O
- PUNCT - O
loaded VERB - O
small ADJ - O
molecule NOUN - O
MGMT NN - B-ORG
inactivator NOUN - O
in ADP - O
mice NOUN - O
bearing VERB - O
temozolomide NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
gliomas NOUN - O
. PUNCT - O

We PRON - O
demonstrate VERB - O
that ADP - O
a DET - O
liposomal NOUN - O
O6-(4-bromothenyl)guanine PROPN - O
( PUNCT - O
O6BTG NNP - B-ORG
) PUNCT - O
derivative ADJ - O
can VERB - O
efficiently ADV - O
target VERB - O
MGMT NNP - B-ORG
, PUNCT - O
thereby ADV - O
sensitizing VERB - O
murine NOUN - O
and CCONJ - O
human ADJ - O
glioma NOUN - O
cells NOUN - O
to PART - O
temozolomide VB - B-MEDICINE
in ADP - O
vitro NOUN - O
. PUNCT - O

Treatment NOUN - O
with ADP - O
this DET - O
new ADJ - O
liposomal ADJ - O
MGMT NN - B-ORG
inactivator NOUN - O
facilitated VERB - O
by ADP - O
LIFU NNP - B-ORG
- PUNCT - O
mediated VERB - O
blood NOUN - O
- PUNCT - O
brain NOUN - O
barrier NOUN - O
opening NOUN - O
reduced VERB - O
tumor NOUN - O
growth NOUN - O
and CCONJ - O
significantly ADV - O
prolonged VERB - O
survival NOUN - O
of ADP - O
glioma NOUN - O
- PUNCT - O
bearing VERB - O
mice NOUN - O
, PUNCT - O
when ADV - O
combined VERB - O
with ADP - O
temozolomide NN - B-MEDICINE
chemotherapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Although ADP - O
chemotherapy NOUN - O
combining VERB - O
5fluorouracil NNP - B-CARDINAL
( PUNCT - O
5FU)-dacarbazine CD - B-ORDINAL
( PUNCT - O
DTIC PROPN - O
) PUNCT - O
or CCONJ - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TEM)-capecitabine PROPN - O
( PUNCT - O
CAP NNP - B-ORG
) PUNCT - O
are VERB - O
extensively ADV - O
used VERB - O
in ADP - O
patients NOUN - O
with ADP - O
neuroendocrine NOUN - O
tumors NOUN - O
( PUNCT - O
NET PROPN - O
) PUNCT - O
, PUNCT - O
they PRON - O
were VERB - O
never ADV - O
compared VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Comparison NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
- PUNCT - O
capecitabine NOUN - O
to ADP - O
5-fluorouracile NUM - O
- PUNCT - O
dacarbazine NOUN - O
in ADP - O
247 CD - B-CARDINAL
patients NOUN - O
with ADP - O
advanced ADJ - O
digestive ADJ - O
neuroendocrine NOUN - O
tumors NOUN - O
using VERB - O
propensity NOUN - O
score NOUN - O
analyses NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
aim NOUN - O
of ADP - O
our ADJ - O
study NOUN - O
was VERB - O
to PART - O
screen VERB - O
Serbian JJ - B-NORP
patients NOUN - O
with ADP - O
primary ADJ - O
glioblastoma NOUN - O
for ADP - O
an DET - O
MGMT NNP - B-ORG
promoter NOUN - O
hypermethylation NOUN - O
and CCONJ - O
to PART - O
evaluate VERB - O
its ADJ - O
associations NOUN - O
with ADP - O
overall ADJ - O
survival NOUN - O
( PUNCT - O
OS NNP - B-ORG
) PUNCT - O
and CCONJ - O
sensitivity NOUN - O
to PART - O
temozolomide VB - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
treatment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Standard ADJ - O
- PUNCT - O
of ADP - O
- PUNCT - O
care NOUN - O
treatment NOUN - O
of ADP - O
glioblastomas NOUN - O
involves VERB - O
maximal ADJ - O
safe ADJ - O
resection NOUN - O
and CCONJ - O
adjuvant ADJ - O
temozolomide NN - B-MEDICINE
chemo NOUN - O
- PUNCT - O
radiotherapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Determining VERB - O
a DET - O
cut VERB - O
- PUNCT - O
off PART - O
residual ADJ - O
tumor NOUN - O
volume NOUN - O
threshold NOUN - O
for ADP - O
patients NOUN - O
with ADP - O
newly ADV - O
diagnosed VERB - O
glioblastoma NOUN - O
treated VERB - O
with ADP - O
temozolomide NN - B-MEDICINE
chemoradiotherapy NOUN - O
: PUNCT - O
A DET - O
multicenter ADJ - O
cohort NOUN - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Objective NOUN - O
: PUNCT - O
To PART - O
explore VERB - O
the DET - O
effects NOUN - O
of ADP - O
pulsed VERB - O
, PUNCT - O
focused VERB - O
, PUNCT - O
and CCONJ - O
microbubble ADJ - O
contrast NOUN - O
agent NOUN - O
- PUNCT - O
enhanced VERB - O
ultrasonography NOUN - O
( PUNCT - O
mCEUS NOUN - O
) PUNCT - O
on ADP - O
blood NOUN - O
- PUNCT - O
brain NOUN - O
barrier NOUN - O
( PUNCT - O
BBB NNP - B-ORG
) PUNCT - O
permeability NOUN - O
and CCONJ - O
the DET - O
efficacy NOUN - O
temozolomide NN - B-MEDICINE
for ADP - O
glioblastoma NOUN - O
. PUNCT - O

After ADP - O
temozolomide NN - B-MEDICINE
chemotherapy NOUN - O
, PUNCT - O
we PRON - O
detected VERB - O
glial ADJ - O
fibrillary NOUN - O
acidic ADJ - O
protein NOUN - O
( PUNCT - O
GFAP PROPN - O
) PUNCT - O
levels NOUN - O
in ADP - O
serum NOUN - O
by ADP - O
enzyme ADV - O
- PUNCT - O
linked VERB - O
immunosorbent NOUN - O
assay NOUN - O
( PUNCT - O
ELISA NNP - B-ORG
) PUNCT - O
and CCONJ - O
in ADP - O
brain NOUN - O
tissue NOUN - O
by ADP - O
western ADJ - O
blot NOUN - O
, PUNCT - O
immunocytochemistry NOUN - O
, PUNCT - O
and CCONJ - O
real ADJ - O
- PUNCT - O
time NOUN - O
quantitative ADJ - O
polymerase NOUN - O
chain NOUN - O
reaction NOUN - O
( PUNCT - O
qPCR PROPN - O
) PUNCT - O
. PUNCT - O

Following VERB - O
temozolomide NN - B-MEDICINE
chemotherapy NOUN - O
, PUNCT - O
levels NOUN - O
of ADP - O
the DET - O
tumor NOUN - O
marker NOUN - O
GFAP PROPN - O
were VERB - O
increased VERB - O
in ADP - O
the DET - O
group NOUN - O
with ADP - O
ultrasonic ADJ - O
cavitation NOUN - O
compared VERB - O
with ADP - O
the DET - O
control NOUN - O
group NOUN - O
( PUNCT - O
P NOUN - O
< X - O
0.05 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

Conclusions NOUN - O
: PUNCT - O
When ADV - O
rats NOUN - O
were VERB - O
treated VERB - O
by ADP - O
mCEUS NOUN - O
with ADP - O
intermittent ADJ - O
launches NOUN - O
( PUNCT - O
interval NOUN - O
, PUNCT - O
400 CD - B-CARDINAL
  SPACE - O
ms NOUN - O
) PUNCT - O
and CCONJ - O
injected VERB - O
with ADP - O
1 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
kg NOUN - O
contrast NOUN - O
agent NOUN - O
, PUNCT - O
BBB NNP - B-ORG
permeability NOUN - O
was VERB - O
increased VERB - O
and CCONJ - O
temozolomide IN - B-MEDICINE
BBB NNP - B-ORG
penetration NOUN - O
was VERB - O
enhanced VERB - O
, PUNCT - O
therapeutic ADJ - O
enhancement NOUN - O
for ADP - O
glioblastoma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
evaluated VERB - O
the DET - O
modulatory ADJ - O
effects NOUN - O
of ADP - O
RFP NNP - B-ORG
knockdown VERB - O
on ADP - O
cis ADJ - O
- PUNCT - O
regulatory ADJ - O
elements NOUN - O
, PUNCT - O
gene NOUN - O
expression NOUN - O
, PUNCT - O
and CCONJ - O
chemosensitivity NOUN - O
to PART - O
temozolomide VB - B-MEDICINE
both DET - O
in ADP - O
glioblastoma NOUN - O
cells NOUN - O
and CCONJ - O
in ADP - O
an DET - O
intracranial ADJ - O
glioblastoma NOUN - O
model NOUN - O
. PUNCT - O

The DET - O
combination NOUN - O
of ADP - O
RFP NNP - B-ORG
knockdown VERB - O
and CCONJ - O
temozolomide NN - B-MEDICINE
treatment NOUN - O
markedly ADV - O
suppressed VERB - O
the DET - O
glioblastoma NOUN - O
cell NOUN - O
growth NOUN - O
due ADJ - O
to ADP - O
oxidative ADJ - O
stress NOUN - O
and CCONJ - O
aberrant NOUN - O
cell NOUN - O
cycle NOUN - O
and CCONJ - O
increased VERB - O
survival NOUN - O
time NOUN - O
in ADP - O
mice NOUN - O
with ADP - O
glioblastoma NOUN - O
. PUNCT - O

This DET - O
study NOUN - O
suggests VERB - O
that ADP - O
RFP NNP - B-ORG
contributes VERB - O
to PART - O
chemoresistance NOUN - O
via ADP - O
aberrant ADJ - O
deacetylation NOUN - O
of ADP - O
histone NOUN - O
H3 NNP - B-ORG
at ADP - O
K27 NNP - B-PRODUCT
, PUNCT - O
whereas ADP - O
dysregulation NOUN - O
of ADP - O
RFP NNP - B-ORG
- PUNCT - O
associated VERB - O
cis ADJ - O
- PUNCT - O
regulatory ADJ - O
elements NOUN - O
in ADP - O
glioma NOUN - O
and CCONJ - O
RFP NNP - B-ORG
knockdown NOUN - O
combined VERB - O
with ADP - O
temozolomide NN - B-MEDICINE
is VERB - O
an DET - O
effective ADJ - O
treatment NOUN - O
strategy NOUN - O
for ADP - O
lethal ADJ - O
glioma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Glioblastoma NNP - B-ORG
multiforme PROPN - O
( PUNCT - O
GBM NNP - B-ORG
) PUNCT - O
is VERB - O
the DET - O
most ADV - O
malignant ADJ - O
tumor NOUN - O
of ADP - O
the DET - O
central ADJ - O
nervous ADJ - O
system NOUN - O
, PUNCT - O
and CCONJ - O
chemoresistance NOUN - O
blunts NOUN - O
the DET - O
effect NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
GBM NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

MiR-7 PROPN - O
- PUNCT - O
5p PROPN - O
suppresses VERB - O
stemness NOUN - O
and CCONJ - O
enhances VERB - O
temozolomide NN - B-MEDICINE
sensitivity NOUN - O
of ADP - O
drug NOUN - O
- PUNCT - O
resistant ADJ - O
glioblastoma NOUN - O
cells NOUN - O
by ADP - O
targeting VERB - O
Yin NNP - B-PERSON
Yang NNP - I-PERSON
1 NUM - O
. PUNCT - O

-DOCSTART- -X- - O

Temozolomide NN - B-MEDICINE
was VERB - O
approved VERB - O
in ADP - O
March NNP - B-DATE
2005 CD - I-DATE
for ADP - O
treatment NOUN - O
of ADP - O
GBM NNP - B-ORG
, PUNCT - O
with ADP - O
the DET - O
Stupp NNP - B-PERSON
protocol NOUN - O
( PUNCT - O
radiotherapy NOUN - O
and CCONJ - O
concomitant ADJ - O
use NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
) PUNCT - O
. PUNCT - O

Despite ADP - O
initial ADJ - O
studies NOUN - O
demonstrating VERB - O
mild ADJ - O
and CCONJ - O
well ADV - O
- PUNCT - O
tolerated VERB - O
side NOUN - O
effects NOUN - O
, PUNCT - O
several ADJ - O
recent ADJ - O
reports NOUN - O
describe VERB - O
severe ADJ - O
hematologic ADJ - O
adverse ADJ - O
effects NOUN - O
associated VERB - O
with ADP - O
temozolomide NN - B-MEDICINE
use NOUN - O
. PUNCT - O

We PRON - O
report VERB - O
the DET - O
case NOUN - O
of ADP - O
a DET - O
51-year CD - B-CARDINAL
- PUNCT - O
old ADJ - O
female NOUN - O
diagnosed VERB - O
with ADP - O
GBM NNS - B-ORG
who NOUN - O
received VERB - O
the DET - O
standard ADJ - O
treatment NOUN - O
protocol NOUN - O
of ADP - O
radiotherapy NOUN - O
and CCONJ - O
concomitant ADJ - O
temozolomide NN - B-MEDICINE
. PUNCT - O

Although ADP - O
temozolomide NN - B-MEDICINE
is VERB - O
regarded VERB - O
as ADP - O
a DET - O
safe ADJ - O
drug NOUN - O
with ADP - O
few ADJ - O
side NOUN - O
effects NOUN - O
, PUNCT - O
severe ADJ - O
hematologic NOUN - O
toxicities NOUN - O
have VERB - O
been VERB - O
reported VERB - O
. PUNCT - O

-DOCSTART- -X- - O

1p19q NUM - O
codeleted VERB - O
compared VERB - O
two CD - B-CARDINAL
different ADJ - O
protocols NOUN - O
( PUNCT - O
radiotherapy NOUN - O
plus CCONJ - O
temozolomide NN - B-MEDICINE
or CCONJ - O
PCV PROPN - O
) PUNCT - O
. PUNCT - O

Twenty CD - B-CARDINAL
- HYPH - I-CARDINAL
one CD - I-CARDINAL
patients NOUN - O
received VERB - O
PCV PROPN - O
and CCONJ - O
27 CD - B-CARDINAL
temozolomide NN - B-MEDICINE
. PUNCT - O

The DET - O
progression NOUN - O
- PUNCT - O
free ADJ - O
survival NOUN - O
and CCONJ - O
overall ADJ - O
survival NOUN - O
in ADP - O
the DET - O
PCV PROPN - O
group NOUN - O
were VERB - O
7.2 CD - B-CARDINAL
and CCONJ - O
10.6 CD - B-DATE
years NNS - I-DATE
respectively ADV - O
and CCONJ - O
temozolomide NN - B-MEDICINE
were VERB - O
6.1 CD - B-CARDINAL
and CCONJ - O
9.2 NUM - O
years NOUN - O
, PUNCT - O
both DET - O
statistically ADV - O
significant ADJ - O
. PUNCT - O

The DET - O
radiological ADJ - O
response NOUN - O
was VERB - O
present ADJ - O
in ADP - O
80.9 CD - B-PERCENT
% NN - I-PERCENT
in ADP - O
PCV PROPN - O
arm NOUN - O
and CCONJ - O
70.2 CD - B-PERCENT
% NN - I-PERCENT
in ADP - O
temozolomide NN - B-MEDICINE
arm NOUN - O
there ADV - O
was VERB - O
not ADV - O
statistical ADJ - O
differences NOUN - O
. PUNCT - O

The DET - O
toxicity NOUN - O
grade NOUN - O
3 CD - B-CARDINAL
or CCONJ - O
4 NUM - O
was VERB - O
present ADJ - O
in ADP - O
42.8 CD - B-PERCENT
% NN - I-PERCENT
in ADP - O
PCV PROPN - O
arm NOUN - O
and CCONJ - O
11.1 CD - B-PERCENT
% NN - I-PERCENT
in ADP - O
temozolomide NN - B-MEDICINE
arm NOUN - O
. PUNCT - O

The DET - O
most ADV - O
common ADJ - O
strategy NOUN - O
in ADP - O
the DET - O
Latin NNP - B-LOC
America NNP - I-LOC
community NOUN - O
is VERB - O
the DET - O
substitution NOUN - O
of ADP - O
the DET - O
PCV PROPN - O
for ADP - O
temozolomide NN - B-MEDICINE
. PUNCT - O

This DET - O
retrospective ADJ - O
study NOUN - O
showed VERB - O
superior ADJ - O
efficacy NOUN - O
of ADP - O
PCV PROPN - O
than ADP - O
temozolomide NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Radiotherapy NNP - B-ORG
plus CCONJ - O
temozolomide NN - B-MEDICINE
or CCONJ - O
PCV PROPN - O
in ADP - O
patients NOUN - O
with ADP - O
anaplastic ADJ - O
oligodendroglioma NOUN - O

-DOCSTART- -X- - O

The DET - O
combination NOUN - O
of ADP - O
capecitabine NOUN - O
( PUNCT - O
CAP NNP - B-ORG
) PUNCT - O
and CCONJ - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TEM NNP - B-ORG
) PUNCT - O
is VERB - O
associated VERB - O
with ADP - O
an DET - O
extremely ADV - O
high ADJ - O
and CCONJ - O
long ADV - O
- PUNCT - O
lasting VERB - O
response NOUN - O
rate NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
metastatic ADJ - O
pancreatic ADJ - O
neuroendocrine NOUN - O
tumors NOUN - O
. PUNCT - O

A DET - O
total NOUN - O
of ADP - O
nine CD - B-CARDINAL
patients NOUN - O
with ADP - O
advanced ADJ - O
atypical ADJ - O
carcinoid NOUN - O
of ADP - O
the DET - O
thymus NOUN - O
in ADP - O
the DT - B-FAC
China NNP - I-FAC
- HYPH - I-FAC
Japan NNP - I-FAC
Friendship NNP - I-FAC
Hospital NNP - I-FAC
were VERB - O
treated VERB - O
with ADP - O
capecitabine NOUN - O
( PUNCT - O
750 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
m2 NOUN - O
twice ADV - O
daily ADV - O
, PUNCT - O
days NOUN - O
1 NUM - O
- SYM - O
14 NUM - O
) PUNCT - O
and CCONJ - O
temozolomide NN - B-MEDICINE
( PUNCT - O
200 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
m2 NOUN - O
once ADV - O
daily ADV - O
, PUNCT - O
days VERB - O
10 CD - B-CARDINAL
- SYM - I-CARDINAL
14 CD - I-CARDINAL
) PUNCT - O
every DT - B-DATE
28 CD - I-DATE
days NNS - I-DATE
between ADP - O
2014 NUM - O
and CCONJ - O
2018 NUM - O
. PUNCT - O

Capecitabine NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
regimen NOUN - O
is VERB - O
effective ADJ - O
and CCONJ - O
well ADV - O
tolerated VERB - O
in ADP - O
patients NOUN - O
with ADP - O
advanced ADJ - O
thymic ADJ - O
atypical ADJ - O
carcinoid NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

miR-222/GAS5 NNP - B-ORG
is VERB - O
involved VERB - O
in ADP - O
DNA NOUN - O
damage NOUN - O
and CCONJ - O
cytotoxic NOUN - O
effects NOUN - O
induced VERB - O
by ADP - O
temozolomide NN - B-MEDICINE
in ADP - O
T98 NNP - B-ORG
G PROPN - O
cell NOUN - O
line NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
found VERB - O
CAXII NOUN - O
and CCONJ - O
P NOUN - O
- PUNCT - O
glycoprotein NOUN - O
( PUNCT - O
Pgp PROPN - O
) PUNCT - O
coexpressed VERB - O
in ADP - O
neurospheres NOUN - O
derived VERB - O
from ADP - O
3 CD - B-CARDINAL
of ADP - O
3 CD - B-CARDINAL
patients NOUN - O
with ADP - O
different ADJ - O
genetic ADJ - O
backgrounds NOUN - O
and CCONJ - O
low ADJ - O
response NOUN - O
to ADP - O
temozolomide NN - B-MEDICINE
( PUNCT - O
time NOUN - O
to ADP - O
recurrence NOUN - O
: PUNCT - O
6 CD - B-DATE
- SYM - I-DATE
9 CD - I-DATE
months NNS - I-DATE
) PUNCT - O
. PUNCT - O

CAXII NNP - B-ORG
was VERB - O
necessary ADJ - O
for ADP - O
the DET - O
Pgp NNP - B-PERSON
efflux NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
and CCONJ - O
second JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
chemotherapeutic ADJ - O
drugs NOUN - O
, PUNCT - O
determining VERB - O
chemoresistance NOUN - O
in ADP - O
neurospheres NOUN - O
. PUNCT - O

Psammaplin NNP - B-PERSON
C NNP - I-PERSON
, PUNCT - O
a DET - O
potent ADJ - O
inhibitor NOUN - O
of ADP - O
CAXII NN - B-ORG
, PUNCT - O
resensitized VERB - O
primary ADJ - O
neurospheres NOUN - O
to PART - O
temozolomide VB - B-MEDICINE
by ADP - O
reducing VERB - O
temozolomide NN - B-MEDICINE
efflux NOUN - O
via ADP - O
Pgp PROPN - O
. PUNCT - O

This DET - O
effect NOUN - O
was VERB - O
independent ADJ - O
of ADP - O
other ADJ - O
known VERB - O
temozolomide NN - B-MEDICINE
resistance NOUN - O
factors NOUN - O
present ADJ - O
in ADP - O
the DET - O
patients NOUN - O
. PUNCT - O

The DET - O
overall ADJ - O
survival NOUN - O
in ADP - O
orthotopic ADJ - O
patient NOUN - O
- PUNCT - O
derived VERB - O
xenografts NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
neurospheres NOUN - O
, PUNCT - O
codosed VERB - O
with ADP - O
Psammaplin NNP - B-ORG
C NNP - I-ORG
and CCONJ - O
temozolomide NN - B-MEDICINE
, PUNCT - O
was VERB - O
significantly ADV - O
increased VERB - O
over ADP - O
temozolomide NN - B-MEDICINE
- PUNCT - O
treated VERB - O
( PUNCT - O
P NOUN - O
< X - O
0.05 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O
untreated ADJ - O
animals NOUN - O
( PUNCT - O
P NOUN - O
< X - O
0.02 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
without ADP - O
detectable ADJ - O
signs NOUN - O
of ADP - O
systemic ADJ - O
toxicity NOUN - O
. PUNCT - O

We PRON - O
propose VERB - O
that ADP - O
a DET - O
CAXII PROPN - O
inhibitor NOUN - O
in ADP - O
combination NOUN - O
with ADP - O
temozolomide NN - B-MEDICINE
may VERB - O
provide VERB - O
a DET - O
new ADJ - O
and CCONJ - O
effective ADJ - O
approach NOUN - O
to PART - O
reverse ADJ - O
chemoresistance NOUN - O
in ADP - O
glioblastoma NOUN - O
stem NOUN - O
cells NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mesoporous ADJ - O
silica NOUN - O
nanoparticles NOUN - O
( PUNCT - O
MSNPs PROPN - O
) PUNCT - O
of ADP - O
a DET - O
small ADJ - O
diameter NOUN - O
were VERB - O
loaded VERB - O
with ADP - O
the DET - O
anticancer NOUN - O
drug NOUN - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ PROPN - O
) PUNCT - O
, PUNCT - O
coated VERB - O
with ADP - O
polydopamine NOUN - O
( PUNCT - O
PDA PROPN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
conjugated VERB - O
with ADP - O
Asn NNP - B-ORG
- HYPH - I-ORG
Gly NNP - I-ORG
- HYPH - I-ORG
Arg NNP - I-ORG
( PUNCT - O
NGR NNP - B-ORG
) PUNCT - O
for ADP - O
use NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
glioma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Combination NOUN - O
of ADP - O
3-methyladenine NUM - O
therapy NOUN - O
and CCONJ - O
Asn NNP - B-ORG
- HYPH - I-ORG
Gly NNP - I-ORG
- HYPH - I-ORG
Arg NNP - I-ORG
( PUNCT - O
NGR)-modified ADJ - O
mesoporous ADJ - O
silica NOUN - O
nanoparticles NOUN - O
loaded VERB - O
with ADP - O
temozolomide NN - B-MEDICINE
for ADP - O
glioma NOUN - O
therapy NOUN - O
in ADP - O
  SPACE - O
vitro NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

At ADP - O
present NOUN - O
, PUNCT - O
there ADV - O
is VERB - O
no DET - O
uniform ADJ - O
consensus NOUN - O
on ADP - O
the DET - O
treatment NOUN - O
of ADP - O
recurrent NOUN - O
glioblastoma NOUN - O
, PUNCT - O
especially ADV - O
the DET - O
re NOUN - O
- NOUN - O
irradiation NOUN - O
dose NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
dose NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Conventionally ADV - O
fractionated VERB - O
stereotactic ADJ - O
radiotherapy NOUN - O
( PUNCT - O
CFRT NNP - B-ORG
) PUNCT - O
in ADP - O
combination NOUN - O
with ADP - O
dose NOUN - O
- PUNCT - O
dense ADJ - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
in ADP - O
relapsed VERB - O
malignant ADJ - O
glioma NOUN - O
: PUNCT - O
A DET - O
case NOUN - O
report NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Treatment NOUN - O
with ADP - O
temozolomide NN - B-MEDICINE
, PUNCT - O
standard NOUN - O
of ADP - O
care NOUN - O
for ADP - O
gliomas NOUN - O
, PUNCT - O
usually ADV - O
results VERB - O
in ADP - O
drug NOUN - O
resistance NOUN - O
and CCONJ - O
tumor NOUN - O
recurrence NOUN - O
. PUNCT - O

We PRON - O
show VERB - O
here ADV - O
that ADP - O
NEO214 NNP - B-ORG
is VERB - O
effective ADJ - O
against ADP - O
both CCONJ - O
temozolomide NN - B-MEDICINE
- PUNCT - O
sensitive ADJ - O
and CCONJ - O
temozolomide RB - B-MEDICINE
- PUNCT - O
resistant ADJ - O
glioma NOUN - O
cells NOUN - O
. PUNCT - O

Furthermore ADV - O
, PUNCT - O
NEO214 NNP - B-ORG
is VERB - O
effective ADJ - O
for ADP - O
different ADJ - O
mechanisms NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
resistance NOUN - O
: PUNCT - O
overexpression NOUN - O
of ADP - O
MGMT NNP - B-ORG
( PUNCT - O
O6-methylguanine ADJ - O
methyl NOUN - O
- PUNCT - O
transferase NOUN - O
) PUNCT - O
; PUNCT - O
deficiency NOUN - O
in ADP - O
specific ADJ - O
mismatch NOUN - O
repair NOUN - O
proteins NOUN - O
; PUNCT - O
and CCONJ - O
overexpression NOUN - O
of ADP - O
base NOUN - O
excision NOUN - O
repair NOUN - O
( PUNCT - O
BER NNP - B-ORG
) PUNCT - O
proteins NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Combination NOUN - O
of ADP - O
veliparib NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
was VERB - O
well ADV - O
- PUNCT - O
tolerated VERB - O
and CCONJ - O
demonstrated VERB - O
clinical ADJ - O
activity NOUN - O
in ADP - O
older ADJ - O
patients NOUN - O
with ADP - O
relapsed ADJ - O
or CCONJ - O
refractory ADJ - O
acute ADJ - O
myeloid ADJ - O
leukemia NOUN - O
( PUNCT - O
AML PROPN - O
) PUNCT - O
or CCONJ - O
AML NNP - B-ORG
arising VERB - O
from ADP - O
pre ADJ - O
- ADJ - O
existing ADJ - O
myeloid ADJ - O
malignancies NOUN - O
. PUNCT - O

Population NOUN - O
pharmacokinetic ADJ - O
analysis NOUN - O
was VERB - O
performed VERB - O
using VERB - O
Phoenix NNP - B-FAC
® . - I-FAC
NLME NNP - I-FAC
with ADP - O
pharmacokinetic ADJ - O
data NOUN - O
obtained VERB - O
from ADP - O
37 CD - B-CARDINAL
subjects NOUN - O
after ADP - O
oral ADJ - O
administration NOUN - O
of ADP - O
veliparib VERB - O
in ADP - O
a DET - O
Phase PROPN - O
I PRON - O
study VERB - O
with ADP - O
and CCONJ - O
without ADP - O
temozolomide NN - B-MEDICINE
. PUNCT - O

Effect NOUN - O
of ADP - O
covariates NOUN - O
( PUNCT - O
age NOUN - O
, PUNCT - O
sex NOUN - O
, PUNCT - O
BMI NNP - B-ORG
, PUNCT - O
creatinine NOUN - O
clearance NOUN - O
( PUNCT - O
CLCR NNP - B-ORG
) PUNCT - O
, PUNCT - O
and CCONJ - O
co NOUN - O
- NOUN - O
administration NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
) PUNCT - O
on ADP - O
the DET - O
pharmacokinetics NOUN - O
of ADP - O
veliparib NOUN - O
were VERB - O
evaluated VERB - O
, PUNCT - O
as ADV - O
well ADV - O
as ADP - O
impact NOUN - O
of ADP - O
veliparib ADJ - O
exposure NOUN - O
on ADP - O
mucositis NOUN - O
( PUNCT - O
dose NOUN - O
- PUNCT - O
limiting VERB - O
toxicity NOUN - O
) PUNCT - O
, PUNCT - O
objective ADJ - O
response NOUN - O
rate NOUN - O
( PUNCT - O
ORR NNP - B-ORG
) PUNCT - O
, PUNCT - O
and CCONJ - O
overall ADJ - O
survival NOUN - O
. PUNCT - O

Veliparib VBN - B-PERSON
with ADP - O
temozolomide NN - B-MEDICINE
presents NOUN - O
a DET - O
promising ADJ - O
combination NOUN - O
for ADP - O
older ADJ - O
patients NOUN - O
with ADP - O
myeloid ADJ - O
leukemias NOUN - O
. PUNCT - O

Further ADV - O
clinical ADJ - O
investigations NOUN - O
aimed VERB - O
at ADP - O
elucidating VERB - O
the DET - O
veliparib ADJ - O
exposure NOUN - O
- PUNCT - O
efficacy NOUN - O
/ SYM - O
safety NOUN - O
relationship NOUN - O
and CCONJ - O
optimizing VERB - O
dosing VERB - O
recommendations NOUN - O
for ADP - O
maximizing VERB - O
benefit NOUN - O
- PUNCT - O
risk NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
advanced ADJ - O
myeloid ADJ - O
malignancies NOUN - O
should VERB - O
study VERB - O
veliparib ADJ - O
doses NOUN - O
ranging VERB - O
up ADP - O
to ADP - O
120 CD - B-CARDINAL
  SPACE - O
mg PRON - O
in ADP - O
combination NOUN - O
with ADP - O
temozolomide NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Population NOUN - O
pharmacokinetics NOUN - O
and CCONJ - O
exposure NOUN - O
- PUNCT - O
response NOUN - O
assessment NOUN - O
of ADP - O
veliparib ADJ - O
co NOUN - O
- VERB - O
administered VERB - O
with ADP - O
temozolomide NN - B-MEDICINE
in ADP - O
patients NOUN - O
with ADP - O
myeloid ADJ - O
leukemias NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Author NOUN - O
Correction PROPN - O
: PUNCT - O
BET NOUN - O
inhibitor NOUN - O
I PROPN - O
- PUNCT - O
BET151 PROPN - O
sensitizes VERB - O
GBM NNP - B-ORG
cells NOUN - O
to PART - O
temozolomide VB - B-MEDICINE
via ADP - O
PUMA PROPN - O
induction NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
particular ADJ - O
, PUNCT - O
temozolomide IN - B-MEDICINE
alone ADV - O
did VERB - O
not ADV - O
improve VERB - O
PFS PROPN - O
with ADP - O
respect NOUN - O
to ADP - O
FU NNP - B-ORG
. PUNCT - O

CONCLUSION PROPN - O
: PUNCT - O
RT NOUN - O
with ADP - O
or CCONJ - O
without ADP - O
chemotherapy NOUN - O
, PUNCT - O
but CCONJ - O
not ADV - O
temozolomide RB - B-MEDICINE
alone ADV - O
, PUNCT - O
could VERB - O
extend VERB - O
PFS NNP - B-ORG
in ADP - O

Moreover ADV - O
, PUNCT - O
temozolomide NN - B-MEDICINE
alone ADV - O
might VERB - O
not ADV - O
be VERB - O
effective ADJ - O
in ADP - O
prolonging VERB - O
progression NOUN - O
- PUNCT - O
free ADJ - O
survival NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To ADP - O
date NOUN - O
, PUNCT - O
the DET - O
role NOUN - O
of ADP - O
the DET - O
hedgehog NOUN - O
pathway NOUN - O
in ADP - O
resistance NOUN - O
to ADP - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
under ADP - O
hypoxia NOUN - O
has VERB - O
not ADV - O
been VERB - O
investigated VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Oroxylin PROPN - O
A DET - O
increases VERB - O
the DET - O
sensitivity NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
on ADP - O
glioma NOUN - O
cells NOUN - O
by ADP - O
hypoxia NOUN - O
- PUNCT - O
inducible ADJ - O
factor NOUN - O
1α CD - B-PERSON
/ SYM - O
hedgehog NOUN - O
pathway NOUN - O
under ADP - O
hypoxia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Synergistic ADJ - O
anticancer NOUN - O
effect NOUN - O
of ADP - O
acteoside NOUN - O
and CCONJ - O
temozolomide RB - B-MEDICINE
- PUNCT - O
based VERB - O
glioblastoma NOUN - O
chemotherapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
total NOUN - O
, PUNCT - O
111 CD - B-CARDINAL
newly ADV - O
, PUNCT - O
histologically ADV - O
diagnosed ADJ - O
glioblastoma NOUN - O
patients NOUN - O
treated VERB - O
at ADP - O
our ADJ - O
oncology NOUN - O
center NOUN - O
with ADP - O
radiotherapy NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
were VERB - O
prospectively ADV - O
enrolled VERB - O
. PUNCT - O

In ADP - O
routine ADJ - O
neurooncology NOUN - O
practice NOUN - O
, PUNCT - O
HRQoL NNP - B-CARDINAL
, PUNCT - O
cognitive ADJ - O
function NOUN - O
, PUNCT - O
and CCONJ - O
psychological ADJ - O
status NOUN - O
did VERB - O
not ADV - O
worsen VERB - O
during ADP - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
treatment NOUN - O
in ADP - O
glioblastoma NOUN - O
patients NOUN - O
receiving VERB - O
standard ADJ - O
radiotherapy NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
treatment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

( PUNCT - O
HGG PROPN - O
) PUNCT - O
patients NOUN - O
receiving VERB - O
a DET - O
combined VERB - O
regimen NOUN - O
of ADP - O
radiotherapy NOUN - O
( PUNCT - O
RT PROPN - O
) PUNCT - O
and CCONJ - O
temozolomide NN - B-MEDICINE
after ADP - O
tumor NOUN - O
resection NOUN - O
was VERB - O
increased VERB - O
. PUNCT - O

-DOCSTART- -X- - O

AIM NNP - B-ORG
: PUNCT - O
To PART - O
investigate VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
lactoferrin ADJ - O
nanoparticles NOUN - O
( PUNCT - O
LfNPs PROPN - O
) PUNCT - O
  SPACE - O
in ADP - O
delivering VERB - O
siRNA NOUN - O
across ADP - O
the DET - O
blood NOUN - O
- PUNCT - O
brain NOUN - O
barrier NOUN - O
to PART - O
treat VERB - O
glioblastoma NOUN - O
multiforme NOUN - O
( PUNCT - O
GBM NNP - B-ORG
) PUNCT - O
and CCONJ - O
with ADP - O
an DET - O
additional ADJ - O
objective NOUN - O
of ADP - O
potentiation NOUN - O
of ADP - O
conventional ADJ - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
chemotherapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Aurora NNP - B-ORG
kinase NOUN - O
B PROPN - O
siRNA PROPN - O
- PUNCT - O
loaded VERB - O
lactoferrin NOUN - O
nanoparticles NOUN - O
potentiate VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
in ADP - O
treating VERB - O
glioblastoma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Image NOUN - O
- PUNCT - O
based VERB - O
metric NOUN - O
of ADP - O
invasiveness ADJ - O
predicts NOUN - O
response NOUN - O
to ADP - O
adjuvant ADJ - O
temozolomide NN - B-MEDICINE
for ADP - O
primary ADJ - O
glioblastoma NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

We PRON - O
showed VERB - O
previously ADV - O
that ADP - O
Dihydrotanshinone NNP - B-ORG
( PUNCT - O
DHT PROPN - O
) PUNCT - O
augments NOUN - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ PROPN - O
) PUNCT - O
efficacy NOUN - O
by ADP - O
inducing VERB - O
reactive ADJ - O
oxygen NOUN - O
species NOUN - O
production NOUN - O
in ADP - O
an DET - O
in X - O
vitro X - O
model NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
role NOUN - O
of ADP - O
PDCD10 NNP - B-NORP
in ADP - O
apoptosis NOUN - O
and CCONJ - O
chemo NOUN - O
- PUNCT - O
resistance NOUN - O
was VERB - O
investigated VERB - O
after ADP - O
treatment NOUN - O
with ADP - O
staurosporine NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
. PUNCT - O

PDCD10-knockdown PROPN - O
accelerated VERB - O
tumor NOUN - O
growth NOUN - O
and CCONJ - O
increased VERB - O
tumor NOUN - O
mass NOUN - O
by ADP - O
2.1-fold CD - B-CARDINAL
and CCONJ - O
led VERB - O
to ADP - O
a DET - O
chemo NOUN - O
- PUNCT - O
resistance NOUN - O
of ADP - O
mice NOUN - O
treated VERB - O
with ADP - O
temozolomide NN - B-MEDICINE
. PUNCT - O

Loss NOUN - O
of ADP - O
programmed VERB - O
cell NOUN - O
death NOUN - O
10 CD - B-CARDINAL
activates NOUN - O
tumor NOUN - O
cells NOUN - O
and CCONJ - O
leads VERB - O
to ADP - O
temozolomide NN - B-MEDICINE
- PUNCT - O
resistance NOUN - O
in ADP - O
GBM NNP - B-ORG
, PUNCT - O
suggesting VERB - O
PDCD10 NNP - B-PERSON
as ADP - O
a DET - O
potential ADJ - O
target NOUN - O
for ADP - O
GBM NNP - B-ORG
therapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Loss NOUN - O
of ADP - O
programmed VERB - O
cell NOUN - O
death NOUN - O
10 CD - B-CARDINAL
activates NOUN - O
tumor NOUN - O
cells NOUN - O
and CCONJ - O
leads VERB - O
to ADP - O
temozolomide NN - B-MEDICINE
- PUNCT - O
resistance NOUN - O
in ADP - O
glioblastoma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Among ADP - O
clinical ADJ - O
and CCONJ - O
demographic ADJ - O
covariates NOUN - O
, PUNCT - O
age NOUN - O
( PUNCT - O
AUC NNP - B-ORG
= SYM - O
0.664 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O
the DET - O
use NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
( PUNCT - O
AUC NNP - B-ORG
= SYM - O
0.606 CD - B-CARDINAL
) PUNCT - O
were VERB - O
the DET - O
most ADV - O
predictive ADJ - O
of ADP - O
survival NOUN - O
. PUNCT - O

While ADP - O
there ADV - O
was VERB - O
a DET - O
clear ADJ - O
association NOUN - O
between ADP - O
age NOUN - O
and CCONJ - O
methylation NOUN - O
, PUNCT - O
the DET - O
integration NOUN - O
of ADP - O
age NOUN - O
, PUNCT - O
the DET - O
use NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
, PUNCT - O
and CCONJ - O
either CCONJ - O
gene NOUN - O
expression NOUN - O
or CCONJ - O
methylation NOUN - O
led VERB - O
to ADP - O
a DET - O
substantial ADJ - O
increase NOUN - O
in ADP - O
AUC NNP - B-ORG
in ADP - O
cross ADJ - O
- ADJ - O
validaton ADJ - O
( PUNCT - O
AUC NNP - B-ORG
= SYM - O
0.718 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Chemotherapy NN - B-PERSON
is VERB - O
the DET - O
main ADJ - O
postsurgical ADJ - O
and CCONJ - O
adjuvant ADJ - O
therapy NOUN - O
for ADP - O
glioma NOUN - O
, PUNCT - O
and CCONJ - O
intrinsic ADJ - O
or CCONJ - O
acquired VERB - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
resistance NOUN - O
may VERB - O
result VERB - O
in ADP - O
poor ADJ - O
prognosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

MiR-181b-5p PROPN - O
modulates NOUN - O
chemosensitivity NOUN - O
of ADP - O
glioma NOUN - O
cells NOUN - O
to PART - O
temozolomide VB - B-MEDICINE
by ADP - O
targeting VERB - O
Bcl-2 PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

PURPOSE PROPN - O
: PUNCT - O
To PART - O
evaluate VERB - O
the DET - O
toxicity NOUN - O
and CCONJ - O
efficacy NOUN - O
of ADP - O
adjuvant ADJ - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
and CCONJ - O
irinotecan PROPN - O
( PUNCT - O
CPT-11 PROPN - O
) PUNCT - O
for ADP - O
12 CD - B-CARDINAL
  SPACE - O
months NNS - B-DATE
after ADP - O
concurrent ADJ - O
chemoradiation NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
newly ADV - O
diagnosed VERB - O
glioblastoma NOUN - O
( PUNCT - O
GBM NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Natural ADJ - O
borneol NOUN - O
is VERB - O
a DET - O
novel NOUN - O
chemosensitizer NOUN - O
that ADJ - O
enhances VERB - O
temozolomide NN - B-MEDICINE
- PUNCT - O
induced VERB - O
anticancer NOUN - O
efficiency NOUN - O
against ADP - O
human ADJ - O
glioma NOUN - O
by ADP - O
triggering VERB - O
mitochondrial ADJ - O
dysfunction NOUN - O
and CCONJ - O
reactive ADJ - O
oxide NOUN - O
species NOUN - O
- PUNCT - O
mediated VERB - O
oxidative ADJ - O
damage NOUN - O

-DOCSTART- -X- - O

Gliomas NNP - B-PERSON
, PUNCT - O
which ADJ - O
are VERB - O
common ADJ - O
in ADP - O
dogs NOUN - O
and CCONJ - O
also ADV - O
represent VERB - O
the DET - O
majority NOUN - O
of ADP - O
fatal ADJ - O
brain NOUN - O
tumours NOUN - O
in ADP - O
humans NOUN - O
, PUNCT - O
can VERB - O
be VERB - O
amenable ADJ - O
to PART - O
chemotherapy NOUN - O
with ADP - O
temozolomide NN - B-MEDICINE
. PUNCT - O

Biopolymer ADJ - O
microcylinders NOUN - O
conjugated VERB - O
with ADP - O
temozolomide NN - B-MEDICINE
and CCONJ - O
gadolinium NOUN - O
were VERB - O
implanted VERB - O
into ADP - O
partially ADV - O
resected VERB - O
tumours NOUN - O
of ADP - O
four CD - B-CARDINAL
client NOUN - O
- PUNCT - O
owned VERB - O
dogs NOUN - O
with ADP - O
gliomas NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Intratumoral ADJ - O
temozolomide NN - B-MEDICINE
in ADP - O
spontaneous ADJ - O
canine NOUN - O
gliomas NOUN - O
: PUNCT - O
feasibility NOUN - O
of ADP - O
a DET - O
novel ADJ - O
therapy NOUN - O
using VERB - O
implanted VERB - O
microcylinders NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
the DET - O
present ADJ - O
study NOUN - O
, PUNCT - O
we PRON - O
found VERB - O
that ADP - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ PROPN - O
) PUNCT - O
treatment NOUN - O
led VERB - O
to ADP - O
a DET - O
decrease NOUN - O
in ADP - O
intracellular ADJ - O
concentration NOUN - O
of ADP - O
Cl- PROPN - O
( PUNCT - O
[ PUNCT - O
Cl-]i PROPN - O
) PUNCT - O
in ADP - O
both CCONJ - O
U87 NNP - B-ORG
and CCONJ - O
TMZ NNP - B-ORG
- PUNCT - O
resistant ADJ - O
U87/R PROPN - O
glioma NOUN - O
cells NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

LRRC8A NNP - B-GPE
potentiates VERB - O
temozolomide VBP - B-MEDICINE
sensitivity NOUN - O
in ADP - O
glioma NOUN - O
cells NOUN - O
via ADP - O
activating VERB - O
mitochondria ADJ - O
- PUNCT - O
dependent ADJ - O
apoptotic ADJ - O
pathway NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Glioblastoma NNP - B-ORG
multiforme PROPN - O
( PUNCT - O
GBM NNP - B-ORG
) PUNCT - O
has VERB - O
a DET - O
poor ADJ - O
prognosis NOUN - O
with ADP - O
an DET - O
overall ADJ - O
survival NOUN - O
of ADP - O
14 CD - B-DATE
- SYM - I-DATE
15 CD - I-DATE
months NNS - I-DATE
after ADP - O
surgery NOUN - O
, PUNCT - O
radiation NOUN - O
and CCONJ - O
chemotherapy NOUN - O
using VERB - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Thioridazine NOUN - O
inhibits VERB - O
autophagy NOUN - O
and CCONJ - O
sensitizes VERB - O
glioblastoma NOUN - O
cells NOUN - O
to PART - O
temozolomide VB - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
assessed VERB - O
the DET - O
reduction NOUN - O
in ADP - O
tumour NOUN - O
volume NOUN - O
following VERB - O
intensity NOUN - O
modulated VERB - O
radiation NOUN - O
therapy NOUN - O
( PUNCT - O
IMRT NNP - B-ORG
) PUNCT - O
and CCONJ - O
temozolomide NN - B-MEDICINE
in ADP - O
this DET - O
favourable ADJ - O
and CCONJ - O
more ADV - O
responsive ADJ - O
tumour NOUN - O
pathology NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Tumour NN - B-ORG
volume NOUN - O
reduction NOUN - O
following VERB - O
PET PROPN - O
guided VERB - O
intensity NOUN - O
modulated VERB - O
radiation NOUN - O
therapy NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
in ADP - O
IDH PROPN - O
mutated VERB - O
anaplastic ADJ - O
glioma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

HERBY NOUN - O
was VERB - O
a DET - O
Phase NNP - B-PRODUCT
II NNP - I-PRODUCT
multicenter NOUN - O
trial NOUN - O
setup NOUN - O
to PART - O
establish VERB - O
the DET - O
efficacy NOUN - O
and CCONJ - O
safety NOUN - O
of ADP - O
adding VERB - O
bevacizumab NOUN - O
to ADP - O
radiation NOUN - O
therapy NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
in ADP - O
pediatric ADJ - O
patients NOUN - O
with ADP - O
newly ADV - O
diagnosed VERB - O
non ADJ - O
- ADJ - O
brain ADJ - O
stem VERB - O
high ADJ - O
- PUNCT - O
grade NOUN - O
gliomas NOUN - O
. PUNCT - O

Pseudoprogression PROPN - O
occurred VERB - O
in ADP - O
10/116 NNP - B-GPE
( PUNCT - O
9 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
cases NOUN - O
, PUNCT - O
8 CD - B-CARDINAL
in ADP - O
the DET - O
radiation NOUN - O
therapy NOUN - O
/ SYM - O
temozolomide NN - B-MEDICINE
arm NOUN - O
and CCONJ - O
2 CD - B-CARDINAL
in ADP - O
the DET - O
bevacizumab NOUN - O
arm NOUN - O
( PUNCT - O
P NOUN - O
< X - O
.01 PUNCT - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Biophysical ADJ - O
interaction NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
and CCONJ - O
its ADJ - O
active ADJ - O
metabolite NOUN - O
with ADP - O
biomembrane NOUN - O
models NOUN - O
: PUNCT - O
The DET - O
relevance NOUN - O
of ADP - O
drug NOUN - O
- PUNCT - O
membrane NOUN - O
interaction NOUN - O
for ADP - O
Glioblastoma NNP - B-PERSON
Multiforme NNP - I-PERSON
therapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Meanwhile ADV - O
, PUNCT - O
downregulation NOUN - O
of ADP - O
miR-196b NOUN - O
remarkably ADV - O
inhibited VERB - O
glioma NOUN - O
cell NOUN - O
growth NOUN - O
and CCONJ - O
colony NOUN - O
formation NOUN - O
when ADV - O
concurrent ADJ - O
with ADP - O
temozolomide NN - B-MEDICINE
administration NOUN - O
. PUNCT - O

Together ADV - O
, PUNCT - O
our ADJ - O
findings NOUN - O
indicate VERB - O
that ADP - O
downregulation NOUN - O
of ADP - O
miR-196b NOUN - O
increased VERB - O
glioma NOUN - O
cell NOUN - O
sensitivity NOUN - O
to PART - O
temozolomide VB - B-MEDICINE
chemotherapy NOUN - O
and CCONJ - O
radiotherapy NOUN - O
and CCONJ - O
may VERB - O
be VERB - O
a DET - O
valuable ADJ - O
target NOUN - O
when ADV - O
treating VERB - O
malignant ADJ - O
gliomas NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Successful ADJ - O
treatment NOUN - O
with ADP - O
temozolomide NN - B-MEDICINE
in ADP - O
an DET - O
elderly ADJ - O
woman NOUN - O
with ADP - O
advanced ADJ - O
pulmonary ADJ - O
large ADJ - O
- PUNCT - O
cell NOUN - O
neuroendocrine NOUN - O
carcinoma NOUN - O
: PUNCT - O
A DET - O
case NOUN - O
report NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
efficacy NOUN - O
of ADP - O
bevacizumab NOUN - O
, PUNCT - O
temozolomide NN - B-MEDICINE
, PUNCT - O
lomustine NOUN - O
( PUNCT - O
CCNU PROPN - O
) PUNCT - O
, PUNCT - O
irinotecan PROPN - O
( PUNCT - O
CPT NOUN - O
11 NUM - O
) PUNCT - O
, PUNCT - O
a DET - O
tyrosine NOUN - O
kinase NOUN - O
inhibitor NOUN - O
( PUNCT - O
sorafenib NOUN - O
) PUNCT - O
, PUNCT - O
a DET - O
selective ADJ - O
MEK1/2 NNP - B-ORG
inhibitor NOUN - O
( PUNCT - O
cobimetinib NOUN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
a DET - O
BRAF NNP - B-ORG
inhibitor NOUN - O
( PUNCT - O
vemurafenib PROPN - O
) PUNCT - O
were VERB - O
assessed VERB - O
in ADP - O
two CD - B-CARDINAL
subcutaneous ADJ - O
xenografts NOUN - O
: PUNCT - O
D645 NNP - B-ORG
PXA NNP - I-ORG
( PUNCT - O
V600E PROPN - O
- PUNCT - O
mutant PROPN - O
) PUNCT - O
and CCONJ - O
D2363 PROPN - O
PXA NNP - B-ORG
( PUNCT - O
V600E PROPN - O
- PUNCT - O
non ADJ - O
- ADJ - O
mutant ADJ - O
) PUNCT - O

These DET - O
findings NOUN - O
suggest VERB - O
that ADP - O
when ADV - O
adjuvant ADJ - O
treatment NOUN - O
is VERB - O
clinically ADV - O
indicated VERB - O
for ADP - O
PXA NNP - B-ORG
, PUNCT - O
temozolomide NN - B-MEDICINE
, PUNCT - O
CPT NOUN - O
11 NUM - O
, PUNCT - O
or CCONJ - O
bevacizumab NOUN - O
may VERB - O
be VERB - O
considered VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Bevacizumab PROPN - O
, PUNCT - O
irinotecan ADJ - O
, PUNCT - O
temozolomide NN - B-MEDICINE
, PUNCT - O
tyrosine NOUN - O
kinase NOUN - O
inhibition NOUN - O
, PUNCT - O
and CCONJ - O
MEK NN - B-ORG
inhibition NOUN - O
are VERB - O
effective ADJ - O
against ADP - O
pleomorphic ADJ - O
xanthoastrocytoma NOUN - O
regardless ADV - O
of ADP - O
V600E NNP - B-ORG
status NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
total NOUN - O
of ADP - O
64 CD - B-CARDINAL
patients NOUN - O
who NOUN - O
received VERB - O
temozolomide NN - B-MEDICINE
chemotherapy NOUN - O
at ADP - O
our ADJ - O
institution NOUN - O
was VERB - O
included VERB - O
; PUNCT - O
35 CD - B-CARDINAL
patients NOUN - O
received VERB - O
full ADV - O
- PUNCT - O
dose NOUN - O
chemo NOUN - O
- PUNCT - O
radiotherapy NOUN - O
as ADP - O
per ADP - O
the DET - O
STUPP PROPN - O
protocol NOUN - O
( PUNCT - O
Group NNP - B-ORG
A NNP - I-ORG
) PUNCT - O
, PUNCT - O
and CCONJ - O
9 CD - B-CARDINAL
patients NOUN - O
received VERB - O
abbreviated ADJ - O
radiotherapy NOUN - O
with ADP - O
concurrent ADJ - O
chemotherapy NOUN - O
( PUNCT - O
Group PROPN - O
B PROPN - O
) PUNCT - O
. PUNCT - O

Twenty CD - B-CARDINAL
patients NOUN - O
received VERB - O
temozolomide RB - B-MEDICINE
alone ADV - O
with ADP - O
an DET - O
intended VERB - O
12 CD - B-CARDINAL
cycles NOUN - O
of ADP - O
therapy NOUN - O
for ADP - O
first JJ - B-ORDINAL
relapse NOUN - O
at IN - B-DATE
least JJS - I-DATE
6 CD - I-DATE
months NNS - I-DATE
after ADP - O
completion NOUN - O
of ADP - O
adjuvant ADJ - O
chemotherapy NOUN - O
( PUNCT - O
Group NNP - B-ORG
C NNP - I-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Clinical ADJ - O
correlates NOUN - O
of ADP - O
severe ADJ - O
thrombocytopenia NOUN - O
from ADP - O
temozolomide NN - B-MEDICINE
in ADP - O
glioblastoma NOUN - O
patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
  SPACE - O
vitro NOUN - O
, PUNCT - O
treatment NOUN - O
with ADP - O
temozolomide NN - B-MEDICINE
, PUNCT - O
the DET - O
most ADV - O
commonly ADV - O
used VERB - O
chemotherapeutic NOUN - O
in ADP - O
glioma NOUN - O
therapy NOUN - O
, PUNCT - O
induced VERB - O
APOBEC3B PROPN - O
expression NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

APOBEC3B NNP - B-ORG
is VERB - O
expressed VERB - O
in ADP - O
human ADJ - O
glioma NOUN - O
, PUNCT - O
and CCONJ - O
influences NOUN - O
cell NOUN - O
proliferation NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
resistance NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Out ADP - O
of ADP - O
these DET - O
, PUNCT - O
two CD - B-CARDINAL
patients NOUN - O
( PUNCT - O
16.6 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
developed VERB - O
metastasis NOUN - O
and CCONJ - O
were VERB - O
shifted VERB - O
to PART - O
capecitabine+temozolomide VERB - O
( PUNCT - O
Cap NNP - B-ORG
- HYPH - I-ORG
Tem NNP - I-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Furthermore ADV - O
, PUNCT - O
we PRON - O
evaluated VERB - O
the DET - O
potential ADJ - O
PK NNP - B-ORG
interactions NOUN - O
between ADP - O
letrozole NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
in ADP - O
Sprague PROPN - O
- PUNCT - O
Dawley PROPN - O
rats NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Plasma NOUN - O
and CCONJ - O
brain NOUN - O
pharmacokinetics NOUN - O
of ADP - O
letrozole NOUN - O
and CCONJ - O
drug NOUN - O
interaction NOUN - O
studies NOUN - O
with ADP - O
temozolomide NN - B-MEDICINE
in ADP - O
NOD NNP - B-ORG
- PUNCT - O
scid PROPN - O
gamma NOUN - O
mice NOUN - O
and CCONJ - O
sprague NOUN - O
dawley NOUN - O
rats NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Despite ADP - O
the DET - O
clinical ADJ - O
success NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
, PUNCT - O
its ADJ - O
sensitivity NOUN - O
remains VERB - O
a DET - O
major ADJ - O
challenge NOUN - O
in ADP - O
glioblastoma NOUN - O
( PUNCT - O
GBM NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

PLK4 PROPN - O
is VERB - O
a DET - O
determinant NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
sensitivity NOUN - O
through ADP - O
phosphorylation NOUN - O
of ADP - O
IKBKE NNP - B-ORG
in ADP - O
glioblastoma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Good ADJ - O
tolerability NOUN - O
of ADP - O
maintenance NOUN - O
temozolomide NN - B-MEDICINE
in ADP - O
glioblastoma NOUN - O
patients NOUN - O
after ADP - O
severe ADJ - O
hematological ADJ - O
toxicity NOUN - O
during ADP - O
concomitant ADJ - O
radiotherapy NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
treatment NOUN - O
: PUNCT - O
report NOUN - O
of ADP - O
two CD - B-CARDINAL
cases NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Retrospective ADJ - O
studies NOUN - O
have VERB - O
suggested VERB - O
that ADP - O
capecitabine NOUN - O
combined VERB - O
with ADP - O
temozolomide NN - B-MEDICINE
( PUNCT - O
CAPTEM NN - B-ORG
) PUNCT - O
is VERB - O
effective ADJ - O
for ADP - O
treating VERB - O
patients NOUN - O
with ADP - O
advanced ADJ - O
neuroendocrine NOUN - O
neoplasms NOUN - O
( PUNCT - O
NENs PROPN - O
) PUNCT - O
; PUNCT - O
however ADV - O
, PUNCT - O
the DET - O
efficacy NOUN - O
and CCONJ - O
safety NOUN - O
of ADP - O
this DET - O
regimen NOUN - O
needs VERB - O
to PART - O
be VERB - O
verified VERB - O
by ADP - O
high ADJ - O
- PUNCT - O
quality NOUN - O
evidence NOUN - O
or CCONJ - O
results NOUN - O
of ADP - O
randomized VERB - O
controlled VERB - O
trials NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Safety NOUN - O
and CCONJ - O
efficacy NOUN - O
of ADP - O
combining VERB - O
capecitabine NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
( PUNCT - O
CAPTEM NNP - B-ORG
) PUNCT - O
to PART - O
treat VERB - O
advanced ADJ - O
neuroendocrine NOUN - O
neoplasms NOUN - O
: PUNCT - O
A DET - O
meta ADJ - O
- PUNCT - O
analysis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
validated VERB - O
methods NOUN - O
were VERB - O
successfully ADV - O
applied VERB - O
to PART - O
plasma VERB - O
samples NOUN - O
donated VERB - O
from ADP - O
cancer NOUN - O
patient NOUN - O
following VERB - O
treatment NOUN - O
with ADP - O
temozolomide NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Development NOUN - O
and CCONJ - O
validation NOUN - O
of ADP - O
simple ADJ - O
step NOUN - O
protein NOUN - O
precipitation NOUN - O
UHPLC NNP - B-PRODUCT
- HYPH - I-PRODUCT
MS NNP - I-PRODUCT
/ SYM - I-PRODUCT
MS NNP - I-PRODUCT
methods NOUN - O
for ADP - O
quantitation NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
in ADP - O
cancer NOUN - O
patient NOUN - O
plasma NOUN - O
samples NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
novel ADJ - O
cytotoxic NOUN - O
agent NOUN - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
is VERB - O
now ADV - O
frequently ADV - O
applied VERB - O
as ADP - O
the DET - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
chemotherapeutic ADJ - O
treatment NOUN - O
for ADP - O
GBM NNP - B-ORG
; PUNCT - O
however ADV - O
, PUNCT - O
a DET - O
considerable ADJ - O
number NOUN - O
of ADP - O
patients NOUN - O
treated VERB - O
with ADP - O
TMZ NNP - B-ORG
turn VERB - O
out PART - O
to PART - O
be VERB - O
refractory ADJ - O
to ADP - O
this DET - O
drug NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

An DET - O
integrated ADJ - O
protocol NOUN - O
combining VERB - O
capecitibine NOUN - O
- PUNCT - O
temozolomide NN - B-MEDICINE
with ADP - O
yttrium-90 ADJ - O
radioembolization NOUN - O
( PUNCT - O
CapTemY90 PROPN - O
) PUNCT - O
for ADP - O
liver NOUN - O
- PUNCT - O
dominant ADJ - O
grade NOUN - O
2 CD - B-CARDINAL
neuroendocrine NOUN - O
tumors NOUN - O
( PUNCT - O
NETs PROPN - O
) PUNCT - O
was VERB - O
designed VERB - O
in ADP - O
the DET - O
hope NOUN - O
of ADP - O
achieving VERB - O
synergistic ADJ - O
improvement NOUN - O
in ADP - O
liver NOUN - O
disease NOUN - O
control NOUN - O
with ADP - O
no DET - O
more ADJ - O
than ADP - O
additive ADJ - O
toxicities NOUN - O
. PUNCT - O

Twenty CD - B-CARDINAL
- HYPH - I-CARDINAL
one CD - I-CARDINAL
patients NOUN - O
with ADP - O
unresectable ADJ - O
grade NOUN - O
2 CD - B-CARDINAL
NET PROPN - O
liver ADV - O
- PUNCT - O
dominant ADJ - O
metastases NOUN - O
without ADP - O
contraindications NOUN - O
to ADP - O
radioembolization NOUN - O
or CCONJ - O
to ADP - O
CapTem NNP - B-ORG
initiated VERB - O
therapy NOUN - O
with ADP - O
capecitabine NOUN - O
600 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
m NOUN - O
twice ADV - O
daily NOUN - O
for ADP - O
14 CD - B-DATE
days NNS - I-DATE
and CCONJ - O
temozolomide IN - B-MEDICINE
150 CD - B-CARDINAL
to IN - I-CARDINAL
200 CD - I-CARDINAL
mg NOUN - O
/ SYM - O
m NOUN - O
in ADP - O
2 CD - B-CARDINAL
divided VERB - O
doses NOUN - O
on ADP - O
days NOUN - O
10 NUM - O
to PART - O
14 CD - B-CARDINAL
, PUNCT - O
with ADP - O
14 CD - B-DATE
days NNS - I-DATE
between ADP - O
cycles NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Cutaneous ADJ - O
melanomas NOUN - O
frequently ADV - O
metastasize VERB - O
to ADP - O
the DET - O
brain NOUN - O
, PUNCT - O
with ADP - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
plus CCONJ - O
radiotherapy NOUN - O
( PUNCT - O
RT PROPN - O
) PUNCT - O
offering VERB - O
little ADJ - O
control NOUN - O
of ADP - O
these DET - O
lesions NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Trehalose NOUN - O
inhibits VERB - O
cell NOUN - O
proliferation NOUN - O
and CCONJ - O
amplifies VERB - O
long ADJ - O
- PUNCT - O
term NOUN - O
temozolomide- NOUN - O
and CCONJ - O
radiation NOUN - O
- PUNCT - O
induced VERB - O
cytotoxicity NOUN - O
in ADP - O
melanoma NOUN - O
cells NOUN - O
: PUNCT - O
A DET - O
role NOUN - O
for ADP - O
autophagy NOUN - O
and CCONJ - O
premature ADJ - O
senescence NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Discriminating VERB - O
between ADP - O
tumor NOUN - O
recurrence NOUN - O
and CCONJ - O
treatment NOUN - O
effects NOUN - O
in ADP - O
glioblastoma NOUN - O
patients NOUN - O
undergoing VERB - O
radiation NOUN - O
- PUNCT - O
temozolomide NN - B-MEDICINE
( PUNCT - O
RT NNP - B-ORG
/ SYM - I-ORG
TMZ NNP - I-ORG
) PUNCT - O
therapy NOUN - O
remains VERB - O
a DET - O
major ADJ - O
clinical ADJ - O
challenge NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Diagnostic ADJ - O
utility NOUN - O
of ADP - O
restriction NOUN - O
spectrum NOUN - O
imaging NOUN - O
( PUNCT - O
RSI NNP - B-ORG
) PUNCT - O
in ADP - O
glioblastoma NOUN - O
patients NOUN - O
after ADP - O
concurrent ADJ - O
radiation NOUN - O
- PUNCT - O
temozolomide NN - B-MEDICINE
treatment NOUN - O
: PUNCT - O
A DET - O
pilot NOUN - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

4 CD - B-CARDINAL
temozolomide NN - B-MEDICINE
) PUNCT - O
one CD - B-DATE
day NN - I-DATE
prior ADV - O
to ADP - O
their ADJ - O
scheduled VERB - O
surgical ADJ - O
resection NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Since ADP - O
the DET - O
development NOUN - O
of ADP - O
the DT - B-ORG
RTOG NNP - I-ORG
- HYPH - I-ORG
RPA NNP - I-ORG
, PUNCT - O
high ADJ - O
- PUNCT - O
grade NOUN - O
gliomas NOUN - O
have VERB - O
seen VERB - O
the DET - O
widespread ADJ - O
introduction NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
and CCONJ - O
tumor NOUN - O
oncogenetics NOUN - O
. PUNCT - O

Generating VERB - O
our ADJ - O
new ADJ - O
RPA NNP - B-ORG
created VERB - O
7 CD - B-CARDINAL
significantly ADV - O
different ADJ - O
survival NOUN - O
classes NOUN - O
( PUNCT - O
P<0.001 NNP - B-GPE
, PUNCT - O
χ=584 NOUN - O
) PUNCT - O
with ADP - O
median ADJ - O
survival NOUN - O
ranging VERB - O
from ADP - O
96.4 CD - B-CARDINAL
to PART - O
2.9 CD - B-DATE
months NNS - I-DATE
based VERB - O
on ADP - O
age NOUN - O
, PUNCT - O
histology NOUN - O
, PUNCT - O
O6-methylguanine ADJ - O
- PUNCT - O
DNA NOUN - O
methyltransferase NOUN - O
methylation NOUN - O
status NOUN - O
, PUNCT - O
radiation NOUN - O
fractions NOUN - O
, PUNCT - O
tumor NOUN - O
location NOUN - O
, PUNCT - O
radiation NOUN - O
dose NOUN - O
, PUNCT - O
temozolomide NN - B-MEDICINE
status NOUN - O
, PUNCT - O
and CCONJ - O
resection NOUN - O
status NOUN - O
. PUNCT - O

Our ADJ - O
second JJ - B-ORDINAL
RPA NNP - B-ORG
of ADP - O
our ADJ - O
genetic ADJ - O
subset NOUN - O
generated VERB - O
5 CD - B-CARDINAL
significantly ADV - O
different ADJ - O
survival NOUN - O
classes NOUN - O
( PUNCT - O
P<0.001 NNP - B-GPE
, PUNCT - O
χ=166 NN - B-GPE
) PUNCT - O
with ADP - O
survival NOUN - O
ranging VERB - O
from ADP - O
65.3 CD - B-DATE
to TO - I-DATE
5.6 CD - I-DATE
months NNS - I-DATE
based VERB - O
on ADP - O
age NOUN - O
, PUNCT - O
isocitrate NOUN - O
dehydrogenase NOUN - O
1 CD - B-CARDINAL
mutation NOUN - O
status NOUN - O
, PUNCT - O
O6-methylguanine ADJ - O
- PUNCT - O
DNA NOUN - O
methyltransferase NOUN - O
methylation NOUN - O
status NOUN - O
, PUNCT - O
neurological ADJ - O
functional ADJ - O
classification NOUN - O
, PUNCT - O
hospitalization NOUN - O
during ADP - O
IMRT NNP - B-ORG
, PUNCT - O
temozolomide NN - B-MEDICINE
status NOUN - O
, PUNCT - O
and CCONJ - O
Karnofsky NNP - B-PERSON
performance NOUN - O
status NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

CNS NNP - B-ORG
inflammatory ADJ - O
disorder NOUN - O
after ADP - O
concurrent ADJ - O
radiotherapy NOUN - O
- PUNCT - O
temozolomide NN - B-MEDICINE
and CCONJ - O
nivolumab NOUN - O
in ADP - O
a DET - O
glioblastoma NOUN - O
patient NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
total ADJ - O
MR NNP - B-ORG
treatment NOUN - O
regimens NOUN - O
also ADV - O
increased VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
against ADP - O
the DET - O
SWB77 NNP - B-ORG
xenograft NOUN - O
when ADV - O
administered VERB - O
at ADP - O
the DET - O
end NOUN - O
of ADP - O
the DET - O
MET NNP - B-ORG
regimen NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
authors NOUN - O
report VERB - O
results NOUN - O
from ADP - O
the DET - O
subsequent ADJ - O
COG NNP - B-ORG
study NOUN - O
( PUNCT - O
ARST08P1 PROPN - O
) PUNCT - O
, PUNCT - O
which ADJ - O
evaluated VERB - O
the DET - O
feasibility NOUN - O
and CCONJ - O
efficacy NOUN - O
of ADP - O
adding VERB - O
cixutumumab NOUN - O
( PUNCT - O
insulin NOUN - O
- PUNCT - O
like ADJ - O
growth NOUN - O
factor-1 ADJ - O
monoclonal ADJ - O
antibody NOUN - O
) PUNCT - O
or CCONJ - O
temozolomide NN - B-MEDICINE
to ADP - O
the DET - O
ARST0431 PROPN - O
intensive ADJ - O
chemotherapy NOUN - O
backbone NOUN - O
. PUNCT - O

In ADP - O
pilot NOUN - O
2 CD - B-CARDINAL
, PUNCT - O
patients NOUN - O
received VERB - O
oral ADJ - O
temozolomide NN - B-MEDICINE
( PUNCT - O
100 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
m2 NOUN - O
) PUNCT - O
daily JJ - B-DATE
for ADP - O
5 CD - B-DATE
days NNS - I-DATE
with ADP - O
irinotecan NOUN - O
. PUNCT - O

With ADP - O
a DET - O
median ADJ - O
follow NOUN - O
- PUNCT - O
up NOUN - O
of ADP - O
2.9 CD - B-DATE
years NNS - I-DATE
, PUNCT - O
the DET - O
3-year CD - B-DATE
event NOUN - O
- PUNCT - O
free ADJ - O
survival NOUN - O
rate NOUN - O
was VERB - O
16 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
confidence NOUN - O
interval NOUN - O
, PUNCT - O
7%-25 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
with ADP - O
cixutumumab NOUN - O
and CCONJ - O
18 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
confidence NOUN - O
interval NOUN - O
, PUNCT - O
2%-35 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
with ADP - O
temozolomide NN - B-MEDICINE
. PUNCT - O

The DET - O
addition NOUN - O
of ADP - O
cixutumumab NOUN - O
or CCONJ - O
temozolomide NN - B-MEDICINE
to ADP - O
intensive ADJ - O
multiagent NOUN - O
chemotherapy NOUN - O
for ADP - O
metastatic ADJ - O
RMS NNP - B-ORG
was VERB - O
safe ADJ - O
and CCONJ - O
feasible ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
addition NOUN - O
of ADP - O
cixutumumab NOUN - O
or CCONJ - O
temozolomide NN - B-MEDICINE
to ADP - O
intensive ADJ - O
multiagent NOUN - O
chemotherapy NOUN - O
is VERB - O
feasible ADJ - O
but CCONJ - O
does VERB - O
not ADV - O
improve VERB - O
outcome NOUN - O
for ADP - O
patients NOUN - O
with ADP - O
metastatic ADJ - O
rhabdomyosarcoma NOUN - O
: PUNCT - O
A DET - O
report NOUN - O
from ADP - O
the DT - B-ORG
Children NNPS - I-ORG
's POS - I-ORG
Oncology NNP - I-ORG
Group NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
combination NOUN - O
of ADP - O
capecitabineandtemozolomide NOUN - O
, PUNCT - O
called VERB - O
CAPTEM NN - B-PRODUCT
regimen NNS - I-PRODUCT
, PUNCT - O
has VERB - O
produced VERB - O
promising ADJ - O
response NOUN - O
rates NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
grade1 NOUN - O
or CCONJ - O
2neuroendocrine CD - B-CARDINAL
tumors NOUN - O
of ADP - O
multiple ADJ - O
origins NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Capecitabine NOUN - O
plus CCONJ - O
temozolomide NN - B-MEDICINE
in PART - O
well ADV - O
or CCONJ - O
moderately ADV - O
differentiated VERB - O
primary ADJ - O
atypical ADJ - O
neuroendocrine NOUN - O
tumors NOUN - O
: PUNCT - O
a DET - O
single ADJ - O
centre NOUN - O
experience NOUN - O
of ADP - O
two CD - B-CARDINAL
cases NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Addition NOUN - O
of ADP - O
bevacizumab NOUN - O
fails VERB - O
to PART - O
improve VERB - O
on ADP - O
temozolomide NN - B-MEDICINE
alone ADV - O
for ADP - O
glioma NOUN - O
therapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

GBM NNP - B-ORG
exhibits VERB - O
high ADJ - O
resistance NOUN - O
to ADP - O
the DET - O
standard ADJ - O
treatment NOUN - O
consisting VERB - O
of ADP - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
combined VERB - O
with ADP - O
radiotherapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Isofuranodiene PROPN - O
synergizes VERB - O
with ADP - O
temozolomide NN - B-MEDICINE
in ADP - O
inducing VERB - O
glioma NOUN - O
cells NOUN - O
death NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
combination NOUN - O
of ADP - O
irinotecan NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
has VERB - O
shown VERB - O
activity NOUN - O
against ADP - O
refractory NOUN - O
/ SYM - O
relapsed ADJ - O
pediatric ADJ - O
solid ADJ - O
tumors NOUN - O
. PUNCT - O

Method NNP - B-PERSON
Thirty CD - I-PERSON
- HYPH - I-PERSON
four CD - I-PERSON
children NOUN - O
with ADP - O
refractory NOUN - O
/ SYM - O
relapsed VERB - O
solid ADJ - O
tumors NOUN - O
who NOUN - O
had VERB - O
previously ADV - O
been VERB - O
heavily ADV - O
pretreated VERB - O
and CCONJ - O
who NOUN - O
were VERB - O
given VERB - O
vincristine ADJ - O
, PUNCT - O
irinotecan ADJ - O
, PUNCT - O
and CCONJ - O
temozolomide NN - B-MEDICINE
as ADP - O
third- NOUN - O
or CCONJ - O
further ADJ - O
line NOUN - O
chemotherapy NOUN - O
during ADP - O
2004 CD - B-DATE
- SYM - I-DATE
2015 CD - I-DATE
were VERB - O
evaluated VERB - O
. PUNCT - O

In ADP - O
heavily ADV - O
pretreated VERB - O
patients NOUN - O
with ADP - O
refractory NOUN - O
/ SYM - O
relapsed VERB - O
solid ADJ - O
tumors NOUN - O
, PUNCT - O
the DET - O
vincristine NOUN - O
, PUNCT - O
irinotecan ADJ - O
, PUNCT - O
and CCONJ - O
temozolomide NN - B-MEDICINE
regimen NOUN - O
seemed VERB - O
promising VERB - O
in ADP - O
Ewing VERB - O
sarcoma ADJ - O
patients NOUN - O
and CCONJ - O
was VERB - O
well ADV - O
tolerated VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Vincristine JJ - B-ORG
, PUNCT - O
irinotecan ADJ - O
, PUNCT - O
and CCONJ - O
temozolomide IN - B-MEDICINE
treatment NOUN - O
for ADP - O
refractory NOUN - O
/ SYM - O
relapsed VERB - O
pediatric ADJ - O
solid ADJ - O
tumors NOUN - O
: PUNCT - O
A DET - O
single ADJ - O
center NOUN - O
experience NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
aim NOUN - O
of ADP - O
the DET - O
present ADJ - O
study NOUN - O
was VERB - O
to PART - O
assess VERB - O
the DET - O
effect NOUN - O
of ADP - O
Endostar NNP - B-PERSON
and CCONJ - O
temozolomide NN - B-MEDICINE
or CCONJ - O
dacarbazine NOUN - O
plus CCONJ - O

Patients NOUN - O
received VERB - O
temozolomide NN - B-MEDICINE
or CCONJ - O
dacarbazine NOUN - O
plus CCONJ - O
5-FU CD - B-DATE
, PUNCT - O
and CCONJ - O
Endostar NNP - B-ORG
. PUNCT - O

Six CD - B-CARDINAL
patients NOUN - O
received VERB - O
temozolomide NN - B-MEDICINE
and CCONJ - O
8 CD - B-CARDINAL
received VERB - O
dacarbazine NOUN - O
+ CCONJ - O
5-FU NUM - O
, PUNCT - O
combined VERB - O
with ADP - O
Endostar NNP - B-ORG
. PUNCT - O

The DET - O
most ADV - O
common ADJ - O
grade NOUN - O
1/2 CD - B-CARDINAL
toxicities NOUN - O
were VERB - O
neutropenia ADJ - O
( PUNCT - O
43 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
and CCONJ - O
leucopenia PROPN - O
( PUNCT - O
21%).Endostar NNP - B-CARDINAL
combined VERB - O
with ADP - O
temozolomide NN - B-MEDICINE
or CCONJ - O
dacarbazine NOUN - O
+ CCONJ - O
5-FU NUM - O
was VERB - O
effective ADJ - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
advanced ADJ - O
pNETs PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

MGMT NN - B-ORG
depletion NOUN - O
modulated VERB - O
by ADP - O
dose NOUN - O
- PUNCT - O
dense ADJ - O
temozolomide NN - B-MEDICINE
( PUNCT - O
ddTMZ PROPN - O
) PUNCT - O
remains VERB - O
a DET - O
debated ADJ - O
therapy NOUN - O
for ADP - O
initial ADJ - O
TMZ NNP - B-ORG
responders NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Dose NOUN - O
- PUNCT - O
dense ADJ - O
temozolomide NN - B-MEDICINE
for ADP - O
recurrent ADJ - O
high ADJ - O
- PUNCT - O
grade NOUN - O
gliomas NOUN - O
: PUNCT - O
a DET - O
single ADJ - O
- PUNCT - O
center NOUN - O
retrospective ADJ - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
standard ADJ - O
treatment NOUN - O
for ADP - O
patients NOUN - O
diagnosed VERB - O
with ADP - O
glioblastoma NOUN - O
is VERB - O
surgical ADJ - O
resection NOUN - O
of ADP - O
tumor NOUN - O
followed VERB - O
by ADP - O
high ADJ - O
dose NOUN - O
radiation NOUN - O
and CCONJ - O
chemotherapy NOUN - O
with ADP - O
temozolomide NN - B-MEDICINE
. PUNCT - O

For ADP - O
patients NOUN - O
who NOUN - O
experience VERB - O
allergic ADJ - O
reactions NOUN - O
to PART - O
temozolomide VB - B-MEDICINE
despite ADP - O
desensitization NOUN - O
protocols NOUN - O
, PUNCT - O
alternative ADJ - O
therapies NOUN - O
must VERB - O
be VERB - O
considered VERB - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
repair NOUN - O
enzyme ADJ - O
O6-methylguanine ADJ - O
- PUNCT - O
DNA NOUN - O
- PUNCT - O
methyltransferase NOUN - O
( PUNCT - O
MGMT NNP - B-ORG
) PUNCT - O
is VERB - O
a DET - O
validated ADJ - O
predictor NOUN - O
of ADP - O
benefit NOUN - O
from ADP - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
in ADP - O
glioblastoma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Refining VERB - O
the DET - O
selection NOUN - O
of ADP - O
patients NOUN - O
with ADP - O
metastatic ADJ - O
colorectal ADJ - O
cancer NOUN - O
for ADP - O
treatment NOUN - O
with ADP - O
temozolomide NN - B-MEDICINE
using VERB - O
proteomic ADJ - O
analysis NOUN - O
of ADP - O
O6-methylguanine ADJ - O
- PUNCT - O
DNA NOUN - O
- PUNCT - O
methyltransferase NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
objective NOUN - O
of ADP - O
this DET - O
phase NOUN - O
1 CD - B-CARDINAL
study NOUN - O
was VERB - O
to PART - O
determine VERB - O
the DET - O
maximum NOUN - O
tolerated VERB - O
doses NOUN - O
( PUNCT - O
MTDs NOUN - O
) PUNCT - O
of ADP - O
combinations NOUN - O
of ADP - O
these DET - O
agents NOUN - O
with ADP - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Phase VERB - O
1 CD - B-CARDINAL
lead NOUN - O
- PUNCT - O
in NOUN - O
to ADP - O
a DET - O
phase NOUN - O
2 CD - B-CARDINAL
factorial ADJ - O
study NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
plus CCONJ - O
memantine NOUN - O
, PUNCT - O
mefloquine NOUN - O
, PUNCT - O
and CCONJ - O
metformin NOUN - O
as ADP - O
postradiation NOUN - O
adjuvant ADJ - O
therapy NOUN - O
for ADP - O
newly ADV - O
diagnosed VERB - O
glioblastoma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

NEO212 NNP - B-ORG
, PUNCT - O
a DET - O
conjugate NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
and CCONJ - O
perillyl NOUN - O
alcohol NOUN - O
, PUNCT - O
blocks VERB - O
EndMT NNP - B-PERSON
induction NOUN - O
and CCONJ - O
reverts VERB - O
the DET - O
mesenchymal ADJ - O
phenotype NOUN - O
of ADP - O
tumor NOUN - O
- PUNCT - O
associated VERB - O
BEC NNP - B-ORG
( PUNCT - O
TuBEC NNP - B-ORG
) PUNCT - O
by ADP - O
blocking VERB - O
TGF NNP - B-ORG
- HYPH - I-ORG
β NNP - I-ORG
and CCONJ - O
Notch NNP - B-ORG
pathways NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

NEO212 NNP - B-ORG
, PUNCT - O
a DET - O
conjugate NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
and CCONJ - O
perillyl NOUN - O
alcohol NOUN - O
, PUNCT - O
blocks VERB - O
the DET - O
endothelial NOUN - O
- PUNCT - O
to ADP - O
- PUNCT - O
mesenchymal ADJ - O
transition NOUN - O
in ADP - O
tumor NOUN - O
- PUNCT - O
associated VERB - O
brain NOUN - O
endothelial NOUN - O
cells NOUN - O
in ADP - O
glioblastoma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
patient NOUN - O
underwent VERB - O
a DET - O
combination NOUN - O
of ADP - O
postoperative ADJ - O
radiotherapy NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
chemotherapy NOUN - O
before ADP - O
leaving VERB - O
the DET - O
hospital NOUN - O
. PUNCT - O

After ADP - O
discharge NOUN - O
, PUNCT - O
she PRON - O
was VERB - O
treated VERB - O
by ADP - O
20 CD - B-CARDINAL
courses NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
chemotherapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Although ADP - O
methylation NOUN - O
of ADP - O
the DET - O
O6-methylguanine JJ - B-LAW
- HYPH - I-LAW
DNA NN - I-LAW
methyltransferase NN - I-LAW
( PUNCT - O
MGMT NNP - B-ORG
) PUNCT - O
gene NOUN - O
promoter NOUN - O
predicts NOUN - O
response NOUN - O
to ADP - O
temozolomide NN - B-MEDICINE
in ADP - O
patients NOUN - O
with ADP - O
glioblastoma NOUN - O
, PUNCT - O
no DET - O
consensus NOUN - O
exists VERB - O
as ADP - O
to ADP - O
which ADJ - O
assay NOUN - O
is VERB - O
best ADJ - O
for ADP - O
its ADJ - O
detection NOUN - O
. PUNCT - O

Only ADV - O
PSQ PROPN - O
and CCONJ - O
MSP NNP - B-ORG
significantly ADV - O
separated VERB - O
patients NOUN - O
who NOUN - O
benefited VERB - O
from ADP - O
temozolomide NN - B-MEDICINE
, PUNCT - O
with ADP - O
PSQ PROPN - O
being VERB - O
the DET - O
superior ADJ - O
method NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
evaluated VERB - O
therapeutic ADJ - O
effects NOUN - O
of ADP - O
anti ADJ - O
- ADJ - O
PD-1 PROPN - O
, PUNCT - O
temozolomide IN - B-MEDICINE
( PUNCT - O
TMZ PROPN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
their ADJ - O
combination NOUN - O
in ADP - O
an DET - O
orthotopic NOUN - O
murine NOUN - O
GBM NNP - B-ORG
model NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
combined VERB - O
anti ADJ - O
- NOUN - O
PD-1 NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
therapy NOUN - O
in ADP - O
glioblastoma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Despite ADP - O
the DET - O
combined VERB - O
adjuvant ADJ - O
treatment NOUN - O
of ADP - O
radiotherapy NOUN - O
plus CCONJ - O
chemotherapy NOUN - O
with ADP - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
followed VERB - O
by ADP - O
6 CD - B-CARDINAL
cycles NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
after ADP - O
surgery NOUN - O
, PUNCT - O
the DET - O
prognosis NOUN - O
of ADP - O
patients NOUN - O
with ADP - O
glioblastoma NOUN - O
remains VERB - O
poor ADJ - O
. PUNCT - O

We PRON - O
conducted VERB - O
a DET - O
monocentric ADJ - O
prospective ADJ - O
study NOUN - O
to PART - O
explore VERB - O
the DET - O
tolerance NOUN - O
and CCONJ - O
potential NOUN - O
efficacy NOUN - O
of ADP - O
an DET - O
early ADJ - O
temozolomide NN - B-MEDICINE
cycle NOUN - O
after ADP - O
surgery NOUN - O
. PUNCT - O

They PRON - O
all DET - O
received VERB - O
a DET - O
cycle NOUN - O
of ADP - O
5 CD - B-DATE
days NNS - I-DATE
of ADP - O
temozolomide NN - B-MEDICINE
between ADP - O
surgery NOUN - O
and CCONJ - O
the DET - O
combined VERB - O
adjuvant ADJ - O
treatment NOUN - O
. PUNCT - O

The DET - O
median NOUN - O
doses VERB - O
of ADP - O
temozolomide NN - B-MEDICINE
administered VERB - O
were VERB - O
respectively ADV - O
265 CD - B-QUANTITY
mg NN - I-QUANTITY
( PUNCT - O
225 CD - B-CARDINAL
- SYM - I-CARDINAL
300 CD - I-CARDINAL
) PUNCT - O
for ADP - O
the DET - O
early ADJ - O
cycle NOUN - O
; PUNCT - O
130 CD - B-CARDINAL
mg NOUN - O
( PUNCT - O
110 CD - B-CARDINAL
- SYM - I-CARDINAL
150 CD - I-CARDINAL
) PUNCT - O
for ADP - O
the DET - O
concomitant ADJ - O
treatment NOUN - O
and CCONJ - O
310 CD - B-CARDINAL
mg NOUN - O
( PUNCT - O
225 CD - B-CARDINAL
- SYM - I-CARDINAL
400 CD - I-CARDINAL
) PUNCT - O
for ADP - O
the DET - O
adjuvant ADJ - O
one NOUN - O
. PUNCT - O

Early ADV - O
postsurgical ADJ - O
temozolomide NN - B-MEDICINE
treatment NOUN - O
prior ADV - O
to ADP - O
standard ADJ - O
adjuvant ADJ - O
therapy NOUN - O
for ADP - O
poor ADJ - O
prognosis NOUN - O
glioblastoma NOUN - O
patients NOUN - O
in ADP - O
our ADJ - O
small ADJ - O
prospective ADJ - O
series NOUN - O
presents VERB - O
toxicity NOUN - O
and CCONJ - O
survival NOUN - O
similar ADJ - O
to ADP - O
those DET - O
published VERB - O
in ADP - O
the DET - O
literature NOUN - O
for ADP - O
the DET - O
general ADJ - O
population NOUN - O
of ADP - O
glioblastoma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Early ADV - O
postsurgical ADJ - O
temozolomide NN - B-MEDICINE
treatment NOUN - O
in ADP - O
newly ADV - O
diagnosed VERB - O
bad ADJ - O
prognosis NOUN - O
glioblastoma NOUN - O
patients NOUN - O
: PUNCT - O
Feasibility NOUN - O
study]. NOUN - O

-DOCSTART- -X- - O

This DET - O
was VERB - O
a DET - O
prospective ADJ - O
, PUNCT - O
single ADJ - O
- PUNCT - O
arm NOUN - O
, PUNCT - O
and CCONJ - O
single ADJ - O
- PUNCT - O
center NOUN - O
dose NOUN - O
escalation NOUN - O
study NOUN - O
to PART - O
investigate VERB - O
the DET - O
safety NOUN - O
and CCONJ - O
preliminary ADJ - O
efficacy NOUN - O
of ADP - O
apatinib NOUN - O
combined VERB - O
with ADP - O
temozolomide NN - B-MEDICINE
in ADP - O
heavily ADV - O
treated VERB - O
advanced ADJ - O
melanoma NOUN - O
patients NOUN - O
. PUNCT - O

Patients NOUN - O
were VERB - O
sequentially ADV - O
admitted VERB - O
to ADP - O
four CD - B-CARDINAL
dose NOUN - O
- PUNCT - O
escalating VERB - O
groups NOUN - O
of ADP - O
apatinib NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
( PUNCT - O
three CD - B-CARDINAL
cases NOUN - O
in ADP - O
each DET - O
group NOUN - O
) PUNCT - O
using VERB - O
a DET - O
traditional ADJ - O
3 CD - B-CARDINAL
  SPACE - O
+ CCONJ - O
  SPACE - O
3 CD - B-CARDINAL
dose NOUN - O
escalation NOUN - O
design NOUN - O
method NOUN - O
. PUNCT - O

In ADP - O
conclusion NOUN - O
, PUNCT - O
apatinib NOUN - O
combined VERB - O
with ADP - O
temozolomide NN - B-MEDICINE
was VERB - O
well ADV - O
tolerated ADJ - O
and CCONJ - O
has VERB - O
demonstrated VERB - O
efficacy NOUN - O
in ADP - O
advanced ADJ - O
melanoma NOUN - O
patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
MFS NNP - B-ORG
PDOX PROPN - O
model NOUN - O
was VERB - O
established VERB - O
in ADP - O
the DET - O
biceps NOUN - O
femoris NOUN - O
of ADP - O
nude ADJ - O
mice NOUN - O
and CCONJ - O
randomized VERB - O
into ADP - O
7 CD - B-CARDINAL
groups NOUN - O
of ADP - O
7 CD - B-CARDINAL
mice NOUN - O
each DET - O
: PUNCT - O
control NOUN - O
; PUNCT - O
doxorubicin PROPN - O
( PUNCT - O
DOX PROPN - O
) PUNCT - O
; PUNCT - O
pazopanib PROPN - O
( PUNCT - O
PAZ PROPN - O
) PUNCT - O
; PUNCT - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TEM NNP - B-ORG
) PUNCT - O
; PUNCT - O
Irinotecan NNP - B-ORG
( PUNCT - O
IRN NNP - B-ORG
) PUNCT - O
; PUNCT - O
IRN NNP - B-ORG
combined VERB - O
with ADP - O
TEM NNP - B-ORG
; PUNCT - O
IRN NNP - B-ORG
combined VERB - O
with ADP - O
cisplatinum NOUN - O
( PUNCT - O
CDDP NNP - B-ORG
) PUNCT - O
and CCONJ - O
Salmonella NNP - B-ORG
typhimurium NN - I-ORG
A1-R NNP - I-ORG

-DOCSTART- -X- - O

A DET - O
combination NOUN - O
of ADP - O
irinotecan NOUN - O
/ SYM - O
cisplatinum NOUN - O
and CCONJ - O
irinotecan ADJ - O
/ SYM - O
temozolomide NN - B-MEDICINE
or CCONJ - O
tumor NOUN - O
- PUNCT - O
targeting VERB - O
Salmonella NNP - B-PERSON
typhimurium NOUN - O
A1-R NOUN - O
arrest VERB - O
doxorubicin- NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
myxofibrosarcoma NOUN - O
in ADP - O
a DET - O
PDOX PROPN - O
mouse NOUN - O
model NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
anticancer NOUN - O
drug NOUN - O
temozolomide NN - B-MEDICINE
is VERB - O
the DET - O
only ADJ - O
drug NOUN - O
with ADP - O
proven VERB - O
activity NOUN - O
against ADP - O
high ADJ - O
- PUNCT - O
grade NOUN - O
gliomas NOUN - O
and CCONJ - O
has VERB - O
therefore ADV - O
become VERB - O
a DET - O
part NOUN - O
of ADP - O
the DET - O
standard ADJ - O
treatment NOUN - O
of ADP - O
these DET - O
tumors NOUN - O
. PUNCT - O

We PRON - O
have VERB - O
studied VERB - O
the DET - O
effect NOUN - O
of ADP - O
P NOUN - O
- PUNCT - O
gp PROPN - O
and CCONJ - O
BCRP VERB - O
on ADP - O
the DET - O
pharmacokinetics NOUN - O
and CCONJ - O
pharmacodynamics NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
, PUNCT - O
making VERB - O
use NOUN - O
of ADP - O
a DET - O
comprehensive ADJ - O
set NOUN - O
of ADP - O
in ADP - O
vitro NOUN - O
transport NOUN - O
experiments NOUN - O
and CCONJ - O
in ADP - O
vivo NOUN - O
pharmacokinetic ADJ - O
and CCONJ - O
antitumor ADJ - O
efficacy NOUN - O
experiments NOUN - O
using VERB - O
wild ADJ - O
- PUNCT - O
type NOUN - O
, PUNCT - O
Abcg2-/- NNP - B-ORG
, PUNCT - O
Abcb1a NNP - B-ORG
/ SYM - I-ORG
b-/- NNS - I-ORG
, PUNCT - O
and CCONJ - O
Abcb1a NNP - B-ORG
/ SYM - I-ORG
b;Abcg2-/- NOUN - O
mice NOUN - O
. PUNCT - O

We PRON - O
here ADV - O
show VERB - O
that ADP - O
the DET - O
combined VERB - O
deletion NOUN - O
of ADP - O
Abcb1a NNP - B-ORG
/ SYM - I-ORG
b NN - I-ORG
and CCONJ - O
Abcg2 PROPN - O
increases VERB - O
the DET - O
brain NOUN - O
penetration NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
by ADP - O
1.5-fold CD - B-PERSON
compared VERB - O
to ADP - O
wild ADJ - O
- PUNCT - O
type NOUN - O
controls NOUN - O
( PUNCT - O
P NOUN - O
< X - O
.001 NUM - O
) PUNCT - O
without ADP - O
changing VERB - O
the DET - O
systemic ADJ - O
drug NOUN - O
exposure NOUN - O
. PUNCT - O

Moreover ADV - O
, PUNCT - O
the DET - O
same ADJ - O
increase NOUN - O
was VERB - O
achieved VERB - O
when ADV - O
temozolomide NN - B-MEDICINE
was VERB - O
given VERB - O
to ADP - O
wild ADJ - O
- PUNCT - O
type NOUN - O
mice NOUN - O
in ADP - O
combination NOUN - O
with ADP - O
the DET - O
dual ADJ - O
P NOUN - O
- PUNCT - O
gp PROPN - O
/ SYM - O
BCRP PROPN - O
inhibitor NOUN - O
elacridar NOUN - O
( PUNCT - O
GF120918 NNP - B-ORG
) PUNCT - O
. PUNCT - O

The DET - O
antitumor NOUN - O
efficacy NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
against ADP - O
three CD - B-CARDINAL
different ADJ - O
intracranial ADJ - O
tumor NOUN - O
models NOUN - O
was VERB - O
significantly ADV - O
enhanced VERB - O
when ADV - O
Abcb1a NNP - B-ORG
/ SYM - I-ORG
b NN - I-ORG
and CCONJ - O
Abcg2 PRON - O
were VERB - O
genetically ADV - O
deficient ADJ - O
or CCONJ - O
pharmacologically ADV - O
inhibited VERB - O
in ADP - O
recipient ADJ - O
mice NOUN - O
. PUNCT - O

These DET - O
findings NOUN - O
call VERB - O
for ADP - O
further ADV - O
clinical ADJ - O
testing NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
in ADP - O
combination NOUN - O
with ADP - O
elacridar NOUN - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
gliomas NOUN - O
, PUNCT - O
as ADP - O
this DET - O
offers VERB - O
the DET - O
perspective NOUN - O
of ADP - O
further ADV - O
improving VERB - O
the DET - O
antitumor NOUN - O
efficacy NOUN - O
of ADP - O
this DET - O
already ADV - O
active ADJ - O
agent NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Optimal ADJ - O
extent NOUN - O
of ADP - O
resection NOUN - O
for ADP - O
glioblastoma NOUN - O
according VERB - O
to ADP - O
site NOUN - O
, PUNCT - O
extension NOUN - O
, PUNCT - O
and CCONJ - O
size NOUN - O
: PUNCT - O
a DET - O
population NOUN - O
- PUNCT - O
based VERB - O
study NOUN - O
in ADP - O
the DET - O
temozolomide NN - B-MEDICINE
era NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

There ADV - O
is VERB - O
a DET - O
widely ADV - O
accepted VERB - O
standard NOUN - O
- PUNCT - O
of ADP - O
- PUNCT - O
care NOUN - O
treatment NOUN - O
protocol NOUN - O
for ADP - O
patients NOUN - O
with ADP - O
newly ADV - O
diagnosed VERB - O
high ADJ - O
- PUNCT - O
grade NOUN - O
glioma NOUN - O
that ADJ - O
includes VERB - O
maximal ADJ - O
safe ADJ - O
resection NOUN - O
followed VERB - O
by ADP - O
radiation NOUN - O
therapy NOUN - O
with ADP - O
concurrent ADJ - O
and CCONJ - O
adjuvant ADJ - O
temozolomide NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Concurrent ADJ - O
radiotherapy NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ PROPN - O
) PUNCT - O
is VERB - O
associated VERB - O
with ADP - O
radiographic ADJ - O
pseudoprogression NOUN - O
( PUNCT - O
PsP NNP - B-ORG
) PUNCT - O
in ADP - O
glioblastoma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Increase NOUN - O
of ADP - O
pseudoprogression NOUN - O
and CCONJ - O
other ADJ - O
treatment NOUN - O
related VERB - O
effects NOUN - O
in ADP - O
low ADJ - O
- PUNCT - O
grade NOUN - O
glioma NOUN - O
patients NOUN - O
treated VERB - O
with ADP - O
proton NOUN - O
radiation NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
systematic ADJ - O
review NOUN - O
aims VERB - O
to PART - O
investigate VERB - O
spinal ADJ - O
cord NOUN - O
glioblastoma NOUN - O
( PUNCT - O
scGBM NOUN - O
) PUNCT - O
and CCONJ - O
correlations NOUN - O
between ADP - O
patient NOUN - O
traits NOUN - O
and CCONJ - O
survival NOUN - O
outcome NOUN - O
, PUNCT - O
as ADV - O
well ADV - O
as ADP - O
differences NOUN - O
in ADP - O
cohorts NOUN - O
administered VERB - O
temozolomide NN - B-MEDICINE
or CCONJ - O
total ADJ - O
resections NOUN - O
, PUNCT - O
through ADP - O
an DET - O
analysis NOUN - O
of ADP - O
published VERB - O
cases NOUN - O
reported VERB - O
up PART - O
to ADP - O
October NNP - B-DATE
2016 CD - I-DATE
. PUNCT - O

Neither CCONJ - O
the DET - O
pediatric ADJ - O
, PUNCT - O
temozolomide JJ - B-MEDICINE
nor CCONJ - O
total ADJ - O
resection NOUN - O
subgroups NOUN - O
had VERB - O
significantly ADV - O
improved VERB - O
survival NOUN - O
characteristics NOUN - O
, PUNCT - O
by ADP - O
log NOUN - O
- PUNCT - O
rank NOUN - O
analysis NOUN - O
, PUNCT - O
relative ADJ - O
to ADP - O
counterparts NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
Phase PROPN - O
I PROPN - O
, PUNCT - O
the DET - O
patients NOUN - O
will VERB - O
undergo VERB - O
an DET - O
induction NOUN - O
carbon NOUN - O
ion NOUN - O
radiotherapy NOUN - O
( PUNCT - O
CIRT NNP - B-ORG
) PUNCT - O
boost NOUN - O
followed VERB - O
by ADP - O
60 CD - B-CARDINAL
GyE PROPN - O
of ADP - O
proton NOUN - O
irradiation NOUN - O
with ADP - O
concurrent ADJ - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
at ADP - O
75 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
m2 NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

He PRON - O
was VERB - O
submitted VERB - O
to ADP - O
multiple ADJ - O
surgical ADJ - O
resections NOUN - O

 SPACE - O
by ADP - O
a DET - O
skilled ADJ - O
surgeon NOUN - O
, PUNCT - O
fractionated ADJ - O
radiotherapy NOUN - O
and CCONJ - O
was VERB - O
eventually ADV - O
treated VERB - O
with ADP - O
temozolomide NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Effective ADJ - O
long ADJ - O
- PUNCT - O
term NOUN - O
temozolomide NN - B-MEDICINE
rechallenge NOUN - O
in ADP - O
a DET - O
macroprolactinoma NOUN - O

-DOCSTART- -X- - O

20(S)-ginsenoside CD - B-CARDINAL
- PUNCT - O
Rg3 NOUN - O
reverses NOUN - O
temozolomide IN - B-MEDICINE
resistance NOUN - O
and CCONJ - O
restrains VERB - O
epithelial ADJ - O
- PUNCT - O
mesenchymal ADJ - O
transition NOUN - O
progression NOUN - O
in ADP - O
glioblastoma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
patient NOUN - O
underwent VERB - O
a DET - O
2-staged CD - B-CARDINAL
operation NOUN - O
with ADP - O
gross ADJ - O
total ADJ - O
resection NOUN - O
of ADP - O
the DET - O
mass NOUN - O
followed VERB - O
by ADP - O
intensity NOUN - O
- PUNCT - O
modulated VERB - O
radiation NOUN - O
therapy NOUN - O
and CCONJ - O
oral ADJ - O
temozolomide NN - B-MEDICINE
, PUNCT - O
a DET - O
regimen NOUN - O
employed VERB - O
for ADP - O
high ADJ - O
- PUNCT - O
grade NOUN - O
intracranial ADJ - O
gliomas NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

MicroRNA-195 NNP - B-ORG
reverses VERB - O
the DET - O
resistance NOUN - O
to PART - O
temozolomide VB - B-MEDICINE
through ADP - O
targeting VERB - O
cyclin NOUN - O
E1 PROPN - O
in ADP - O
glioma NOUN - O
cells NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
79-year CD - B-MONEY
- HYPH - I-MONEY
old JJ - I-MONEY
woman NOUN - O
with ADP - O
anaplastic ADJ - O
oligodendroglioma NOUN - O
developed VERB - O
a DET - O
fever NOUN - O
and CCONJ - O
gross ADJ - O
hematuria NOUN - O
after ADP - O
8 CD - B-DATE
weeks NNS - I-DATE
of ADP - O
standard ADJ - O
radiotherapy NOUN - O
with ADP - O
concomitant ADJ - O
temozolomide NN - B-MEDICINE
treatment NOUN - O
. PUNCT - O

CMV NN - B-ORG
monitoring NOUN - O
is VERB - O
needed VERB - O
when ADV - O
patients NOUN - O
develop VERB - O
symptoms NOUN - O
related VERB - O
to ADP - O
opportunistic ADJ - O
infections NOUN - O
during ADP - O
temozolomide NN - B-MEDICINE
treatment NOUN - O
for ADP - O
malignant ADJ - O
glioma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
review NOUN - O
compares VERB - O
the DET - O
epigenetic ADJ - O
changes NOUN - O
brought VERB - O
about PART - O
by ADP - O
histone NOUN - O
mutations NOUN - O
to ADP - O
those DET - O
by ADP - O
isocitrate NOUN - O
dehydrogenase NOUN - O
- PUNCT - O
mutant NOUN - O
gliomas NOUN - O
, PUNCT - O
which ADJ - O
frequently ADV - O
have VERB - O
methylated VERB - O
MGMT NNP - B-ORG
promoters NOUN - O
and CCONJ - O
are VERB - O
known VERB - O
to PART - O
be VERB - O
sensitive ADJ - O
to PART - O
temozolomide NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Hypofractionated ADJ - O
radiation NOUN - O
with ADP - O
concurrent ADJ - O
and CCONJ - O
adjuvant ADJ - O
temozolomide NN - B-MEDICINE
has VERB - O
been VERB - O
shown VERB - O
to PART - O
increase VERB - O
survival NOUN - O
without ADP - O
worsened VERB - O
quality NOUN - O
of ADP - O
life NOUN - O
in ADP - O
elderly ADJ - O
patients NOUN - O
with ADP - O
good ADJ - O
functional ADJ - O
status NOUN - O
. PUNCT - O

Single ADJ - O
modality NOUN - O
radiation NOUN - O
therapy NOUN - O
or CCONJ - O
temozolomide NN - B-MEDICINE
therapy NOUN - O
are VERB - O
frequently ADV - O
used VERB - O
in ADP - O
this DET - O
population NOUN - O
, PUNCT - O
and CCONJ - O
while ADP - O
neither DET - O
has VERB - O
demonstrated VERB - O
superiority NOUN - O
, PUNCT - O
O6-methylguanine ADJ - O
- PUNCT - O
DNA NOUN - O
methyltransferase NOUN - O
( PUNCT - O
MGMT NNP - B-ORG
) PUNCT - O
methylation NOUN - O
status NOUN - O
is VERB - O
predictive ADJ - O
of ADP - O
improved VERB - O
survival NOUN - O
with ADP - O
temozolomide NN - B-MEDICINE
over ADP - O
radiation NOUN - O
therapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
synergistic ADJ - O
therapeutic ADJ - O
effect NOUN - O
of ADP - O
JCo NOUN - O
extract NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
on ADP - O
glioma NOUN - O
cells NOUN - O
was VERB - O
examined VERB - O
by ADP - O
MTT NN - B-ORG
analysis NOUN - O
. PUNCT - O

The DET - O
JCo NOUN - O
extract NOUN - O
had VERB - O
a DET - O
stronger ADJ - O
cytotoxicity NOUN - O
and CCONJ - O
a DET - O
larger ADJ - O
range NOUN - O
of ADP - O
IC50 PROPN - O
values NOUN - O
in ADP - O
glioma NOUN - O
than ADP - O
in ADP - O
normal ADJ - O
cells NOUN - O
as ADP - O
compared VERB - O
to ADP - O
those DET - O
effects NOUN - O
caused VERB - O
by ADP - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Based VERB - O
on ADP - O
the DET - O
results NOUN - O
of ADP - O
our ADJ - O
earlier ADJ - O
work NOUN - O
, PUNCT - O
which ADJ - O
showed VERB - O
a DET - O
reduction NOUN - O
of ADP - O
PD NNP - B-GPE
- PUNCT - O
L1 PROPN - O
expression NOUN - O
in ADP - O
patients NOUN - O
treated VERB - O
with ADP - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
, PUNCT - O
we PRON - O
aimed VERB - O
to PART - O
investigate VERB - O
the DET - O
link NOUN - O
between ADP - O
TMZ NNP - B-ORG
therapy NOUN - O
and CCONJ - O
the DET - O
immune ADJ - O
control NOUN - O
point NOUN - O
target NOUN - O
PD PROPN - O
- PUNCT - O
L1 PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Synergistic ADJ - O
effect NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
and CCONJ - O
thymoquinone NOUN - O
on ADP - O
human ADJ - O
glioblastoma NOUN - O
multiforme NOUN - O
cell NOUN - O
line NOUN - O
( PUNCT - O
U87MG PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
recently ADV - O
identified VERB - O
that ADP - O
combination NOUN - O
drug NOUN - O
treatment NOUN - O
of ADP - O
mannitol NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
improved VERB - O
BBB NNP - B-ORG
permeability NOUN - O
in ADP - O
vitro NOUN - O
. PUNCT - O

After ADP - O
then ADV - O
, PUNCT - O
rats NOUN - O
were VERB - O
administered VERB - O
human ADJ - O
umbilical ADJ - O
cord NOUN - O
- PUNCT - O
derived VERB - O
mesenchymal ADJ - O
stromal ADJ - O
cells NOUN - O
( PUNCT - O
hUC NOUN - O
- PUNCT - O
MSCs NOUN - O
) PUNCT - O
by ADP - O
intravenous ADJ - O
injection NOUN - O
with ADP - O
or CCONJ - O
without ADP - O
combination NOUN - O
drug NOUN - O
treatment NOUN - O
of ADP - O
mannitol NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
. PUNCT - O

Although ADP - O
no DET - O
hUC NOUN - O
- PUNCT - O
MSCs NOUN - O
were VERB - O
detected VERB - O
in ADP - O
any DET - O
group NOUN - O
, PUNCT - O
treatment NOUN - O
with ADP - O
stem NOUN - O
cells NOUN - O
and CCONJ - O
combination NOUN - O
drug NOUN - O
of ADP - O
mannitol NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
increased VERB - O
the DET - O
intracerebral ADJ - O
delivery NOUN - O
of ADP - O
hCD63-positive NOUN - O
microvesicles NOUN - O
compared VERB - O
with ADP - O
stem NOUN - O
cell NOUN - O
only ADV - O
treatment NOUN - O
. PUNCT - O

The DET - O
combination NOUN - O
drug NOUN - O
treatment NOUN - O
of ADP - O
mannitol NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
allowed VERB - O
for ADP - O
the DET - O
efficient ADJ - O
delivery NOUN - O
of ADP - O
hUC NOUN - O
- PUNCT - O
MSC NN - B-ORG
- PUNCT - O
derived VERB - O
microvesicles NOUN - O
into ADP - O
the DET - O
brain NOUN - O
in ADP - O
a DET - O
chronic ADJ - O
stroke NOUN - O
rat NOUN - O
model NOUN - O
. PUNCT - O

Thus ADV - O
, PUNCT - O
combination NOUN - O
drug NOUN - O
treatment NOUN - O
of ADP - O
mannitol NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
could VERB - O
be VERB - O
a DET - O
novel ADJ - O
therapeutic ADJ - O
option NOUN - O
for ADP - O
patients NOUN - O
with ADP - O
chronic ADJ - O
ischemic ADJ - O
stroke NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
combination NOUN - O
of ADP - O
mannitol NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
increases VERB - O
the DET - O
effectiveness NOUN - O
of ADP - O
stem NOUN - O
cell NOUN - O
treatment NOUN - O
in ADP - O
a DET - O
chronic ADJ - O
stroke NOUN - O
model NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
mechanism NOUN - O
of ADP - O
cellular ADJ - O
death NOUN - O
and CCONJ - O
the DET - O
synergistic ADJ - O
effect NOUN - O
of ADP - O
the DET - O
extract NOUN - O
with ADP - O
the DET - O
alkylating VERB - O
agent NOUN - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
were VERB - O
investigated VERB - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
treatment NOUN - O
with ADP - O
temozolomide NN - B-MEDICINE
and CCONJ - O
whole ADJ - O
brain NOUN - O
radiation NOUN - O
was VERB - O
completed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Patients NOUN - O
should VERB - O
receive VERB - O
chemoradiotherapy NOUN - O
with ADP - O
temozolomide NN - B-MEDICINE
with ADP - O
the DET - O
radiation NOUN - O
schedule NOUN - O
adapted VERB - O
to ADP - O
performance NOUN - O
status NOUN - O
, PUNCT - O
age NOUN - O
and CCONJ - O
tumor NOUN - O
location NOUN - O
. PUNCT - O

The DET - O
use NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
may VERB - O
be VERB - O
reconsidered VERB - O
according VERB - O
to ADP - O
methylguanine NOUN - O
DNA NOUN - O
methyltransferase NOUN - O
( PUNCT - O
MGMT NNP - B-ORG
) PUNCT - O
promoter NOUN - O
methylation NOUN - O
status NOUN - O
; PUNCT - O
patients NOUN - O
with ADP - O
an DET - O
active ADJ - O
promoter NOUN - O
may VERB - O
be VERB - O
subjected VERB - O
to ADP - O
a DET - O
trial NOUN - O
or CCONJ - O
further ADJ - O
molecular ADJ - O
work NOUN - O
- PUNCT - O
up NOUN - O
in ADP - O
order NOUN - O
to PART - O
potentially ADV - O
replace VERB - O
temozolomide NN - B-MEDICINE
; PUNCT - O
patients NOUN - O
with ADP - O
an DET - O
inactive ADJ - O
( PUNCT - O
hypermethylated VERB - O
) PUNCT - O
MGMT NNP - B-ORG
promoter NOUN - O
may VERB - O
be VERB - O
counseled VERB - O
for ADP - O
the DET - O
co NOUN - O
- NOUN - O
treatment NOUN - O
with ADP - O
the DET - O
methylating NOUN - O
and CCONJ - O
alkylating VERB - O
compound NOUN - O
lomustine NOUN - O
in ADP - O
addition NOUN - O
to ADP - O
temozolomide NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
assessed VERB - O
the DET - O
efficacy NOUN - O
and CCONJ - O
safety NOUN - O
of ADP - O
iniparib NOUN - O
with ADP - O
standard ADJ - O
radiotherapy NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
in ADP - O
patients NOUN - O
with ADP - O
newly ADV - O
diagnosed VERB - O
glioblastoma NOUN - O
( PUNCT - O
GBM NNP - B-ORG
) PUNCT - O
. PUNCT - O

A DET - O
safety NOUN - O
run NOUN - O
- PUNCT - O
in PART - O
component NOUN - O
of ADP - O
radiotherapy NOUN - O
+ CCONJ - O
temozolomide NN - B-MEDICINE
+ CCONJ - O
iniparib NOUN - O
( PUNCT - O
n NUM - O
= SYM - O
5 CD - B-CARDINAL
) PUNCT - O
was VERB - O
followed VERB - O
by ADP - O
an DET - O
efficacy NOUN - O
study NOUN - O
( PUNCT - O
n NOUN - O
= SYM - O
76 CD - B-CARDINAL
) PUNCT - O
with ADP - O
the DET - O
recommended VERB - O
phase NOUN - O
II NNP - B-ORG
doses NOUN - O
of ADP - O
iniparib NOUN - O
( PUNCT - O
8.0 CD - B-QUANTITY
mg NNS - I-QUANTITY
/ SYM - I-QUANTITY
kg NNS - I-QUANTITY
i.v VERB - O
. PUNCT - O

twice RB - B-DATE
/ SYM - I-DATE
week NN - I-DATE
with ADP - O
radiotherapy NOUN - O
+ CCONJ - O
daily ADJ - O
temozolomide NN - B-MEDICINE
followed VERB - O
by ADP - O
8.6 CD - B-QUANTITY
mg NNS - I-QUANTITY
/ SYM - I-QUANTITY
kg NNS - I-QUANTITY
i.v VERB - O
. PUNCT - O

twice RB - B-DATE
/ SYM - I-DATE
week NN - I-DATE
with ADP - O
5/28-day NNP - B-DATE
temozolomide NN - B-MEDICINE
) PUNCT - O
. PUNCT - O

Iniparib NOUN - O
is VERB - O
well ADV - O
tolerated VERB - O
with ADP - O
radiotherapy NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
in ADP - O
patients NOUN - O
with ADP - O
newly ADV - O
diagnosed VERB - O
GBM NNS - B-ORG
at ADP - O
up ADP - O
to ADP - O
17.2 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
kg NOUN - O
weekly RB - B-DATE
. PUNCT - O

-DOCSTART- -X- - O

Exosomal ADJ - O
transfer NOUN - O
of ADP - O
miR-151a NOUN - O
enhances VERB - O
chemosensitivity NOUN - O
to PART - O
temozolomide VB - B-MEDICINE
in ADP - O
drug NOUN - O
- PUNCT - O
resistant ADJ - O
glioblastoma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Patients NOUN - O
were VERB - O
assigned VERB - O
to PART - O
receive VERB - O
either DET - O
temozolomide NN - B-MEDICINE
( PUNCT - O
150 CD - B-CARDINAL
- SYM - O
200 NUM - O
mg NOUN - O
/ SYM - O
m2 NOUN - O
, PUNCT - O
orally ADV - O
) PUNCT - O
monotherapy NOUN - O
on ADP - O
days NNS - B-DATE
1 CD - I-DATE
- SYM - I-DATE
5 CD - I-DATE
every DT - I-DATE
4 CD - I-DATE
weeks NNS - I-DATE
for ADP - O
a DET - O
maximum NOUN - O
of ADP - O
12 CD - B-CARDINAL
cycles NOUN - O
, PUNCT - O
or CCONJ - O
the DET - O
same ADJ - O
temozolomide NN - B-MEDICINE
regimen NOUN - O
in ADP - O
combination NOUN - O
with ADP - O
bevacizumab ADJ - O
( PUNCT - O
10 CD - B-QUANTITY
mg NN - I-QUANTITY
/ SYM - I-QUANTITY
kg NNS - I-QUANTITY
, PUNCT - O
intravenously ADV - O
) PUNCT - O
every DT - B-DATE
2 CD - I-DATE
weeks NNS - I-DATE
until ADP - O
progression NOUN - O
. PUNCT - O

Overall ADJ - O
survival NOUN - O
in ADP - O
the DET - O
per ADP - O
- PUNCT - O
protocol NOUN - O
population NOUN - O
at ADP - O
12 CD - B-DATE
months NNS - I-DATE
was VERB - O
achieved VERB - O
by ADP - O
44 CD - B-CARDINAL
( PUNCT - O
61 CD - B-PERCENT
% NN - I-PERCENT
[ PUNCT - O
80 CD - B-PERCENT
% NN - I-PERCENT
CI NNP - B-ORG
53 NUM - O
- SYM - O
69 NUM - O
] PUNCT - O
) PUNCT - O
of ADP - O
72 CD - B-CARDINAL
patients NOUN - O
in ADP - O
the DET - O
temozolomide NN - B-MEDICINE
group NOUN - O
and CCONJ - O
38 CD - B-CARDINAL
( PUNCT - O
55 CD - B-PERCENT
% NN - I-PERCENT
[ PUNCT - O
47 CD - B-CARDINAL
- SYM - I-CARDINAL
69 CD - I-CARDINAL
] PUNCT - O
) PUNCT - O
of ADP - O
69 CD - B-CARDINAL
in ADP - O
the DET - O
combination NOUN - O
group NOUN - O
. PUNCT - O

One CD - B-CARDINAL
treatment NOUN - O
- PUNCT - O
related VERB - O
death NOUN - O
was VERB - O
reported VERB - O
in ADP - O
the DET - O
combination NOUN - O
group NOUN - O
( PUNCT - O
infection NOUN - O
after ADP - O
intratumoral ADJ - O
haemorrhage NOUN - O
during ADP - O
a DET - O
treatment NOUN - O
- PUNCT - O
related VERB - O
grade NOUN - O
4 CD - B-CARDINAL
thrombocytopenia).We PROPN - O
found VERB - O
no DET - O
evidence NOUN - O
of ADP - O
improved VERB - O
overall ADJ - O
survival NOUN - O
with ADP - O
bevacizumab NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
combination NOUN - O
treatment NOUN - O
versus ADP - O
temozolomide NN - B-MEDICINE
monotherapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Bevacizumab PROPN - O
and CCONJ - O
temozolomide RB - B-MEDICINE
in ADP - O
patients NOUN - O
with ADP - O
first JJ - B-ORDINAL
recurrence NOUN - O
of ADP - O
WHO PROPN - O
grade NOUN - O
II NNP - B-ORG
and CCONJ - O
III CD - B-PERSON
glioma NOUN - O
, PUNCT - O
without ADP - O
1p/19q CD - B-CARDINAL
co NOUN - O
- NOUN - O
deletion NOUN - O
( PUNCT - O
TAVAREC PROPN - O
) PUNCT - O
: PUNCT - O
a DET - O
randomised ADJ - O
controlled VERB - O
phase NOUN - O
2 CD - B-CARDINAL
EORTC NNP - B-ORG
trial NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
miR-16 NOUN - O
- SYM - O
5p NOUN - O
on ADP - O
glioma NOUN - O
cell NOUN - O
viability NOUN - O
, PUNCT - O
apoptosis NOUN - O
and CCONJ - O
response NOUN - O
to ADP - O
irradiation NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ PROPN - O
) PUNCT - O
were VERB - O
assessed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Currently ADV - O
, PUNCT - O
patients NOUN - O
were VERB - O
treated VERB - O
by ADP - O
resection NOUN - O
followed VERB - O
by ADP - O
radiotherapy NOUN - O
plus CCONJ - O
concurrent ADJ - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
chemotherapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Silencing VERB - O
SATB1 NOUN - O
overcomes NOUN - O
temozolomide IN - B-MEDICINE
resistance NOUN - O
by ADP - O
downregulating VERB - O
MGMT NNP - B-ORG
expression NOUN - O
and CCONJ - O
upregulating VERB - O
SLC22A18 VERB - O
expression NOUN - O
in ADP - O
human ADJ - O
glioblastoma NOUN - O
cells NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Honokiol NOUN - O
enhances VERB - O
temozolomide NN - B-MEDICINE
- PUNCT - O
induced VERB - O
apoptotic ADJ - O
insults NOUN - O
to ADP - O
malignant ADJ - O
glioma NOUN - O
cells NOUN - O
via ADP - O
an DET - O
intrinsic ADJ - O
mitochondrion NOUN - O
- PUNCT - O
dependent ADJ - O
pathway NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
report VERB - O
a DET - O
patient NOUN - O
with ADP - O
recurrent ADJ - O
PCNSL NNP - B-ORG
who NOUN - O
has VERB - O
been VERB - O
successfully ADV - O
treated VERB - O
with ADP - O
stereotactic ADJ - O
brachytherapy NOUN - O
( PUNCT - O
SBT PROPN - O
) PUNCT - O
with ADP - O
iodine-125 NOUN - O
seeds NOUN - O
plus CCONJ - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

BCNU NOUN - O
- PUNCT - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O

-DOCSTART- -X- - O

The DET - O
initial ADJ - O
report NOUN - O
of ADP - O
NRG NNP - B-ORG
Oncology NNP - I-ORG
/ SYM - I-ORG
Radiation NNP - I-ORG
Therapy NNP - I-ORG
Oncology NNP - I-ORG
Group NNP - I-ORG
( PUNCT - O
RTOG NNP - B-ORG
) PUNCT - O
0424 CD - B-DATE
demonstrated VERB - O
a DET - O
3-year CD - B-CARDINAL
overall ADJ - O
survival NOUN - O
benefit VERB - O
with ADP - O
the DET - O
addition NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
to PART - O
radiotherapy VERB - O
compared VERB - O
with ADP - O
a DET - O
historical ADJ - O
control NOUN - O
. PUNCT - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
MGMT NNP - B-ORG
promoter NOUN - O
methylation NOUN - O
was VERB - O
an DET - O
independent ADJ - O
prognostic ADJ - O
biomarker NOUN - O
of ADP - O
high ADJ - O
- PUNCT - O
risk NOUN - O
, PUNCT - O
low ADJ - O
- PUNCT - O
grade NOUN - O
glioma NOUN - O
treated VERB - O
with ADP - O
temozolomide NN - B-MEDICINE
and CCONJ - O
radiotherapy NOUN - O
. PUNCT - O

This DET - O
is VERB - O
the DET - O
first JJ - B-ORDINAL
study NOUN - O
, PUNCT - O
to ADP - O
our ADJ - O
knowledge NOUN - O
, PUNCT - O
to PART - O
validate VERB - O
the DET - O
prognostic ADJ - O
importance NOUN - O
of ADP - O
MGMT NNP - B-ORG
promoter NOUN - O
methylation NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
grade NOUN - O
II NNP - B-ORG
glioma NOUN - O
treated VERB - O
with ADP - O
combined ADJ - O
radiotherapy NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
and CCONJ - O
highlights VERB - O
its ADJ - O
potential ADJ - O
prognostic ADJ - O
value NOUN - O
beyond ADP - O
IDH1/2 PROPN - O
mutation NOUN - O
status NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
evaluated VERB - O
the DET - O
asparagine NOUN - O
/ SYM - O
glutamine NOUN - O
- PUNCT - O
deaminating VERB - O
agent NOUN - O
Erwinaze NNP - B-PERSON
with ADP - O
/ SYM - O
without ADP - O
temozolomide NN - B-MEDICINE
against ADP - O
brain NOUN - O
tumor NOUN - O
cells NOUN - O
and CCONJ - O
mouse NOUN - O
medulloblastomas NOUN - O
. PUNCT - O

Erwinaze NNP - B-ORG
at ADP - O
< X - O
1 CD - B-CARDINAL
IU NN - B-ORG
/ SYM - I-ORG
ml NNP - I-ORG
reduced VERB - O
temozolomide IN - B-MEDICINE
IC50s PROPN - O
by ADP - O
3.6- CD - B-CARDINAL
to ADP - O
13-fold CD - B-CARDINAL
( PUNCT - O
300 CD - B-CARDINAL
- SYM - O
1,200 NUM - O
μM NOUN - O
to ADP - O
40 CD - B-CARDINAL
- SYM - O
330 NUM - O
μM NOUN - O
) PUNCT - O
. PUNCT - O

Seven CD - B-DATE
- HYPH - I-DATE
week NN - I-DATE
- HYPH - I-DATE
old JJ - I-DATE
SMO NNP - B-ORG
/ SYM - I-ORG
SMO NNP - I-ORG
mice NOUN - O
treated VERB - O
with ADP - O
Erwinaze NNP - B-PERSON
( PUNCT - O
regardless ADV - O
of ADP - O
temozolomide NN - B-MEDICINE
treatment NOUN - O
) PUNCT - O
had VERB - O
better ADJ - O
survival NOUN - O
11 CD - B-DATE
weeks NNS - I-DATE
post NOUN - O
- NOUN - O
therapy ADJ - O
, PUNCT - O
compared VERB - O
to ADP - O
those DET - O
not ADV - O
treated VERB - O
with ADP - O
Erwinaze NNP - B-ORG
( PUNCT - O
81.25 CD - B-PERCENT
% NN - I-PERCENT
vs. ADP - O
46.15 CD - B-CARDINAL
, PUNCT - O
p=0.08 NOUN - O
) PUNCT - O
. PUNCT - O

All DET - O
16 CD - B-CARDINAL
mice NOUN - O
treated VERB - O
with ADP - O
temozolomide NN - B-MEDICINE
( PUNCT - O
regardless ADV - O
of ADP - O
Erwinaze NNP - B-PRODUCT
treatment NOUN - O
) PUNCT - O
succumbed VERB - O
by ADP - O
40-weeks CD - B-CARDINAL
of ADP - O
age NOUN - O
, PUNCT - O
whereas ADP - O
5/8 CD - B-CARDINAL
animals NOUN - O
treated VERB - O
with ADP - O
Erwinaze NNP - B-ORG
alone ADJ - O
and CCONJ - O
2/6 CD - B-CARDINAL
controls NOUN - O
survived VERB - O
( PUNCT - O
p=0.035).Erwinaze PROPN - O
enhances VERB - O
cytotoxicity NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
in ADP - O
vitro NOUN - O
, PUNCT - O
and CCONJ - O
improves VERB - O
survival NOUN - O
in ADP - O
SMO NNP - B-ORG
/ SYM - I-ORG
SMO NNP - I-ORG
mice NOUN - O
, PUNCT - O
likely ADJ - O
by ADP - O
reducing VERB - O
cerebrospinal ADJ - O
fluid ADJ - O
glutamine NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
temozolomide NN - B-MEDICINE
resistance NOUN - O
glioblastoma NOUN - O
, PUNCT - O
nZn NOUN - O
- PUNCT - O
CuO NOUN - O
NPs NOUN - O
disturb ADJ - O
cell NOUN - O
growth NOUN - O
and CCONJ - O
sphere ADJ - O
formation NOUN - O
by ADP - O
inhibiting VERB - O
AKT NNP - B-ORG
and CCONJ - O
ERK1/2 NNP - B-ORG
activation NOUN - O
. PUNCT - O

nZn NOUN - O
- PUNCT - O
CuO NOUN - O
NPs NOUN - O
possess VERB - O
the DET - O
potential NOUN - O
to PART - O
be VERB - O
developed VERB - O
as ADP - O
a DET - O
novel ADJ - O
anti ADJ - O
- ADJ - O
tumor ADJ - O
agent NOUN - O
, PUNCT - O
especially ADV - O
to PART - O
treat VERB - O
temozolomide NN - B-MEDICINE
resistance NOUN - O
glioblastoma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Zinc NOUN - O
- PUNCT - O
doped VERB - O
copper NOUN - O
oxide NOUN - O
nanocomposites NOUN - O
reverse VERB - O
temozolomide IN - B-MEDICINE
resistance NOUN - O
in ADP - O
glioblastoma NOUN - O
by ADP - O
inhibiting VERB - O
AKT NNP - B-ORG
and CCONJ - O
ERK1/2 NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Early ADJ - O
platelet NOUN - O
variation NOUN - O
during ADP - O
concomitant ADJ - O
chemo NOUN - O
- PUNCT - O
radiotherapy NOUN - O
predicts NOUN - O
adjuvant ADJ - O
temozolomide NN - B-MEDICINE
- PUNCT - O
induced VERB - O
thrombocytopenia NOUN - O
in ADP - O
newly ADV - O
diagnosed VERB - O
glioblastoma NOUN - O
patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
antiglioma ADJ - O
drug NOUN - O
temozolomide NN - B-MEDICINE
shows NOUN - O
decreasing VERB - O
therapeutic ADJ - O
efficacy NOUN - O
as ADP - O
treatment NOUN - O
progresses VERB - O
. PUNCT - O

As ADP - O
the DET - O
integrated ADJ - O
stress NOUN - O
response NOUN - O
( PUNCT - O
ISR PROPN - O
) PUNCT - O
may VERB - O
be VERB - O
a DET - O
resistance NOUN - O
factor NOUN - O
and CCONJ - O
severe ADJ - O
stress NOUN - O
might VERB - O
transform VERB - O
the DET - O
protective ADJ - O
effect NOUN - O
of ADP - O
the DET - O
ISR NNP - B-ORG
into ADP - O
a DET - O
damage NOUN - O
effect NOUN - O
, PUNCT - O
pharmacological ADJ - O
regulation NOUN - O
of ADP - O
ISR NNP - B-ORG
may VERB - O
be VERB - O
an DET - O
effective ADJ - O
way NOUN - O
to PART - O
sensitize VERB - O
glioma NOUN - O
to ADP - O
temozolomide NN - B-MEDICINE
. PUNCT - O

The DET - O
aim NOUN - O
of ADP - O
the DET - O
present ADJ - O
study NOUN - O
was VERB - O
to PART - O
investigate VERB - O
the DET - O
mechanisms NOUN - O
of ADP - O
the DET - O
ISR NNP - B-ORG
in ADP - O
regulating VERB - O
the DET - O
therapeutic ADJ - O
effect NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
in ADP - O
the DET - O
human ADJ - O
glioblastoma NOUN - O
multiforme NOUN - O
cell NOUN - O
line NOUN - O

Cultured VERB - O
U87MG ADJ - O
cells NOUN - O
were VERB - O
treated VERB - O
with ADP - O
temozolomide NN - B-MEDICINE
and CCONJ - O
PCR NNP - B-ORG
array NOUN - O
was VERB - O
used VERB - O
to PART - O
screen VERB - O
key ADJ - O
factors NOUN - O
in ADP - O
the DET - O
response NOUN - O
to ADP - O
treatment NOUN - O
. PUNCT - O

Cells NOUN - O
were VERB - O
co VERB - O
- VERB - O
treated VERB - O
with ADP - O
temozolomide NN - B-MEDICINE
and CCONJ - O
the DET - O
eIF2α NOUN - O
phosphatase NOUN - O
inhibitor NOUN - O
salubrinal ADJ - O
, PUNCT - O
and CCONJ - O
cell NOUN - O
apoptosis NOUN - O
was VERB - O
measured VERB - O
. PUNCT - O

Combination NOUN - O
treatment NOUN - O
with ADP - O
temozolomide NN - B-MEDICINE
and CCONJ - O
salubrinal NOUN - O
had VERB - O
a DET - O
synergistic ADJ - O
effect NOUN - O
on ADP - O
cell NOUN - O
viability NOUN - O
. PUNCT - O

Salubrinal PROPN - O
could VERB - O
upregulate VERB - O
the DET - O
expression NOUN - O
of ADP - O
ATF4 NNP - B-PERSON
, PUNCT - O
a DET - O
key ADJ - O
factor NOUN - O
in ADP - O
the DET - O
ISR NNP - B-ORG
, PUNCT - O
and CCONJ - O
enhance VERB - O
temozolomide NN - B-MEDICINE
- PUNCT - O
induced VERB - O
apoptosis NOUN - O
. PUNCT - O

These DET - O
findings NOUN - O
suggest VERB - O
that ADP - O
ISR NNP - B-ORG
and CCONJ - O
ATF4 NNP - B-ORG
are VERB - O
involved VERB - O
in ADP - O
the DET - O
death NOUN - O
crosstalk NOUN - O
between ADP - O
the DET - O
endoplasmic ADJ - O
reticulum NOUN - O
and CCONJ - O
mitochondria NOUN - O
and CCONJ - O
might VERB - O
be VERB - O
a DET - O
potential ADJ - O
target NOUN - O
to PART - O
enhance VERB - O
the DET - O
therapeutic ADJ - O
effect NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
in ADP - O
patients NOUN - O
with ADP - O
glioblastoma NOUN - O
multiforme NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Importantly ADV - O
, PUNCT - O
MGMT NN - B-ORG
- PUNCT - O
negative ADJ - O
glioma NOUN - O
cells NOUN - O
can VERB - O
take VERB - O
up PART - O
RAS NNP - B-ORG
- PUNCT - O
EXOs PROPN - O
and CCONJ - O
acquire VERB - O
a DET - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ)-resistant PUNCT - O
phenotype NOUN - O
via ADP - O
the DET - O
translation NOUN - O
of ADP - O
exogenous ADJ - O
exosomal NOUN - O
MGMT NNP - B-ORG
mRNA PROPN - O
both CCONJ - O
in ADP - O
vitro X - O
and CCONJ - O
in ADP - O
vivo NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Delivery NOUN - O
of ADP - O
MGMT NNP - B-ORG
mRNA PROPN - O
to ADP - O
glioma NOUN - O
cells NOUN - O
by ADP - O
reactive ADJ - O
astrocyte NOUN - O
- PUNCT - O
derived VERB - O
exosomes NOUN - O
confers NOUN - O
a DET - O
temozolomide NN - B-MEDICINE
resistance NOUN - O
phenotype NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Prolonged VERB - O
exposure NOUN - O
to ADP - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
could VERB - O
improve VERB - O
clinical ADJ - O
outcomes NOUN - O
in ADP - O
recurrent NOUN - O
glioblastoma NOUN - O
multiforme NOUN - O
( PUNCT - O
GBM NNP - B-ORG
) PUNCT - O
patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
right ADJ - O
chance NOUN - O
for ADP - O
temozolomide NN - B-MEDICINE
in ADP - O
metastatic ADJ - O
colorectal ADJ - O
cancer NOUN - O
? PUNCT - O

-DOCSTART- -X- - O

Recent ADJ - O
evidence NOUN - O
has VERB - O
documented VERB - O
a DET - O
utility NOUN - O
for ADP - O
adjuvant ADJ - O
chemotherapy NOUN - O
with ADP - O
procarbazine NOUN - O
, PUNCT - O
CCNU NNP - B-ORG
( PUNCT - O
lomustine NOUN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
vincristine NOUN - O
( PUNCT - O
PCV PROPN - O
) PUNCT - O
or CCONJ - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
. PUNCT - O

Adjuvant ADJ - O
therapy NOUN - O
with ADP - O
temozolomide NN - B-MEDICINE
was VERB - O
associated VERB - O
with ADP - O
lower ADJ - O
toxicity NOUN - O
than ADP - O
therapy NOUN - O
with ADP - O
PCV PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Procarbazine NOUN - O
, PUNCT - O
CCNU NN - B-ORG
and CCONJ - O
vincristine NOUN - O
( PUNCT - O
PCV PROPN - O
) PUNCT - O
versus ADP - O
temozolomide NN - B-MEDICINE
chemotherapy NOUN - O
for ADP - O
patients NOUN - O
with ADP - O
low ADJ - O
- PUNCT - O
grade NOUN - O
glioma NOUN - O
: PUNCT - O
a DET - O
systematic ADJ - O
review NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mismatch JJ - B-NORP
repair NOUN - O
( PUNCT - O
MMR NNP - B-ORG
) PUNCT - O
deficiency NOUN - O
through ADP - O
MSH6 PROPN - O
inactivation NOUN - O
has VERB - O
been VERB - O
identified VERB - O
in ADP - O
up IN - B-PERCENT
to TO - I-PERCENT
30 CD - I-PERCENT
% NN - I-PERCENT
of ADP - O
recurrent ADJ - O
high ADJ - O
- PUNCT - O
grade NOUN - O
gliomas NOUN - O
, PUNCT - O
and CCONJ - O
represents VERB - O
a DET - O
key ADJ - O
molecular ADJ - O
mechanism NOUN - O
underlying VERB - O
the DET - O
acquired VERB - O
resistance NOUN - O
to ADP - O
the DET - O
alkylating VERB - O
agent NOUN - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
we PRON - O
aimed VERB - O
to PART - O
evaluate VERB - O
the DET - O
expression NOUN - O
and CCONJ - O
functions NOUN - O
of ADP - O
MAPK8 NNP - B-ORG
in ADP - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O

-DOCSTART- -X- - O

MAPK8 PROPN - O
mediates VERB - O
resistance NOUN - O
to ADP - O
temozolomide NN - B-MEDICINE
and CCONJ - O
apoptosis NOUN - O
of ADP - O
glioblastoma NOUN - O
cells NOUN - O
through ADP - O
MAPK NNP - B-ORG
signaling VERB - O
pathway NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Statins NOUN - O
: PUNCT - O
a DET - O
new ADJ - O
approach NOUN - O
to PART - O
combat VERB - O
temozolomide NN - B-MEDICINE
chemoresistance NOUN - O
in ADP - O
glioblastoma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ)-resitance NOUN - O
cases NOUN - O
, PUNCT - O
it PRON - O
is VERB - O
suggested VERB - O
to PART - O
use VERB - O
complementary ADJ - O
strategies NOUN - O
such ADJ - O
as ADP - O
using VERB - O
HDACis PROPN - O
and CCONJ - O
a DET - O
combination NOUN - O
of ADP - O
a DET - O
STAT3 PROPN - O

-DOCSTART- -X- - O

Moreover ADV - O
, PUNCT - O
two CD - B-CARDINAL
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
treatments NOUN - O
for ADP - O
GBM NNP - B-ORG
, PUNCT - O
IR NNP - B-ORG
and CCONJ - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
, PUNCT - O
as ADV - O
well ADV - O
as ADP - O
rapamycin PROPN - O
( PUNCT - O
Rap PROPN - O
) PUNCT - O
, PUNCT - O
the DET - O
prototypic ADJ - O
MTOR NNP - B-ORG
inhibitor NOUN - O
, PUNCT - O
decreased VERB - O
MIR93 PROPN - O
expression NOUN - O
that ADP - O
, PUNCT - O
in ADP - O
turn NOUN - O
, PUNCT - O
stimulated VERB - O
autophagic ADJ - O
processes NOUN - O
in ADP - O
GSCs NOUN - O
. PUNCT - O

; PUNCT - O
MIRC PROPN - O
: PUNCT - O
a DET - O
control NOUN - O
miRNA NOUN - O
; PUNCT - O
miRNA NOUN - O
/ SYM - O
miR NOUN - O
: PUNCT - O
microRNA PROPN - O
; PUNCT - O
MTOR PROPN - O
: PUNCT - O
mechanistic ADJ - O
target NOUN - O
of ADP - O
rapamycin NOUN - O
kinase NOUN - O
; PUNCT - O
NSC NNP - B-ORG
: PUNCT - O
NSC185085 NN - B-CARDINAL
; PUNCT - O
PN PROPN - O
: PUNCT - O
proneural NOUN - O
; PUNCT - O
qRT PROPN - O
- PUNCT - O
PCR PROPN - O
: PUNCT - O
quantitative ADJ - O
reverse ADJ - O
transcription NOUN - O
- PUNCT - O
polymerase NOUN - O
chain NOUN - O
reaction NOUN - O
; PUNCT - O
Rap NOUN - O
: PUNCT - O
rapamycin NOUN - O
; PUNCT - O
SQSTM1/p62 NNP - B-ORG
: PUNCT - O
sequestosome ADP - O
1 CD - B-CARDINAL
; PUNCT - O
TCGA PROPN - O
: PUNCT - O
the DET - O
cancer NOUN - O
genome DET - O
atlas NOUN - O
; PUNCT - O
TMZ NNP - B-ORG
: PUNCT - O
temozolomide NN - B-MEDICINE
; PUNCT - O
WT NNP - B-ORG
: PUNCT - O
wild ADJ - O
type NOUN - O
; PUNCT - O
ZIP93 NNS - B-PERSON
: PUNCT - O

-DOCSTART- -X- - O

Tumoral NNP - B-ORG
MGMT NNP - I-ORG
content NOUN - O
predicts VERB - O
survival NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
aggressive ADJ - O
pituitary ADJ - O
tumors NOUN - O
and CCONJ - O
pituitary ADJ - O
carcinomas NOUN - O
given VERB - O
treatment NOUN - O
with ADP - O
temozolomide NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Optimization NOUN - O
of ADP - O
a DET - O
preclinical ADJ - O
therapy NOUN - O
of ADP - O
cannabinoids NOUN - O
in ADP - O
combination NOUN - O
with ADP - O
temozolomide NN - B-MEDICINE
against ADP - O
glioma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
determine VERB - O
an DET - O
optimal ADJ - O
protocol NOUN - O
for ADP - O
temozolomide NN - B-MEDICINE
using VERB - O
population NOUN - O
variability NOUN - O
and CCONJ - O
dynamic ADJ - O
optimization NOUN - O
techniques NOUN - O
inspired VERB - O
by ADP - O
artificial ADJ - O
intelligence NOUN - O
. PUNCT - O

We PRON - O
use VERB - O
a DET - O
Pharmacokinetics NNP - B-ORG
/ SYM - I-ORG
Pharmacodynamics NNP - I-ORG
( PUNCT - O
PK NNP - B-ORG
/ SYM - I-ORG
PD NNP - I-ORG
) PUNCT - O
model NOUN - O
based VERB - O
on ADP - O
Faivre NNP - B-PERSON
and CCONJ - O
coauthors NOUN - O
( PUNCT - O
Faivre NNP - B-PERSON
, PUNCT - O
et PROPN - O
al PROPN - O
. PROPN - O
, PUNCT - O
2013 CD - B-DATE
) PUNCT - O
for ADP - O
the DET - O
pharmacokinetics NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
, PUNCT - O
as ADV - O
well ADV - O
as ADP - O
the DET - O
pharmacodynamics NOUN - O
of ADP - O
its ADJ - O
efficacy NOUN - O
. PUNCT - O

For ADP - O
toxicity NOUN - O
, PUNCT - O
which ADJ - O
is VERB - O
measured VERB - O
by ADP - O
the DET - O
nadir NOUN - O
of ADP - O
the DET - O
normalized VERB - O
absolute ADJ - O
neutrophil NOUN - O
count NOUN - O
, PUNCT - O
we PRON - O
formalize VERB - O
the DET - O
myelosuppression NOUN - O
effect NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
with ADP - O
the DET - O
physiological ADJ - O
model NOUN - O
of ADP - O
Panetta NNP - B-GPE
and CCONJ - O
coauthors NOUN - O
( PUNCT - O
Panetta NNP - B-PERSON
, PUNCT - O
et PROPN - O
al PROPN - O
. PROPN - O
, PUNCT - O
2003 CD - B-DATE
) PUNCT - O
. PUNCT - O

Overall ADV - O
, PUNCT - O
our ADJ - O
protocol NOUN - O
, PUNCT - O
obtained VERB - O
with ADP - O
a DET - O
very ADV - O
flexible ADJ - O
method NOUN - O
, PUNCT - O
gives VERB - O
significant ADJ - O
results NOUN - O
for ADP - O
the DET - O
present ADJ - O
case NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
and CCONJ - O
calls VERB - O
for ADP - O
further ADJ - O
research NOUN - O
mixing VERB - O
operational ADJ - O
research NOUN - O
or CCONJ - O
artificial ADJ - O
intelligence NOUN - O
and CCONJ - O
clinical ADJ - O
research NOUN - O
in ADP - O
oncology NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Optimal ADJ - O
dynamic ADJ - O
regimens NOUN - O
with ADP - O
artificial ADJ - O
intelligence NOUN - O
: PUNCT - O
The DET - O
case NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Chemotherapy NN - B-PERSON
alone ADV - O
( PUNCT - O
mainly ADV - O
, PUNCT - O
capecitabine NOUN - O
/ SYM - O
temozolomide NN - B-MEDICINE
) PUNCT - O
or CCONJ - O
in ADP - O
combination NOUN - O
showed VERB - O
the DET - O
best ADJ - O
results NOUN - O
, PUNCT - O
with ADP - O
≥10 NNS - B-PERCENT
% NN - I-PERCENT
TS PROPN - O
ranging VERB - O
from ADP - O
65 CD - B-PERCENT
% NN - I-PERCENT
to TO - I-PERCENT
93 CD - I-PERCENT
% NN - I-PERCENT
. PUNCT - O

-DOCSTART- -X- - O

Methylated ADJ - O
DNA PROPN - O
, PUNCT - O
such ADJ - O
as ADP - O
that DET - O
produced VERB - O
by ADP - O
methyl ADJ - O
methanesulfonate NOUN - O
( PUNCT - O
MMS NNP - B-ORG
) PUNCT - O
and CCONJ - O
temozolomide NN - B-MEDICINE
, PUNCT - O
exists VERB - O
for ADP - O
days NNS - B-DATE
in ADP - O
organisms NOUN - O
. PUNCT - O

These DET - O
observations NOUN - O
reveal VERB - O
the DET - O
possibility NOUN - O
that ADP - O
such ADJ - O
DPCs NOUN - O
may VERB - O
contribute VERB - O
to ADP - O
the DET - O
cytotoxicity NOUN - O
of ADP - O
monofunctional ADJ - O
alkylating VERB - O
agents NOUN - O
, PUNCT - O
such ADJ - O
as ADP - O
MMS NNP - B-ORG
, PUNCT - O
N NNP - B-ORG
- PUNCT - O
methyl PROPN - O
- PUNCT - O
N NOUN - O
- PUNCT - O
nitrosourea NOUN - O
, PUNCT - O
and CCONJ - O
temozolomide NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Down ADP - O
- PUNCT - O
regulation NOUN - O
of ADP - O
ABCE1 NNP - B-ORG
inhibited VERB - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
resistance NOUN - O
of ADP - O
glioma NOUN - O
cells NOUN - O
in ADP - O
vitro NOUN - O
and CCONJ - O
in ADP - O
vivo NOUN - O

-DOCSTART- -X- - O

Down ADP - O
- PUNCT - O
regulation NOUN - O
of ADP - O
ABCE1 NNP - B-ORG
inhibits VERB - O
temozolomide IN - B-MEDICINE
resistance NOUN - O
in ADP - O
glioma NOUN - O
through ADP - O
the DT - B-FAC
PI3K NNP - I-FAC
/ SYM - I-FAC
Akt NNP - I-FAC
/ SYM - I-FAC
NF NNP - I-FAC
- HYPH - I-FAC
κB NNP - I-FAC
signaling VERB - O
pathway NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Case NOUN - O
: PUNCT - O
A DET - O
35-year CD - B-MONEY
- HYPH - I-MONEY
old JJ - I-MONEY
woman NOUN - O
presented VERB - O
with ADP - O
an DET - O
aggressive ADJ - O
ACTH NNP - B-ORG
- PUNCT - O
secreting VERB - O
pituitary ADJ - O
adenoma NOUN - O
that ADJ - O
initially ADV - O
responded VERB - O
to PART - O
concurrent VERB - O
temozolomide NN - B-MEDICINE
and CCONJ - O
capecitabine NOUN - O
prior ADV - O
to ADP - O
metastasizing VERB - O
to ADP - O
the DET - O
liver NOUN - O
. PUNCT - O

Simultaneously ADV - O
, PUNCT - O
her ADJ - O
plasma NOUN - O
ACTH PROPN - O
level NOUN - O
decreased VERB - O
from ADP - O
45,550 CD - B-CARDINAL
pg NOUN - O
/ SYM - O
mL NOUN - O
to ADP - O
66 CD - B-CARDINAL
pg NOUN - O
/ SYM - O
mL. PROPN - O
Molecular PROPN - O
Evaluation NOUN - O
: PUNCT - O
Both DET - O
prospective ADJ - O
clinical ADJ - O
sequencing NOUN - O
with ADP - O
Memorial NNP - B-PERSON
Sloan NNP - I-PERSON
Kettering NNP - I-PERSON
- HYPH - I-PERSON
Integrated NNP - I-PERSON
Mutation PROPN - O
Profiling PROPN - O
of ADP - O
Actionable PROPN - O
Cancer PROPN - O
Targets PROPN - O
and CCONJ - O
retrospective ADJ - O
whole ADJ - O
- PUNCT - O
exome NOUN - O
sequencing NOUN - O
were VERB - O
performed VERB - O
to PART - O
characterize VERB - O
the DET - O
molecular ADJ - O
alterations NOUN - O
in ADP - O
the DET - O
chemotherapy ADJ - O
- PUNCT - O
naive ADJ - O
pituitary ADJ - O
adenoma NOUN - O
and CCONJ - O
the DET - O
temozolomide NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
liver NOUN - O
metastasis NOUN - O
. PUNCT - O

Resistance NOUN - O
to PART - O
temozolomide VB - B-MEDICINE
treatment NOUN - O
, PUNCT - O
acquisition NOUN - O
of ADP - O
new ADJ - O
oncogenic ADJ - O
drivers NOUN - O
, PUNCT - O
and CCONJ - O
subsequent ADJ - O
sensitivity NOUN - O
to PART - O
immunotherapy VERB - O
may VERB - O
be VERB - O
attributed VERB - O
to ADP - O
hypermutation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
present VERB - O
the DET - O
case NOUN - O
of ADP - O
a DET - O
9-year NUM - O
- PUNCT - O
old ADJ - O
boy NOUN - O
with ADP - O
disseminated VERB - O
anaplastic ADJ - O
astrocytoma NOUN - O
treated VERB - O
with ADP - O
subtotal ADJ - O
resection NOUN - O
, PUNCT - O
craniospinal ADJ - O
radiation NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
, PUNCT - O
with ADP - O
8-year NUM - O
survival NOUN - O
despite ADP - O
metastatic ADJ - O
disease NOUN - O
at ADP - O
presentation NOUN - O
and CCONJ - O
subtotal ADJ - O
resection NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Combinations NOUN - O
of ADP - O
four CD - B-CARDINAL
or CCONJ - O
more ADJ - O
CpGs NNP - B-GPE
methylation NOUN - O
present ADJ - O
equivalent ADJ - O
predictive ADJ - O
value NOUN - O
for ADP - O
MGMT PROPN - O
expression NOUN - O
and CCONJ - O
temozolomide IN - B-MEDICINE
therapeutic ADJ - O
prognosis NOUN - O
in ADP - O
gliomas NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
aim NOUN - O
of ADP - O
our ADJ - O
research NOUN - O
was VERB - O
the DET - O
synthesis NOUN - O
of ADP - O
a DET - O
nanocarrier ADJ - O
of ADP - O
quercetin NOUN - O
combined VERB - O
with ADP - O
temozolomide NN - B-MEDICINE
, PUNCT - O
to PART - O
enhance VERB - O
the DET - O
specificity NOUN - O
and CCONJ - O
efficacy NOUN - O
of ADP - O
this DET - O
anticancer NOUN - O
drug NOUN - O
commonly ADV - O
used VERB - O
in ADP - O
glioblastoma NOUN - O
treatment NOUN - O
. PUNCT - O

The DET - O
nanohydrogel NOUN - O
increased VERB - O
the DET - O
internalization NOUN - O
and CCONJ - O
cytotoxicity NOUN - O
of ADP - O
quercetin NOUN - O
in ADP - O
human ADJ - O
glioblastoma NOUN - O
cells NOUN - O
and CCONJ - O
, PUNCT - O
when ADV - O
co VERB - O
- VERB - O
delivered VERB - O
with ADP - O
temozolomide NN - B-MEDICINE
, PUNCT - O
contribute VERB - O
to ADP - O
an DET - O
improved ADJ - O
anticancer NOUN - O
effect NOUN - O
. PUNCT - O

This DET - O
targeted ADJ - O
therapy NOUN - O
lead NOUN - O
to ADP - O
an DET - O
improved ADJ - O
therapeutic ADJ - O
efficacy NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
by ADP - O
modulating VERB - O
the DET - O
brain NOUN - O
tumor NOUN - O
microenvironment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Novel ADJ - O
nanohydrogel NOUN - O
of ADP - O
hyaluronic ADJ - O
acid NOUN - O
loaded VERB - O
with ADP - O
quercetin ADJ - O
alone ADJ - O
and CCONJ - O
in ADP - O
combination NOUN - O
with ADP - O
temozolomide NN - B-MEDICINE
as ADP - O
new ADJ - O
therapeutic ADJ - O
tool NOUN - O
, PUNCT - O
CD44 PROPN - O
targeted VERB - O
based VERB - O
, PUNCT - O
of ADP - O
glioblastoma NOUN - O
multiforme NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

During ADP - O
the DT - B-DATE
past JJ - I-DATE
decade NN - I-DATE
, PUNCT - O
the DET - O
systemic ADJ - O
treatment NOUN - O
landscape NOUN - O
has VERB - O
improved VERB - O
significantly ADV - O
: PUNCT - O
new ADJ - O
options NOUN - O
include VERB - O
everolimus NOUN - O
, PUNCT - O
an DET - O
inhibitor NOUN - O
of ADP - O
the DET - O
mammalian ADJ - O
target NOUN - O
of ADP - O
rapamycin PROPN - O
( PUNCT - O
mTOR PROPN - O
) PUNCT - O
, PUNCT - O
sunitinib NOUN - O
, PUNCT - O
an DET - O
angiogenesis NOUN - O
inhibitor NOUN - O
, PUNCT - O
and CCONJ - O
cytotoxic NOUN - O
regimens NOUN - O
such ADJ - O
as ADP - O
capecitabine NOUN - O
and CCONJ - O
temozolomide NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Furthermore ADV - O
, PUNCT - O
we PRON - O
evaluated VERB - O
the DET - O
effect NOUN - O
of ADP - O
ASA NNP - B-ORG
alone ADV - O
or CCONJ - O
in ADP - O
combination NOUN - O
with ADP - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
, PUNCT - O
bevacizumab PROPN - O
( PUNCT - O
BEV NNP - B-ORG
) PUNCT - O
, PUNCT - O
and CCONJ - O
sunitinib PROPN - O
( PUNCT - O
SUN NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
phase NOUN - O
II NN - B-ORG
study NOUN - O
, PUNCT - O
we PRON - O
investigate VERB - O
clinical ADJ - O
outcomes NOUN - O
and CCONJ - O
tolerability NOUN - O
of ADP - O
hypofractionated ADJ - O
radiotherapy NOUN - O
( PUNCT - O
HRT PROPN - O
) PUNCT - O
combined VERB - O
with ADP - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
to PART - O
treat VERB - O
elderly ADJ - O
patients NOUN - O
with ADP - O
glioblastoma NOUN - O
( PUNCT - O
GBM).Patients NOUN - O
70 CD - B-DATE
years NNS - I-DATE
of IN - I-DATE
age NN - I-DATE
or CC - I-DATE
older JJR - I-DATE
with ADP - O
newly ADV - O
diagnosed VERB - O
GBM NNS - B-ORG
received VERB - O
HRT NNP - B-ORG
to ADP - O
a DET - O
dose NOUN - O
of ADP - O
34 CD - B-CARDINAL
Gy NNP - B-PERSON
given VERB - O
in ADP - O
ten CD - B-CARDINAL
fractions NOUN - O
over ADP - O
2 CD - B-DATE
weeks NNS - I-DATE
, PUNCT - O
delivered VERB - O
with ADP - O
concurrent ADJ - O
and CCONJ - O
adjuvant ADJ - O
TMZ.In PROPN - O
this DET - O
interim ADJ - O
analysis NOUN - O
, PUNCT - O
ten CD - B-CARDINAL
patients NOUN - O
were VERB - O
enrolled VERB - O
on ADP - O
trial NOUN - O
from ADP - O
12/1/2015 CD - B-ORDINAL
to ADP - O
4/5/2017 CD - B-CARDINAL
. PUNCT - O

-DOCSTART- -X- - O

Non ADJ - O
- ADJ - O
randomized VERB - O
studies NOUN - O
showed VERB - O
that ADP - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
achieves VERB - O
an DET - O
average ADJ - O
10 CD - B-PERCENT
% NN - I-PERCENT
response NOUN - O
rate NOUN - O
in ADP - O
heavily ADV - O
pretreated VERB - O
metastatic ADJ - O
colorectal ADJ - O
cancer NOUN - O
( PUNCT - O
mCRC NOUN - O
) PUNCT - O
patients NOUN - O
with ADP - O
promoter NOUN - O
methylation NOUN - O
of ADP - O
the DET - O
DNA NOUN - O
repair NOUN - O
gene NOUN - O
O6-methylguanine NOUN - O
- PUNCT - O
DNA NOUN - O
methyltransferase NOUN - O
( PUNCT - O
MGMT NNP - B-ORG
) PUNCT - O
. PUNCT - O

In ADP - O
this DET - O
phase NOUN - O
II NNP - B-ORG
trial NOUN - O
, PUNCT - O
irinotecan ADJ - O
and CCONJ - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TEMIRI NOUN - O
) PUNCT - O
combination NOUN - O
regimen NOUN - O
was VERB - O
assessed VERB - O
in ADP - O
irinotecan ADJ - O
- PUNCT - O
sensitive ADJ - O
, PUNCT - O
MGMT NNP - B-ORG
methylated VERB - O
/ SYM - O

-DOCSTART- -X- - O

The DET - O
combination NOUN - O
of ADP - O
radioiodinated VERB - O
VCN NNP - B-ORG
plus CCONJ - O
temozolomide NN - B-MEDICINE
( PUNCT - O
a DET - O
DNA NOUN - O
alkylating VERB - O
agent NOUN - O
) PUNCT - O
significantly ADV - O
prolonged VERB - O
survival NOUN - O
of ADP - O
glioma NOUN - O
- PUNCT - O
bearing VERB - O
mice NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
retrospectively ADV - O
analyzed VERB - O
the DET - O
safety NOUN - O
and CCONJ - O
efficacy NOUN - O
of ADP - O
hypofractionated VERB - O
radiotherapy NOUN - O
( PUNCT - O
45 CD - B-CARDINAL
  SPACE - O
Gy/15 PROPN - O
fr X - O
) PUNCT - O
combined VERB - O
with ADP - O
temozolomide NN - B-MEDICINE
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
followed VERB - O
by ADP - O
bevacizumab PROPN - O
( PUNCT - O
BEV NNP - B-ORG
) PUNCT - O
salvage NOUN - O
treatment NOUN - O
in ADP - O
18 CD - B-CARDINAL
glioblastoma NOUN - O
patients NOUN - O
aged VERB - O
  SPACE - O

-DOCSTART- -X- - O

Treatment NOUN - O
outcomes NOUN - O
of ADP - O
hypofractionated VERB - O
radiotherapy NOUN - O
combined VERB - O
with ADP - O
temozolomide NN - B-MEDICINE
followed VERB - O
by ADP - O
bevacizumab NOUN - O
salvage NOUN - O
therapy NOUN - O
in ADP - O
glioblastoma NOUN - O
patients NOUN - O
aged VERB - O
> X - O
  SPACE - O
75 CD - B-DATE
  _SP - I-DATE
years NNS - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

Gross ADJ - O
tumor NOUN - O
resection NOUN - O
followed VERB - O
by ADP - O
concomitant ADJ - O
and CCONJ - O
adjuvant ADJ - O
radiotherapy NOUN - O
and CCONJ - O
chemotherapy NOUN - O
with ADP - O
temozolomide NN - B-MEDICINE
was VERB - O
performed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
assessed VERB - O
the DET - O
efficacy NOUN - O
and CCONJ - O
safety NOUN - O
of ADP - O
bevacizumab NOUN - O
( PUNCT - O
BEV NNP - B-ORG
) PUNCT - O
through ADP - O
multiple ADJ - O
lines NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
recurrent NOUN - O
glioblastoma NOUN - O
who NOUN - O
had VERB - O
progressed VERB - O
after ADP - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
treatment NOUN - O
with ADP - O
radiotherapy NOUN - O
, PUNCT - O
temozolomide NN - B-MEDICINE
, PUNCT - O
and CCONJ - O
BEV.<label PROPN - O
> X - O
PATIENTS PROPN - O
AND CCONJ - O
METHODS</label PROPN - O
> X - O
TAMIGA PROPN - O
( PUNCT - O
NCT01860638 NNP - B-CARDINAL
) PUNCT - O
was VERB - O
a DET - O
phase NOUN - O
II NNP - B-ORG
, PUNCT - O
randomized VERB - O
, PUNCT - O
double ADJ - O
- PUNCT - O
blind ADJ - O
, PUNCT - O
placebo NOUN - O
- PUNCT - O
controlled VERB - O
, PUNCT - O
multicenter ADJ - O
trial NOUN - O
in ADP - O
adult NOUN - O
patients NOUN - O
with ADP - O
glioblastoma NOUN - O
. PUNCT - O

Following VERB - O
surgery NOUN - O
, PUNCT - O
patients NOUN - O
with ADP - O
newly ADV - O
diagnosed VERB - O
glioblastoma NOUN - O
received VERB - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
treatment NOUN - O
consisting VERB - O
of ADP - O
radiotherapy NOUN - O
plus CCONJ - O
temozolomide NN - B-MEDICINE
and CCONJ - O
BEV NNP - B-ORG
, PUNCT - O
followed VERB - O
by ADP - O
six CD - B-CARDINAL
cycles NOUN - O
of ADP - O
temozolomide NN - B-MEDICINE
and CCONJ - O
BEV NNP - B-ORG
, PUNCT - O
then ADV - O
BEV NNP - B-ORG
monotherapy NOUN - O
until ADP - O
disease NOUN - O
progression NOUN - O
( PUNCT - O
PD1 PROPN - O
) PUNCT - O
. PUNCT - O

No DET - O
survival NOUN - O
benefit NOUN - O
was VERB - O
observed VERB - O
with ADP - O
the DET - O
use NOUN - O
of ADP - O
BEV NNP - B-ORG
through ADP - O
multiple ADJ - O
lines NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
glioblastoma NOUN - O
who NOUN - O
had VERB - O
progressed VERB - O
after ADP - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
treatment NOUN - O
( PUNCT - O
radiotherapy NOUN - O
+ CCONJ - O
temozolomide NN - B-MEDICINE
+ CCONJ - O
BEV NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Comparative PROPN - O
Bioavailability PROPN - O
of ADP - O
Metformin NNP - B-ORG
Hydrochloride NNP - I-ORG
Oral NNP - I-ORG
Solution NNP - I-ORG

Versus PROPN - O
Metformin NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
Tablets PROPN - O
in ADP - O
Fasting NNP - B-GPE
Mexican NNP - B-NORP
Healthy NNP - B-PERSON
Volunteers NNPS - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Transdermal JJ - B-ORG
Delivery NN - I-ORG
of ADP - O
Metformin NNP - B-PERSON
Hydrochloride NNP - I-PERSON
from ADP - O
a DET - O
Semisolid NNP - B-GPE
Vehicle NNP - I-GPE
. PUNCT - O

-DOCSTART- -X- - O

Study NOUN - O
on ADP - O
Drug PROPN - O
- PUNCT - O
Drug NOUN - O
Interactions NOUN - O
Between ADP - O
Chiglitazar PROPN - O
, PUNCT - O
a DET - O
Novel PROPN - O
PPAR PROPN - O
Pan PROPN - O
- PROPN - O
Agonist PROPN - O
, PUNCT - O
and CCONJ - O
Metformin NNP - B-PERSON
Hydrochloride NNP - I-PERSON
in ADP - O
Healthy PROPN - O
Subjects PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Development PROPN - O
of ADP - O
USP NNP - B-ORG
Apparatus NNP - I-ORG
3 CD - I-ORG
Dissolution NNP - I-ORG
Method NNP - I-ORG
with ADP - O
IVIVC NNP - B-ORG
for ADP - O
Extended ADJ - O
Release PROPN - O
Tablets PROPN - O
of ADP - O
Metformin NNP - B-ORG
Hydrochloride NNP - I-ORG
and CC - I-ORG
Development NNP - I-ORG
of ADP - O
a DET - O
Generic PROPN - O
Formulation PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Transdermal NNP - B-ORG
Cubic NNP - I-ORG
Phases NNPS - I-ORG
of ADP - O
Metformin NNP - B-ORG
Hydrochloride NNP - I-ORG
: PUNCT - O

-DOCSTART- -X- - O

Metformin NNP - B-PERSON
Hydrochloride NNP - I-PERSON
- HYPH - I-PERSON
Plga NNP - I-PERSON
Nanoparticles NNPS - I-PERSON
in ADP - O
Diabetic NNP - B-LOC
Rats NNS - I-LOC
in ADP - O
A DT - B-WORK_OF_ART
Periodontal NNP - I-WORK_OF_ART
Disease NNP - I-WORK_OF_ART
Experimental NNP - I-WORK_OF_ART
Model NNP - I-WORK_OF_ART

-DOCSTART- -X- - O

Metformin NNP - B-PERSON
Hydrochloride NNP - I-PERSON
- HYPH - I-PERSON
Loaded JJ - I-PERSON
PLGA NOUN - O
Nanoparticle PROPN - O
in ADP - O
Periodontal PROPN - O
Disease PROPN - O
Experimental PROPN - O
Model PROPN - O
Using VERB - O
Diabetic PROPN - O
Rats NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Metformin NNP - B-PERSON
Hydrochloride NNP - I-PERSON
- HYPH - I-PERSON
In NNP - I-PERSON
Vitro NNP - B-PERSON
and CCONJ - O
In ADP - O
Vivo PROPN - O
Evaluation PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Improved NNP - B-ORG
Chromatographic NNP - I-ORG
Separation NNP - I-ORG
of IN - I-ORG
Sitagliptin PROPN - O
Phosphate PROPN - O
and CCONJ - O
Metformin NNP - B-PERSON
Hydrochloride NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Co NNP - B-ORG
- NNP - I-ORG
Amorphous JJ - I-ORG
Combination NNP - I-ORG
of IN - I-ORG
Nateglinide NNP - I-ORG
- PUNCT - O
Metformin NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
for ADP - O
Dissolution NNP - B-ORG
Enhancement NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Voltammetric NNP - B-PERSON
Assay NNP - I-PERSON
of ADP - O
Metformin NNP - B-ORG
Hydrochloride NNP - I-ORG
Using VERB - O
Pyrogallol NN - B-PERSON
Modified VBN - I-PERSON
Carbon PROPN - O
Paste PROPN - O
Electrode PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Mathematical PROPN - O
Model PROPN - O
- PUNCT - O
Based PROPN - O
Accelerated PROPN - O
Development PROPN - O
of ADP - O
Extended PROPN - O
- PUNCT - O
release NOUN - O
Metformin NNP - B-ORG
Hydrochloride NNP - I-ORG
Tablet NNP - I-ORG
Formulation NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Formulation PROPN - O
and CCONJ - O
Evaluation PROPN - O
of ADP - O
Multilayered PROPN - O
Tablets PROPN - O
of ADP - O
Pioglitazone PROPN - O
Hydrochloride PROPN - O
and CCONJ - O
Metformin NNP - B-PERSON
Hydrochloride NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Study NOUN - O
of ADP - O
the DET - O
Effect PROPN - O
of ADP - O
Dillenia PROPN - O
indica PROPN - O
Fruit NNP - B-PERSON
Mucilage NNP - I-PERSON
on ADP - O
the DET - O
Properties PROPN - O
of ADP - O
Metformin NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
Loaded ADJ - O
Spray NOUN - O
Dried VERB - O
Microspheres PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Spectrophotometric NNP - B-PERSON
Methods NNPS - I-PERSON
for ADP - O
the DT - B-ORG
Determination NNP - I-ORG
of IN - I-ORG
Linagliptin NNP - I-ORG
in ADP - O
Binary NNP - B-GPE
Mixture NNP - I-GPE
with ADP - O
Metformin NNP - B-PERSON
Hydrochloride NNP - I-PERSON
and CCONJ - O
Simultaneous PROPN - O
Determination PROPN - O
of ADP - O
Linagliptin NNP - B-GPE
and CCONJ - O
Metformin NNP - B-PERSON
Hydrochloride NNP - I-PERSON
using VERB - O
High PROPN - O
Performance PROPN - O
Liquid PROPN - O
Chromatography PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Stability NOUN - O
Indicating PROPN - O
RP PROPN - O
- PUNCT - O
HPLC PROPN - O
Method PROPN - O
for ADP - O
the DET - O
Simultaneous PROPN - O
Determination PROPN - O
of ADP - O
Atorvastatin PROPN - O
Calcium PROPN - O
, PUNCT - O
Metformin NNP - B-PERSON
Hydrochloride NNP - I-PERSON
, PUNCT - O
and CCONJ - O
Glimepiride NNP - B-ORG
in IN - I-ORG
Bulk NNP - I-ORG
and CC - I-ORG
Combined NNP - I-ORG
Tablet NNP - I-ORG
Dosage NN - I-ORG
Form NN - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
present ADJ - O
study NOUN - O
involves VERB - O
preparation NOUN - O
and CCONJ - O
evaluation NOUN - O
of ADP - O
gastric NOUN - O
- PUNCT - O
mucoadhesive NOUN - O
microparticles NOUN - O
with ADP - O
Metformin NNP - B-PERSON
Hydrochloride NNP - I-PERSON
as ADP - O
model NOUN - O
drug NOUN - O
for ADP - O
prolongation NOUN - O
of ADP - O
gastric ADJ - O
residence NOUN - O
time NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Formulation PROPN - O
and CCONJ - O
Evaluation NOUN - O
of ADP - O
In PROPN - O
- PUNCT - O
vitro NOUN - O
Characterization NOUN - O
of ADP - O
Gastic PROPN - O
- PUNCT - O
Mucoadhesive NOUN - O
Microparticles PROPN - O
/ SYM - O
Discs PROPN - O
Containing PROPN - O
Metformin NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Preparation PROPN - O
and CCONJ - O
Characterization PROPN - O
of ADP - O
Metformin NNP - B-PERSON
Hydrochloride NNP - I-PERSON
- HYPH - I-PERSON
Compritol NNP - I-PERSON
888 NUM - O
ATO PROPN - O
Solid PROPN - O
Dispersion PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
Aqueous PROPN - O
Extract PROPN - O
of ADP - O
Fresh PROPN - O
Leaves PROPN - O
of ADP - O
Abroma PROPN - O
augusta PROPN - O
L. NNP - B-PERSON
on ADP - O
Oral PROPN - O
Absorption PROPN - O
of ADP - O
Glucose PROPN - O
and CCONJ - O
Metformin NNP - B-PERSON
Hydrochloride NNP - I-PERSON
in ADP - O
Experimental NNP - B-LOC
Rats NNS - I-LOC
. PUNCT - O

-DOCSTART- -X- - O

Simultaneous ADJ - O
Determination PROPN - O
of ADP - O
Sitagliptin PROPN - O
Phosphate PROPN - O
Monohydrate PROPN - O
and CCONJ - O
Metformin NNP - B-PERSON
Hydrochloride NNP - I-PERSON
in ADP - O
Tablets PROPN - O
by ADP - O
a DET - O
Validated NNP - B-ORG
UPLC NNP - I-ORG
Method NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Water NOUN - O
- PUNCT - O
soluble ADJ - O
Fraction NNP - B-ORG
of IN - I-ORG
Abelmoschus NNP - I-ORG
esculentus NOUN - O
L PROPN - O
Interacts PROPN - O
with ADP - O
Glucose NNP - B-ORG
and CCONJ - O
Metformin NNP - B-ORG
Hydrochloride NNP - I-ORG
and CCONJ - O
Alters PROPN - O
Their ADJ - O
Absorption PROPN - O
Kinetics PROPN - O
after ADP - O
Coadministration PROPN - O
in ADP - O
Rats PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Formulation NOUN - O
and CCONJ - O
In ADP - O
vitro NOUN - O
Evaluation PROPN - O
of ADP - O
Sustained PROPN - O
Release PROPN - O
Dosage PROPN - O
Form NOUN - O
with ADP - O
Taste NNP - B-PERSON
Masking NNP - I-PERSON
of ADP - O
Metformin NNP - B-PERSON
Hydrochloride NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Metformin NNP - B-PERSON
Hydrochloride NNP - I-PERSON
( PUNCT - O
MF NNP - B-ORG
) PUNCT - O
is VERB - O
glucose NOUN - O
lowering VERB - O
agent NOUN - O
that ADJ - O
is VERB - O
widely ADV - O
used VERB - O
for ADP - O
management NOUN - O
for ADP - O
type NOUN - O
II CD - B-ORG
diabetes NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Simultaneous PROPN - O
Estimation PROPN - O
of ADP - O
Metformin NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
and CCONJ - O
Pioglitazone NNP - B-ORG
Hydrochloride NNP - I-ORG
by ADP - O
RPHPLC NNP - B-PERSON
Method NNP - I-PERSON
from ADP - O
Combined PROPN - O
Tablet PROPN - O
Dosage NOUN - O
Form NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Metformin NNP - B-PERSON
Hydrochloride NNP - I-PERSON
tablets NOUN - O

-DOCSTART- -X- - O

Nickel PROPN - O
and CCONJ - O
Copper PROPN - O
Toxicity PROPN - O
and CCONJ - O
Plant NNP - B-ORG
Response NNP - I-ORG
Mechanisms NNP - I-ORG
in ADP - O
White NNP - B-ORG
Birch NNP - I-ORG
( PUNCT - O
Betula NNP - B-PERSON
papyrifera PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Comprehensive PROPN - O
Transcriptome PROPN - O
Analysis PROPN - O
of ADP - O
Response PROPN - O
to ADP - O
Nickel PROPN - O
Stress PROPN - O
in ADP - O
White NNP - B-ORG
Birch NNP - I-ORG
( PUNCT - O
Betula NNP - B-PERSON
papyrifera PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Correction NOUN - O
: PUNCT - O
Development NOUN - O
of ADP - O
SSR PROPN - O
Markers PROPN - O
and CCONJ - O
Genetic PROPN - O
Diversity NOUN - O
in ADP - O
White NNP - B-FAC
Birch NNP - I-FAC
( PUNCT - O
Betula NNP - B-PERSON
platyphylla NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Development PROPN - O
of ADP - O
SSR NNP - B-ORG
Markers NNPS - I-ORG
and CC - I-ORG
Genetic NNP - I-ORG
Diversity NN - I-ORG
in ADP - O
White NNP - B-FAC
Birch NNP - I-FAC
( PUNCT - O
Betula NNP - B-PERSON
platyphylla NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Influence NOUN - O
of ADP - O
Temperature PROPN - O
Programmed PROPN - O
Rate PROPN - O
on ADP - O
Pyrolysis PROPN - O
Rate PROPN - O
of ADP - O
the DET - O
Stalk PROPN - O
of ADP - O
Soybeans PROPN - O
and CCONJ - O
White NNP - B-ORG
Birch NNP - I-ORG

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
has VERB - O
recently ADV - O
been VERB - O
reported VERB - O
to PART - O
upregulate VERB - O
Alas1 PUNCT - O
but CCONJ - O
downregulate VERB - O
Fech NNP - B-ORG
protein NOUN - O
levels NOUN - O
in ADP - O
mice NOUN - O
; PUNCT - O
however ADV - O
, PUNCT - O
the DET - O
mechanism NOUN - O
by ADP - O
which ADJ - O
isoniazid NN - B-MEDICINE
mediates VERB - O
disruption NOUN - O
of ADP - O
heme NOUN - O
synthesis NOUN - O
has VERB - O
been VERB - O
unclear ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Isoniazid NNP - B-MEDICINE
Metabolites PROPN - O
Hydrazine PROPN - O
and CCONJ - O
Pyridoxal NNP - B-ORG
Isonicotinoyl NNP - I-ORG
Hydrazone NNP - I-ORG
Modulate JJ - B-ORG
Heme NNP - I-ORG
Biosynthesis NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
is VERB - O
a DET - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
anti ADJ - O
- ADJ - O
tuberculosis ADJ - O
drug NOUN - O
recommended VERB - O
for ADP - O
treatment NOUN - O
of ADP - O
drug NOUN - O
- PUNCT - O
susceptible ADJ - O
Mycobacterium PROPN - O
tuberculosis NOUN - O
infections NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Exposure NOUN - O
of ADP - O
Infants PROPN - O
to ADP - O
Isoniazid NNP - B-MEDICINE
via ADP - O
Breast NNP - B-ORG
Milk NN - I-ORG

-DOCSTART- -X- - O

Response NOUN - O
to ADP - O
Isoniazid NNP - B-MEDICINE
- PUNCT - O
Resistant PROPN - O
Tuberculosis PROPN - O
in ADP - O
Homeless PROPN - O
Shelters PROPN - O
, PUNCT - O
Georgia NNP - B-GPE
, PUNCT - O
USA NNP - B-GPE
, PUNCT - O
2015 CD - B-DATE
- SYM - I-DATE
2017 CD - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

Improved VERB - O
Outcomes PROPN - O
with ADP - O
High PROPN - O
- PUNCT - O
Dose PROPN - O
Isoniazid NNP - B-MEDICINE
in ADP - O
Multidrug NNP - B-ORG
- HYPH - I-ORG
Resistant NNP - I-ORG
Tuberculosis NNP - I-ORG
Treatment NNP - I-ORG
in ADP - O
Haiti NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
concentrations NOUN - O
from ADP - O
150 CD - B-CARDINAL
patients NOUN - O
were VERB - O
available ADJ - O
for ADP - O
analysis NOUN - O
, PUNCT - O
and CCONJ - O
79 CD - B-CARDINAL
of ADP - O
these DET - O
( PUNCT - O
53 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
also ADV - O
had VERB - O
concentrations NOUN - O
of ADP - O
acetyl NOUN - O
- PUNCT - O
isoniazid NN - B-MEDICINE
. PUNCT - O

Isoniazid NNP - B-MEDICINE
pharmacokinetics NOUN - O
was VERB - O
best ADV - O
described VERB - O
with ADP - O
a DET - O
two CD - B-CARDINAL
- PUNCT - O
compartment NOUN - O
disposition NOUN - O
model NOUN - O
with ADP - O
lagged VERB - O
first JJ - B-ORDINAL
- PUNCT - O
order NOUN - O
absorption NOUN - O
and CCONJ - O
elimination NOUN - O
using VERB - O
a DET - O
semi ADJ - O
- PUNCT - O
mechanistic ADJ - O
model NOUN - O
describing VERB - O
hepatic ADJ - O
extraction NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
( PUNCT - O
INH NNP - B-ORG
) PUNCT - O
was VERB - O
the DET - O
first JJ - B-ORDINAL
synthesized VERB - O
drug NOUN - O
that ADJ - O
mediated VERB - O
bactericidal NOUN - O
killing NOUN - O
of ADP - O
the DET - O
bacterium NOUN - O
Mycobacterium PROPN - O
tuberculosis NOUN - O
, PUNCT - O
a DET - O
major ADJ - O
clinical ADJ - O
breakthrough NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Isoniazid NNP - B-MEDICINE
Paradigm PROPN - O
of ADP - O
Killing PROPN - O
, PUNCT - O
Resistance NNP - B-GPE
, PUNCT - O
and CCONJ - O
Persistence NNP - B-PERSON
in ADP - O
Mycobacterium PROPN - O
tuberculosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
pharmacokinetics NOUN - O
were VERB - O
described VERB - O
by ADP - O
a DET - O
one CD - B-CARDINAL
- PUNCT - O
compartment NOUN - O
disposition NOUN - O
model NOUN - O
with ADP - O
a DET - O
transit NOUN - O
absorption NOUN - O
model NOUN - O
( PUNCT - O
fixed VERB - O
, PUNCT - O
n DET - O
= SYM - O
  SPACE - O
5 NUM - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
preventive ADJ - O
therapy NOUN - O
is VERB - O
one NUM - O
of ADP - O
the DET - O
key ADJ - O
interventions NOUN - O
in ADP - O
reducing VERB - O
the DET - O
risk NOUN - O
of ADP - O
active ADJ - O
disease NOUN - O
among ADP - O
children NOUN - O
exposed VERB - O
to ADP - O
tuberculosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NN - B-MEDICINE
- PUNCT - O
induced VERB - O
liver NOUN - O
disorder NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
tuberculosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
Bactericidal PROPN - O
Activity PROPN - O
Involves VERB - O
Electron PROPN - O
Transport PROPN - O
Chain PROPN - O
Perturbation PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
is VERB - O
a DET - O
drug NOUN - O
that ADJ - O
is VERB - O
widely ADV - O
used VERB - O
against ADP - O
tuberculosis NOUN - O
. PUNCT - O

Isoniazid NNP - B-MEDICINE
was VERB - O
eluted VERB - O
in ADP - O
less ADJ - O
than ADP - O
5 NUM - O
min NOUN - O
without ADP - O
interference NOUN - O
from ADP - O
other ADJ - O
compounds NOUN - O
of ADP - O
the DET - O
urine NOUN - O
using VERB - O
a DET - O
mobile ADJ - O
phase NOUN - O
containing VERB - O
0.15 CD - B-PERCENT
SDS⁻12.5 CD - I-PERCENT
% NN - I-PERCENT
1-propanol PROPN - O

-DOCSTART- -X- - O

Optimization NOUN - O
and CCONJ - O
Validation PROPN - O
of ADP - O
a DET - O
Chromatographic PROPN - O
Method PROPN - O
for ADP - O
the DT - B-ORG
Quantification NNP - I-ORG
of IN - I-ORG
Isoniazid NNP - I-MEDICINE
in IN - I-ORG
Urine NNP - I-ORG
of IN - I-ORG
Tuberculosis NNP - I-ORG
Patients NNS - I-ORG

-DOCSTART- -X- - O

Isoniazid NN - B-MEDICINE
- PUNCT - O
loaded VERB - O
chitosan NOUN - O
/ SYM - O
carbon NOUN - O
nanotubes NOUN - O
microspheres NOUN - O
promote VERB - O
secondary ADJ - O
wound NOUN - O
healing NOUN - O
of ADP - O
bone NOUN - O
tuberculosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
pro ADJ - O
drug NOUN - O
Isoniazid NNP - B-MEDICINE
( PUNCT - O
INH NNP - B-ORG
) PUNCT - O
interacts VERB - O
with ADP - O
an DET - O
enzyme ADJ - O
catalase NOUN - O
peroxidase NOUN - O
to PART - O
get VERB - O
converted VERB - O
into ADP - O
its ADJ - O
active ADJ - O
form NOUN - O
and CCONJ - O
upon ADP - O
activation NOUN - O
stops VERB - O
the DET - O
cell NOUN - O
wall NOUN - O
synthesis NOUN - O
thus ADV - O
killing VERB - O
the DET - O
Mycobacterium NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
resistance NOUN - O
in ADP - O
Mycobacterium PROPN - O
tuberculosis NOUN - O
is VERB - O
a DET - O
heterogeneous ADJ - O
phenotype NOUN - O
comprised VERB - O
of ADP - O
overlapping VERB - O
MIC NNP - B-ORG
distributions NOUN - O
with ADP - O
different ADJ - O
underlying ADJ - O
resistance NOUN - O
mechanisms NOUN - O

-DOCSTART- -X- - O

Isoniazid NN - B-MEDICINE
- PUNCT - O
induced VERB - O
liver NOUN - O
injury NOUN - O
is VERB - O
associated VERB - O
to ADP - O
ERS PROPN - O
- PUNCT - O
related VERB - O
excessive ADJ - O
apoptosis NOUN - O
and CCONJ - O
the DET - O
therapeutic ADJ - O
effect NOUN - O
of ADP - O
bicyclol NOUN - O
on ADP - O
drug NOUN - O
- PUNCT - O
induced VERB - O
liver NOUN - O
injury NOUN - O
may VERB - O
minimize VERB - O
ERS NOUN - O
- PUNCT - O
induced VERB - O
apoptosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
preventive ADJ - O
therapy NOUN - O
for ADP - O
children NOUN - O
in ADP - O
sub NOUN - O
- PUNCT - O
Saharan NNP - B-GPE
Africa NNP - I-GPE
. PUNCT - O

-DOCSTART- -X- - O

Tolerability NOUN - O
of ADP - O
Isoniazid NNP - B-MEDICINE
Preventive PROPN - O
Therapy PROPN - O
in ADP - O
an DET - O
HIV PROPN - O
- PUNCT - O
Infected PROPN - O
Cohort PROPN - O
of ADP - O
Paediatric NNP - B-ORG
and CC - I-ORG
Adolescent NNP - I-ORG
Patients NNPS - I-ORG
on IN - I-ORG
Antiretroviral NNP - I-ORG
Therapy NNP - I-ORG
from ADP - O
a DET - O
Resource PROPN - O
- PUNCT - O
Limited PROPN - O
Setting NOUN - O
: PUNCT - O
A DET - O
Retrospective PROPN - O
Cohort PROPN - O
Study PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Introduction NOUN - O
: PUNCT - O
Isoniazid NNP - B-MEDICINE
- PUNCT - O
induced VERB - O
seizure NOUN - O
, PUNCT - O
often ADV - O
described VERB - O
as ADP - O
Status NNP - B-ORG
Epilepticus NNP - I-ORG
( PUNCT - O
SE PROPN - O
) PUNCT - O
, PUNCT - O
is VERB - O
an DET - O
emergency NOUN - O
condition NOUN - O
characterized VERB - O
by ADP - O
repeated VERB - O
convulsive ADJ - O
episodes NOUN - O
that ADJ - O
responds VERB - O
poorly ADV - O
to ADP - O
the DET - O
currently ADV - O
available ADJ - O
anticonvulsant ADJ - O
drugs NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
Jobelyn NNP - B-FAC
® . - I-FAC
on ADP - O
Isoniazid NNP - B-MEDICINE
- HYPH - I-ORG
Induced NNP - I-ORG
Seizures NNPS - I-ORG
, , - I-ORG
Biomarkers NNPS - B-ORG
of IN - I-ORG
Oxidative NNP - I-ORG
Stress NNP - I-ORG
and CC - I-ORG
Glutamate NNP - I-ORG
Decarboxylase NNP - I-ORG
Activity NN - I-ORG
in ADP - O
Mice NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
shows VERB - O
no DET - O
binding VERB - O
affinity NOUN - O
to ADP - O
mutant NOUN - O
InhA PROPN - O
( PUNCT - O
2015 CD - B-DATE
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NN - B-MEDICINE
and CCONJ - O
ethambutol VERB - O
induced VERB - O
toxic ADJ - O
optic ADJ - O
neuropathy NOUN - O
although ADP - O
not ADV - O
common ADJ - O
, PUNCT - O
may VERB - O
have VERB - O
some DET - O
potential ADJ - O
devastating ADJ - O
effects NOUN - O
on ADP - O
vision NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
, PUNCT - O
rifampin ADJ - O
susceptible ADJ - O
tuberculosis NOUN - O
( PUNCT - O
INHR PROPN - O
- PUNCT - O
TB PROPN - O
) PUNCT - O
is VERB - O
the DET - O
most ADV - O
common ADJ - O
form NOUN - O
of ADP - O
drug NOUN - O
resistant ADJ - O
TB PROPN - O
globally ADV - O
. PUNCT - O

-DOCSTART- -X- - O

3D PROPN - O
- PUNCT - O
Printed VERB - O
Isoniazid NNP - B-MEDICINE
Tablets PROPN - O
for ADP - O
the DET - O
Treatment PROPN - O
and CCONJ - O
Prevention PROPN - O
of ADP - O
Tuberculosis PROPN - O
- PUNCT - O
Personalized PROPN - O
Dosing PROPN - O
and CCONJ - O
Drug PROPN - O
Release PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
is VERB - O
one NUM - O
of ADP - O
the DET - O
most ADV - O
hepatotoxic ADJ - O
first JJ - B-ORDINAL
line NOUN - O
antitubercular ADJ - O
drugs NOUN - O
. PUNCT - O

extract VERB - O
against ADP - O
Isoniazid- PROPN - O
induced VERB - O
liver NOUN - O
injury NOUN - O
in ADP - O
Swiss NNP - B-NORP
Albino PROPN - O
Mice PROPN - O
. PUNCT - O

Treatment NOUN - O
of ADP - O
Mice PROPN - O
orally ADV - O
with ADP - O
Vernonia NNP - B-PERSON
Amygdalina NNP - I-PERSON
Del NNP - I-PERSON
extract VERB - O
at ADP - O
dose NOUN - O
of ADP - O
250mg NN - B-ORG
/ SYM - I-ORG
kg NN - I-ORG
and CC - I-ORG
375 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
kg NOUN - O
significantly ADV - O
lowered VERB - O
( PUNCT - O
P<0.05 PROPN - O
) PUNCT - O
the DET - O
serum ADJ - O
level NOUN - O
of ADP - O
liver NOUN - O
enzymes NOUN - O
in ADP - O
Isoniazid NNP - B-MEDICINE
pretreated VERB - O
mice NOUN - O
. PUNCT - O

Isoniazid NNP - B-MEDICINE
induced VERB - O
hepatic ADJ - O
injury NOUN - O
as ADP - O
supported VERB - O
by ADP - O
the DET - O
photomi NOUN - O
- PUNCT - O
crographs NOUN - O
of ADP - O
liver NOUN - O
section NOUN - O
of ADP - O
mice NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
( PUNCT - O
INH NNP - B-ORG
) PUNCT - O
is VERB - O
one NUM - O
of ADP - O
the DET - O
oldest ADJ - O
drugs NOUN - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
tuberculosis NOUN - O
( PUNCT - O
TB PROPN - O
) PUNCT - O
and CCONJ - O
is VERB - O
of ADP - O
continual ADJ - O
clinical ADJ - O
and CCONJ - O
research NOUN - O
interest NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
induces VERB - O
a DET - O
monocytic ADJ - O
- PUNCT - O
like ADJ - O
phenotype NOUN - O
in ADP - O
HL-60 NNP - B-ORG
  SPACE - O
cells NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Lower PROPN - O
Dose PROPN - O
of ADP - O
Efavirenz PROPN - O
Can VERB - O
Be VERB - O
Coadministered ADJ - O
With ADP - O
Rifampicin PROPN - O
and CCONJ - O
Isoniazid NNP - B-MEDICINE
in ADP - O
Tuberculosis PROPN - O
Patients PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid- NOUN - O
and CCONJ - O
moxifloxacin ADV - O
- PUNCT - O
induced VERB - O
mycobacterial ADJ - O
death NOUN - O
correlated VERB - O
with ADP - O
a DET - O
transient ADJ - O
increase NOUN - O
in ADP - O
intracellular ADJ - O
ATP NNP - B-ORG
that ADJ - O
was VERB - O
dissipated VERB - O
by ADP - O
co NOUN - O
- NOUN - O
incubation NOUN - O
with ADP - O
energy NOUN - O
metabolism NOUN - O
inhibitors NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
- PUNCT - O
induced VERB - O
pure ADJ - O
red ADJ - O
cell NOUN - O
aplasia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

High ADJ - O
Completion NOUN - O
Rate NOUN - O
for ADP - O
12 CD - B-CARDINAL
Weekly PROPN - O
Doses PROPN - O
of ADP - O
Isoniazid NNP - B-MEDICINE
and CCONJ - O
Rifapentine PROPN - O
as ADP - O
Treatment PROPN - O
for ADP - O
Latent PROPN - O
Mycobacterium PROPN - O
tuberculosis NOUN - O
Infection NNP - B-NORP
in ADP - O
the DT - B-ORG
Federal NNP - I-ORG
Bureau NNP - I-ORG
of IN - I-ORG
Prisons NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
( PUNCT - O
INH NNP - B-ORG
) PUNCT - O
is VERB - O
known VERB - O
to PART - O
cause VERB - O
the DET - O
exclusive ADJ - O
lethal ADJ - O
action NOUN - O
to ADP - O
Mycobacterium PROPN - O
tuberculosis NOUN - O
( PUNCT - O
M. PROPN - O
tb PROPN - O
. PUNCT - O
) PUNCT - O
cells NOUN - O
because ADP - O
of ADP - O
the DET - O
pathogen NOUN - O
's PART - O
own ADJ - O
catalase NOUN - O
- PUNCT - O
peroxidase NOUN - O
( PUNCT - O
katG PROPN - O
) PUNCT - O
enzyme ADJ - O
that ADP - O
converts VERB - O
INH NNP - B-ORG
to ADP - O
a DET - O
very ADV - O
reactive ADJ - O
radical NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pulmonary JJ - B-ORG
Delivery NN - I-ORG
of IN - I-ORG
Isoniazid NNP - I-MEDICINE
in ADP - O
Nanogel NNP - B-GPE
- HYPH - I-GPE
Loaded VBN - I-GPE
Chitosan NNP - B-PERSON
Hybrid NN - I-PERSON
Microparticles NNPS - I-PERSON
for ADP - O
Inhalation PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Intermediate ADJ - O
Susceptibility PROPN - O
Dose PROPN - O
- PUNCT - O
Dependent PROPN - O
Breakpoints NOUN - O
For ADP - O
High PROPN - O
- PUNCT - O
Dose PROPN - O
Rifampin PROPN - O
, PUNCT - O
Isoniazid NNP - B-MEDICINE
, PUNCT - O
and CCONJ - O
Pyrazinamide NNP - B-ORG
Treatment NNP - I-ORG
in ADP - O
Multidrug PROPN - O
- PUNCT - O
Resistant ADJ - O
Tuberculosis PROPN - O
Programs PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Once ADP - O
Daily PROPN - O
Coadministered VERB - O
With ADP - O
Isoniazid NNP - B-MEDICINE
and CCONJ - O
Rifampicin PROPN - O
in ADP - O
Human PROPN - O
Immunodeficiency PROPN - O

-DOCSTART- -X- - O

Aqueous ADJ - O
Extract PROPN - O
of ADP - O
Wood NNP - B-ORG
Ear NNP - I-ORG
Mushroom NNP - I-ORG
, PUNCT - O
Auricularia NNP - B-GPE
polytricha NOUN - O
( PUNCT - O
Agaricomycetes PROPN - O
) PUNCT - O
, PUNCT - O
Demonstrated PROPN - O
Antiepileptic PROPN - O
Activity PROPN - O
against ADP - O
Seizure PROPN - O
Induced VERB - O
by ADP - O
Maximal PROPN - O
Electroshock PROPN - O
and CCONJ - O
Isoniazid NNP - B-MEDICINE
in ADP - O
Experimental PROPN - O
Animals PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Treating VERB - O
More ADJ - O
with ADP - O
Less ADJ - O
: PUNCT - O
Effectiveness NOUN - O
and CCONJ - O
Event PROPN - O
Outcomes PROPN - O
of ADP - O
Antituberculosis PROPN - O
Fixed VERB - O
- PUNCT - O
dose NOUN - O
Combination PROPN - O
Drug PROPN - O
versus ADP - O
Separate PROPN - O
- PUNCT - O
drug NOUN - O
Formulation PROPN - O
( PUNCT - O
Ethambutol NNP - B-ORG
, PUNCT - O
Isoniazid NNP - B-MEDICINE
, PUNCT - O
Rifampicin PROPN - O
and CCONJ - O
Pyrazinamide NNP - B-PRODUCT
) PUNCT - O
for ADP - O
Pulmonary NNP - B-ORG
Tuberculosis NNP - I-ORG
Patients NNPS - I-ORG
in ADP - O
Real ADJ - O
- PUNCT - O
world NOUN - O
Clinical NNP - B-ORG
Practice NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
- PUNCT - O
Resistant PROPN - O
Rifampicin PROPN - O
- PUNCT - O
Susceptible ADJ - O
Tuberculosis NOUN - O
in ADP - O
Children PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Use PROPN - O
of ADP - O
N NNP - B-ORG
- HYPH - I-ORG
Acetylcysteine NNP - I-ORG
for IN - I-ORG
Prevention NNP - I-ORG
and CC - I-ORG
Treatment NNP - I-ORG
of IN - I-ORG
Isoniazid NNP - I-MEDICINE
Induced NNP - I-ORG
Liver NNP - I-ORG
Injury NNP - I-ORG
During IN - I-ORG
Treatment NNP - I-ORG
of IN - I-ORG
Mycobacterial NNP - I-ORG
Infections NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Multivariate NNP - B-ORG
Control NNP - I-ORG
Chart NNP - I-ORG
Approach NNP - I-ORG
for ADP - O
Calibration NNP - B-ORG
Transfer NNP - I-ORG
between ADP - O
NIR NNP - B-ORG
Spectrometers NNPS - I-ORG
for IN - I-ORG
Simultaneous NNP - I-ORG
Determination NNP - I-ORG
of IN - I-ORG
Rifampicin NNP - I-ORG
and CCONJ - O
Isoniazid NNP - B-MEDICINE
in ADP - O
Pharmaceutical NNP - B-ORG
Formulation NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

With ADP - O
Isoniazid NNP - B-MEDICINE
and CCONJ - O
Rifapentine NNP - B-PERSON
Versus NNP - I-PERSON
Isoniazid NNP - B-MEDICINE
Alone ADJ - O
in ADP - O
High PROPN - O
- PUNCT - O
Burden PROPN - O
Settings PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Smartly ADV - O
Engineered ADJ - O
PEGylated PROPN - O
Di PROPN - O
- PUNCT - O
Block PROPN - O
Nanopolymeric PROPN - O
Micelles PROPN - O
: PUNCT - O
Duo NNP - B-PERSON
Delivery NN - I-PERSON
of ADP - O
Isoniazid NNP - B-MEDICINE
and CCONJ - O
Rifampicin NNP - B-ORG
Against NNP - I-ORG
Mycobacterium NNP - I-ORG
tuberculosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
preventive ADJ - O
therapy NOUN - O
( PUNCT - O
IPT PROPN - O
) PUNCT - O
is VERB - O
a DET - O
proven VERB - O
means NOUN - O
to PART - O
prevent VERB - O
tuberculosis NOUN - O
( PUNCT - O
TB PROPN - O
) PUNCT - O
disease NOUN - O
among ADP - O
people NOUN - O
living VERB - O
with ADP - O
HIV PROPN - O
( PUNCT - O
PLHIV PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Correlation NOUN - O
between ADP - O
GenoType PROPN - O
MTBDRplus PROPN - O
Assay PROPN - O
and CCONJ - O
Phenotypic PROPN - O
Susceptibility PROPN - O
Test PROPN - O
for ADP - O
Prothionamide PROPN - O
in ADP - O
Patients PROPN - O
with ADP - O
Genotypic PROPN - O
Isoniazid NNP - B-MEDICINE
Resistance PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
targets VERB - O
the DET - O
cell NOUN - O
wall NOUN - O
of ADP - O
mycobacteria NOUN - O
found VERB - O
in ADP - O
extracellular ADJ - O
compartments NOUN - O
and CCONJ - O
within ADP - O
monocytes NOUN - O
, PUNCT - O
macrophages NOUN - O
, PUNCT - O
dendritic ADJ - O
cells NOUN - O
, PUNCT - O
and CCONJ - O
lymphatic ADJ - O
endothelial ADJ - O
cells NOUN - O
. PUNCT - O

Isoniazid NNP - B-MEDICINE
's PART - O
dual ADJ - O
- PUNCT - O
purpose NOUN - O
potential NOUN - O
as ADP - O
an DET - O
antibiotic ADJ - O
and CCONJ - O
elicitor NOUN - O
is VERB - O
supported VERB - O
by ADP - O
knowledge NOUN - O
of ADP - O
latent ADJ - O
infection NOUN - O
dynamics NOUN - O
, PUNCT - O
time NOUN - O
- PUNCT - O
kill NOUN - O
kinetics NOUN - O
, PUNCT - O
and CCONJ - O
new ADJ - O
detection NOUN - O
techniques NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
is VERB - O
a DET - O
commonly ADV - O
used VERB - O
drug NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
and CCONJ - O
prophylaxis NOUN - O
of ADP - O
tuberculosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Is VERB - O
It PRON - O
Isoniazid NNP - B-MEDICINE
- PUNCT - O
Induced VERB - O
Psychosis PROPN - O
? PUNCT - O

-DOCSTART- -X- - O

Clofazimine PROPN - O
, PUNCT - O
but CCONJ - O
Not ADV - O
Isoniazid NNP - B-MEDICINE
or CCONJ - O
Rifampicin NNP - B-ORG
, PUNCT - O
Augments NNP - B-ORG
Platelet NNP - I-ORG
Activation NNP - I-ORG
in ADP - O
vitro NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
is VERB - O
recommended VERB - O
for ADP - O
prevention NOUN - O
of ADP - O
tuberculosis NOUN - O
( PUNCT - O
TB PROPN - O
) PUNCT - O
in ADP - O
HIV PROPN - O
- PUNCT - O
infected VERB - O
adults NOUN - O
, PUNCT - O
but CCONJ - O
its ADJ - O
efficacy NOUN - O
in ADP - O
children NOUN - O
living VERB - O
with ADP - O
HIV PROPN - O
( PUNCT - O
CLHIV PROPN - O
) PUNCT - O
is VERB - O
not ADV - O
known VERB - O
. PUNCT - O

Isoniazid NNP - B-MEDICINE
did VERB - O
not ADV - O
reduce VERB - O
the DET - O
incidence NOUN - O
of ADP - O
TB NNP - B-ORG
in ADP - O
CLHIV NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
for ADP - O
the DT - B-ORG
Prevention NNP - I-ORG
of IN - I-ORG
Tuberculosis NNP - I-ORG
in ADP - O
HIV PROPN - O
- PUNCT - O
Infected PROPN - O
Children NOUN - O
: PUNCT - O
A PROPN - O
Systematic PROPN - O
Review PROPN - O
and CCONJ - O
Meta NNP - B-ORG
- HYPH - I-ORG
Analysis NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
preventive ADJ - O
therapy NOUN - O
( PUNCT - O
IPT PROPN - O
) PUNCT - O
has VERB - O
shown VERB - O
to PART - O
be VERB - O
effective ADJ - O
in ADP - O
reducing VERB - O
TB PROPN - O
incidence NOUN - O
among ADP - O
HIV PROPN - O
infected VERB - O
adults NOUN - O
in ADP - O
Dar NNP - B-GPE
es NNP - I-GPE
Salaam NNP - I-GPE
. PUNCT - O

-DOCSTART- -X- - O

Safety PROPN - O
and CCONJ - O
Side PROPN - O
Effects PROPN - O
of ADP - O
Rifampin PROPN - O
versus ADP - O
Isoniazid NNP - B-MEDICINE
in ADP - O
Children PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Stratification NOUN - O
by ADP - O
MIRU NNP - B-ORG
- HYPH - I-ORG
VNTR NNP - I-ORG
identified VERB - O
one CD - B-CARDINAL
genotype NOUN - O
with ADP - O
a DET - O
high ADJ - O
rate NOUN - O
of ADP - O
drug NOUN - O
resistance NOUN - O
against ADP - O
Rifampicin NNP - B-PERSON
and CCONJ - O
Isoniazid NNP - B-MEDICINE
and CCONJ - O
circulation NOUN - O
of ADP - O
a DET - O
potential ADJ - O
MDR NNP - B-ORG
- PUNCT - O
TB PROPN - O
clone NOUN - O
is VERB - O
proposed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-PERSON
Efficacy NN - I-PERSON
of IN - I-PERSON
the DT - I-PERSON
Interferon NNP - I-PERSON
- HYPH - I-PERSON
γ NNP - I-PERSON
Releasing VBG - I-PERSON
Assay NNP - I-PERSON
- HYPH - I-PERSON
Based VBN - I-PERSON
Isoniazid NNP - I-MEDICINE
Treatment PROPN - O
for ADP - O
Preventing VERB - O
Active PROPN - O
Tuberculosis PROPN - O
in ADP - O
Kidney PROPN - O
Transplant PROPN - O
Recipients PROPN - O
: PUNCT - O
A DET - O
Quasi PROPN - O
- PUNCT - O
experimental ADJ - O
Study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Four CD - B-DATE
Months NNPS - I-DATE
of ADP - O
Rifampin NNP - B-GPE
or CCONJ - O
Nine NNP - B-ORG
Months NNPS - I-ORG
of ADP - O
Isoniazid NNP - B-MEDICINE
for ADP - O
Latent PROPN - O
Tuberculosis PROPN - O
in ADP - O
Adults NNPS - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Tuberculosis PROPN - O
Prevention PROPN - O
in ADP - O
the DET - O
Private PROPN - O
Sector PROPN - O
: PUNCT - O
Using VERB - O
Claims PROPN - O
- PUNCT - O
Based VERB - O
Methods NOUN - O
to PART - O
Identify VB - B-ORG
and CC - I-ORG
Evaluate NNP - I-ORG
Latent NNP - I-ORG
Tuberculosis NNP - I-ORG
Infection NNP - I-ORG
Treatment NN - I-ORG
With IN - I-ORG
Isoniazid NNP - I-MEDICINE
Among ADP - O
the DET - O
Commercially ADV - O
Insured VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
( PUNCT - O
INH NNP - B-ORG
) PUNCT - O
is VERB - O
a DET - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
therapy NOUN - O
for ADP - O
bone NOUN - O
tuberculosis NOUN - O
( PUNCT - O
TB PROPN - O
) PUNCT - O
, PUNCT - O
but CCONJ - O
its ADJ - O
clinic NOUN - O
benefits NOUN - O
are VERB - O
limited VERB - O
by ADP - O
severe ADJ - O
side NOUN - O
- PUNCT - O
effects NOUN - O
after ADP - O
long ADJ - O
- PUNCT - O
time NOUN - O
administration NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
( PUNCT - O
INH NNP - B-ORG
) PUNCT - O
is VERB - O
one NUM - O
among ADP - O
the DET - O
four CD - B-CARDINAL
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
drugs NOUN - O
used VERB - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
tuberculosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

With ADP - O
Once PROPN - O
- PUNCT - O
Weekly PROPN - O
Isoniazid NNP - B-MEDICINE
and CCONJ - O
Rifapentine NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
- HYPH - I-ORG
Rifapentine NNP - I-ORG
for IN - I-ORG
Latent NNP - I-ORG
Tuberculosis NNP - I-ORG
Infection NNP - I-ORG
: : - I-ORG
A NNP - I-ORG
Systematic NNP - I-ORG
Review NNP - I-ORG
and CCONJ - O
Meta PROPN - O
- PUNCT - O
analysis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
, PUNCT - O
rifampicin NOUN - O
- PUNCT - O
susceptible ADJ - O
tuberculosis NOUN - O
in ADP - O
India NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

On ADP - O
- PUNCT - O
Chip NOUN - O
Isoniazid NNP - B-MEDICINE
Exposure PROPN - O
of ADP - O
Mycobacterium PROPN - O
smegmatis NOUN - O
Penicillin NNP - B-ORG
- HYPH - I-ORG
Binding NNP - I-ORG
Protein NNP - I-ORG
( PUNCT - O
PBP NNP - B-ORG
) PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Rifampin PROPN - O
- PUNCT - O
Isoniazid NNP - B-MEDICINE
- PUNCT - O
Containing PROPN - O
Antituberculosis PROPN - O
Therapy PROPN - O
on ADP - O
Efavirenz PROPN - O
Pharmacokinetics PROPN - O
in ADP - O
HIV PROPN - O
- PUNCT - O
Infected PROPN - O
Children NOUN - O
3 NUM - O
to ADP - O
14 NUM - O
Years NOUN - O
Old PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Delayed VBN - B-ORG
Sputum NNP - I-ORG
Culture NN - I-ORG
Conversion NNP - I-ORG
in ADP - O
Tuberculosis PROPN - O
- PUNCT - O
Human PROPN - O
Immunodeficiency PROPN - O
Virus PROPN - O
- PUNCT - O
Coinfected VERB - O
Patients NOUN - O
With ADP - O
Low PROPN - O
Isoniazid NNP - B-MEDICINE
and CCONJ - O
Rifampicin NNP - B-ORG
Concentrations NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
- PUNCT - O
induced VERB - O
subacute NOUN - O
cutaneous ADJ - O
lupus NOUN - O
erythematosus NOUN - O
in ADP - O
an DET - O
HIV PROPN - O
- PUNCT - O
positive ADJ - O
woman NOUN - O
: PUNCT - O
a DET - O
rare ADJ - O
side NOUN - O
effect NOUN - O
to PART - O
be VERB - O
aware ADJ - O
of ADP - O
with ADP - O
the DET - O
current ADJ - O
expansion NOUN - O
of ADP - O
isoniazid NN - B-MEDICINE
preventive ADJ - O
therapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
( PUNCT - O
INH NNP - B-ORG
) PUNCT - O
is VERB - O
a DET - O
well ADV - O
- PUNCT - O
known VERB - O
therapeutic ADJ - O
and CCONJ - O
preventive ADJ - O
agent NOUN - O
against ADP - O
tuberculosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
- PUNCT - O
induced VERB - O
hepatotoxicity NOUN - O
and CCONJ - O
neurotoxicity NOUN - O
in ADP - O
rats NOUN - O
investigated VERB - O
by ADP - O
1H NNP - B-ORG
NMR NNP - I-ORG
based VERB - O
metabolomics NOUN - O
approach VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
, PUNCT - O
rifampin NOUN - O
, PUNCT - O
pyrazinamide NOUN - O
, PUNCT - O
and CCONJ - O
ethambutol VERB - O
for ADP - O
the DET - O
initial ADJ - O
two CD - B-DATE
- HYPH - I-DATE
month NN - I-DATE
phase NOUN - O
followed VERB - O
by ADP - O
isoniazid NN - B-MEDICINE
and CCONJ - O
rifampin VERB - O
for ADP - O
4 CD - B-DATE
to TO - I-DATE
7 CD - I-DATE
months NNS - I-DATE
is VERB - O
standard ADJ - O
treatment NOUN - O
for ADP - O
people NOUN - O
at ADP - O
low ADJ - O
risk NOUN - O
for ADP - O
drug NOUN - O
- PUNCT - O
resistant ADJ - O
disease NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
0.5- NUM - O
and CCONJ - O
6.0-mg NNP - B-ORG
/ SYM - I-ORG
mL NNS - I-ORG
solutions NOUN - O
in ADP - O
0.9 CD - B-PERCENT
% NN - I-PERCENT
sodium NOUN - O
chloride NOUN - O
injection NOUN - O
were VERB - O
stable ADJ - O
for ADP - O
up IN - B-TIME
to TO - I-TIME
72 CD - I-TIME
hours NNS - I-TIME
at ADP - O
room NOUN - O
temperature NOUN - O
or CCONJ - O
under ADP - O
refrigeration NOUN - O
. PUNCT - O

Isoniazid NNP - B-MEDICINE
6.0-mg PROPN - O
/ SYM - O
mL PROPN - O
solutions NOUN - O
in ADP - O
5 CD - B-PERCENT
% NN - I-PERCENT
dextrose NOUN - O
injection NOUN - O
were VERB - O
stable ADJ - O
for ADP - O
24 CD - B-TIME
hours NNS - I-TIME
at ADP - O
room NOUN - O
temperature NOUN - O
and CCONJ - O
for ADP - O
48 CD - B-TIME
hours NNS - I-TIME
under ADP - O
refrigeration NOUN - O
. PUNCT - O

Isoniazid NN - B-MEDICINE
solutions NOUN - O
of ADP - O
0.5 CD - B-CARDINAL
and CCONJ - O
6.0 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
mL PROPN - O
in ADP - O
0.9 CD - B-PERCENT
% NN - I-PERCENT
sodium NOUN - O
chloride NOUN - O
injection NOUN - O
were VERB - O
stable ADJ - O
under ADP - O
light ADJ - O
protection NOUN - O
for ADP - O
up IN - B-TIME
to TO - I-TIME
72 CD - I-TIME
hours NNS - I-TIME
when ADV - O
stored VERB - O
at ADP - O
room NOUN - O
temperature NOUN - O
or CCONJ - O
under ADP - O
refrigeration NOUN - O
. PUNCT - O

Isoniazid NNP - B-MEDICINE
injection NOUN - O
was VERB - O
less ADV - O
stable ADJ - O
in ADP - O
5 CD - B-PERCENT
% NN - I-PERCENT
dextrose NOUN - O
injection NOUN - O
, PUNCT - O
especially ADV - O
at ADP - O
a DET - O
concentration NOUN - O
of ADP - O
0.5 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
mL X - O
at ADP - O
room NOUN - O
temperature NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
report VERB - O
herein NOUN - O
that ADP - O
under ADP - O
our ADJ - O
experimental ADJ - O
conditions NOUN - O
, PUNCT - O
TCH NNP - B-ORG
inhibits VERB - O
M. NNP - B-PERSON
tuberculosis NOUN - O
in ADP - O
solid ADJ - O
but CCONJ - O
not ADV - O
in ADP - O
liquid ADJ - O
medium NOUN - O
, PUNCT - O
and CCONJ - O
that ADP - O
in ADP - O
spite NOUN - O
of ADP - O
resembling VERB - O
Isoniazid NNP - B-MEDICINE
and CC - I-WORK_OF_ART
Ethionamide NNP - B-ORG
, PUNCT - O
it PRON - O
does VERB - O
not ADV - O
affect VERB - O
mycolic NOUN - O
acid NOUN - O
synthesis NOUN - O
. PUNCT - O

To PART - O
understand VERB - O
the DET - O
mechanisms NOUN - O
of ADP - O
action NOUN - O
of ADP - O
TCH PROPN - O
we PRON - O
isolated VERB - O
M. NNP - B-PERSON
tuberculosis NOUN - O
TCH NNP - B-ORG
resistant ADJ - O
mutants NOUN - O
which ADJ - O
fell VERB - O
into ADP - O
two CD - B-CARDINAL
groups NOUN - O
; PUNCT - O
one CD - B-CARDINAL
resistant ADJ - O
to ADP - O
TCH NNP - B-ORG
and CCONJ - O
Isoniazid NNP - B-MEDICINE
but CCONJ - O
not ADV - O
to ADP - O
Ethionamide NNP - B-ORG
or CCONJ - O
Triclosan NNP - B-GPE
, PUNCT - O
and CCONJ - O
the DET - O
other ADJ - O
resistant ADJ - O
only ADV - O
to ADP - O
TCH PROPN - O
with ADP - O
no DET - O
, PUNCT - O
or CCONJ - O
marginal ADJ - O
, PUNCT - O
cross VERB - O
resistance NOUN - O
to ADP - O
Isoniazid NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
katG NOUN - O
S315 NNP - B-PERSON
T PROPN - O
or CCONJ - O
an DET - O
ahpC ADJ - O
promoter NOUN - O
mutation NOUN - O
mediate NOUN - O
Mycobacterium NNP - B-PERSON
tuberculosis NOUN - O
resistance NOUN - O
to ADP - O
2-thiophen CD - B-GPE
carboxylic NN - I-GPE
acid NOUN - O
hydrazide NOUN - O
, PUNCT - O
an DET - O
inhibitor NOUN - O
resembling VERB - O
the DET - O
anti ADJ - O
- ADJ - O
tubercular ADJ - O
drugs NOUN - O
Isoniazid NNP - B-MEDICINE
and CCONJ - O
Ethionamide NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NN - B-MEDICINE
- PUNCT - O
loaded VERB - O
orodispersible ADJ - O
strips NOUN - O
: PUNCT - O
Methodical ADJ - O
design NOUN - O
, PUNCT - O
optimization NOUN - O
and CCONJ - O
in ADP - O
vitro NOUN - O
- PUNCT - O
in PART - O
silico ADJ - O
characterization NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
Pharmacokinetics NNP - I-ORG
in ADP - O
the DET - O
Presence PROPN - O
of ADP - O
Ofloxacin PROPN - O
and CCONJ - O
Norfloxacin NNP - B-ORG
Antibiotics NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Pharmacokinetics NOUN - O
of ADP - O
Isoniazid NNP - B-MEDICINE
- PUNCT - O
induced VERB - O
Rhabdomyolysis PROPN - O
in ADP - O
a DET - O
Girl NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Using VBG - B-ORG
Video NNP - I-ORG
Technology NNP - I-ORG
to TO - I-ORG
Increase VB - I-ORG
Treatment NNP - I-ORG
Completion NN - I-ORG
for IN - I-ORG
Patients NNPS - I-ORG
With IN - I-ORG
Latent NNP - I-ORG
Tuberculosis NNP - I-ORG
Infection NNP - I-ORG
on ADP - O
3-Month PROPN - O
Isoniazid NNP - B-MEDICINE
and CCONJ - O
Rifapentine NNP - B-GPE
: PUNCT - O
An DT - B-WORK_OF_ART
Implementation NNP - I-WORK_OF_ART
Study NNP - I-WORK_OF_ART
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
basic ADJ - O
treatment NOUN - O
scheme NOUN - O
was VERB - O
based VERB - O
on ADP - O
Ethambutol NNP - B-ORG
, PUNCT - O
Rifampicin NNP - B-ORG
, PUNCT - O
Pyrazinamide NNP - B-ORG
, PUNCT - O
and CCONJ - O
Isoniazid NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
( PUNCT - O
INH NNP - B-ORG
) PUNCT - O
and CCONJ - O
ethambutol VERB - O
( PUNCT - O
EMB NNP - B-ORG
) PUNCT - O
are VERB - O
two CD - B-CARDINAL
major ADJ - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
drugs NOUN - O
for ADP - O
managing VERB - O
tuberculosis NOUN - O
( PUNCT - O
TB PROPN - O
) PUNCT - O
, PUNCT - O
caused VERB - O
by ADP - O
the DET - O
microbe NOUN - O
Mycobacterium PROPN - O
tuberculosis NOUN - O
Although ADP - O
co NOUN - O
- NOUN - O
use NOUN - O
of ADP - O
these DET - O
two CD - B-CARDINAL
drugs NOUN - O
is VERB - O
common ADJ - O
in ADP - O
clinical ADJ - O
practice NOUN - O
, PUNCT - O
the DET - O
mechanism NOUN - O
for ADP - O
the DET - O
potential ADJ - O
synergistic ADJ - O
interplay NOUN - O
between ADP - O
them PRON - O
remains VERB - O
unclear ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Fifty CD - B-PERCENT
- HYPH - I-PERCENT
nine CD - I-PERCENT
percent NN - I-PERCENT
isolates NOUN - O
were VERB - O
sensitive ADJ - O
to ADP - O
all DET - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
drugs NOUN - O
( PUNCT - O
Isoniazid NNP - B-MEDICINE
, PUNCT - O
rifampicin NOUN - O
, PUNCT - O
pyrazinamide NOUN - O
, PUNCT - O
ethambutol VERB - O
and CCONJ - O
streptomycin NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
( PUNCT - O
INH NNP - B-ORG
) PUNCT - O
is VERB - O
still ADV - O
the DET - O
most ADV - O
important ADJ - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
antitubercular ADJ - O
drug NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Isoniazid NNP - B-MEDICINE
resistance NOUN - O
showed VERB - O
a DET - O
sensitivity NOUN - O
of ADP - O
90.2 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
specificity NOUN - O
of ADP - O
93.9 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
positive ADJ - O
predictive ADJ - O
value NOUN - O
of ADP - O
91.1 CD - B-PERCENT
% NN - I-PERCENT
and CCONJ - O
negative ADJ - O
predictive ADJ - O
value NOUN - O
of ADP - O
93.3 CD - B-PERCENT
% NN - I-PERCENT
. PUNCT - O

-DOCSTART- -X- - O

Development NOUN - O
of ADP - O
Floating VERB - O
Delivery NOUN - O
for ADP - O
Solid PROPN - O
Self PROPN - O
Micro PROPN - O
- PUNCT - O
Emulsifying PROPN - O
Drug PROPN - O
Delivery PROPN - O
System PROPN - O
of ADP - O
Prochlorperazine NNP - B-MEDICINE
Maleate NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Doxorubicin NNP - B-PERSON
Hydrochloride NNP - I-PERSON
- HYPH - I-PERSON
Loaded VBN - I-PERSON

-DOCSTART- -X- - O

Gels NNS - B-PERSON
as ADP - O
an DET - O
Excellent PROPN - O
Platform NOUN - O
Loaded VERB - O
with ADP - O
Doxorubicin NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
for ADP - O
pH PROPN - O
- PUNCT - O
Triggered PROPN - O
Drug PROPN - O
Release PROPN - O
and CCONJ - O
Anticancer PROPN - O
Effect PROPN - O

-DOCSTART- -X- - O

Gels NNS - B-PERSON
as ADP - O
an DET - O
Excellent PROPN - O
Platform NOUN - O
Loaded VERB - O
with ADP - O
Doxorubicin NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
for ADP - O
pH PROPN - O
- PUNCT - O
Triggered PROPN - O
Drug PROPN - O
Release PROPN - O
and CCONJ - O
Anticancer NNP - B-ORG
Effect NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Cutaneous NNP - B-ORG
Toxicity NNP - I-ORG
in IN - I-ORG
a DT - I-ORG
Laboratory NNP - I-ORG
Beagle NNP - I-ORG
( PUNCT - O
Canis PROPN - O
lupus NOUN - O
familiaris NOUN - O
) PUNCT - O
after ADP - O
Chronic NNP - B-ORG
Administration NNP - I-ORG
of IN - I-ORG
Doxorubicin NNP - I-ORG
Hydrochloride NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Unveiling PROPN - O
the DET - O
Aggregation PROPN - O
Behavior PROPN - O
of ADP - O
Doxorubicin NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
in ADP - O
Aqueous PROPN - O
Solution PROPN - O
of ADP - O
1-Octyl-3-methylimidazolium PROPN - O
Chloride PROPN - O
and CCONJ - O
the DT - B-ORG
Effect NNP - I-ORG
of IN - I-ORG
Bile NNP - I-ORG
Salt NNP - I-ORG
on IN - I-ORG
These DT - I-ORG
Aggregates NNPS - I-ORG
: PUNCT - O
A DET - O
Microscopic PROPN - O
Study PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Chemical NNP - B-ORG
Binding NNP - I-ORG
of ADP - O
Doxorubicin NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
to ADP - O
Gold PROPN - O
Nanoparticles PROPN - O
, PUNCT - O
Versus NNP - B-ORG
Electrostatic NNP - I-ORG
Adsorption NNP - I-ORG
, PUNCT - O
on ADP - O
the DET - O
In PROPN - O
Vitro NNP - B-PRODUCT
Drug NNP - I-PRODUCT
Release NNP - I-PRODUCT
and CCONJ - O
Cytotoxicity PROPN - O
to ADP - O
Breast PROPN - O
Cancer NNP - B-GPE
Cells NNPS - I-GPE
. PUNCT - O

-DOCSTART- -X- - O

Click VERB - O
Biotinylation PROPN - O
of ADP - O
PLGA PROPN - O
Template PROPN - O
for ADP - O
Biotin PROPN - O
Receptor PROPN - O
Oriented PROPN - O
Delivery NOUN - O
of ADP - O
Doxorubicin NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
in ADP - O
4T1 NNP - B-CARDINAL
Cell NNP - B-ORG
- HYPH - I-ORG
Induced NNP - I-ORG
Breast NNP - I-ORG
Cancer NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Doxorubicin NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
Loaded VERB - O
Zymosan NNP - B-ORG
- HYPH - I-ORG
Polyethylenimine NNP - I-ORG
Biopolymeric NNP - I-ORG
Nanoparticles NNP - I-ORG
for ADP - O
Dual PROPN - O
' PUNCT - O
Chemoimmunotherapeutic ADJ - O
' PUNCT - O
Intervention NOUN - O
in ADP - O
Breast PROPN - O
Cancer PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Rational PROPN - O
Design PROPN - O
of ADP - O
Metal PROPN - O
Organic PROPN - O
Framework PROPN - O
Nanocarrier PROPN - O
- PUNCT - O
Based PROPN - O
Codelivery PROPN - O
System PROPN - O
of ADP - O
Doxorubicin NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
/ SYM - O
Verapamil PROPN - O
Hydrochloride PROPN - O
for ADP - O
Overcoming PROPN - O
Multidrug PROPN - O
Resistance PROPN - O
with ADP - O
Efficient PROPN - O
Targeted PROPN - O
Cancer PROPN - O
Therapy PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Photocontrollable NNP - B-PERSON
Intermittent NNP - I-PERSON
Release NNP - I-PERSON
of ADP - O
Doxorubicin NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
from ADP - O
Liposomes PROPN - O
Embedded VERB - O
by ADP - O
Azobenzene NNP - B-PERSON
- HYPH - I-PERSON
Contained NNP - I-PERSON
Glycolipid NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Biodegradable NNP - B-PERSON
Polymersomes NNP - I-PERSON
as ADP - O
Nanocarriers NNPS - B-PERSON
for ADP - O
Doxorubicin NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
: PUNCT - O

-DOCSTART- -X- - O

Doxorubicin NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
- PUNCT - O
Loaded VERB - O
Mesoporous PROPN - O
Silica PROPN - O
Nanoparticles PROPN - O
Inhibit PROPN - O
Non PROPN - O
- PROPN - O
Small PROPN - O
Cell PROPN - O
Lung PROPN - O
Cancer PROPN - O
Metastasis PROPN - O
by ADP - O
Suppressing VERB - O
VEGF PROPN - O
- PUNCT - O
Mediated PROPN - O
Angiogenesis PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Chemical NNP - B-ORG
and CCONJ - O
Physical PROPN - O
Characteristics PROPN - O
of ADP - O
Doxorubicin NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
Drug PROPN - O
- PUNCT - O
Doped PROPN - O
Salmon PROPN - O
DNA NOUN - O
Thin PROPN - O
Films PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
Situ PROPN - O
Lipidization PROPN - O
as ADP - O
a DET - O
New PROPN - O
Approach PROPN - O
for ADP - O
the DET - O
Design PROPN - O
of ADP - O
a DET - O
Self PROPN - O
Microemulsifying PROPN - O
Drug NOUN - O
Delivery PROPN - O
System PROPN - O
( PUNCT - O
SMEDDS PROPN - O
) PUNCT - O
of ADP - O
Doxorubicin NNP - B-ORG
Hydrochloride NNP - I-ORG
for IN - I-ORG
Oral NNP - I-ORG
Administration NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Hybrid NNP - B-PERSON
Vesicles NNPS - I-PERSON
for ADP - O
Tumoral NNP - B-ORG
pH PROPN - O
- PUNCT - O
Triggered PROPN - O
Intracellular ADJ - O
Delivery NOUN - O
of ADP - O
Doxorubicin NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Adsorption PROPN - O
Properties PROPN - O
of ADP - O
Doxorubicin NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
onto ADP - O
Graphene PROPN - O
Oxide PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

Herein NNP - B-PERSON
, PUNCT - O
a DET - O
succinct ADJ - O
strategy NOUN - O
was VERB - O
proposed VERB - O
for ADP - O
the DET - O
preparation NOUN - O
of ADP - O
targeted ADJ - O
lignin NOUN - O
- PUNCT - O
based VERB - O
drug NOUN - O
delivery NOUN - O
NPs NOUN - O
to PART - O
load VERB - O
Doxorubicin NNP - B-PERSON
Hydrochloride NNP - I-PERSON
( PUNCT - O
DOX PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
successfully ADV - O
co VERB - O
- ADJ - O
encapsulated VERB - O
Doxorubicin NNP - B-PERSON
Hydrochloride NNP - I-PERSON
, PUNCT - O
Docetaxel NNP - B-ORG
, PUNCT - O
and CCONJ - O
contrast NOUN - O
agents NOUN - O
and CCONJ - O
achieved VERB - O
a DET - O
significantly ADV - O
higher ADJ - O
concomitant ADJ - O
accumulation NOUN - O
in ADP - O
tumor NOUN - O
versus ADP - O
free ADJ - O
drugs NOUN - O
, PUNCT - O
demonstrating VERB - O
that ADP - O
nanoparticles NOUN - O
can VERB - O
improve VERB - O
synergistic ADJ - O
cancer NOUN - O
chemotherapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
patient NOUN - O
began VERB - O
chemotherapy NOUN - O
with ADP - O
the DET - O
intravenous ADJ - O
drip NOUN - O
infusion NOUN - O
of ADP - O
Doxorubicin NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
Liposome PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Development NOUN - O
of ADP - O
smart ADJ - O
hydrogels NOUN - O
of ADP - O
etherified ADJ - O
gum NOUN - O
ghatti NOUN - O
for ADP - O
sustained ADJ - O
oral ADJ - O
delivery NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
four CD - B-CARDINAL
- PUNCT - O
step NOUN - O
, PUNCT - O
three CD - B-CARDINAL
- PUNCT - O
stage NOUN - O
synthesis NOUN - O
of ADP - O
the DET - O
API NN - B-ORG
ropinirole NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
has VERB - O
been VERB - O
developed VERB - O
from ADP - O
a DET - O
commercially ADV - O
available ADJ - O
naphthalene NOUN - O
derivative NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
development NOUN - O
of ADP - O
a DET - O
short ADJ - O
route NOUN - O
to ADP - O
the DET - O
API NN - B-ORG
ropinirole NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
the DET - O
current ADJ - O
study NOUN - O
, PUNCT - O
the DET - O
ex X - O
vivo NOUN - O
permeation NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
( PUNCT - O
RH NNP - B-ORG
) PUNCT - O
across ADP - O
porcine ADJ - O
buccal ADJ - O
mucosa NOUN - O
in ADP - O
the DET - O
presence NOUN - O
of ADP - O
three CD - B-CARDINAL
permeation NOUN - O
enhancers NOUN - O
, PUNCT - O
namely ADV - O
N NOUN - O
- PUNCT - O
trimethyl ADV - O
chitosan ADJ - O
( PUNCT - O
TMC NNP - B-ORG
) PUNCT - O
( PUNCT - O
positively ADV - O
charged VERB - O
) PUNCT - O
a DET - O
chitosan ADJ - O
derivative ADJ - O
, PUNCT - O
sulfobutyl NOUN - O
ether NOUN - O
- PUNCT - O
β PROPN - O
- PUNCT - O
cyclodextrin PROPN - O
( PUNCT - O
SBE PROPN - O
- PUNCT - O
β PROPN - O
- PUNCT - O
CD NOUN - O
) PUNCT - O
( PUNCT - O
negatively ADV - O
charged VERB - O
) PUNCT - O
and CCONJ - O
hydroxypropyl ADJ - O
- PUNCT - O
β DET - O
- PUNCT - O
cyclodextrin PROPN - O
( PUNCT - O
HP PROPN - O
- PUNCT - O
β PROPN - O
- PUNCT - O
CD NOUN - O
) PUNCT - O
( PUNCT - O
neutral ADJ - O
) PUNCT - O
, PUNCT - O
was VERB - O
investigated VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Ex PROPN - O
vivo NOUN - O
buccal ADJ - O
drug NOUN - O
delivery NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
in ADP - O
the DET - O
presence NOUN - O
of ADP - O
permeation NOUN - O
enhancers NOUN - O
: PUNCT - O
the DET - O
effect NOUN - O
of ADP - O
charge NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
the DET - O
present ADJ - O
study NOUN - O
we PRON - O
investigated VERB - O
polymer NOUN - O
- PUNCT - O
lipid ADJ - O
microparticles NOUN - O
loaded VERB - O
with ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
( PUNCT - O
RH NNP - B-ORG
) PUNCT - O
for ADP - O
nasal NOUN - O
delivery NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

PLGA NOUN - O
/ SYM - O
DPPC NOUN - O
/ SYM - O
trimethylchitosan ADJ - O
spray NOUN - O
- PUNCT - O
dried VERB - O
microparticles NOUN - O
for ADP - O
the DET - O
nasal ADJ - O
delivery NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
: PUNCT - O
in ADP - O
vitro NOUN - O
, PUNCT - O
ex X - O
vivo NOUN - O
and CCONJ - O
cytocompatibility NOUN - O
assessment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
present ADJ - O
study NOUN - O
focuses VERB - O
on ADP - O
the DET - O
formulation NOUN - O
of ADP - O
ethosomal ADJ - O
gel NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
( PUNCT - O
ropinirole ADJ - O
HCl NOUN - O
) PUNCT - O
, PUNCT - O
an DET - O
anti JJ - B-NORP
- JJ - I-NORP
Parkinsonian JJ - I-NORP
drug NOUN - O
, PUNCT - O
for ADP - O
delivery NOUN - O
as ADP - O
a DET - O
carrier NOUN - O
for ADP - O
transdermal ADJ - O
application NOUN - O
. PUNCT - O

From ADP - O
the DET - O
results NOUN - O
it PRON - O
can VERB - O
fairly ADV - O
be VERB - O
concluded VERB - O
that ADP - O
ethosomes NOUN - O
are VERB - O
capable ADJ - O
of ADP - O
delivering VERB - O
ropinirole NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
into ADP - O
systemic ADJ - O
circulation NOUN - O
by ADP - O
transdermal ADJ - O
route NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Formulation NOUN - O
and CCONJ - O
optimization NOUN - O
of ADP - O
ethosomes NOUN - O
for ADP - O
transdermal ADJ - O
delivery NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
objective NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
investigate VERB - O
the DET - O
effect NOUN - O
of ADP - O
modulated VERB - O
current ADJ - O
application NOUN - O
using VERB - O
iontophoresis- NOUN - O
and CCONJ - O
microneedle NOUN - O
- PUNCT - O
mediated VERB - O
delivery NOUN - O
on ADP - O
transdermal ADJ - O
permeation NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
. PUNCT - O

Combination NOUN - O
of ADP - O
modulated VERB - O
iontophoresis NOUN - O
and CCONJ - O
microneedles NOUN - O
( PUNCT - O
46.50 CD - B-CARDINAL
± PUNCT - O
6.46 CD - B-CARDINAL
µg NOUN - O
/ SYM - O
cm(2 PROPN - O
) PUNCT - O
) PUNCT - O
showed VERB - O
significantly ADV - O
higher ADJ - O
delivery NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
compared VERB - O
to ADP - O
modulated VERB - O
iontophoresis NOUN - O
alone ADV - O
( PUNCT - O
84.91 CD - B-CARDINAL
± PUNCT - O
9.21 CD - B-CARDINAL
µg NOUN - O
/ SYM - O
cm(2 PROPN - O
) PUNCT - O
) PUNCT - O
. PUNCT - O

Modulated VERB - O
iontophoresis NOUN - O
can VERB - O
help VERB - O
in ADP - O
maintaining VERB - O
precise ADJ - O
control NOUN - O
over ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
delivery NOUN - O
for ADP - O
dose NOUN - O
titration NOUN - O
in ADP - O
Parkinson NNP - B-ORG
's PART - O
disease NOUN - O
therapy NOUN - O
and CCONJ - O
deliver VERB - O
therapeutic ADJ - O
amounts NOUN - O
over ADP - O
a DET - O
suitable ADJ - O
patch NOUN - O
area NOUN - O
and CCONJ - O
time NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Controlled VERB - O
delivery NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
through ADP - O
skin NOUN - O
using VERB - O
modulated VERB - O
iontophoresis NOUN - O
and CCONJ - O
microneedles NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
invention NOUN - O
is VERB - O
directed VERB - O
to ADP - O
a DET - O
process NOUN - O
for ADP - O
the DET - O
preparation NOUN - O
of ADP - O
pure ADJ - O
ropinirole NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
with ADP - O
purity NOUN - O
of ADP - O
equal ADJ - O
to ADP - O
or CCONJ - O
greater JJR - B-PERCENT
than IN - I-PERCENT
99.8 CD - I-PERCENT
% NN - I-PERCENT
and CCONJ - O
less ADJ - O
than ADP - O
0.1 CD - B-PERCENT
% NN - I-PERCENT
isatine ADJ - O
impurity NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fabrication NOUN - O
and CCONJ - O
statistical ADJ - O
optimization NOUN - O
of ADP - O
surface NOUN - O
engineered VERB - O
PLGA NN - B-ORG
nanoparticles NOUN - O
for ADP - O
naso NOUN - O
- PUNCT - O
brain NOUN - O
delivery NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
: PUNCT - O
in ADP - O
- PUNCT - O
vitro X - O
- PUNCT - O
ex NOUN - O
- PUNCT - O
vivo NOUN - O
studies NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

An DET - O
emulsion NOUN - O
solvent NOUN - O
evaporation NOUN - O
method NOUN - O
was VERB - O
employed VERB - O
to PART - O
prepare VERB - O
microspheres NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
, PUNCT - O
a DET - O
highly ADV - O
water NOUN - O
soluble ADJ - O
drug NOUN - O
, PUNCT - O
by ADP - O
using VERB - O
ethylcellulose NOUN - O
and CCONJ - O
PEG PROPN - O
with ADP - O
the DET - O
help NOUN - O
of ADP - O
32 CD - B-CARDINAL
full ADJ - O
factorial ADJ - O
design NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Sustained ADJ - O
release NOUN - O
microspheres NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
: PUNCT - O
effect NOUN - O
of ADP - O
process NOUN - O
parameters NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
simple ADJ - O
, PUNCT - O
sensitive ADJ - O
, PUNCT - O
rapid ADJ - O
, PUNCT - O
accurate ADJ - O
and CCONJ - O
precise ADJ - O
spectrophotometric ADJ - O
method NOUN - O
has VERB - O
been VERB - O
developed VERB - O
for ADP - O
estimation NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
in ADP - O
bulk NOUN - O
and CCONJ - O
tablet NOUN - O
dosage NOUN - O
forms NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Spectrophotometric ADJ - O
estimation NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
in ADP - O
tablets NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Present ADJ - O
investigation NOUN - O
deals NOUN - O
with ADP - O
intranasal NOUN - O
delivery NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
( PUNCT - O
ROPI PROPN - O
HCl NOUN - O
) PUNCT - O
, PUNCT - O
loaded VERB - O
in ADP - O
solid ADJ - O
lipid ADJ - O
nanoparticles NOUN - O
( PUNCT - O
SLNs NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Novel ADJ - O
surface NOUN - O
modified VERB - O
solid ADJ - O
lipid ADJ - O
nanoparticles NOUN - O
as ADP - O
intranasal NOUN - O
carriers NOUN - O
for ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
: PUNCT - O
application NOUN - O
of ADP - O
factorial ADJ - O
design NOUN - O
approach NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
invention NOUN - O
relates VERB - O
to ADP - O
a DET - O
method NOUN - O
for ADP - O
preparing VERB - O
ropinirole NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
, PUNCT - O
comprising VERB - O
the DET - O
followings NOUN - O
in ADP - O
turn NOUN - O
: PUNCT - O
( PUNCT - O
1 LS - B-CARDINAL
) PUNCT - O
beta NOUN - O
- PUNCT - O
phenylethyl NOUN - O
alcohol NOUN - O
reacts VERB - O
with ADP - O
paraformaldehyde NOUN - O
to PART - O
produce VERB - O
isochroman NOUN - O
( PUNCT - O
2 LS - B-CARDINAL
) PUNCT - O
the DET - O
product NOUN - O
obtained VERB - O
in ADP - O
step NOUN - O
( PUNCT - O
1 CD - B-CARDINAL
) PUNCT - O
reacts VERB - O
with ADP - O
bromide NOUN - O
to PART - O
produce VERB - O
2-bromoethyl CD - B-CARDINAL
benzaldehyde NOUN - O
( PUNCT - O
3 LS - B-CARDINAL
) PUNCT - O
the DET - O
product NOUN - O
obtained VERB - O
in ADP - O
step NOUN - O
( PUNCT - O
2 LS - B-CARDINAL
) PUNCT - O
reacts VERB - O
with ADP - O
nitromethane NOUN - O
to PART - O
produce VERB - O
2-bromoethyl CD - B-CARDINAL
nitrostyrolene NOUN - O
( PUNCT - O
4 CD - B-CARDINAL
) PUNCT - O
the DET - O
product NOUN - O
obtained VERB - O
in ADP - O
step NOUN - O
( PUNCT - O
3 LS - B-CARDINAL
) PUNCT - O
reacts VERB - O
with ADP - O
acetyl ADJ - O
chloride NOUN - O
to PART - O
produce VERB - O
4-bromoethyl-3-chloride-1 NUM - O
, PUNCT - O
3-dihydro-2H NUM - O
- PUNCT - O
indole-2-ketone NOUN - O
( PUNCT - O
5 CD - B-CARDINAL
) PUNCT - O
4-bromoethyl-1 NUM - O
, PUNCT - O
3- LS - B-CARDINAL

the DET - O
product NOUN - O
obtained VERB - O
in ADP - O
step NOUN - O
( PUNCT - O
7 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O
di X - O
- PUNCT - O
n NOUN - O
- PUNCT - O
propylamine NOUN - O
undergo NOUN - O
reflux NOUN - O
reaction NOUN - O
in ADP - O
water NOUN - O
and CCONJ - O
pH NOUN - O
value NOUN - O
is VERB - O
regulated VERB - O
by ADP - O
hydrochloric ADJ - O
acid NOUN - O
to ADP - O
1 CD - B-CARDINAL
- SYM - O
2 NUM - O
to PART - O
obtain VERB - O
the DET - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Preparation NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE

-DOCSTART- -X- - O

Here ADV - O
we PRON - O
report VERB - O
fabrication NOUN - O
and CCONJ - O
evaluation NOUN - O
of ADP - O
novel ADJ - O
surface NOUN - O
modified VERB - O
polymer NOUN - O
- PUNCT - O
lipid ADJ - O
hybrid ADJ - O
nanoparticles NOUN - O
( PUNCT - O
PLN PROPN - O
) PUNCT - O
as ADP - O
robust ADJ - O
carriers NOUN - O
for ADP - O
intranasal NOUN - O
delivery NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
( PUNCT - O
ROPI PROPN - O
HCl NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Novel ADJ - O
surface NOUN - O
modified VERB - O
polymer NOUN - O
- PUNCT - O
lipid ADJ - O
hybrid ADJ - O
nanoparticles NOUN - O
as ADP - O
intranasal NOUN - O
carriers NOUN - O
for ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
: PUNCT - O
in ADP - O
vitro NOUN - O
, PUNCT - O
ex X - O
vivo NOUN - O
and CCONJ - O
in ADP - O
vivo NOUN - O
pharmacodynamic ADJ - O
evaluation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
purpose NOUN - O
of ADP - O
the DET - O
present ADJ - O
study NOUN - O
was VERB - O
to PART - O
control VERB - O
in ADP - O
vitro X - O
burst VERB - O
effect NOUN - O
of ADP - O
the DET - O
highly ADV - O
water NOUN - O
- PUNCT - O
soluble ADJ - O
drug NOUN - O
, PUNCT - O
ropinirole NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
to PART - O
reduce VERB - O
in ADP - O
vivo NOUN - O
dose VERB - O
dumping VERB - O
and CCONJ - O
to PART - O
establish VERB - O
in ADP - O
vitro X - O
- PUNCT - O
in PART - O
vivo NOUN - O
correlation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Controlled VERB - O
release NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
from ADP - O
a DET - O
multiple ADJ - O
barrier NOUN - O
layer NOUN - O
tablet NOUN - O
dosage NOUN - O
form NOUN - O
: PUNCT - O
effect NOUN - O
of ADP - O
polymer NOUN - O
type NOUN - O
on ADP - O
pharmacokinetics NOUN - O
and CCONJ - O
IVIVC NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
was VERB - O
conducted VERB - O
to PART - O
evaluate VERB - O
the DET - O
steady ADJ - O
- PUNCT - O
state NOUN - O
pharmacokinetics NOUN - O
, PUNCT - O
safety NOUN - O
and CCONJ - O
efficacy NOUN - O
after ADP - O
repeated VERB - O
oral ADJ - O
administration NOUN - O
of ADP - O
prolonged VERB - O
- PUNCT - O
release NOUN - O
tablets NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
in ADP - O
the DET - O
absence NOUN - O
of ADP - O
L NOUN - O
- PUNCT - O
dopa NOUN - O
preparations NOUN - O
in ADP - O
Japanese JJ - B-NORP
patients NOUN - O
with ADP - O
Parkinson PROPN - O
's PART - O
disease NOUN - O
( PUNCT - O
PD PROPN - O
) PUNCT - O
. PUNCT - O

After ADP - O
repeated VERB - O
oral ADJ - O
administration NOUN - O
of ADP - O
prolonged VERB - O
- PUNCT - O
release NOUN - O
tablets NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
in ADP - O
Japanese JJ - B-NORP
patients NOUN - O
with ADP - O
PD PROPN - O
, PUNCT - O
ropinirole NOUN - O
, PUNCT - O
SK&F104557 NNP - B-GPE
and CCONJ - O
low ADJ - O
levels NOUN - O
of ADP - O
SK&F89124 PROPN - O
were VERB - O
detected VERB - O
in ADP - O
plasma NOUN - O
. PUNCT - O

The DET - O
trough ADJ - O
concentrations NOUN - O
of ADP - O
ropinirole NOUN - O
and CCONJ - O
the DET - O
two CD - B-CARDINAL
metabolites NOUN - O
increased VERB - O
in ADP - O
proportion NOUN - O
to ADP - O
the DET - O
dose NOUN - O
when ADV - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
prolonged VERB - O
- PUNCT - O
release NOUN - O
tablets NOUN - O
were VERB - O
administered VERB - O
at ADP - O
doses NOUN - O
ranging VERB - O
from ADP - O
2 CD - B-CARDINAL
to ADP - O
16 CD - B-DATE
mg NNS - I-DATE
/ SYM - I-DATE
day NN - I-DATE
. PUNCT - O

After ADP - O
administration NOUN - O
of ADP - O
prolonged VERB - O
- PUNCT - O
release NOUN - O
tablets NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
in ADP - O
the DET - O
absence NOUN - O
of ADP - O
L NOUN - O
- PUNCT - O
dopa NOUN - O
preparations NOUN - O
in ADP - O
Japanese JJ - B-NORP
patients NOUN - O
with ADP - O
PD NNP - B-ORG
, PUNCT - O
the DET - O
plasma NOUN - O
pharmacokinetics NOUN - O
of ADP - O
ropinirole NOUN - O
and CCONJ - O
its ADJ - O
metabolites NOUN - O
was VERB - O
linear ADJ - O
and CCONJ - O
not ADV - O
affected VERB - O
by ADP - O
food NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pharmacokinetics NOUN - O
and CCONJ - O
effect NOUN - O
of ADP - O
food NOUN - O
after ADP - O
oral ADJ - O
administration NOUN - O
of ADP - O
prolonged VERB - O
- PUNCT - O
release NOUN - O
tablets NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
in ADP - O
Japanese JJ - B-NORP
patients NOUN - O
with ADP - O
Parkinson PROPN - O
's PART - O
disease NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
present ADJ - O
invention NOUN - O
provides VERB - O
an DET - O
improved ADJ - O
process NOUN - O
for ADP - O
the DET - O
purification NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
. PUNCT - O

The DET - O
process NOUN - O
includes VERB - O
( PUNCT - O
i NOUN - O
) PUNCT - O
treating VERB - O
ropinirole NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
with ADP - O
sodium NOUN - O
dithionate ADJ - O
and CCONJ - O
charcoal VERB - O
in ADP - O
suitable ADJ - O
alcoholic ADJ - O
solvent NOUN - O
( PUNCT - O
ii ADJ - O
) PUNCT - O
triturating VERB - O
the DET - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
obtained VERB - O
in ADP - O
step NOUN - O
( PUNCT - O
i NOUN - O
) PUNCT - O
with ADP - O
ethanol NOUN - O
( PUNCT - O
iii PROPN - O
) PUNCT - O
reacting VERB - O
the DET - O
triturated VERB - O
solid ADJ - O
with ADP - O
base NOUN - O
in ADP - O
water NOUN - O
immiscible ADJ - O
solvent NOUN - O
and CCONJ - O
isolating VERB - O
the DET - O
free ADJ - O
base NOUN - O
and CCONJ - O

( PUNCT - O
iv NOUN - O
) PUNCT - O
treating VERB - O
the DET - O
free ADJ - O
base NOUN - O
obtained VERB - O
in ADP - O
step NOUN - O
( PUNCT - O
iii PROPN - O
) PUNCT - O
with ADP - O
ethanolic NOUN - O
HCl NOUN - O
to PART - O
give VERB - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

An DET - O
improved ADJ - O
process NOUN - O
is VERB - O
described VERB - O
for ADP - O
the DET - O
purification NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
. PUNCT - O

The DET - O
process NOUN - O
includes VERB - O
( PUNCT - O
i PUNCT - O
) PUNCT - O
dissolving VERB - O
ropinirole NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
in ADP - O
water NOUN - O
( PUNCT - O
ii ADJ - O
) PUNCT - O
treating VERB - O
the DET - O
solution NOUN - O
obtained VERB - O
in ADP - O
step NOUN - O
( PUNCT - O
i NOUN - O
) PUNCT - O
with ADP - O
sodium NOUN - O
dithionate ADJ - O
and CCONJ - O
charcoal ADJ - O
( PUNCT - O
iii PROPN - O
) PUNCT - O
treating VERB - O
the DET - O
filtrate NOUN - O
obtained VERB - O
in ADP - O
step NOUN - O
( PUNCT - O
ii NOUN - O
) PUNCT - O
with ADP - O
water NOUN - O
immiscible ADJ - O
solvent NOUN - O
and CCONJ - O
base NOUN - O
and CCONJ - O
isolating VERB - O
the DET - O
free ADJ - O
base NOUN - O
and CCONJ - O

( PUNCT - O
iv NOUN - O
) PUNCT - O
treating VERB - O
the DET - O
free ADJ - O
base NOUN - O
obtained VERB - O
in ADP - O
step NOUN - O
( PUNCT - O
iii PROPN - O
) PUNCT - O
with ADP - O
ethanolic NOUN - O
HCl NOUN - O
to PART - O
give VERB - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
process NOUN - O
for ADP - O
the DET - O
purification NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE

-DOCSTART- -X- - O

The DET - O
aim NOUN - O
of ADP - O
our ADJ - O
study NOUN - O
was VERB - O
to PART - O
determine VERB - O
the DET - O
applicability NOUN - O
of ADP - O
content NOUN - O
uniformity NOUN - O
and CCONJ - O
dissolution NOUN - O
variation NOUN - O
test NOUN - O
on ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
tablets NOUN - O
. PUNCT - O

According VERB - O
to ADP - O
the DET - O
results NOUN - O
obtained VERB - O
, PUNCT - O
we PRON - O
may VERB - O
conclude VERB - O
that ADP - O
analyzed VERB - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
tablets NOUN - O
satisfied ADJ - O
pharmacopeial ADJ - O
requirements NOUN - O
concerning VERB - O
content NOUN - O
uniformity NOUN - O
and CCONJ - O
dissolution NOUN - O
testing NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Study NOUN - O
of ADP - O
the DET - O
applicabilty NOUN - O
of ADP - O
content NOUN - O
uniformity NOUN - O
and CCONJ - O
dissolution NOUN - O
variation NOUN - O
test NOUN - O
on ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
tablets NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Pharmacological ADJ - O
profiles NOUN - O
and CCONJ - O
clinical ADJ - O
effects NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
( PUNCT - O
ReQuip)]. PROPN - O

-DOCSTART- -X- - O

Three CD - B-CARDINAL
impurities NOUN - O
in ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
drug NOUN - O
substance NOUN - O
at ADP - O
levels NOUN - O
approximately ADV - O
0.06 NUM - O
- SYM - O
0.15 NUM - O
% NOUN - O
were VERB - O
detected VERB - O
by ADP - O
reverse NOUN - O
- PUNCT - O
phase NOUN - O
high ADJ - O
performance NOUN - O
liquid NOUN - O
chromatography NOUN - O
( PUNCT - O
HPLC NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Isolation NOUN - O
and CCONJ - O
characterization NOUN - O
of ADP - O
some DET - O
potential ADJ - O
impurities NOUN - O
in ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
invention NOUN - O
relates VERB - O
to ADP - O
a DET - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
slow ADJ - O
- PUNCT - O
release NOUN - O
preparation NOUN - O
. PUNCT - O

At RB - B-CARDINAL
least RBS - I-CARDINAL
one CD - I-CARDINAL
layer NOUN - O
of ADP - O
a DET - O
coating VERB - O
membrance NOUN - O
containing VERB - O
a DET - O
hydrophobic ADJ - O
substance NOUN - O
and CCONJ - O
a DET - O
plastic ADJ - O
excipient NOUN - O
or CCONJ - O
a DET - O
coating ADJ - O
membrance NOUN - O
containing VERB - O
the DET - O
compositions NOUN - O
and CCONJ - O
an DET - O
enteric ADJ - O
- PUNCT - O
coated ADJ - O
macromolecular ADJ - O
substance NOUN - O
is VERB - O
used VERB - O
to PART - O
coat VERB - O
particles NOUN - O
containing VERB - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
so ADP - O
as ADP - O
to PART - O
form VERB - O
coated ADJ - O
particles NOUN - O
and CCONJ - O
the DET - O
coated ADJ - O
particles NOUN - O
and CCONJ - O
other ADJ - O
excipients NOUN - O
and CCONJ - O
disintegrating VERB - O
agents NOUN - O
are VERB - O
encapsulated VERB - O
into ADP - O
a DET - O
hard ADJ - O
capsule NOUN - O
or CCONJ - O
pressed VERB - O
into ADP - O
a DET - O
tablet NOUN - O
together ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Three CD - B-CARDINAL
sensitive ADJ - O
, PUNCT - O
selective ADJ - O
, PUNCT - O
accurate ADJ - O
spectrophotometric ADJ - O
and CCONJ - O
spectrofluorimetric ADJ - O
methods NOUN - O
have VERB - O
been VERB - O
developed VERB - O
for ADP - O
the DET - O
determination NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
in ADP - O
tablets NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Highly ADV - O
sensitive ADJ - O
and CCONJ - O
selective ADJ - O
spectrophotometric ADJ - O
and CCONJ - O
spectrofluorimetric ADJ - O
methods NOUN - O
for ADP - O
the DET - O
determination NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
in ADP - O
tablets NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Subtantially ADV - O
pure ADJ - O
ropinirole NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
, PUNCT - O
polymorphic ADJ - O
form NOUN - O
of ADP - O
ropinirole NOUN - O
and CCONJ - O
process NOUN - O
for ADP - O
their ADJ - O
preparation NOUN - O

-DOCSTART- -X- - O

This DET - O
work NOUN - O
explores VERB - O
the DET - O
possibility NOUN - O
of ADP - O
achieving VERB - O
therapeutic ADJ - O
levels NOUN - O
of ADP - O
the DET - O
anti JJ - B-NORP
- JJ - I-NORP
Parkinsonian JJ - I-NORP
drug NOUN - O
, PUNCT - O
ropinirole NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
( PUNCT - O
RHCl PROPN - O
) PUNCT - O
, PUNCT - O
by ADP - O
transdermal ADJ - O
iontophoretic ADJ - O
delivery NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
vivo NOUN - O
iontophoretic ADJ - O
administration NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Osmotic ADJ - O
pumping NOUN - O
sustained ADJ - O
preparation NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
and CCONJ - O
its ADJ - O
preparing VERB - O
method NOUN - O

-DOCSTART- -X- - O

Involvement NOUN - O
of ADP - O
dopamine NOUN - O
( PUNCT - O
DA)/serotonin PROPN - O
( PUNCT - O
5-HT)/sigma CD - B-CARDINAL
( PUNCT - O
sigma NOUN - O
) PUNCT - O
receptor NOUN - O
modulation NOUN - O
in ADP - O
mediating VERB - O
the DET - O
antidepressant ADJ - O
action NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
, PUNCT - O
a DET - O
D2/D3 NNP - B-ORG
dopamine NOUN - O
receptor NOUN - O
agonist NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
objectives NOUN - O
of ADP - O
this DET - O
work NOUN - O
were VERB - O
1 CD - B-CARDINAL
) PUNCT - O
to PART - O
establish VERB - O
the DET - O
feasibility NOUN - O
of ADP - O
the DET - O
transdermal ADJ - O
iontophoretic ADJ - O
delivery NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
; PUNCT - O
2 LS - B-CARDINAL
) PUNCT - O
to PART - O
investigate VERB - O
the DET - O
possibility NOUN - O
of ADP - O
delivering VERB - O
therapeutic ADJ - O
doses NOUN - O
of ADP - O
this DET - O
drug NOUN - O
; PUNCT - O
and CCONJ - O
3 LS - B-CARDINAL
) PUNCT - O
to PART - O
determine VERB - O
the DET - O
key ADJ - O
factors NOUN - O
that ADJ - O
control VERB - O
ropinirole NOUN - O
electrotransport NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Iontophoretic ADJ - O
delivery NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
: PUNCT - O
effect NOUN - O
of ADP - O
current ADJ - O
density NOUN - O
and CCONJ - O
vehicle NOUN - O
formulation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
demonstrate VERB - O
this DET - O
using VERB - O
piezo NOUN - O
- PUNCT - O
activated VERB - O
inkjetting VERB - O
to ADP - O
3D ADJ - O
print NOUN - O
ropinirole NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Dextran ADJ - O
sulfate NOUN - O
sodium NOUN - O
( PUNCT - O
DS NNP - B-PERSON
) PUNCT - O
was VERB - O
allowed VERB - O
to PART - O
interact VERB - O
ionically ADV - O
with ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
( PUNCT - O
ROPI PROPN - O
HCl NOUN - O
, PUNCT - O
an DET - O
anti JJ - B-NORP
- JJ - I-NORP
Parkinsonian JJ - I-NORP
agent NOUN - O
) PUNCT - O
to PART - O
synthesize VERB - O
self NOUN - O
- PUNCT - O
assembled VERB - O
ROPI NNP - B-ORG
- PUNCT - O
DS PROPN - O
nanoplex ADV - O
. PUNCT - O

-DOCSTART- -X- - O

REQUIP NNP - B-ORG
XL NNP - I-ORG
, PUNCT - O
prolonged VERB - O
release NOUN - O
formulation NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
( PUNCT - O
RH PROPN - O
) PUNCT - O
in ADP - O
market NOUN - O
, PUNCT - O
could VERB - O
release VERB - O
ropinirole NOUN - O
constantly ADV - O
and CCONJ - O
showed VERB - O
satisfactory ADJ - O
therapeutic ADJ - O
effect NOUN - O
and CCONJ - O
good ADJ - O
compliance NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
dopamine NOUN - O
agonist NOUN - O
, PUNCT - O
ropinirole NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
, PUNCT - O
reduced VERB - O
her ADJ - O
choreic ADJ - O
movements NOUN - O
, PUNCT - O
suggesting VERB - O
that ADP - O
levodopa ADJ - O
and/or CCONJ - O
dopamine NOUN - O
agonists NOUN - O
may VERB - O
compensate VERB - O
for ADP - O
underdeveloped ADJ - O
dopaminergic ADJ - O
pathways NOUN - O
in ADP - O
this DET - O
disorder NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

For ADP - O
the DET - O
first JJ - B-ORDINAL
time NOUN - O
, PUNCT - O
the DET - O
binding NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
( PUNCT - O
ROP PROPN - O
) PUNCT - O
and CCONJ - O
aspirin NOUN - O
( PUNCT - O
ASA NNP - B-ORG
) PUNCT - O
to ADP - O
human ADJ - O
holo NOUN - O
- PUNCT - O
transferrin NOUN - O
( PUNCT - O
hTf NOUN - O
) PUNCT - O
has VERB - O
been VERB - O
investigated VERB - O
by ADP - O
spectroscopic ADJ - O
approaches NOUN - O
( PUNCT - O
fluorescence NOUN - O
quenching NOUN - O
, PUNCT - O
synchronous ADJ - O
fluorescence NOUN - O
, PUNCT - O
time NOUN - O
- PUNCT - O
resolved VERB - O
fluorescence NOUN - O
, PUNCT - O
three CD - B-CARDINAL
- PUNCT - O
dimensional ADJ - O
fluorescence NOUN - O
, PUNCT - O
UV NOUN - O
- PUNCT - O
vis X - O
absorption NOUN - O
, PUNCT - O
circular ADJ - O
dichroism NOUN - O
, PUNCT - O
resonance NOUN - O
light NOUN - O
scattering NOUN - O
) PUNCT - O
, PUNCT - O
as ADV - O
well ADV - O
as ADP - O
zeta NOUN - O
potential ADJ - O
and CCONJ - O
molecular ADJ - O
modeling NOUN - O
techniques NOUN - O
, PUNCT - O
under ADP - O
simulated VERB - O
physiological ADJ - O
conditions NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Simple ADJ - O
and CCONJ - O
reproducible ADJ - O
spectrophotometric ADJ - O
methods NOUN - O
have VERB - O
been VERB - O
developed VERB - O
for ADP - O
determination NOUN - O
of ADP - O
dopaminergic ADJ - O
drugs NOUN - O
used VERB - O
for ADP - O
Parkinson PROPN - O
's PART - O
disease NOUN - O
, PUNCT - O
cabergoline NOUN - O
( PUNCT - O
CAB NNP - B-ORG
) PUNCT - O
and CCONJ - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
( PUNCT - O
ROP PROPN - O
) PUNCT - O
, PUNCT - O
in ADP - O
pharmaceutical ADJ - O
preparations NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Although ADP - O
most ADJ - O
studies NOUN - O
have VERB - O
suggested VERB - O
an DET - O
increased VERB - O
risk NOUN - O
of ADP - O
valvulopathy ADJ - O
( PUNCT - O
primarily ADV - O
regurgitation NOUN - O
) PUNCT - O
with ADP - O
pergolide ADJ - O
mesylate NOUN - O
use NOUN - O
, PUNCT - O
one CD - B-CARDINAL
study NOUN - O
suggested VERB - O
that ADP - O
this DET - O
problem NOUN - O
may VERB - O
also ADV - O
occur VERB - O
with ADP - O
use NOUN - O
of ADP - O
the DET - O
non ADJ - O
- ADJ - O
ergot VERB - O
- PUNCT - O
derived VERB - O
dopamine NOUN - O
agonists VERB - O
pramipexole NOUN - O
dihydrochloride NOUN - O
and CCONJ - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Patients NOUN - O
with ADP - O
Parkinson PROPN - O
disease NOUN - O
( PUNCT - O
PD PROPN - O
) PUNCT - O
treated VERB - O
with ADP - O
the DET - O
nonergot NOUN - O
dopamine NOUN - O
agonists VERB - O
pramipexole NOUN - O
dihydrochloride NOUN - O
and CCONJ - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
have VERB - O
been VERB - O
reported VERB - O
to PART - O
have VERB - O
sleep NOUN - O
attacks NOUN - O
without ADP - O
warning NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

It PRON - O
is VERB - O
preferred VERB - O
that ADJ - O
said VERB - O
dopamine NOUN - O
D2-receptor NN - B-ORG
agonist NOUN - O
component NOUN - O
be VERB - O
bromocriptine ADJ - O
mesylate NOUN - O
, PUNCT - O
naxagolide ADJ - O
hydrochloride NOUN - O
, PUNCT - O
cabergoline NOUN - O
, PUNCT - O
pergolide ADJ - O
mesylate NOUN - O
, PUNCT - O
quinpirole ADJ - O
hydrochloride NOUN - O
, PUNCT - O
or CCONJ - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
and CCONJ - O
that ADJ - O
said VERB - O
anti ADJ - O
- ADJ - O
cholinergic ADJ - O
agent NOUN - O
component NOUN - O
be VERB - O
tiotropium NOUN - O
bromide ADV - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
disposition NOUN - O
and CCONJ - O
metabolic ADJ - O
fate NOUN - O
of ADP - O
ropinirole NOUN - O
, PUNCT - O
a DET - O
novel NOUN - O
compound NOUN - O
indicated VERB - O
for ADP - O
the DET - O
symptomatic ADJ - O
treatment NOUN - O
of ADP - O
Parkinson PROPN - O
's PART - O
disease NOUN - O
, PUNCT - O
was VERB - O
studied VERB - O
in ADP - O
the DET - O
mouse NOUN - O
, PUNCT - O
rat NOUN - O
, PUNCT - O
cynomolgus NOUN - O
monkey NOUN - O
and CCONJ - O
man NOUN - O
, PUNCT - O
following VERB - O
oral ADJ - O
and CCONJ - O
intravenous ADJ - O
administration NOUN - O
of ADP - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
. PUNCT - O

In ADP - O
all DET - O
species NOUN - O
, PUNCT - O
nearly ADV - O
all DET - O
of ADP - O
the DET - O
p.o NOUN - O
. PUNCT - O
administered VERB - O
dose NOUN - O
( PUNCT - O
94 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
was VERB - O
rapidly ADV - O
absorbed VERB - O
from ADP - O
the DET - O
gastrointestinal ADJ - O
tract NOUN - O
following VERB - O
administration NOUN - O
of ADP - O
14C NUM - O
- PUNCT - O
ropinirole NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

NS-2330 NNP - B-ORG
; PUNCT - O
Olopatadine CD - B-ORG
hydrochloride NOUN - O
, PUNCT - O
omalizumab NOUN - O
, PUNCT - O
oxcarbazepine NOUN - O
, PUNCT - O
oxycodone NOUN - O
hydrochloride NOUN - O
; PUNCT - O
Paclitaxel NNP - B-ORG
, PUNCT - O
paracetamol NOUN - O
, PUNCT - O
piribedil NOUN - O
, PUNCT - O
pramipexole NOUN - O
hydrochloride NOUN - O
, PUNCT - O
pravastatin NOUN - O
sodium NOUN - O
, PUNCT - O
prednisone NOUN - O
; PUNCT - O
Quetiapine NNP - B-GPE
fumarate NOUN - O
; PUNCT - O
Raloxifene NNP - B-PERSON
hydrochloride NOUN - O
, PUNCT - O
rituximab NOUN - O
, PUNCT - O
rizatriptan NOUN - O
sulfate NOUN - O
, PUNCT - O
Ro-63 NNP - B-CARDINAL
- PUNCT - O
8695 NUM - O
, PUNCT - O
ropinirole NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
, PUNCT - O
rosiglitazone ADJ - O
maleate NOUN - O
; PUNCT - O

-DOCSTART- -X- - O

This DET - O
issue NOUN - O
focuses VERB - O
on ADP - O
the DET - O
following VERB - O
selection NOUN - O
of ADP - O
drugs NOUN - O
: PUNCT - O
Abacavir JJ - B-ORG
sulfate NOUN - O
, PUNCT - O
abarelix ADJ - O
, PUNCT - O
abciximab NOUN - O
, PUNCT - O
acarbose NOUN - O
, PUNCT - O
alefacept NOUN - O
, PUNCT - O
alteplase NOUN - O
, PUNCT - O
amisulpride NOUN - O
, PUNCT - O
amoxicillin NOUN - O
trihydrate NOUN - O
, PUNCT - O
apomorphine ADJ - O
hydrochloride NOUN - O
, PUNCT - O
aprepitant NOUN - O
, PUNCT - O
argatroban ADJ - O
monohydrate NOUN - O
, PUNCT - O
aspirin NOUN - O
, PUNCT - O
atenolol NOUN - O
; PUNCT - O
Betamethasone PROPN - O
dipropionate VERB - O
, PUNCT - O
betamethasone ADJ - O
valerate NOUN - O
, PUNCT - O
bicalutamide NOUN - O
, PUNCT - O
bleomycin NOUN - O
sulfate NOUN - O
; PUNCT - O
Calcium NN - B-ORG
carbonate NOUN - O
, PUNCT - O
candesartan ADJ - O
cilexetil NOUN - O
, PUNCT - O
celecoxib NOUN - O
, PUNCT - O
cetirizine NOUN - O
hydrochloride NOUN - O
, PUNCT - O
cisplatin ADJ - O
, PUNCT - O
clarithromycin NOUN - O
, PUNCT - O
clavulanate NOUN - O
potassium NOUN - O
, PUNCT - O
clomethiazole ADJ - O
edisilate NOUN - O
, PUNCT - O
clopidogrel NOUN - O
hydrogensulfate NOUN - O
, PUNCT - O
cyclophosphamide NOUN - O
, PUNCT - O
chorionic ADJ - O
gonadotropin NOUN - O
( PUNCT - O
human ADJ - O
) PUNCT - O
; PUNCT - O
Dalteparin PROPN - O
sodium NOUN - O
, PUNCT - O
desloratadine NOUN - O
, PUNCT - O
dexamethasone NOUN - O
, PUNCT - O
doxorubicin NOUN - O
, PUNCT - O
DPC-083 NNP - B-ORG
; PUNCT - O
Efalizumab NNP - B-ORG
, PUNCT - O
efavirenz ADJ - O
, PUNCT - O
enoxaparin ADJ - O
sodium NOUN - O
, PUNCT - O
eprosartan NOUN - O
mesilate NOUN - O
, PUNCT - O
etanercept ADJ - O
, PUNCT - O
etoposide NOUN - O
, PUNCT - O
ezetimibe NOUN - O
; PUNCT - O
Faropenem NOUN - O
daloxate VERB - O
, PUNCT - O
fenofibrate NOUN - O
, PUNCT - O
fluocinolone NOUN - O
acetonide NOUN - O
, PUNCT - O
flutamide NOUN - O
, PUNCT - O
fluvastatin NOUN - O
sodium NOUN - O
, PUNCT - O
follitropin NOUN - O
beta NOUN - O
, PUNCT - O
fondaparinux NOUN - O
sodium NOUN - O
; PUNCT - O
Gabapentin NNP - B-ORG
, PUNCT - O
glibenclamide NOUN - O
, PUNCT - O
goserelin NOUN - O
, PUNCT - O
granisetron NOUN - O
hydrochloride NOUN - O
; PUNCT - O
Haloperidol NNP - B-PERSON
, PUNCT - O
hydrochlorothiazide NOUN - O
; PUNCT - O
Imiquimod NN - B-PERSON
, PUNCT - O
interferon NOUN - O
beta-1a NOUN - O
, PUNCT - O
irbesartan NOUN - O
, PUNCT - O
iseganan ADJ - O
hydrochloride NOUN - O
; PUNCT - O
L-758298 NN - B-PERSON
, PUNCT - O
lamivudine NOUN - O
, PUNCT - O
lanoteplase NOUN - O
, PUNCT - O
leflunomide VERB - O
, PUNCT - O
leuprorelin NOUN - O
acetate ADJ - O
, PUNCT - O
loratadine NOUN - O
, PUNCT - O
losartan ADJ - O
potassium NOUN - O
; PUNCT - O
Melagatran NNP - B-ORG
, PUNCT - O
metformin NOUN - O
hydrochloride NOUN - O
, PUNCT - O
methotrexate NOUN - O
, PUNCT - O
metronidazole NOUN - O
, PUNCT - O
micafungin NOUN - O
sodium NOUN - O
, PUNCT - O
mitoxantrone ADJ - O
hydrochloride NOUN - O
; PUNCT - O
Nelfinavir JJ - B-NORP
mesilate NOUN - O
, PUNCT - O
neutral ADJ - O
insulin NOUN - O
injection NOUN - O
, PUNCT - O
nizatidine NOUN - O
; PUNCT - O
Olopatadine CD - B-ORG
hydrochloride NOUN - O
, PUNCT - O
omeprazole NOUN - O
, PUNCT - O
ondansetron NOUN - O
hydrochloride NOUN - O
; PUNCT - O
Pamidronate NNP - B-ORG
sodium NOUN - O
, PUNCT - O
paracetamol NOUN - O
, PUNCT - O
paroxetine NOUN - O
hydrochloride NOUN - O
, PUNCT - O
perindopril NOUN - O
, PUNCT - O
pimecrolimus NOUN - O
, PUNCT - O
pioglitazone NOUN - O
hydrochloride NOUN - O
, PUNCT - O
piroxicam NOUN - O
, PUNCT - O
pleconaril X - O
, PUNCT - O
pralmorelin NOUN - O
, PUNCT - O
pravastatin ADJ - O
sodium NOUN - O
, PUNCT - O
prednisolone ADJ - O
, PUNCT - O
prednisone NOUN - O
, PUNCT - O
propofol NOUN - O
; PUNCT - O
Raloxifene JJ - B-PERSON
hydrochloride NOUN - O
, PUNCT - O
ranpirnase INTJ - O
, PUNCT - O
remifentanil ADJ - O
hydrochloride NOUN - O
, PUNCT - O
risedronate NOUN - O
sodium NOUN - O
, PUNCT - O
risperidone NOUN - O
, PUNCT - O
rofecoxib NOUN - O
, PUNCT - O
ropinirole NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
, PUNCT - O
rosuvastatin NOUN - O
calcium NOUN - O
; PUNCT - O
Sevoflurane NNP - B-PERSON
, PUNCT - O
sildenafil NOUN - O
citrate NOUN - O
, PUNCT - O
simvastatin ADJ - O
, PUNCT - O
somatropin NOUN - O
; PUNCT - O
Tacrolimus NNP - B-ORG
, PUNCT - O
tamoxifen NOUN - O
citrate NOUN - O
, PUNCT - O
telmisartan ADJ - O
, PUNCT - O
temozolomide ADV - O
, PUNCT - O
thiopental ADJ - O
sodium NOUN - O
, PUNCT - O
tinzaparin NOUN - O
sodium NOUN - O
, PUNCT - O
tirofiban ADJ - O
hydrochloride NOUN - O
, PUNCT - O
treosulfan NOUN - O
, PUNCT - O
triamcinolone NOUN - O
acetonide NOUN - O
; PUNCT - O
Urokinase NNP - B-ORG
; PUNCT - O
Valsartan NNP - B-ORG
, PUNCT - O
vardenafil NOUN - O
, PUNCT - O
vincristine NOUN - O
; PUNCT - O
Warfarin NNP - B-NORP
sodium NOUN - O
; PUNCT - O
Ximelagatran NNP - B-GPE
; PUNCT - O
Zidovudine NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

It PRON - O
is VERB - O
preferred VERB - O
that ADJ - O
said VERB - O
dopamine NOUN - O
D2-receptor NN - B-ORG
agonist NOUN - O
component NOUN - O
be VERB - O
bromocriptine ADJ - O
mesylate NOUN - O
, PUNCT - O
naxagolide ADJ - O
hydrochloride NOUN - O
, PUNCT - O
cabergoline NOUN - O
, PUNCT - O
pergolide ADJ - O
mesylate NOUN - O
, PUNCT - O
quinpirole ADJ - O
hydrochloride NOUN - O
, PUNCT - O
or CCONJ - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
; PUNCT - O
and CCONJ - O
that DET - O
said VERB - O
anti ADJ - O
- ADJ - O
cholinergic ADJ - O
agent NOUN - O
component NOUN - O
be VERB - O
tiotropium NOUN - O
bromide ADV - O
. PUNCT - O

-DOCSTART- -X- - O

It PRON - O
is VERB - O
preferred VERB - O
that ADJ - O
said VERB - O
dopamine NOUN - O
D2-receptor NN - B-ORG
agonist NOUN - O
component NOUN - O
be VERB - O
bromocriptine ADJ - O
mesylate NOUN - O
, PUNCT - O
naxagolide ADJ - O
hydrochloride NOUN - O
, PUNCT - O
cabergoline NOUN - O
, PUNCT - O
pergolide ADJ - O
mesylate NOUN - O
, PUNCT - O
quinpirole ADJ - O
hydrochloride NOUN - O
, PUNCT - O
or CCONJ - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
; PUNCT - O
and CCONJ - O
that DET - O
said VERB - O
anti ADJ - O
- ADJ - O
cholinergic ADJ - O
agent NOUN - O
component NOUN - O
be VERB - O
tiotropium NOUN - O
bromide ADV - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
evaluate VERB - O
ropinirole NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
as ADP - O
dopaminergic ADJ - O
monotherapy NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
early ADJ - O
Parkinson PROPN - O
disease NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

0 CD - B-CARDINAL
. NOUN - O
125 CD - B-CARDINAL
, PUNCT - O
or CCONJ - O
0.25 CD - B-CARDINAL
mg NOUN - O
) PUNCT - O
, PUNCT - O
pramipexole NOUN - O
dihydrochloride NOUN - O
( PUNCT - O
0.125 CD - B-CARDINAL
mg NOUN - O
) PUNCT - O
, PUNCT - O
or CCONJ - O
ropinirole JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
( PUNCT - O
0.125 CD - B-CARDINAL
or CCONJ - O
0.25 CD - B-CARDINAL
mg NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Serotonin ADJ - O
5-HT3 ADJ - O
receptor NOUN - O
antagonists NOUN - O
such ADJ - O
as ADP - O
ondansetron NN - B-MEDICINE
have VERB - O
been VERB - O
investigated VERB - O
to PART - O
attenuate VERB - O
opioid ADJ - O
withdrawal NOUN - O
signs NOUN - O
in ADP - O
studies NOUN - O
. PUNCT - O

Male ADJ - O
adults NOUN - O
who NOUN - O
were VERB - O
addicted VERB - O
to ADP - O
opioids NOUN - O
, PUNCT - O
aged VERB - O
18 CD - B-DATE
to TO - I-DATE
79 CD - I-DATE
years NNS - I-DATE
were VERB - O
enrolled VERB - O
( PUNCT - O
n=96 SYM - O
) PUNCT - O
and CCONJ - O
randomized VERB - O
into ADP - O
two CD - B-CARDINAL
oral ADJ - O
doses NOUN - O
( PUNCT - O
4 CD - B-CARDINAL
& CC - I-CARDINAL
8 CD - I-CARDINAL
mg NOUN - O
) PUNCT - O
of ADP - O
ondansetron NN - B-MEDICINE
( PUNCT - O
n=32 PROPN - O
) PUNCT - O
and CCONJ - O
placebo NOUN - O
( PUNCT - O
n=32 PROPN - O
) PUNCT - O
. PUNCT - O

We PRON - O
indicated VERB - O
that ADP - O
ondansetron NN - B-MEDICINE
demonstrated VERB - O
significant ADJ - O
differences NOUN - O
with ADP - O
few ADJ - O
vital ADJ - O
outcomes NOUN - O
including VERB - O
systolic ADJ - O
blood NOUN - O
pressure NOUN - O
( PUNCT - O
BPS PROPN - O
) PUNCT - O
20 CD - B-CARDINAL
( PUNCT - O
BPS PROPN - O
3 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O
50 CD - B-QUANTITY
min NN - I-QUANTITY
( PUNCT - O
BPS PROPN - O
4 NUM - O
) PUNCT - O
after ADP - O
injection NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
during ADP - O
the DET - O
period NOUN - O
of ADP - O
the DET - O
surgery NOUN - O
. PUNCT - O

Furthermore ADV - O
, PUNCT - O
requirement NOUN - O
for ADP - O
further ADJ - O
administration NOUN - O
of ADP - O
opioid ADJ - O
analgesic ADJ - O
drugs NOUN - O
such ADJ - O
as ADP - O
pethidine NOUN - O
were VERB - O
significantly ADV - O
reduced VERB - O
in ADP - O
the DET - O
ondansetron NN - B-MEDICINE
groups NOUN - O
. PUNCT - O

Objective ADJ - O
opioid ADJ - O
withdrawal NOUN - O
scale NOUN - O
( PUNCT - O
OOWS PROPN - O
) PUNCT - O
results NOUN - O
indicated VERB - O
that ADP - O
few ADJ - O
clinical ADJ - O
parameters NOUN - O
including VERB - O
tremor NOUN - O
, PUNCT - O
hot ADJ - O
and CCONJ - O
cold ADJ - O
flushes NOUN - O
and CCONJ - O
anxiety NOUN - O
were VERB - O
significantly ADV - O
attenuated VERB - O
in ADP - O
addicted ADJ - O
patients NOUN - O
who NOUN - O
received VERB - O
ondansetron NN - B-MEDICINE
. PUNCT - O

This DET - O
study NOUN - O
demonstrated VERB - O
a DET - O
few ADJ - O
evidence NOUN - O
for ADP - O
beneficial ADJ - O
treatment NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
for ADP - O
control NOUN - O
of ADP - O
withdrawal NOUN - O
symptoms NOUN - O
and CCONJ - O
pain NOUN - O
in ADP - O
addicted ADJ - O
patients NOUN - O
, PUNCT - O
and CCONJ - O
more ADJ - O
clinical ADJ - O
studies NOUN - O
are VERB - O
suggested VERB - O
in ADP - O
this DET - O
regard NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Impact NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
on ADP - O
withdrawal NOUN - O
signs NOUN - O
, PUNCT - O
fentanyl VERB - O
requirement NOUN - O
and CCONJ - O
pain NOUN - O
relief NOUN - O
in ADP - O
opioid ADJ - O
addicted ADJ - O
patients NOUN - O
under ADP - O
general ADJ - O
anesthesia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
pharmacokinetics NOUN - O
of ADP - O
R-(-)ondansetron NNP - B-ORG
( PUNCT - O
R PROPN - O
- PUNCT - O
ond NOUN - O
) PUNCT - O
compared VERB - O
with ADP - O
that DET - O
of ADP - O
S-(-)ondansetron PROPN - O
( PUNCT - O
S PROPN - O
- PUNCT - O
ond PROPN - O
) PUNCT - O
was VERB - O
studied VERB - O
in ADP - O
rats NOUN - O
. PUNCT - O

The DET - O
stability NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
enantiomers NOUN - O
in ADP - O
rat NOUN - O
was VERB - O
determined VERB - O
by ADP - O
chiral NOUN - O
HPLC NNP - B-ORG
, PUNCT - O
and CCONJ - O
the DET - O
concentrations NOUN - O
of ADP - O
R NOUN - O
- PUNCT - O
ond NOUN - O
and CCONJ - O
S PROPN - O
- PUNCT - O
ond PROPN - O
in ADP - O
plasma NOUN - O
were VERB - O
determined VERB - O
by ADP - O
an DET - O
LC PROPN - O
/ SYM - O
MS PROPN - O
/ SYM - O
MS PROPN - O
method NOUN - O
. PUNCT - O

The DET - O
pharmacokinetics NOUN - O
of ADP - O
R NOUN - O
- PUNCT - O
ond NOUN - O
and CCONJ - O
S PROPN - O
- PUNCT - O
ond PROPN - O
are VERB - O
stereoselective ADJ - O
in ADP - O
rat NOUN - O
, PUNCT - O
which ADJ - O
indicates VERB - O
substantial ADJ - O
stereoselectivity NOUN - O
in ADP - O
the DET - O
disposition NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
enantiomers NOUN - O
in ADP - O
rat NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pharmacokinetics NOUN - O
of ADP - O
R-(-)ondansetron NNP - B-ORG
compared VERB - O
with ADP - O
that DET - O
of ADP - O
S-(-)ondansetron PROPN - O
in ADP - O
rats NOUN - O
using VERB - O
an DET - O
LC PROPN - O
- PUNCT - O
MS PROPN - O
/ SYM - O
MS PROPN - O
method NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Observational ADJ - O
studies NOUN - O
suggest VERB - O
that ADP - O
ondansetron NN - B-MEDICINE
reduces VERB - O
the DET - O
incidence NOUN - O
of ADP - O
post ADJ - O
- ADJ - O
spinal ADJ - O
hypotension NOUN - O
( PUNCT - O
PSH NOUN - O
) PUNCT - O
and CCONJ - O
support VERB - O
the DET - O
use NOUN - O
of ADP - O
combined ADJ - O
fluid ADJ - O
preloading NOUN - O
and CCONJ - O
vasoconstrictors NOUN - O
for ADP - O
this DET - O
purpose NOUN - O
( PUNCT - O
but CCONJ - O
with ADP - O
limited ADJ - O
doses NOUN - O
) PUNCT - O
to PART - O
avoid VERB - O
side ADJ - O
effects NOUN - O
as ADP - O
fluid ADJ - O
overload NOUN - O
and CCONJ - O
tachycardia NOUN - O
respectively ADV - O
. PUNCT - O

As ADP - O
no DET - O
RCT PROPN - O
had VERB - O
ever ADV - O
compared VERB - O
the DET - O
use NOUN - O
of ADP - O
Ondansetron NNP - B-GPE
alone ADJ - O
with ADP - O
combined ADJ - O
vasoconstrictors NOUN - O
and CCONJ - O
fluid NOUN - O
preload NOUN - O
, PUNCT - O
so CCONJ - O
, PUNCT - O
this DET - O
randomised VERB - O
controlled VERB - O
trial NOUN - O
has VERB - O
evaluated VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
the DET - O
use NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
alone ADV - O
compared VERB - O
to ADP - O
the DET - O
combined VERB - O
use NOUN - O
of ADP - O
fluid ADJ - O
preload NOUN - O
and CCONJ - O
vasoconstrictors NOUN - O
to PART - O
decrease VERB - O
the DET - O
incidence NOUN - O
of ADP - O
spinal ADJ - O
hypotension NOUN - O
. PUNCT - O

Group NOUN - O
I PRON - O
patients VERB - O
( PUNCT - O
ondansetron NN - B-MEDICINE
group NOUN - O
) PUNCT - O
received VERB - O
4 CD - B-CARDINAL
mg PART - O
ondansetron NN - B-MEDICINE
in ADP - O
5 CD - B-CARDINAL
ml ADJ - O
normal ADJ - O
saline NOUN - O
( PUNCT - O
IV NNP - B-ORG
) PUNCT - O
15 CD - B-TIME
minutes NNS - I-TIME
before ADP - O
induction NOUN - O
of ADP - O
spinal ADJ - O
anaesthesia NOUN - O
. PUNCT - O

The DET - O
incidence NOUN - O
of ADP - O
hypotension NOUN - O
following VERB - O
the DET - O
subarachnoid NOUN - O
block NOUN - O
in ADP - O
Group NNP - B-ORG
I PRP - I-ORG
( PUNCT - O
ondansetron NN - B-MEDICINE
group NOUN - O
) PUNCT - O
was VERB - O
17.6 CD - B-PERCENT
% NN - I-PERCENT
versus ADP - O
group NOUN - O
II NNP - B-ORG
( PUNCT - O
combination NOUN - O
group NOUN - O
) PUNCT - O
was VERB - O
13.3 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
while ADP - O
difference NOUN - O
among ADP - O
the DET - O
groups NOUN - O
is VERB - O
statistically ADV - O
insignificant ADJ - O
( PUNCT - O
P NOUN - O
= SYM - O
0.082 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
determine VERB - O
the DET - O
incidence NOUN - O
of ADP - O
akathisia NOUN - O
after ADP - O
PONV PROPN - O
prophylaxis NOUN - O
with ADP - O
two CD - B-CARDINAL
doses NOUN - O
of ADP - O
droperidol NOUN - O
in ADP - O
comparison NOUN - O
with ADP - O
ondansetron NN - B-MEDICINE
, PUNCT - O
in ADP - O
patients NOUN - O
undergoing VERB - O
ambulatory ADJ - O
surgery NOUN - O
. PUNCT - O

We PRON - O
hypothesised VERB - O
that ADP - O
the DET - O
incidence NOUN - O
of ADP - O
akathisia NOUN - O
is VERB - O
higher ADJ - O
with ADP - O
droperidol NOUN - O
than ADP - O
that DET - O
with ADP - O
ondansetron NN - B-MEDICINE
. PUNCT - O

PATIENTS NOUN - O
: PUNCT - O
Patients NOUN - O
( PUNCT - O
n=297 NNP - B-CARDINAL
) PUNCT - O
undergoing VERB - O
general ADJ - O
anaesthesia NOUN - O
for ADP - O
ambulatory ADJ - O
surgery NOUN - O
were VERB - O
randomly ADV - O
allocated VERB - O
to PART - O
receive VERB - O
PONV PROPN - O
prophylaxis NOUN - O
with ADP - O
droperidol ADJ - O
( PUNCT - O
0.625 CD - B-CARDINAL
or CCONJ - O
1.25 CD - B-CARDINAL
  _SP - I-CARDINAL
mg PRON - O
) PUNCT - O
or CCONJ - O
ondansetron NN - B-MEDICINE
4 NUM - O
  SPACE - O
mg NOUN - O
; PUNCT - O
patients NOUN - O
of ADP - O
the DET - O
three CD - B-CARDINAL
groups NOUN - O
also ADV - O
received VERB - O
4 CD - B-MONEY
  _SP - I-MONEY
mg PRON - O
of ADP - O
dexamethasone NOUN - O
. PUNCT - O

Exclusion NOUN - O
criteria NOUN - O
were VERB - O
contraindication NOUN - O
to ADP - O
droperidol NOUN - O
and CCONJ - O
ondansetron NN - B-MEDICINE
, PUNCT - O
use NOUN - O
of ADP - O
psychotropic ADJ - O
medications NOUN - O
or CCONJ - O
benzodiazepines NOUN - O
or CCONJ - O
history NOUN - O
of ADP - O
psychotic ADJ - O
illness NOUN - O
. PUNCT - O

Participants NOUN - O
received VERB - O
droperidol NOUN - O
( PUNCT - O
0.625 CD - B-CARDINAL
or CCONJ - O
1.25 CD - B-CARDINAL
  _SP - I-CARDINAL
mg PRON - O
) PUNCT - O
or CCONJ - O
ondansetron NN - B-MEDICINE
4 CD - B-MONEY
  _SP - I-MONEY
mg NOUN - O
during ADP - O
general ADJ - O
anaesthesia NOUN - O
. PUNCT - O

The DET - O
number NOUN - O
of ADP - O
akathisia NOUN - O
observed VERB - O
was VERB - O
1/118 CD - B-DATE
( PUNCT - O
0.8 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
in ADP - O
the DET - O
ondansetron NN - B-MEDICINE
group NOUN - O
, PUNCT - O
1/84 CD - B-CARDINAL
( PUNCT - O
1.2 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
in ADP - O
droperidol NOUN - O
0.625 CD - B-MONEY
  _SP - I-MONEY
mg NOUN - O
group NOUN - O
, PUNCT - O
and CCONJ - O
3/87 CD - B-CARDINAL
( PUNCT - O
3.4 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
in ADP - O
droperidol NOUN - O
1.25 CD - B-CARDINAL
mg NOUN - O
group NOUN - O
. PUNCT - O

The DET - O
use NOUN - O
of ADP - O
droperidol NOUN - O
or CCONJ - O
ondansetron NN - B-MEDICINE
for ADP - O
PONV PROPN - O
prophylaxis NOUN - O
is VERB - O
associated VERB - O
to ADP - O
a DET - O
low ADJ - O
incidence NOUN - O
of ADP - O
akathisia NOUN - O
( PUNCT - O
0.8 CD - B-PERCENT
to TO - I-PERCENT
3.4 CD - I-PERCENT
% NN - I-PERCENT
) PUNCT - O
after ADP - O
general ADJ - O
anaesthesia NOUN - O
for ADP - O
ambulatory ADJ - O
surgery NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Incidence NOUN - O
of ADP - O
akathisia NOUN - O
after ADP - O
postoperative ADJ - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
prophylaxis NOUN - O
with ADP - O
droperidol NOUN - O
and CCONJ - O
ondansetron NN - B-MEDICINE
in ADP - O
outpatient NOUN - O
surgery NOUN - O
: PUNCT - O
A DET - O
multicentre ADV - O
controlled VERB - O
randomised VERB - O
trial NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
aim NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
evaluate VERB - O
the DET - O
effects NOUN - O
of ADP - O
dexamethasone NOUN - O
and CCONJ - O
ondansetron NN - B-MEDICINE
for ADP - O
preventing VERB - O
PONV PROPN - O
in ADP - O
patients NOUN - O
who NOUN - O
underwent VERB - O
microvascular ADJ - O
decompression NOUN - O
( PUNCT - O
MVD NNP - B-ORG
) PUNCT - O
surgery NOUN - O
. PUNCT - O

4 CD - B-CARDINAL
  SPACE - O
mg PRON - O
iv PROPN - O
and CCONJ - O
ondansetron NN - B-MEDICINE
4 CD - B-CARDINAL
  SPACE - O

Conclusion NOUN - O
: PUNCT - O
Administration NOUN - O
of ADP - O
dexamethasone NOUN - O
and CCONJ - O
ondansetron NN - B-MEDICINE
4 CD - B-CARDINAL
  SPACE - O

Therefore ADV - O
, PUNCT - O
further ADJ - O
studies NOUN - O
are VERB - O
to PART - O
be VERB - O
carried VERB - O
out PART - O
by ADP - O
escalating VERB - O
either CCONJ - O
dexamethasone NOUN - O
dose NOUN - O
or CCONJ - O
the DET - O
dose NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
or CCONJ - O
both DET - O
. PUNCT - O

-DOCSTART- -X- - O

Regarding VERB - O
the DET - O
effectiveness NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
in ADP - O
Parkinson PROPN - O
's PART - O
disease NOUN - O
, PUNCT - O
we PRON - O
planned VERB - O
to PART - O
test VERB - O
its ADJ - O
effect NOUN - O
on ADP - O
levodopa ADV - O
- PUNCT - O
induced VERB - O
dyskinesia NOUN - O
( PUNCT - O
LID NNP - B-ORG
) PUNCT - O
. PUNCT - O

Then ADV - O
, PUNCT - O
animals NOUN - O
with ADP - O
positive ADJ - O
symptoms NOUN - O
for ADP - O
Parkinsonism NNP - B-NORP
divided VERB - O
into ADP - O
4 CD - B-CARDINAL
equal ADJ - O
groups NOUN - O
, PUNCT - O
the DET - O
first JJ - B-ORDINAL
group NOUN - O
treated VERB - O
with ADP - O
levodopa ADJ - O
50 CD - B-CARDINAL
  SPACE - O
mg PROPN - O
/ SYM - O
kg NOUN - O
i.p PROPN - O
, PUNCT - O
the DET - O
second JJ - B-ORDINAL
group NOUN - O
received VERB - O
only ADV - O
distilled VERB - O
water NOUN - O
, PUNCT - O
the DET - O
third JJ - B-ORDINAL
and CCONJ - O
forth ADJ - O
groups NOUN - O
treated VERB - O
with ADP - O
levodopa ADJ - O
50 CD - B-CARDINAL
  SPACE - O
mg PROPN - O
/ SYM - O
kg NOUN - O
i.p DET - O
plus CCONJ - O
two CD - B-CARDINAL
different ADJ - O
doses NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
( PUNCT - O
0.04 CD - B-CARDINAL
and CCONJ - O
0.08 CD - B-CARDINAL
  SPACE - O
mg PROPN - O
/ SYM - O
kg NOUN - O
i.p PROPN - O
) PUNCT - O
for ADP - O
3 CD - B-DATE
weeks NNS - I-DATE
. PUNCT - O

Animals NOUN - O
tested VERB - O
for ADP - O
dyskinesia NOUN - O
using VERB - O
AIMs NOUN - O
and CCONJ - O
rotarod ADJ - O
tests VERB - O
at ADP - O
specific ADJ - O
days NNS - B-DATE
and CCONJ - O
a DET - O
week NOUN - O
after ADP - O
discontinuation NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
. PUNCT - O

Evaluations NOUN - O
of ADP - O
AIMs NOUN - O
test NOUN - O
showed VERB - O
significant ADJ - O
changes NOUN - O
in ADP - O
dyskinetic ADJ - O
movements NOUN - O
and CCONJ - O
reduction NOUN - O
in ADP - O
scores NOUN - O
in ADP - O
groups NOUN - O
treating VERB - O
with ADP - O
ondansetron NN - B-MEDICINE
when ADV - O
compared VERB - O
with ADP - O
the DET - O
first JJ - B-ORDINAL
group NOUN - O
. PUNCT - O

Upon ADP - O
discontinuations NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
in ADP - O
the DET - O
last ADJ - O
two CD - B-CARDINAL
groups NOUN - O
, PUNCT - O
AIMs NOUN - O
scores NOUN - O
significantly ADV - O
increased VERB - O
. PUNCT - O

While ADP - O
in ADP - O
rotarod ADJ - O
test NOUN - O
, PUNCT - O
ondansetron NN - B-MEDICINE
had VERB - O
no DET - O
additional ADJ - O
benefit NOUN - O
when ADV - O
added VERB - O
to PART - O
levodopa VERB - O
in ADP - O
motor NOUN - O
coordination NOUN - O
of ADP - O
animals NOUN - O
. PUNCT - O

Findings NOUN - O
of ADP - O
this DET - O
study NOUN - O
suggest VERB - O
that ADP - O
co NOUN - O
administration NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
with ADP - O
levodopa ADJ - O
is VERB - O
effective ADJ - O
in ADP - O
attenuating ADJ - O
dyskinesia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
vitro ADJ - O
metabolism NOUN - O
studies NOUN - O
have VERB - O
shown VERB - O
that ADP - O
ondansetron NN - B-MEDICINE
is VERB - O
a DET - O
substrate NOUN - O
for ADP - O
human ADJ - O
hepatic ADJ - O
cytochrome NOUN - O
P450 PROPN - O
enzymes VERB - O
. PUNCT - O

2D6 CD - B-CARDINAL
inhibitor NOUN - O
quinidine NOUN - O
reduced VERB - O
in ADP - O
vitro NOUN - O
hydroxylation NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
, PUNCT - O
which ADJ - O
indicates VERB - O
the DET - O
important ADJ - O
role NOUN - O
of ADP - O
CYP2D6 NN - B-PERSON
in ADP - O
ondansetron NN - B-MEDICINE
metabolism NOUN - O
. PUNCT - O

The DET - O
aim NOUN - O
of ADP - O
our ADJ - O
study NOUN - O
was VERB - O
to PART - O
evaluate VERB - O
whether ADP - O
the DET - O
pharmacological ADJ - O
prevention NOUN - O
of ADP - O
PONV PROPN - O
with ADP - O
ondansetron NN - B-MEDICINE
depends VERB - O
on ADP - O
the DET - O
most ADV - O
common ADJ - O
CYP2D6 NOUN - O
alleles NOUN - O
( PUNCT - O
CYP2D6 PROPN - O

Our ADJ - O
results NOUN - O
suggest VERB - O
that ADP - O
PONV PROPN - O
treatment NOUN - O
with ADP - O
ondansetron PRP - B-MEDICINE
could VERB - O
be VERB - O
improved VERB - O
by ADP - O
basic ADJ - O
, PUNCT - O
widely ADV - O
available ADJ - O
and CCONJ - O
inexpensive ADJ - O
PCR PROPN - O
- PUNCT - O
RFLP PROPN - O
genetic ADJ - O
tests NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

CYP2D6 NOUN - O
basic ADJ - O
genotyping VERB - O
as ADP - O
a DET - O
potential ADJ - O
tool NOUN - O
to PART - O
improve VERB - O
the DET - O
antiemetic ADJ - O
efficacy NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
in ADP - O
prophylaxis NOUN - O
of ADP - O
postoperative ADJ - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
current ADJ - O
manuscript NOUN - O
describes VERB - O
a DET - O
validated VERB - O
, PUNCT - O
responsive ADJ - O
and CCONJ - O
rapid ADJ - O
spectrofluorimetric ADJ - O
method NOUN - O
for ADP - O
quantifying VERB - O
ondansetron NN - B-MEDICINE
( PUNCT - O
OND NNP - B-ORG
) PUNCT - O
in ADP - O
authentic ADJ - O
form NOUN - O
, PUNCT - O
spiked VERB - O
human ADJ - O
plasma NOUN - O
and CCONJ - O
dosage NOUN - O
forms NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

There ADV - O
is VERB - O
growing VERB - O
evidence NOUN - O
that ADP - O
adjunctive ADJ - O
ondansetron NN - B-MEDICINE
treatment NOUN - O
improves VERB - O
symptomatology VERB - O
associated VERB - O
with ADP - O
schizophrenia NOUN - O
, PUNCT - O
particularly ADV - O
with ADP - O
respect NOUN - O
to ADP - O
the DET - O
positive ADJ - O
, PUNCT - O
negative ADJ - O
and CCONJ - O
cognitive ADJ - O
symptoms NOUN - O
. PUNCT - O

AIMS::This DET - O
randomized VERB - O
control NOUN - O
trial NOUN - O
compared VERB - O
adjunctive ADJ - O
( PUNCT - O
8 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
daily ADV - O
) PUNCT - O
ondansetron NN - B-MEDICINE
or CCONJ - O
placebo NOUN - O
to PART - O
commonly ADV - O
prescribed VERB - O
atypical ADJ - O
antipsychotics NOUN - O
for ADP - O
people NOUN - O
suffering VERB - O
with ADP - O
chronic ADJ - O
schizophrenia NOUN - O
( PUNCT - O
ClinicalTrials.gov PROPN - O
NCT01121042 PROPN - O
) PUNCT - O
. PUNCT - O

RESULTS::Longitudinal JJ - B-CARDINAL
analyses NOUN - O
revealed VERB - O
adjunctive ADJ - O
ondansetron NN - B-MEDICINE
provided VERB - O
significant ADJ - O
improvement NOUN - O
in ADP - O
the DET - O
cognitive ADJ - O
domain NOUN - O
( PUNCT - O
p<0.05 NOUN - O
) PUNCT - O
as ADP - O
measured VERB - O
by ADP - O
the DET - O
Positive ADJ - O
and CCONJ - O
Negative PROPN - O
Syndrome PROPN - O
Scale PROPN - O
between IN - B-DATE
baseline NN - I-DATE
and CC - I-DATE
week NN - I-DATE
12 CD - I-DATE
. PUNCT - O

The DET - O
analysis NOUN - O
of ADP - O
" PUNCT - O
Combination NNP - B-WORK_OF_ART
" PUNCT - O
showed VERB - O
ondansetron NN - B-MEDICINE
effect NOUN - O
on ADP - O
Total PROPN - O
Positive PROPN - O
and CCONJ - O
Negative PROPN - O
Syndrome PROPN - O
Scale PROPN - O
, PUNCT - O
approaching VERB - O
significance NOUN - O
by ADP - O
week NN - B-DATE
12 CD - I-DATE
( PUNCT - O
p=0.06 NOUN - O
) PUNCT - O
. PUNCT - O

CONCLUSION::This NN - B-PERSON
treatment NOUN - O
trial NOUN - O
provides VERB - O
some DET - O
support NOUN - O
for ADP - O
adjunctive ADJ - O
ondansetron NN - B-MEDICINE
medication NOUN - O
as ADP - O
a DET - O
treatment NOUN - O
for ADP - O
the DET - O
cognitive ADJ - O
disorganization NOUN - O
symptoms NOUN - O
of ADP - O
schizophrenia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Use NOUN - O
of ADP - O
palonosetron NOUN - O
and CCONJ - O
ondansetron NN - B-MEDICINE
in ADP - O
the DET - O
prophylaxis NOUN - O
of ADP - O
postoperative ADJ - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
in ADP - O
women NOUN - O
60 CD - B-DATE
years NNS - I-DATE
of IN - I-DATE
age NN - I-DATE
or CCONJ - O
older ADJ - O
undergoing VERB - O
laparoscopic ADJ - O
cholecystectomy NOUN - O
: PUNCT - O
A DET - O
randomised ADJ - O
double ADJ - O
- PUNCT - O
blind ADJ - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
aim NOUN - O
of ADP - O
this DET - O
randomized VERB - O
controlled VERB - O
triple ADJ - O
blind ADJ - O
trial NOUN - O
was VERB - O
to PART - O
compare VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
clonidine NOUN - O
with ADP - O
dexamethasone NOUN - O
versus ADP - O
ondansetron NN - B-MEDICINE
with ADP - O
dexamethasone NOUN - O
for ADP - O
postoperative ADJ - O
pain NOUN - O
, PUNCT - O
nausea NOUN - O
and CCONJ - O
vomiting VERB - O
prevention NOUN - O
in ADP - O
orthognathic ADJ - O
surgery NOUN - O
patients NOUN - O
. PUNCT - O

These DET - O
subjects NOUN - O
were VERB - O
randomly ADV - O
assigned VERB - O
to ADP - O
two CD - B-CARDINAL
equal ADJ - O
number NOUN - O
groups NOUN - O
, PUNCT - O
ondansetron NN - B-MEDICINE
or CCONJ - O
clonidine NOUN - O
. PUNCT - O

Patients NOUN - O
received VERB - O
either DET - O
oral ADJ - O
ondansetron NN - B-MEDICINE
8 CD - B-CARDINAL
mg NOUN - O
or CCONJ - O
oral ADJ - O
clonidine NOUN - O
150μg PROPN - O
as ADP - O
premedication NOUN - O
, PUNCT - O
1 CD - B-TIME
hour NN - I-TIME
before ADP - O
the DET - O
surgery NOUN - O
( PUNCT - O
both DET - O
dissolved VERB - O
in ADP - O
20 CD - B-CARDINAL
cc NOUN - O
of ADP - O
water NOUN - O
) PUNCT - O
. PUNCT - O

The DET - O
frequency NOUN - O
of ADP - O
postoperative ADJ - O
nausea NOUN - O
( PUNCT - O
PON NNP - B-ORG
) PUNCT - O
in ADP - O
the DET - O
ondansetron NN - B-MEDICINE
group NOUN - O
was VERB - O
less ADJ - O
than ADP - O
clonidine ADJ - O
( PUNCT - O
53.3 CD - B-PERCENT
% NN - I-PERCENT
vs ADP - O
73.3 CD - B-PERCENT
% NN - I-PERCENT
respectively ADV - O
) PUNCT - O
. PUNCT - O

There ADV - O
was VERB - O
no DET - O
postoperative NOUN - O
vomiting VERB - O
( PUNCT - O
POV NNP - B-ORG
) PUNCT - O
in ADP - O
the DET - O
ondansetron NN - B-MEDICINE
group NOUN - O
, PUNCT - O
but CCONJ - O
6.7 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
cases NOUN - O
in ADP - O
clonidine ADJ - O
group NOUN - O
suffered VERB - O
POV NNP - B-ORG
. PUNCT - O

Post ADJ - O
- ADJ - O
operative ADJ - O
nausea NOUN - O
in ADP - O
ondansetron NN - B-MEDICINE
group NOUN - O
occurred VERB - O
significantly ADV - O
later ADV - O
than ADP - O
clonidine ADJ - O
( PUNCT - O
525.0±233.2 CD - B-CARDINAL
vs ADP - O
100.0±34.0 CD - B-DATE
min NOUN - O
; PUNCT - O
p X - O
< X - O
0.001 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

On ADP - O
the DET - O
other ADJ - O
hand NOUN - O
, PUNCT - O
the DET - O
incidence NOUN - O
time NOUN - O
of ADP - O
post ADJ - O
- ADJ - O
operative ADJ - O
severe ADJ - O
pain NOUN - O
or CCONJ - O
in ADP - O
other ADJ - O
word NOUN - O
the DET - O
analgesia NOUN - O
time NOUN - O
in ADP - O
clonidine ADJ - O
group NOUN - O
was VERB - O
significantly ADV - O
more ADJ - O
than ADP - O
ondansetron NN - B-MEDICINE
one NUM - O
( PUNCT - O
875/0±68/5 CD - B-CARDINAL
vs ADP - O
614.3±159.1 CD - B-PRODUCT
min NOUN - O
; PUNCT - O
p VERB - O
< X - O
0.001 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
investigates VERB - O
risk NOUN - O
of ADP - O
specific ADJ - O
structural ADJ - O
birth NOUN - O
defects NOUN - O
associated VERB - O
with ADP - O
ondansetron NN - B-MEDICINE
exposure NOUN - O
during ADP - O
the DET - O
first JJ - B-ORDINAL
trimester NOUN - O
in ADP - O
a DET - O
large ADJ - O
US NNP - B-GPE
commercially ADV - O
- PUNCT - O
insured VERB - O
population NOUN - O
. PUNCT - O

Logistic ADJ - O
regression NOUN - O
was VERB - O
used VERB - O
to PART - O
measure VERB - O
the DET - O
association NOUN - O
between ADP - O
first JJ - B-ORDINAL
trimester NOUN - O
exposure NOUN - O
to ADP - O
ondansetron NN - B-MEDICINE
and CCONJ - O
risk NOUN - O
of ADP - O
cardiac ADJ - O
defects NOUN - O
, PUNCT - O
orofacial ADJ - O
clefts NOUN - O
and CCONJ - O
other ADJ - O
specific ADJ - O
structural ADJ - O
defects NOUN - O
in ADP - O
offspring NOUN - O
. PUNCT - O

First JJ - B-ORDINAL
trimester NOUN - O
exposure NOUN - O
to ADP - O
ondansetron NN - B-MEDICINE
was VERB - O
associated VERB - O
with ADP - O
increased VERB - O
risk NOUN - O
of ADP - O
cardiac ADJ - O
( PUNCT - O
OR CCONJ - O
: PUNCT - O
1.52 CD - B-PERCENT
95 CD - I-PERCENT
% NN - I-PERCENT
CI NOUN - O
: PUNCT - O
1.35 CD - B-CARDINAL
- SYM - O
1.70 NUM - O
) PUNCT - O
and CCONJ - O
orofacial NOUN - O
cleft NOUN - O
defects NOUN - O
( PUNCT - O
OR CCONJ - O
: PUNCT - O
1.32 CD - B-PERCENT
95 CD - I-PERCENT
% NN - I-PERCENT
CI NOUN - O
: PUNCT - O
0.76 CD - B-CARDINAL
- SYM - O
2.28 NUM - O
) PUNCT - O
in ADP - O
offspring NOUN - O
compared VERB - O
to ADP - O
women NOUN - O
with ADP - O
no DET - O
antiemetic ADJ - O
exposure NOUN - O
during ADP - O
pregnancy NOUN - O
. PUNCT - O

In ADP - O
a DET - O
large ADJ - O
, PUNCT - O
US NNP - B-GPE
population NOUN - O
we PRON - O
found VERB - O
a DET - O
statistically ADV - O
significant ADJ - O
association NOUN - O
between ADP - O
early ADJ - O
pregnancy NOUN - O
ondansetron NN - B-MEDICINE
exposure NOUN - O
and CCONJ - O
specific ADJ - O
structural ADJ - O
birth NOUN - O
defects VERB - O
in ADP - O
offspring NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

First JJ - B-ORDINAL
trimester NOUN - O
ondansetron NN - B-MEDICINE
exposure NOUN - O
and CCONJ - O
risk NOUN - O
of ADP - O
structural ADJ - O
birth NOUN - O
defects NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Importance NOUN - O
: PUNCT - O
Evidence NOUN - O
for ADP - O
the DET - O
fetal ADJ - O
safety NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
, PUNCT - O
a DET - O
5-HT3 ADJ - O
receptor NOUN - O
antagonist NOUN - O
that ADJ - O
is VERB - O
commonly ADV - O
prescribed VERB - O
for ADP - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
during ADP - O
pregnancy NOUN - O
, PUNCT - O
is VERB - O
limited ADJ - O
and CCONJ - O
conflicting ADJ - O
. PUNCT - O

Objective NOUN - O
: PUNCT - O
To PART - O
evaluate VERB - O
the DET - O
association NOUN - O
between ADP - O
ondansetron NN - B-MEDICINE
exposure NOUN - O
during ADP - O
pregnancy NOUN - O
and CCONJ - O
risk NOUN - O
of ADP - O
congenital ADJ - O
malformations NOUN - O
. PUNCT - O

Among ADP - O
1 CD - B-CARDINAL
  SPACE - O
816 CD - B-CARDINAL
  SPACE - O
414 CD - B-CARDINAL
pregnancies NOUN - O
( PUNCT - O
mean VERB - O
age NOUN - O
of ADP - O
mothers NOUN - O
, PUNCT - O
24.3 CD - B-CARDINAL
[ PUNCT - O
5.8 CD - B-CARDINAL
] PUNCT - O
years NOUN - O
) PUNCT - O
, PUNCT - O
88 CD - B-CARDINAL
  SPACE - O
467 CD - B-CARDINAL
( PUNCT - O
4.9 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
were VERB - O
exposed VERB - O
to ADP - O
ondansetron NN - B-MEDICINE
during ADP - O
the DET - O
first JJ - B-ORDINAL
trimester NOUN - O
. PUNCT - O

Among ADP - O
offspring NOUN - O
of ADP - O
mothers NOUN - O
enrolled VERB - O
in ADP - O
Medicaid NNP - B-ORG
, PUNCT - O
first JJ - B-ORDINAL
- PUNCT - O
trimester NOUN - O
exposure NOUN - O
to ADP - O
ondansetron NN - B-MEDICINE
was VERB - O
not ADV - O
associated VERB - O
with ADP - O
cardiac ADJ - O
malformations NOUN - O
or CCONJ - O
congenital ADJ - O
malformations NOUN - O
overall ADV - O
after ADP - O
accounting VERB - O
for ADP - O
measured ADJ - O
confounders NOUN - O
but CCONJ - O
was VERB - O
associated VERB - O
with ADP - O
a DET - O
small ADJ - O
increased VERB - O
risk NOUN - O
of ADP - O
oral ADJ - O
clefts NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

AIM PROPN - O
: PUNCT - O
To PART - O
compare VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
metoclopramide NOUN - O
and CCONJ - O
ondansetron NN - B-MEDICINE
in ADP - O
improving VERB - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
in ADP - O
patients NOUN - O
referred VERB - O
to ADP - O
the DET - O
emergency NOUN - O
department NOUN - O
with ADP - O
a DET - O
chief ADJ - O
complaint NOUN - O
of ADP - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
. PUNCT - O

Group NOUN - O
1 CD - B-CARDINAL
consisted VERB - O
of ADP - O
90 CD - B-CARDINAL
subjects NOUN - O
receiving VERB - O
10 CD - B-CARDINAL
mg PART - O
intravenous ADJ - O
metoclopramide NOUN - O
and CCONJ - O
group NOUN - O
2 CD - B-CARDINAL
including VERB - O
90 CD - B-CARDINAL
subjects NOUN - O
receiving VERB - O
4 CD - B-CARDINAL
mg ADV - O
intravenous ADJ - O
ondansetron NN - B-MEDICINE
. PUNCT - O

Mean VERB - O
and CCONJ - O
standard ADJ - O
deviation NOUN - O
of ADP - O
vomiting VERB - O
at ADP - O
0 CD - B-TIME
minutes NNS - I-TIME
showed VERB - O
no DET - O
significant ADJ - O
difference NOUN - O
between ADP - O
the DET - O
two CD - B-CARDINAL
groups NOUN - O
, PUNCT - O
but CCONJ - O
the DT - B-TIME
remaining VBG - I-TIME
minutes NNS - I-TIME
, PUNCT - O
15 CD - B-DATE
, PUNCT - O
30 CD - B-DATE
, PUNCT - O
45 CD - B-DATE
, PUNCT - O
60 CD - B-DATE
and CCONJ - O
120 CD - B-CARDINAL
, PUNCT - O
exhibited VERB - O
significant ADJ - O
difference NOUN - O
as ADP - O
a DET - O
comparison NOUN - O
of ADP - O
two CD - B-CARDINAL
groups NOUN - O
, PUNCT - O
indicating VERB - O
that ADP - O
vomiting NOUN - O
in ADP - O
the DET - O
metoclopramide NOUN - O
group NOUN - O
was VERB - O
higher ADJ - O
than ADP - O
ondansetron NN - B-MEDICINE
group NOUN - O
. PUNCT - O

Our ADJ - O
findings NOUN - O
indicated VERB - O
that ADP - O
ondansetron NN - B-MEDICINE
was VERB - O
more ADV - O
effective ADJ - O
than ADP - O
metoclopramide VERB - O
in ADP - O
preventing VERB - O
and CCONJ - O
improving VERB - O
vomiting NOUN - O
in ADP - O
patients NOUN - O
referred VERB - O
to ADP - O
emergency NOUN - O
renal ADJ - O
colic NOUN - O
, PUNCT - O
where ADV - O
can VERB - O
be VERB - O
used VERB - O
with ADP - O
more ADJ - O
efficacy NOUN - O
and CCONJ - O
more ADV - O
acceptable ADJ - O
side NOUN - O
effects NOUN - O
to PART - O
improve VERB - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
determine VERB - O
whether ADP - O
single ADJ - O
- PUNCT - O
dose NOUN - O
oral ADJ - O
ondansetron NN - B-MEDICINE
administration NOUN - O
to ADP - O
children NOUN - O
with ADP - O
vomiting VERB - O
as ADP - O
a DET - O
result NOUN - O
of ADP - O
acute ADJ - O
gastroenteritis NOUN - O
without ADP - O
dehydration NOUN - O
reduces VERB - O
administration NOUN - O
of ADP - O
intravenous ADJ - O
fluid ADJ - O
rehydration NOUN - O
. PUNCT - O

Patients NOUN - O
were VERB - O
randomly ADV - O
assigned VERB - O
( PUNCT - O
1:1 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
through ADP - O
an DET - O
Internet NOUN - O
- PUNCT - O
based VERB - O
randomization NOUN - O
service NOUN - O
using VERB - O
a DET - O
stratified ADJ - O
variable ADJ - O
- PUNCT - O
block NOUN - O
randomization NOUN - O
scheme NOUN - O
, PUNCT - O
to ADP - O
single ADJ - O
- PUNCT - O
dose NOUN - O
oral ADJ - O
ondansetron NN - B-MEDICINE
or CCONJ - O
placebo NOUN - O
. PUNCT - O

Intravenous ADJ - O
rehydration NOUN - O
use NOUN - O
was VERB - O
12.1 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
38/314 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O
11.9 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
37/312 LS - B-ORG
) PUNCT - O
in ADP - O
the DET - O
placebo NOUN - O
and CCONJ - O
ondansetron NN - B-MEDICINE
groups NOUN - O
, PUNCT - O
respectively ADV - O
( PUNCT - O
odds NOUN - O
ratio NOUN - O
0.98 CD - B-CARDINAL
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
confidence NOUN - O
interval NOUN - O
[ PUNCT - O
CI NNP - B-ORG
] PUNCT - O
0.60 CD - B-CARDINAL
to ADP - O
1.61 CD - B-CARDINAL
; PUNCT - O
difference NOUN - O
0.2 CD - B-PERCENT
% NN - I-PERCENT
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
of ADP - O
the DET - O
difference NOUN - O

Bolus PROPN - O
fluid ADJ - O
administration NOUN - O
occurred VERB - O
within ADP - O
72 CD - B-TIME
hours NNS - I-TIME
of ADP - O
randomization NOUN - O
in ADP - O
10.8 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
34/314 NNP - B-CARDINAL
) PUNCT - O
and CCONJ - O
10.3 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
27/312 NOUN - O
) PUNCT - O
of ADP - O
children NOUN - O
administered VERB - O
placebo NOUN - O
and CCONJ - O
ondansetron NN - B-MEDICINE
, PUNCT - O
respectively ADV - O
( PUNCT - O
odds NOUN - O
ratio NOUN - O
0.95 CD - B-CARDINAL
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NOUN - O
0.56 NUM - O
to ADP - O
1.59 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

Oral ADJ - O
administration NOUN - O
of ADP - O
a DET - O
single ADJ - O
dose NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
did VERB - O
not ADV - O
result VERB - O
in ADP - O
a DET - O
reduction NOUN - O
in ADP - O
intravenous ADJ - O
rehydration NOUN - O
use NOUN - O
. PUNCT - O

In ADP - O
children NOUN - O
without ADP - O
dehydration NOUN - O
, PUNCT - O
ondansetron NN - B-MEDICINE
does VERB - O
not ADV - O
improve VERB - O
clinical ADJ - O
outcomes NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
selective ADJ - O
5-HT3 ADJ - O
receptor NOUN - O
antagonist NOUN - O
ondansetron NN - B-MEDICINE
decreases VERB - O
the DET - O
activity NOUN - O
of ADP - O
interneurons NOUN - O
with ADP - O
a DET - O
concomitant ADJ - O
increase NOUN - O
in ADP - O
the DET - O
activity NOUN - O
of ADP - O
pyramidal ADJ - O
neurons NOUN - O
in ADP - O
the DET - O
hippocampus NOUN - O
of ADP - O
freely ADV - O
moving VERB - O
rats NOUN - O
. PUNCT - O

We PRON - O
investigated VERB - O
the DET - O
effects NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
alone ADJ - O
and CCONJ - O
in ADP - O
combination NOUN - O
with ADP - O
donepezil NOUN - O
on ADP - O
hippocampal ADJ - O
oscillations NOUN - O
using VERB - O
in ADP - O
vivo NOUN - O
electrophysiology NOUN - O
. PUNCT - O

In ADP - O
addition NOUN - O
, PUNCT - O
potential ADJ - O
pharmacokinetic ADJ - O
interactions NOUN - O
between ADP - O
donepezil NOUN - O
and CCONJ - O
ondansetron NN - B-MEDICINE
were VERB - O
assessed ADJ - O
. PUNCT - O

This DET - O
study NOUN - O
demonstrates VERB - O
that ADP - O
ondansetron NN - B-MEDICINE
potentiates VERB - O
the DET - O
effects NOUN - O
of ADP - O
donepezil NOUN - O
on ADP - O
elicited VERB - O
neuronal ADJ - O
oscillations NOUN - O
and CCONJ - O
suggests VERB - O
that ADP - O
5-HT3 JJ - B-CARDINAL
receptor NOUN - O
antagonists NOUN - O
may VERB - O
be VERB - O
beneficial ADJ - O
as ADP - O
adjunctive ADJ - O
therapy NOUN - O
to ADP - O
AChEIs NNP - B-PERSON
for ADP - O
the DET - O
symptomatic ADJ - O
treatment NOUN - O
of ADP - O
cognitive ADJ - O
deficits NOUN - O
in ADP - O
AD NN - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
5-HT3 JJ - B-CARDINAL
receptor NOUN - O
antagonist NOUN - O
ondansetron NN - B-MEDICINE
potentiates VERB - O
the DET - O
effects NOUN - O
of ADP - O
the DET - O
acetylcholinesterase ADJ - O
inhibitor NOUN - O
donepezil NOUN - O
on ADP - O
neuronal ADJ - O
network NOUN - O
oscillations NOUN - O
in ADP - O
the DET - O
rat NOUN - O
dorsal NOUN - O
hippocampus NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
objective NOUN - O
of ADP - O
this DET - O
trial NOUN - O
was VERB - O
to PART - O
evaluate VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
dexmedetomidine NOUN - O
and CCONJ - O
ondansetron NN - B-MEDICINE
to PART - O
reduce VERB - O
the DET - O
incidence NOUN - O
and CCONJ - O
severity NOUN - O
of ADP - O
shivering NOUN - O
after ADP - O
intrathecal ADJ - O
blocks NOUN - O
. PUNCT - O

Group NNP - B-ORG
S NNP - I-ORG
patients NOUN - O
( PUNCT - O
placebo NOUN - O
) PUNCT - O
were VERB - O
administered VERB - O
saline NOUN - O
, PUNCT - O
Group NNP - B-ORG
O NNP - I-ORG
( PUNCT - O
ondansetron NN - B-MEDICINE
) PUNCT - O
were VERB - O
given VERB - O
8 CD - B-CARDINAL
  SPACE - O
mg ADP - O
ondansetron NN - B-MEDICINE
, PUNCT - O
and CCONJ - O
Group PROPN - O
D PROPN - O
( PUNCT - O
dexmedetomidine NOUN - O
) PUNCT - O
were VERB - O
given VERB - O
1 CD - B-CARDINAL
  SPACE - O
μg PROPN - O
/ SYM - O
kg NOUN - O
of ADP - O
dexmedetomidine NOUN - O
. PUNCT - O

Prophylactic ADJ - O
administrations NOUN - O
of ADP - O
dexmedetomidine NOUN - O
or CCONJ - O
ondansetron NN - B-MEDICINE
efficiently ADV - O
decrease VERB - O
the DET - O
incidence NOUN - O
and CCONJ - O
severity NOUN - O
of ADP - O
shivering NOUN - O
after ADP - O
spinal ADJ - O
anesthesia NOUN - O
as ADP - O
compared VERB - O
to ADP - O
placebo VERB - O
without ADP - O
significant ADJ - O
difference NOUN - O
between ADP - O
their ADJ - O
efficacies NOUN - O
when ADV - O
compared VERB - O
to ADP - O
each DET - O
other ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
was VERB - O
aimed VERB - O
to PART - O
compare VERB - O
the DET - O
effects NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
, PUNCT - O
haloperidol NOUN - O
, PUNCT - O
and CCONJ - O
dexmedetomidine NOUN - O
for ADP - O
reducing VERB - O
postoperative ADJ - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
( PUNCT - O
PONV PROPN - O
) PUNCT - O
after ADP - O
laparoscopic ADJ - O
cholecystectomy NOUN - O
. PUNCT - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
114 CD - B-CARDINAL
patients NOUN - O
with ADP - O
abdominal ADJ - O
hysterectomy NOUN - O
were VERB - O
randomly ADV - O
assigned VERB - O
to ADP - O
three CD - B-CARDINAL
groups NOUN - O
( PUNCT - O
ondansetron NN - B-MEDICINE
, PUNCT - O
haloperidol NOUN - O
, PUNCT - O
and CCONJ - O
dexmedetomidine NOUN - O
) PUNCT - O
using VERB - O
the DET - O
cubull ADJ - O
randomisation NOUN - O
method NOUN - O
. PUNCT - O

The DET - O
results NOUN - O
revealed VERB - O
a DET - O
significant ADJ - O
difference NOUN - O
between ADP - O
the DET - O
three CD - B-CARDINAL
groups NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
, PUNCT - O
haloperidol NOUN - O
and CCONJ - O
dexmedetomidine NOUN - O
in ADP - O
terms NOUN - O
of ADP - O
scorpion NOUN - O
vomiting VERB - O
in ADP - O
recovery NOUN - O
, PUNCT - O
2 CD - B-TIME
and CC - I-TIME
4 CD - I-TIME
hours NNS - I-TIME
after ADP - O
surgery NOUN - O
, PUNCT - O
and CCONJ - O
vomiting VERB - O
score NOUN - O
was VERB - O
significantly ADV - O
lower ADJ - O
in ADP - O
the DET - O
ondansetron NN - B-MEDICINE
group NOUN - O
compared VERB - O
with ADP - O
the DET - O
other ADJ - O
two CD - B-CARDINAL
groups NOUN - O
( PUNCT - O
P NOUN - O
= SYM - O
0.04 CD - B-CARDINAL
; PUNCT - O
P NOUN - O
= SYM - O
0.02 CD - B-CARDINAL
; PUNCT - O
P NOUN - O
= SYM - O
0.001 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

There ADV - O
was VERB - O
a DET - O
significant ADJ - O
difference NOUN - O
between ADP - O
the DET - O
three CD - B-CARDINAL
groups NOUN - O
of ADP - O
e NOUN - O
ondansetron NN - B-MEDICINE
, PUNCT - O
haloperidol NOUN - O
and CCONJ - O
dexmedetomidine NOUN - O
regarding VERB - O
the DET - O
mean NOUN - O
dose NOUN - O
of ADP - O
metoclopramide NOUN - O
in ADP - O
mg NOUN - O
for ADP - O
24 CD - B-TIME
hours NNS - I-TIME
after ADP - O
surgery NOUN - O
. PUNCT - O

Therefore ADV - O
, PUNCT - O
the DET - O
dosage NOUN - O
of ADP - O
dexmedetomidine NOUN - O
in ADP - O
the DET - O
ondansetron NN - B-MEDICINE
group NOUN - O
was VERB - O
less ADJ - O
than ADP - O
the DET - O
other ADJ - O
two CD - B-CARDINAL
groups NOUN - O
( PUNCT - O
P NOUN - O
= SYM - O
0.001 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

However ADV - O
, PUNCT - O
the DET - O
effect NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
was VERB - O
found VERB - O
to PART - O
be VERB - O
more ADJ - O
than ADP - O
the DET - O
other ADJ - O
two CD - B-CARDINAL
drugs NOUN - O
in ADP - O
reducing VERB - O
PONV PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Domperidone NOUN - O
and CCONJ - O
ondansetron NN - B-MEDICINE
are VERB - O
the DET - O
most ADV - O
commonly ADV - O
known VERB - O
antiemetic ADJ - O
drugs NOUN - O
. PUNCT - O

A DET - O
single ADJ - O
oral ADJ - O
dose NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
has VERB - O
been VERB - O
shown VERB - O
to PART - O
reduce VERB - O
the DET - O
risk NOUN - O
of ADP - O
recurrent NOUN - O
vomiting NOUN - O
, PUNCT - O
the DET - O
need NOUN - O
for ADP - O
intravenous ADJ - O
fluids NOUN - O
and CCONJ - O
hospital NOUN - O
admissions NOUN - O
in ADP - O
children NOUN - O
with ADP - O
acute ADJ - O
gastroenteritis NOUN - O
. PUNCT - O

There ADV - O
is VERB - O
enough ADJ - O
evidence NOUN - O
to PART - O
support VERB - O
ondansetron NN - B-MEDICINE
administration NOUN - O
in ADP - O
children NOUN - O
, PUNCT - O
so ADP - O
the DET - O
clinical ADJ - O
use NOUN - O
can VERB - O
be VERB - O
defined VERB - O
as ADP - O
" PUNCT - O
off ADP - O
- PUNCT - O
label NOUN - O
/ PUNCT - O
on ADP - O
evidence NOUN - O
" PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Nausea NOUN - O
was VERB - O
reduced VERB - O
more ADV - O
significantly ADV - O
in ADP - O
the DET - O
ondansetron NN - B-MEDICINE
- PUNCT - O
treated VERB - O
group NOUN - O
( PUNCT - O
P NOUN - O
  SPACE - O
< X - O
  SPACE - O
0.05 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

There ADV - O
were VERB - O
more ADJ - O
side NOUN - O
- PUNCT - O
effects NOUN - O
seen VERB - O
in ADP - O
the DET - O
promethazine NOUN - O
- PUNCT - O
treated VERB - O
when ADV - O
compared VERB - O
to ADP - O
the DET - O
group NOUN - O
with ADP - O
ondansetron NN - B-MEDICINE
treatment NOUN - O
( PUNCT - O
P NOUN - O
  SPACE - O
< X - O
  SPACE - O
0.001 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

The DET - O
ondansetron NN - B-MEDICINE
- PUNCT - O
treated VERB - O
group NOUN - O
showed VERB - O
a DET - O
greater ADJ - O
need NOUN - O
for ADP - O
re NOUN - O
- NOUN - O
administration NOUN - O
of ADP - O
the DET - O
medication NOUN - O
( PUNCT - O
50.6 CD - B-PERCENT
% NN - I-PERCENT
vs. ADP - O
27.1 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
. PUNCT - O

The DET - O
relief NOUN - O
score NOUN - O
was VERB - O
significantly ADV - O
higher ADJ - O
in ADP - O
the DET - O
ondansetron NN - B-MEDICINE
- PUNCT - O
treated VERB - O
group NOUN - O
compared VERB - O
with ADP - O
the DET - O
group NOUN - O
received VERB - O
promethazine NOUN - O
( PUNCT - O
P NOUN - O
  SPACE - O
< X - O
  SPACE - O
0.001 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

Our ADJ - O
results NOUN - O
indicated VERB - O
that ADP - O
while ADP - O
promethazine NOUN - O
cures VERB - O
peripheral ADJ - O
vertigo NOUN - O
more ADV - O
efficiently ADV - O
, PUNCT - O
ondansetron NN - B-MEDICINE
is VERB - O
more ADV - O
beneficial ADJ - O
for ADP - O
the DET - O
improvement NOUN - O
of ADP - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
prophylactic ADJ - O
ondansetron NN - B-MEDICINE
and/or CCONJ - O
continuous ADJ - O
infusion NOUN - O
of ADP - O
phenylephrine NOUN - O
on ADP - O
spinal ADJ - O
anesthesia NOUN - O
- PUNCT - O
induced VERB - O
hypotension NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
separately ADV - O
compare VERB - O
effectiveness NOUN - O
of ADP - O
intravenous ADJ - O
( PUNCT - O
IV NNP - B-ORG
) PUNCT - O
droperidol NOUN - O
1.25 CD - B-CARDINAL
mg PRON - O
and CCONJ - O
ondansetron NN - B-MEDICINE
8 CD - B-CARDINAL
mg NOUN - O
IV NNP - B-ORG
with ADP - O
0.9 CD - B-PERCENT
% NN - I-PERCENT
saline NOUN - O
placebo NOUN - O
for ADP - O
adult NOUN - O
emergency NOUN - O
department NOUN - O
( PUNCT - O
ED NNP - B-ORG
) PUNCT - O
patients NOUN - O
with ADP - O
nausea NOUN - O
. PUNCT - O

Of ADP - O
215 CD - B-CARDINAL
patients NOUN - O
, PUNCT - O
73 CD - B-CARDINAL
( PUNCT - O
34 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
71 CD - B-DATE
( PUNCT - O
33 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
and CCONJ - O
71 CD - B-DATE
( PUNCT - O
33 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
received VERB - O
droperidol NOUN - O
, PUNCT - O
ondansetron NN - B-MEDICINE
and CCONJ - O
placebo NOUN - O
. PUNCT - O

For ADP - O
adult NOUN - O
ED NNP - B-ORG
patients NOUN - O
with ADP - O
nausea NOUN - O
, PUNCT - O
superiority NOUN - O
was VERB - O
not ADV - O
demonstrated VERB - O
for ADP - O
droperidol NOUN - O
or CCONJ - O
ondansetron NN - B-MEDICINE
over ADP - O
placebo NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Randomized ADJ - O
placebo NOUN - O
- PUNCT - O
controlled VERB - O
trial NOUN - O
of ADP - O
droperidol NOUN - O
and CCONJ - O
ondansetron NN - B-MEDICINE
for ADP - O
adult NOUN - O
emergency NOUN - O
department NOUN - O
patients NOUN - O
with ADP - O
nausea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
potent ADJ - O
hERG NOUN - O
channel NOUN - O
blocking VERB - O
drug NOUN - O
ondansetron NN - B-MEDICINE
is VERB - O
used VERB - O
off ADP - O
- PUNCT - O
label NOUN - O
for ADP - O
treatment NOUN - O
of ADP - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
in ADP - O
early ADJ - O
pregnancy NOUN - O
. PUNCT - O

Some DET - O
human ADJ - O
epidemiological ADJ - O
studies NOUN - O
have VERB - O
associated VERB - O
ondansetron NN - B-MEDICINE
with ADP - O
fetal ADJ - O
cardiovascular ADJ - O
defects NOUN - O
and CCONJ - O
orofacial NOUN - O
clefts NOUN - O
. PUNCT - O

Together ADV - O
the DET - O
results NOUN - O
suggest VERB - O
that ADP - O
ondansetron NN - B-MEDICINE
can VERB - O
have VERB - O
teratogenic ADJ - O
potential NOUN - O
in ADP - O
rats NOUN - O
and CCONJ - O
humans NOUN - O
mediated VERB - O
via ADP - O
hERG NOUN - O
block NOUN - O
and CCONJ - O
severe ADJ - O
heart NOUN - O
rhythm NOUN - O
disturbances NOUN - O
in ADP - O
the DET - O
embryo NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Recently ADV - O
, PUNCT - O
5-HT3 ADJ - O
antagonist NOUN - O
ondansetron NN - B-MEDICINE
has VERB - O
been VERB - O
associated VERB - O
with ADP - O
reduction NOUN - O
of ADP - O
bowel NOUN - O
movement NOUN - O
in ADP - O
a DET - O
small ADJ - O
series NOUN - O
. PUNCT - O

The DET - O
aim NOUN - O
of ADP - O
this DET - O
analysis NOUN - O
was VERB - O
to PART - O
assess VERB - O
effectiveness NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
for ADP - O
symptomatic ADJ - O
treatment NOUN - O
of ADP - O
carcinoid NOUN - O
syndrome NOUN - O
. PUNCT - O

We PRON - O
have VERB - O
analyzed VERB - O
patients NOUN - O
given VERB - O
ondansetron NN - B-MEDICINE
as ADP - O
bridging VERB - O
therapy NOUN - O
for ADP - O
refractory ADJ - O
carcinoid NOUN - O
syndrome NOUN - O
. PUNCT - O

Remarkably ADV - O
, PUNCT - O
in ADP - O
85 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
11/13 CD - B-CARDINAL
) PUNCT - O
ondansetron NN - B-MEDICINE
resulted VERB - O
in ADP - O
a DET - O
clinically ADV - O
relevant ADJ - O
decrease NOUN - O
of ADP - O
bowel NOUN - O
movements NOUN - O
to ADP - O
a DET - O
median NOUN - O
of ADP - O
3 CD - B-CARDINAL
( PUNCT - O
1 NUM - O
- SYM - O
4 NUM - O
) PUNCT - O
. PUNCT - O

The DET - O
median ADJ - O
time NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
intake NOUN - O
was VERB - O
29 CD - B-DATE
days NNS - I-DATE
( PUNCT - O
7 CD - B-DATE
days NNS - I-DATE
to IN - I-DATE
29 CD - I-DATE
months NNS - I-DATE
) PUNCT - O
. PUNCT - O

In ADP - O
four CD - B-CARDINAL
patients NOUN - O
, PUNCT - O
diarrhea NOUN - O
recurred VERB - O
after ADP - O
initial ADJ - O
improvement NOUN - O
at ADP - O
an DET - O
interval NOUN - O
of ADP - O
22 CD - B-DATE
- SYM - I-DATE
43 CD - I-DATE
days NNS - I-DATE
, PUNCT - O
whereas ADP - O
the DET - O
remaining VERB - O
seven CD - B-CARDINAL
had VERB - O
an DET - O
ongoing ADJ - O
benefit NOUN - O
, PUNCT - O
including VERB - O
two CD - B-CARDINAL
long ADJ - O
- PUNCT - O
term NOUN - O
responders NOUN - O
who NOUN - O
refused VERB - O
further ADJ - O
therapy NOUN - O
because ADP - O
of ADP - O
pronounced VERB - O
decrease NOUN - O
of ADP - O
symptoms NOUN - O
( PUNCT - O
ondansetron NN - B-MEDICINE
for ADP - O
14 CD - B-CARDINAL
+ NOUN - O
and CCONJ - O
29 CD - B-DATE
+ NNS - I-DATE
months NNS - I-DATE
) PUNCT - O
. PUNCT - O

In ADP - O
this DET - O
article NOUN - O
, PUNCT - O
the DET - O
authors NOUN - O
suggest VERB - O
the DET - O
5-HT3 JJ - B-CARDINAL
receptor NOUN - O
antagonist NOUN - O
ondansetron NN - B-MEDICINE
as ADP - O
potential ADJ - O
symptomatic ADJ - O
therapy NOUN - O
for ADP - O
patients NOUN - O
with ADP - O
refractory ADJ - O
diarrhea NOUN - O
due ADJ - O
to ADP - O
carcinoid ADJ - O
syndrome NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

At ADP - O
the DET - O
time NOUN - O
of ADP - O
wound NOUN - O
closure NOUN - O
, PUNCT - O
patients NOUN - O
in ADP - O
group NOUN - O
A DET - O
received VERB - O
ondansetron NN - B-MEDICINE
8 CD - B-QUANTITY
mg NN - I-QUANTITY
intravenous ADJ - O
( PUNCT - O
IV NNP - B-ORG
) PUNCT - O
+ CCONJ - O
dexamethasone NOUN - O
4 CD - B-CARDINAL
mg NOUN - O
IV NN - B-ORG
and CCONJ - O
group NOUN - O
B PROPN - O
received VERB - O
palonosetron NOUN - O
0.075 CD - B-QUANTITY
mg NN - I-QUANTITY
IV NNP - I-QUANTITY
+ CC - I-QUANTITY
dexamethasone NOUN - O
4 CD - B-CARDINAL
mg NOUN - O
IV NNP - B-ORG
. PUNCT - O

Postoperatively ADV - O
for ADP - O
48 CD - B-TIME
hours NNS - I-TIME
, PUNCT - O
group NOUN - O
A DET - O
patients NOUN - O
received VERB - O
ondansetron NN - B-MEDICINE
4 CD - B-CARDINAL
mg NUM - O
8 CD - B-CARDINAL
hourly ADJ - O
IV NNP - B-ORG
, PUNCT - O
group NOUN - O
B NOUN - O
patients NOUN - O
received VERB - O
normal ADJ - O
saline NOUN - O
8 CD - B-CARDINAL
hourly ADJ - O
IV NNP - B-ORG
in ADP - O
2 CD - B-CARDINAL
cc NOUN - O
syringe NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparison NOUN - O
of ADP - O
palonosetron NOUN - O
and CCONJ - O
dexamethasone VERB - O
with ADP - O
ondansetron NN - B-MEDICINE
and CCONJ - O
dexamethasone VERB - O
for ADP - O
postoperative ADJ - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
in ADP - O
postchemotherapy ADJ - O
ovarian ADJ - O
cancer NOUN - O
surgeries NOUN - O
requiring VERB - O
opioid ADV - O
- PUNCT - O
based VERB - O
patient NOUN - O
- PUNCT - O
controlled VERB - O
analgesia NOUN - O
: PUNCT - O
A DET - O
randomised ADJ - O
, PUNCT - O
double ADJ - O
- PUNCT - O
blind ADJ - O
, PUNCT - O
active ADJ - O
controlled VERB - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
aimed VERB - O
to PART - O
evaluate VERB - O
the DET - O
effect NOUN - O
of ADP - O
a DET - O
pharmacist NOUN - O
- PUNCT - O
led VERB - O
educational ADJ - O
intervention NOUN - O
on ADP - O
administration NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
in ADP - O
patients NOUN - O
receiving VERB - O
IV NNP - B-ORG
opioid ADJ - O
analgesia NOUN - O
in ADP - O
the DET - O
emergency NOUN - O
department NOUN - O
. PUNCT - O

During ADP - O
October NNP - B-DATE
and CCONJ - O
November NNP - B-DATE
2015 CD - I-DATE
, PUNCT - O
emergency NOUN - O
medicine NOUN - O
pharmacists NOUN - O
completed VERB - O
an DET - O
educational ADJ - O
initiative NOUN - O
targeting VERB - O
medical ADJ - O
and CCONJ - O
nursing NOUN - O
staff NOUN - O
designed VERB - O
to PART - O
reduce VERB - O
prophylactic ADJ - O
administration NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
. PUNCT - O

The DET - O
primary ADJ - O
outcome NOUN - O
was VERB - O
the DET - O
change NOUN - O
in ADP - O
the DET - O
proportion NOUN - O
of ADP - O
prophylactic ADJ - O
administration NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
with ADP - O
IV NNP - B-ORG
opioids NOUN - O
for ADP - O
acute ADJ - O
pain NOUN - O
in ADP - O
the DET - O
emergency NOUN - O
department NOUN - O
. PUNCT - O

The DET - O
proportion NOUN - O
of ADP - O
patients NOUN - O
administered VERB - O
prophylactic ADJ - O
ondansetron NN - B-MEDICINE
decreased VERB - O
from ADP - O
41 CD - B-PERCENT
% NN - I-PERCENT
in ADP - O
the DET - O
preintervention NOUN - O
period NOUN - O
to ADP - O
26 CD - B-PERCENT
% NN - I-PERCENT
in ADP - O
the DET - O
postintervention NOUN - O
period NOUN - O
( PUNCT - O
difference NOUN - O
95 CD - B-PERCENT
% NN - I-PERCENT
confidence NOUN - O
interval NOUN - O
[ PUNCT - O
CI NNP - B-ORG
] PUNCT - O
4.8 CD - B-CARDINAL
to ADP - O
25.9 CD - B-CARDINAL
, PUNCT - O
P NOUN - O
  SPACE - O
= SYM - O
0.005 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

An DET - O
overall ADJ - O
decrease NOUN - O
in ADP - O
the DET - O
incidence NOUN - O
of ADP - O
administration NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
from ADP - O
85 CD - B-PERCENT
% NN - I-PERCENT
to IN - I-PERCENT
61 CD - I-PERCENT
% NN - I-PERCENT
was VERB - O
observed VERB - O
( PUNCT - O
difference NOUN - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
14.4 NUM - O
to ADP - O
33.6 CD - B-CARDINAL
, PUNCT - O
P NOUN - O
< X - O
0.001 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

Medical ADJ - O
and CCONJ - O
nursing NOUN - O
staff NOUN - O
education NOUN - O
yielded VERB - O
a DET - O
significant ADJ - O
reduction NOUN - O
in ADP - O
the DET - O
administration NOUN - O
of ADP - O
prophylactic ADJ - O
ondansetron NN - B-MEDICINE
for ADP - O
patients NOUN - O
receiving VERB - O
IV NNP - B-ORG
opioids NOUN - O
in ADP - O
the DET - O
emergency NOUN - O
department NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
isolation NOUN - O
and CCONJ - O
identification NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
metabolites NOUN - O
were VERB - O
investigated VERB - O
in ADP - O
our ADJ - O
research NOUN - O
. PUNCT - O

The DET - O
feces NOUN - O
and CCONJ - O
bile NOUN - O
samples NOUN - O
collected VERB - O
after ADP - O
oral ADJ - O
administration NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
were VERB - O
extracted VERB - O
and CCONJ - O
then ADV - O
isolated VERB - O
by ADP - O
semi ADJ - O
- ADJ - O
preparative ADJ - O
HPLC NNP - B-ORG
. PUNCT - O

In ADP - O
rats NOUN - O
feces NOUN - O
, PUNCT - O
a DET - O
total NOUN - O
of ADP - O
four CD - B-CARDINAL
metabolites NOUN - O
were VERB - O
isolated VERB - O
and CCONJ - O
elucidated VERB - O
including VERB - O
7-hydroxyl CD - B-QUANTITY
- HYPH - I-QUANTITY
ondansetron NN - I-MEDICINE
( PUNCT - O
M1 PROPN - O
) PUNCT - O
, PUNCT - O
8-hydroxyl CD - B-QUANTITY
- HYPH - I-QUANTITY
ondansetron NN - I-MEDICINE
( PUNCT - O
M2 PROPN - O
) PUNCT - O
, PUNCT - O
7-hydroxyl CD - B-PERSON
- HYPH - I-PERSON
N NN - I-PERSON
- PUNCT - O
desmethyl NOUN - O
- PUNCT - O
ondansetron NN - B-MEDICINE
( PUNCT - O
M3 PROPN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
8-hydroxyl CD - B-CARDINAL
- PUNCT - O
N NOUN - O
- PUNCT - O
desmethyl NOUN - O
- PUNCT - O
ondansetron NN - B-MEDICINE
( PUNCT - O
M4 PROPN - O
) PUNCT - O
. PUNCT - O

In ADP - O
addition NOUN - O
, PUNCT - O
a DET - O
kind NOUN - O
of ADP - O
metabolite NOUN - O
of ADP - O
phase NOUN - O
II NNP - B-ORG
isolated VERB - O
in ADP - O
rats NOUN - O
bile NOUN - O
was VERB - O
characterized VERB - O
as ADP - O
N NOUN - O
- PUNCT - O
desmethyl NOUN - O
- PUNCT - O
ondansetron-7-O ADP - O
- PUNCT - O
β PROPN - O
- PUNCT - O
D PROPN - O
- PUNCT - O
glucuronide PROPN - O
( PUNCT - O
M5 PROPN - O
) PUNCT - O
. PUNCT - O

The DET - O
systematic ADJ - O
metabolites NOUN - O
isolation NOUN - O
and CCONJ - O
elucidation NOUN - O
provided VERB - O
metabolite NOUN - O
reference NOUN - O
standards NOUN - O
for ADP - O
metabolites NOUN - O
detection NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Identification NOUN - O
of ADP - O
novel NOUN - O
ondansetron NN - B-MEDICINE
metabolites VERB - O
using VERB - O
LC PROPN - O
/ SYM - O
MSn NOUN - O
and CCONJ - O
NMR NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
weight NOUN - O
- PUNCT - O
based VERB - O
dosing NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
to PART - O
reduce VERB - O
hypotension NOUN - O
has VERB - O
never ADV - O
been VERB - O
investigated VERB - O
. PUNCT - O

The DET - O
aim NOUN - O
of ADP - O
this DET - O
study NOUN - O
is VERB - O
to PART - O
determine VERB - O
the DET - O
optimal NOUN - O
dose NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
required VERB - O
based VERB - O
on ADP - O
the DET - O
patient NOUN - O
's PART - O
weight NOUN - O
to PART - O
reduce VERB - O
hypotension NOUN - O
following VERB - O
spinal ADJ - O
anesthesia NOUN - O
for ADP - O
cesarean ADJ - O
section NOUN - O
. PUNCT - O

In ADP - O
this DET - O
prospective ADJ - O
, PUNCT - O
triple ADJ - O
- PUNCT - O
blinded ADJ - O
, PUNCT - O
parallel ADJ - O
group NOUN - O
, PUNCT - O
randomized VERB - O
controlled VERB - O
trial NOUN - O
, PUNCT - O
a DET - O
total NOUN - O
of ADP - O
228 CD - B-CARDINAL
pregnant ADJ - O
women NOUN - O
were VERB - O
randomized VERB - O
to PART - O
receive VERB - O
either CCONJ - O
normal ADJ - O
saline NOUN - O
( PUNCT - O
group NOUN - O
NS PROPN - O
) PUNCT - O
or CCONJ - O
ondansetron NN - B-MEDICINE
0.05 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
kg PROPN - O
( PUNCT - O
group NOUN - O
O1 PROPN - O
) PUNCT - O
or CCONJ - O
ondansetron NN - B-MEDICINE
0.1 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
kg PROPN - O
( PUNCT - O
group NOUN - O
O2 PROPN - O
) PUNCT - O
intravenously ADV - O
5 CD - B-CARDINAL
  SPACE - O
min NOUN - O
before ADP - O
induction NOUN - O
of ADP - O
spinal ADJ - O
anesthesia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Minimal ADJ - O
effective ADJ - O
weight NOUN - O
- PUNCT - O
based VERB - O
dosing NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
to PART - O
reduce VERB - O
hypotension NOUN - O
in ADP - O
cesarean ADJ - O
section NOUN - O
under ADP - O
spinal ADJ - O
anesthesia NOUN - O
: PUNCT - O
a DET - O
randomized VERB - O
controlled VERB - O
superiority NOUN - O
trial NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Our ADJ - O
primary ADJ - O
objective NOUN - O
was VERB - O
to PART - O
compare VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
the DET - O
combination NOUN - O
of ADP - O
dexamethasone NOUN - O
- PUNCT - O
ondansetron NN - B-MEDICINE
and CCONJ - O
dexamethasone NOUN - O
- PUNCT - O
aprepitant NOUN - O
in ADP - O
patients NOUN - O
undergoing VERB - O
laparoscopic ADJ - O
surgery NOUN - O
. PUNCT - O

Patients NOUN - O
in ADP - O
the DET - O
dexamethasone NOUN - O
- PUNCT - O
aprepitant NOUN - O
group NOUN - O
( PUNCT - O
group NOUN - O
DA PROPN - O
, PUNCT - O
n=35 NOUN - O
) PUNCT - O
received VERB - O
40 CD - B-QUANTITY
mg NN - I-QUANTITY
of ADP - O
aprepitant NOUN - O
orally ADV - O
1 CD - B-TIME
- SYM - I-TIME
2 CD - I-TIME
hours NNS - I-TIME
before ADP - O
the DET - O
induction NOUN - O
of ADP - O
anaesthesia NOUN - O
and CCONJ - O
2 CD - B-CARDINAL
mL NOUN - O
saline VERB - O
intravenously ADV - O
( PUNCT - O
iv PUNCT - O
) PUNCT - O
within ADP - O
the DT - B-TIME
last JJ - I-TIME
30 CD - I-TIME
minutes NNS - I-TIME
of ADP - O
surgery NOUN - O
; PUNCT - O
patients NOUN - O
in ADP - O
the DET - O
dexamethasone NOUN - O
- PUNCT - O
ondansetron NN - B-MEDICINE
group NOUN - O
( PUNCT - O
group NOUN - O
DO PROPN - O
, PUNCT - O
n=35 NOUN - O
) PUNCT - O
received VERB - O
oral ADJ - O
placebo NOUN - O
identical ADJ - O
to ADP - O
aprepitant VERB - O
1 CD - B-TIME
- SYM - I-TIME
2 CD - I-TIME
hours NNS - I-TIME
before ADP - O
the DET - O
induction NOUN - O
of ADP - O
anaesthesia NOUN - O
and CCONJ - O
4 CD - B-CARDINAL
mg NOUN - O
ondansetron VB - B-MEDICINE
iv PRON - O
within ADP - O
the DT - B-TIME
last JJ - I-TIME
30 CD - I-TIME
minutes NNS - I-TIME
of ADP - O
surgery NOUN - O
. PUNCT - O

The DET - O
study NOUN - O
was VERB - O
designed VERB - O
to PART - O
evaluate VERB - O
whether ADP - O
the DET - O
combination NOUN - O
of ADP - O
dexamethasone NOUN - O
- PUNCT - O
aprepitant NOUN - O
is VERB - O
better ADJ - O
than ADP - O
the DET - O
combination NOUN - O
of ADP - O
dexamethasone NOUN - O
- PUNCT - O
ondansetron NN - B-MEDICINE
regarding VERB - O
the DET - O
complete ADJ - O
response NOUN - O
for ADP - O
PONV PROPN - O
in ADP - O
patients NOUN - O
undergoing VERB - O
laparoscopic ADJ - O
surgery NOUN - O
. PUNCT - O

The DET - O
results NOUN - O
however ADV - O
showed VERB - O
that ADP - O
dexamethasone NOUN - O
- PUNCT - O
aprepitant NOUN - O
has VERB - O
not ADV - O
improved VERB - O
the DET - O
complete ADJ - O
response NOUN - O
for ADP - O
PONV PROPN - O
compared VERB - O
to ADP - O
dexamethasone NOUN - O
- PUNCT - O
ondansetron NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
use VERB - O
data NOUN - O
from ADP - O
two CD - B-CARDINAL
large ADJ - O
studies NOUN - O
of ADP - O
birth NOUN - O
defects NOUN - O
to PART - O
describe VERB - O
time NOUN - O
trends NOUN - O
in ADP - O
ondansetron NN - B-MEDICINE
use NOUN - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
first JJ - B-ORDINAL
- PUNCT - O
trimester NOUN - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
of ADP - O
pregnancy NOUN - O
and CCONJ - O
to PART - O
investigate VERB - O
associations NOUN - O
, PUNCT - O
either CCONJ - O
previously ADV - O
reported VERB - O
or CCONJ - O
undescribed VERB - O
, PUNCT - O
between ADP - O
first JJ - B-ORDINAL
- PUNCT - O
trimester NOUN - O
ondansetron NN - B-MEDICINE
use NOUN - O
and CCONJ - O
major ADJ - O
birth NOUN - O
defects NOUN - O
. PUNCT - O

The DET - O
prevalence NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
use NOUN - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
first JJ - B-ORDINAL
- PUNCT - O
trimester NOUN - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
of ADP - O
pregnancy NOUN - O
among ADP - O
control NOUN - O
patients NOUN - O
was VERB - O
calculated VERB - O
in ADP - O
2-year CD - B-DATE
intervals NOUN - O
. PUNCT - O

Using VERB - O
women NOUN - O
with ADP - O
untreated ADJ - O
first JJ - B-ORDINAL
- PUNCT - O
trimester NOUN - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
of ADP - O
pregnancy NOUN - O
as ADP - O
the DET - O
reference NOUN - O
, PUNCT - O
we PRON - O
calculated VERB - O
adjusted ADJ - O
odds NOUN - O
ratios NOUN - O
( PUNCT - O
ORs NOUN - O
) PUNCT - O
and CCONJ - O
95 CD - B-PERCENT
% NN - I-PERCENT
CIs NOUN - O
for ADP - O
associations NOUN - O
between ADP - O
first JJ - B-ORDINAL
- PUNCT - O
trimester NOUN - O
ondansetron NN - B-MEDICINE
use NOUN - O
for ADP - O
treatment NOUN - O
of ADP - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
of ADP - O
pregnancy NOUN - O
and CCONJ - O
specific ADJ - O
birth NOUN - O
defects NOUN - O
. PUNCT - O

Among ADP - O
women NOUN - O
in ADP - O
the DET - O
control NOUN - O
group NOUN - O
, PUNCT - O
ondansetron NN - B-MEDICINE
exposure NOUN - O
increased VERB - O
from ADP - O
less JJR - B-PERCENT
than IN - I-PERCENT
1 CD - B-PERCENT
% NN - I-PERCENT
before ADP - O
2000 CD - B-DATE
to ADP - O
13 CD - B-PERCENT
% NN - I-PERCENT
in ADP - O
2013 CD - B-DATE
- SYM - I-DATE
2014 CD - I-DATE
. PUNCT - O

Off ADP - O
- PUNCT - O
label NOUN - O
use NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
of ADP - O
pregnancy NOUN - O
increased VERB - O
to ADP - O
13 CD - B-PERCENT
% NN - I-PERCENT
by ADP - O
the DET - O
end NOUN - O
of ADP - O
the DET - O
study NOUN - O
period NOUN - O
. PUNCT - O

For ADP - O
the DET - O
majority NOUN - O
of ADP - O
specific ADJ - O
birth NOUN - O
defects NOUN - O
investigated VERB - O
, PUNCT - O
there ADV - O
was VERB - O
no DET - O
increased VERB - O
risk NOUN - O
associated VERB - O
with ADP - O
first JJ - B-ORDINAL
- PUNCT - O
trimester NOUN - O
use NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
for ADP - O
treatment NOUN - O
of ADP - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
of ADP - O
pregnancy NOUN - O
compared VERB - O
with ADP - O
no DET - O
treatment NOUN - O
, PUNCT - O
although ADP - O
modest ADJ - O
associations NOUN - O
with ADP - O
cleft ADJ - O
palate NOUN - O
and CCONJ - O
renal ADJ - O
agenesis NOUN - O
- PUNCT - O
dysgenesis NOUN - O
warrant NOUN - O
further ADJ - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Review NOUN - O
of ADP - O
her ADJ - O
medications NOUN - O
revealed VERB - O
several ADJ - O
serotonergic ADJ - O
agents NOUN - O
, PUNCT - O
including VERB - O
duloxetine NOUN - O
, PUNCT - O
tramadol NOUN - O
, PUNCT - O
and CCONJ - O
ondansetron NN - B-MEDICINE
. PUNCT - O

Our ADJ - O
case NOUN - O
also ADV - O
demonstrates VERB - O
the DET - O
importance NOUN - O
of ADP - O
recognizing VERB - O
serotonin ADJ - O
syndrome NOUN - O
, PUNCT - O
as ADP - O
the DET - O
supportive ADJ - O
ondansetron NN - B-MEDICINE
we PRON - O
gave VERB - O
to PART - O
alleviate VERB - O
her ADJ - O
nausea NOUN - O
and CCONJ - O
vomiting VERB - O
likely ADV - O
exacerbated VERB - O
her ADJ - O
serotonin ADJ - O
syndrome NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
blinded ADJ - O
, PUNCT - O
randomized VERB - O
prospective ADJ - O
study NOUN - O
compared VERB - O
the DET - O
quality NOUN - O
of ADP - O
clinical ADJ - O
recovery NOUN - O
and CCONJ - O
duration NOUN - O
of ADP - O
hospitalization NOUN - O
in ADP - O
canine NOUN - O
parvoviral ADJ - O
dogs NOUN - O
receiving VERB - O
either CCONJ - O
maropitant NOUN - O
( PUNCT - O
1 CD - B-QUANTITY
mg NN - I-QUANTITY
/ SYM - I-QUANTITY
kg NNS - I-QUANTITY
[ PUNCT - O
0.45 NUM - O
mg NOUN - O
/ SYM - O
lb PROPN - O
] PUNCT - O
IV NNP - B-ORG
q DET - O
24 CD - B-CARDINAL
hr NOUN - O
, PUNCT - O
n NOUN - O
= SYM - O
11 CD - B-CARDINAL
) PUNCT - O
or CCONJ - O
ondansetron NN - B-MEDICINE
( PUNCT - O
0.5 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
kg NOUN - O

When ADV - O
comparing VERB - O
dogs NOUN - O
receiving VERB - O
maropitant NOUN - O
versus ADP - O
ondansetron NN - B-MEDICINE
, PUNCT - O
respectively ADV - O
, PUNCT - O
there ADV - O
were VERB - O
no DET - O
differences NOUN - O
in ADP - O
duration NOUN - O
of ADP - O
hospitalization NOUN - O
( PUNCT - O
3.36 CD - B-CARDINAL
± PUNCT - O
0.56 CD - B-CARDINAL
versus ADP - O
2.73 CD - B-CARDINAL
± NUM - O
0.38 CD - B-DATE
days NNS - I-DATE
, PUNCT - O
P NOUN - O
= SYM - O
.36 PUNCT - O
) PUNCT - O
, PUNCT - O
requirement NOUN - O
of ADP - O
rescue NOUN - O
antiemetic ADJ - O
( PUNCT - O
3/11 CD - B-CARDINAL
versus ADP - O
5/11 CD - B-CARDINAL
dogs NOUN - O
, PUNCT - O
P NOUN - O
= SYM - O
.66 PUNCT - O
) PUNCT - O
, PUNCT - O
duration NOUN - O
of ADP - O
vomiting VERB - O
( PUNCT - O
5 CD - B-CARDINAL
versus ADP - O
4 CD - B-DATE
days NNS - I-DATE
, PUNCT - O
P NOUN - O
= SYM - O
.65 NOUN - O
) PUNCT - O
, PUNCT - O
or CCONJ - O
days NNS - B-DATE
to ADP - O
voluntary ADJ - O
food NOUN - O
intake NOUN - O
( PUNCT - O
2 CD - B-CARDINAL
versus ADP - O
1.5 NUM - O
days NOUN - O
, PUNCT - O
P NOUN - O
= SYM - O
1.0 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

Results NOUN - O
of ADP - O
this DET - O
study NOUN - O
suggest VERB - O
that ADP - O
maropitant NOUN - O
and CCONJ - O
ondansetron NN - B-MEDICINE
are VERB - O
equally ADV - O
effective ADJ - O
in ADP - O
controlling VERB - O
clinical ADJ - O
signs NOUN - O
associated VERB - O
with ADP - O
parvoviral ADJ - O
enteritis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
systematic ADJ - O
review NOUN - O
identified VERB - O
published VERB - O
studies NOUN - O
that ADJ - O
evaluated VERB - O
the DET - O
use NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
in ADP - O
individuals NOUN - O
with ADP - O
psychosis NOUN - O
associated VERB - O
with ADP - O
dementia NOUN - O
. PUNCT - O

A DET - O
literature NOUN - O
search NOUN - O
was VERB - O
conducted VERB - O
of ADP - O
PubMed NNP - B-ORG
, PUNCT - O
MEDLINE NNP - B-ORG
, PUNCT - O
EMBASE NNP - B-ORG
, PUNCT - O
PsycINFO NNP - B-GPE
, PUNCT - O
and CCONJ - O
Cochrane NNP - B-ORG
Collaboration NNP - I-ORG
databases VERB - O
for ADP - O
randomized VERB - O
controlled VERB - O
trials NOUN - O
( PUNCT - O
RCTs PROPN - O
) PUNCT - O
, PUNCT - O
cohort NOUN - O
studies NOUN - O
, PUNCT - O
and CCONJ - O
case NOUN - O
reports VERB - O
that ADJ - O
evaluated VERB - O
the DET - O
use NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
for ADP - O
individuals NOUN - O
with ADP - O
psychosis NOUN - O
associated VERB - O
with ADP - O
dementia NOUN - O
. PUNCT - O

A DET - O
total NOUN - O
of ADP - O
4 CD - B-CARDINAL
studies NOUN - O
were VERB - O
identified VERB - O
, PUNCT - O
all DET - O
of ADP - O
which ADJ - O
were VERB - O
open ADJ - O
- PUNCT - O
label NOUN - O
trials NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
for ADP - O
psychosis NOUN - O
associated VERB - O
with ADP - O
Parkinson PROPN - O
's PART - O
disease NOUN - O
. PUNCT - O

There ADV - O
is VERB - O
a DET - O
paucity NOUN - O
of ADP - O
evidence NOUN - O
for ADP - O
the DET - O
use NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
for ADP - O
psychosis NOUN - O
associated VERB - O
with ADP - O
other ADJ - O
forms NOUN - O
of ADP - O
dementia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Is VERB - O
ondansetron NN - B-MEDICINE
beneficial ADJ - O
for ADP - O
psychosis NOUN - O
associated VERB - O
with ADP - O
dementia NOUN - O
? PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
5-HT3 JJ - B-CARDINAL
receptor NOUN - O
antagonist NOUN - O
ondansetron NN - B-MEDICINE
is VERB - O
a DET - O
good ADJ - O
candidate NOUN - O
for ADP - O
the DET - O
modulation NOUN - O
of ADP - O
interoceptive ADJ - O
circuits NOUN - O
, PUNCT - O
as ADP - O
5-HT3 ADJ - O
receptors NOUN - O
are VERB - O
located VERB - O
abundantly ADV - O
on ADP - O
sensory ADJ - O
pathways NOUN - O
and CCONJ - O
ondansetron NN - B-MEDICINE
has VERB - O
shown VERB - O
some DET - O
clinical ADJ - O
utility NOUN - O
in ADP - O
disorders NOUN - O
characterized VERB - O
by ADP - O
sensory ADJ - O
and CCONJ - O
interoceptive ADJ - O
abnormalities NOUN - O
. PUNCT - O

The DET - O
present ADJ - O
study NOUN - O
tested VERB - O
the DET - O
ability NOUN - O
of ADP - O
three CD - B-CARDINAL
different ADJ - O
doses NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
to PART - O
engage VERB - O
neural ADJ - O
regions NOUN - O
involved VERB - O
in ADP - O
interoception NOUN - O
to PART - O
determine VERB - O
the DET - O
drug NOUN - O
's PART - O
utility NOUN - O
as ADP - O
a DET - O
therapeutic ADJ - O
agent NOUN - O
to PART - O
target VERB - O
circuit NOUN - O
abnormalities NOUN - O
in ADP - O
patients NOUN - O
. PUNCT - O

18 CD - B-CARDINAL
) PUNCT - O
dose NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
and CCONJ - O
placebo NOUN - O
before ADP - O
MRI PROPN - O
scanning VERB - O
on ADP - O
separate ADJ - O
days NOUN - O
. PUNCT - O

These DET - O
effects NOUN - O
were VERB - O
driven VERB - O
by ADP - O
a DET - O
robust ADJ - O
reduction NOUN - O
in ADP - O
activation NOUN - O
for ADP - O
ondansetron NN - B-MEDICINE
compared VERB - O
to PART - O
placebo VERB - O
for ADP - O
the DET - O
24-mg CD - B-CARDINAL
group NOUN - O
, PUNCT - O
with ADP - O
weaker ADJ - O
effects NOUN - O
for ADP - O
the DET - O
16-mg NUM - O
and CCONJ - O
8-mg CD - B-CARDINAL
groups NOUN - O
. PUNCT - O

In ADP - O
conclusion NOUN - O
, PUNCT - O
high ADJ - O
- PUNCT - O
dose NOUN - O
ondansetron NN - B-MEDICINE
reduces VERB - O
activation NOUN - O
of ADP - O
several ADJ - O
areas NOUN - O
important ADJ - O
for ADP - O
interoception NOUN - O
, PUNCT - O
including VERB - O
insula NOUN - O
and CCONJ - O
sensorimotor VERB - O
cortical ADJ - O
regions NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

High ADV - O
- PUNCT - O
dose NOUN - O
ondansetron NN - B-MEDICINE
reduces VERB - O
activation NOUN - O
of ADP - O
interoceptive ADJ - O
and CCONJ - O
sensorimotor NOUN - O
brain NOUN - O
regions NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
objective NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
investigate VERB - O
and CCONJ - O
compare VERB - O
the DET - O
prophylactic ADJ - O
effects NOUN - O
of ADP - O
intravenously ADV - O
administered VERB - O
palonosetron NOUN - O
, PUNCT - O
ondansetron NN - B-MEDICINE
and CCONJ - O
granisetron VERB - O
on ADP - O
prevention NOUN - O
of ADP - O
postoperative ADJ - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
after ADP - O
general ADJ - O
anesthesia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
study NOUN - O
prospectively ADV - O
compared VERB - O
an DET - O
olanzapine NOUN - O
- PUNCT - O
containing VERB - O
regimen NOUN - O
( PUNCT - O
acute ADJ - O
phase NOUN - O
: PUNCT - O
olanzapine NOUN - O
, PUNCT - O
ondansetron NN - B-MEDICINE
, PUNCT - O
dexamethasone NOUN - O
; PUNCT - O
delayed VERB - O
phase NOUN - O
: PUNCT - O
olanzapine NOUN - O
, PUNCT - O
ondansetron NN - B-MEDICINE
) PUNCT - O
with ADP - O
an DET - O
ondansetron NN - B-MEDICINE
/ SYM - O
dexamethasone ADJ - O
regimen NOUN - O
( PUNCT - O
acute ADJ - O
phase NOUN - O
: PUNCT - O
ondansetron NN - B-MEDICINE
, PUNCT - O
dexamethasone NOUN - O
; PUNCT - O
delayed VERB - O
phase NOUN - O
: PUNCT - O
ondansetron NN - B-MEDICINE
) PUNCT - O
in ADP - O
adult NOUN - O
patients NOUN - O
with ADP - O
cancer NOUN - O
receiving VERB - O
HEC PROPN - O
or CCONJ - O
MEC NNP - B-ORG
. PUNCT - O

The DET - O
study NOUN - O
included VERB - O
131 CD - B-CARDINAL
patients NOUN - O
( PUNCT - O
olanzapine ADV - O
- PUNCT - O
containing VERB - O
: PUNCT - O
50 CD - B-CARDINAL
patients NOUN - O
; PUNCT - O
ondansetron NN - B-MEDICINE
/ SYM - O
dexamethasone NOUN - O
: PUNCT - O
81 CD - B-CARDINAL
patients NOUN - O
) PUNCT - O
. PUNCT - O

CR NN - B-GPE
and CCONJ - O
nausea NOUN - O
control NOUN - O
were VERB - O
higher ADJ - O
in ADP - O
the DET - O
olanzapine NOUN - O
- PUNCT - O
containing VERB - O
than ADP - O
in ADP - O
the DET - O
ondansetron NN - B-MEDICINE
/ SYM - O
dexamethasone ADJ - O
regimen NOUN - O
( PUNCT - O
CR NOUN - O
: PUNCT - O
acute ADJ - O
phase NOUN - O
, PUNCT - O
86 CD - B-PERCENT
% NN - I-PERCENT
v NOUN - O
71.6 CD - B-PERCENT
% NN - I-PERCENT
; PUNCT - O
P NOUN - O
= SYM - O
.086 NUM - O
; PUNCT - O
delayed VERB - O
phase NOUN - O
, PUNCT - O
72 CD - B-PERCENT
% NN - I-PERCENT
v NOUN - O
30.9 CD - B-PERCENT
% NN - I-PERCENT
; PUNCT - O

-DOCSTART- -X- - O

The DET - O
most ADV - O
common ADJ - O
off ADJ - O
- PUNCT - O
label NOUN - O
drugs NOUN - O
were VERB - O
ondansetron NN - B-MEDICINE
( PUNCT - O
18.5 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
fentanyl NOUN - O
( PUNCT - O
12.9 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
oxycodone NOUN - O
( PUNCT - O
8.8 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
and CCONJ - O
paracetamol NOUN - O
( PUNCT - O
6.1 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Children NOUN - O
recruited VERB - O
to ADP - O
arm NOUN - O
- PUNCT - O
A NOUN - O
received VERB - O
intravenous ADJ - O
ondansetron NN - B-MEDICINE
plus CCONJ - O
dexamethasone NOUN - O
followed VERB - O
by ADP - O
fosaprepitant ADJ - O
infusion NOUN - O
. PUNCT - O

Addition NOUN - O
of ADP - O
fosaprepitant NOUN - O
to ADP - O
ondansetron NN - B-MEDICINE
and CCONJ - O
dexamethasone VERB - O
improved VERB - O
chemotherapy NOUN - O
- PUNCT - O
induced VERB - O
vomiting NOUN - O
control NOUN - O
in ADP - O
children NOUN - O
treated VERB - O
with ADP - O
moderately ADV - O
or CCONJ - O
highly ADV - O
emetogenic ADJ - O
chemotherapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
sham ADJ - O
rats NOUN - O
, PUNCT - O
block NOUN - O
of ADP - O
spinal ADJ - O
5-HT3Rs CD - B-CARDINAL
with ADP - O
ondansetron NN - B-MEDICINE
revealed VERB - O
tonic ADJ - O
facilitation NOUN - O
of ADP - O
noxious ADJ - O
punctate ADJ - O
mechanical ADJ - O
stimulation NOUN - O
, PUNCT - O
whereas ADP - O
blocking VERB - O
5-HT2ARs CD - B-PRODUCT
with ADP - O
ketanserin NOUN - O
had VERB - O
minimal ADJ - O
effect NOUN - O
on ADP - O
neuronal ADJ - O
responses NOUN - O
to ADP - O
evoked ADJ - O
stimuli NOUN - O
. PUNCT - O

The DET - O
inhibitory NOUN - O
profiles NOUN - O
of ADP - O
both DET - O
drugs NOUN - O
were VERB - O
altered VERB - O
in ADP - O
SNL NNP - B-ORG
rats NOUN - O
; PUNCT - O
ondansetron NN - B-MEDICINE
additionally ADV - O
inhibited VERB - O
neuronal ADJ - O
responses NOUN - O
to ADP - O
lower ADJ - O
intensity NOUN - O
punctate VERB - O
mechanical ADJ - O
stimuli NOUN - O
and CCONJ - O
noxious ADJ - O
heat NOUN - O
evoked VERB - O
responses NOUN - O
, PUNCT - O
whereas ADP - O
ketanserin ADV - O
inhibited VERB - O
innocuous ADJ - O
and CCONJ - O
noxious ADJ - O
evaporative ADJ - O
cooling VERB - O
evoked VERB - O
responses NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Antinociceptive ADJ - O
actions NOUN - O
of ADP - O
GLP-1 PROPN - O
and CCONJ - O
GLP-2 PROPN - O
were VERB - O
significantly ADV - O
decreased VERB - O
with ADP - O
ondansetron NN - B-MEDICINE
and CCONJ - O
naloxone NOUN - O
, PUNCT - O
and CCONJ - O
paw VERB - O
shaking VERB - O
behavior NOUN - O
significantly ADV - O
increased VERB - O
with ADP - O
naloxone NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
reverse VERB - O
MDR NNP - B-ORG
more ADV - O
effectively ADV - O
, PUNCT - O
a DET - O
new ADJ - O
strategy NOUN - O
was VERB - O
raised VERB - O
, PUNCT - O
that ADV - O
is ADV - O
, PUNCT - O
circumventing VERB - O
MDR NN - B-ORG
by ADP - O
the DET - O
coadministration NOUN - O
of ADP - O
DMY NNP - B-GPE
and CCONJ - O
ondansetron NN - B-MEDICINE
( PUNCT - O
OND NNP - B-ORG
) PUNCT - O
, PUNCT - O
a DET - O
common ADJ - O
antiemetic ADJ - O
drug NOUN - O
, PUNCT - O
during ADP - O
cancer NOUN - O
chemotherapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Combination NOUN - O
of ADP - O
dihydromyricetin NOUN - O
and CCONJ - O
ondansetron NN - B-MEDICINE
strengthens VERB - O
antiproliferative ADJ - O
efficiency NOUN - O
of ADP - O
adriamycin NOUN - O
in ADP - O
K562/ADR NNP - B-GPE
through ADP - O
downregulation NOUN - O
of ADP - O
SORCIN PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

Objective:5-HT3 ADJ - O
receptor NOUN - O
antagonist NOUN - O
( PUNCT - O
ondansetron NN - B-MEDICINE
) PUNCT - O
has VERB - O
been VERB - O
reported VERB - O
to PART - O
have VERB - O
nephrotoxic ADJ - O
effect NOUN - O
when ADV - O
combined VERB - O
with ADP - O
cisplatin ADJ - O
in ADP - O
mice NOUN - O
; PUNCT - O
however ADV - O
, PUNCT - O
little ADJ - O
evidence NOUN - O
exists VERB - O
in ADP - O
explaining VERB - O
its ADJ - O
nephrotoxic ADJ - O
effects NOUN - O
on ADP - O
patients NOUN - O
. PUNCT - O

We PRON - O
retrospectively ADV - O
reviewed VERB - O
600 CD - B-CARDINAL
tumor NOUN - O
patients NOUN - O
which ADJ - O
were VERB - O
treated VERB - O
with ADP - O
cisplatin ADJ - O
( PUNCT - O
⩾60 VERB - O
  SPACE - O
mg PROPN - O
/ SYM - O
m2 NOUN - O
) PUNCT - O
as ADP - O
a DET - O
first JJ - B-ORDINAL
- PUNCT - O
time NOUN - O
chemotherapy NOUN - O
and CCONJ - O
combined VERB - O
with ADP - O
5-HT3 ADJ - O
receptor NOUN - O
antagonist NOUN - O
( PUNCT - O
i.e. X - O
, PUNCT - O
ondansetron NN - B-MEDICINE
, PUNCT - O
tropisetron NOUN - O
, PUNCT - O
or CCONJ - O
ramosetron NOUN - O
, PUNCT - O
each DET - O
kind NOUN - O
of ADP - O
5-HT3 ADJ - O
receptor NOUN - O
antagonist NOUN - O
contains VERB - O
200 CD - B-CARDINAL
cases NOUN - O
) PUNCT - O
between IN - B-DATE
January NNP - I-DATE
2010 CD - I-DATE
and CCONJ - O
December NNP - B-DATE
2015 CD - I-DATE
. PUNCT - O

: PUNCT - O
The DET - O
incidence NOUN - O
of ADP - O
Grade NNP - B-ORG
⩾ NNP - I-ORG
2 CD - I-ORG
serum NOUN - O
creatinine NOUN - O
elevation NOUN - O
in ADP - O
cisplatin NOUN - O
+ CCONJ - O
ondansetron NN - B-MEDICINE
group NOUN - O
was VERB - O
significantly ADV - O
higher ADJ - O
than ADP - O
cisplatin ADJ - O
+ CCONJ - O
tropisetron ADJ - O
group NOUN - O
( PUNCT - O
P NOUN - O
= SYM - O
0.04 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
but CCONJ - O
no DET - O
significant ADJ - O
difference NOUN - O
was VERB - O
found VERB - O
between ADP - O
cisplatin NOUN - O
+ CCONJ - O
ondansetron NN - B-MEDICINE
group NOUN - O
and CCONJ - O
cisplatin NOUN - O
+ CCONJ - O
ramosetron NOUN - O
group NOUN - O
( PUNCT - O
P NOUN - O
= SYM - O
0.3 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

Higher ADJ - O
cisplatin ADJ - O
dosage NOUN - O
and CCONJ - O
regular ADJ - O
use NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
combined VERB - O
with ADP - O
cisplatin ADJ - O
are VERB - O
more ADV - O
likely ADJ - O
to PART - O
increase VERB - O
the DET - O
incidence NOUN - O
of ADP - O
nephrotoxicity NOUN - O
; PUNCT - O
tropisetron NOUN - O
showed VERB - O
the DET - O
relatively ADV - O
mild ADJ - O
effect NOUN - O
on ADP - O
kidney NOUN - O
function NOUN - O
, PUNCT - O
suggesting VERB - O
that ADP - O
tropisetron NOUN - O
is VERB - O
a DET - O
preferable ADJ - O
alternative NOUN - O
in ADP - O
the DET - O
process NOUN - O
of ADP - O
cisplatin ADJ - O
chemotherapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
aim NOUN - O
of ADP - O
the DET - O
present ADJ - O
study NOUN - O
is VERB - O
to PART - O
observe VERB - O
if ADP - O
the DET - O
effects NOUN - O
of ADP - O
the DET - O
5HT3 NUM - O
receptor NOUN - O
antagonist NOUN - O
ondansetron NN - B-MEDICINE
on ADP - O
initial ADJ - O
alcohol NOUN - O
consumption NOUN - O
are VERB - O
modulated VERB - O
by ADP - O
post ADJ - O
- ADJ - O
natal ADJ - O
NS NNP - B-NORP
manipulation NOUN - O
. PUNCT - O

Moreover ADV - O
, PUNCT - O
0.1 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
kg NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
decreased VERB - O
alcohol NOUN - O
consumption NOUN - O
, PUNCT - O
but CCONJ - O
only ADV - O
in ADP - O
the DET - O
post ADJ - O
- ADJ - O
natal ADJ - O
finasteride ADJ - O
group NOUN - O
, PUNCT - O
suggesting VERB - O
a DET - O
possible ADJ - O
increase NOUN - O
in ADP - O
5HT3 NUM - O
receptor NOUN - O
sensitivity NOUN - O
in ADP - O
these DET - O
animals NOUN - O
. PUNCT - O

In ADP - O
conclusion NOUN - O
, PUNCT - O
NS PROPN - O
manipulation NOUN - O
in ADP - O
crucial ADJ - O
stages NOUN - O
of ADP - O
development NOUN - O
, PUNCT - O
such ADJ - O
as ADP - O
early ADJ - O
post ADJ - O
- ADJ - O
natal ADJ - O
periods NOUN - O
, PUNCT - O
seems VERB - O
to PART - O
play VERB - O
an DET - O
important ADJ - O
role NOUN - O
on ADP - O
the DET - O
effects NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
on ADP - O
alcohol NOUN - O
intake NOUN - O
and CCONJ - O
in ADP - O
the DET - O
vulnerability NOUN - O
to PART - O
develop VERB - O
drug NOUN - O
use NOUN - O
or CCONJ - O
abuse NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Early ADJ - O
post ADJ - O
- ADJ - O
natal ADJ - O
neuroactive ADJ - O
steroid NOUN - O
manipulation NOUN - O
modulates NOUN - O
ondansetron VBP - B-MEDICINE
effects NOUN - O
on ADP - O
initial ADJ - O
periods NOUN - O
of ADP - O
alcohol NOUN - O
consumption NOUN - O
in ADP - O
rats NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
number NOUN - O
of ADP - O
recent ADJ - O
lawsuits NOUN - O
have VERB - O
highlighted VERB - O
the DET - O
possibility NOUN - O
that ADP - O
ondansetron NN - B-MEDICINE
may VERB - O
cause VERB - O
congenital ADJ - O
malformations NOUN - O
. PUNCT - O

The DET - O
aim NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
systematically ADV - O
review VERB - O
epidemiological ADJ - O
evidence NOUN - O
on ADP - O
the DET - O
potential ADJ - O
association NOUN - O
of ADP - O
prenatal ADJ - O
exposure NOUN - O
to ADP - O
ondansetron NN - B-MEDICINE
and CCONJ - O
congenital ADJ - O
malformations NOUN - O
. PUNCT - O

Full ADJ - O
papers NOUN - O
( PUNCT - O
RCTs PROPN - O
, PUNCT - O
cohort NOUN - O
, PUNCT - O
and CCONJ - O
case NOUN - O
- PUNCT - O
control NOUN - O
studies NOUN - O
) PUNCT - O
were VERB - O
eligible ADJ - O
for ADP - O
inclusion NOUN - O
if ADP - O
they PRON - O
reported VERB - O
fetal ADJ - O
outcomes NOUN - O
of ADP - O
prenatal ADJ - O
ondansetron NN - B-MEDICINE
exposure NOUN - O
in ADP - O
humans NOUN - O
. PUNCT - O

Excluded VERB - O
were VERB - O
: PUNCT - O
case NOUN - O
reports NOUN - O
, PUNCT - O
studies NOUN - O
involving VERB - O
pre ADJ - O
- ADJ - O
medication NOUN - O
with ADP - O
ondansetron NN - B-MEDICINE
prior ADV - O
to ADP - O
CS NNP - B-ORG
, PUNCT - O
animal NOUN - O
studies NOUN - O
, PUNCT - O
and CCONJ - O
foreign ADJ - O
languages NOUN - O
studies NOUN - O
. PUNCT - O

Sample PROPN - O
sizes NOUN - O
ranged VERB - O
from ADP - O
17 CD - B-CARDINAL
to IN - I-CARDINAL
1 CD - I-CARDINAL
  SPACE - O
501 CD - B-CARDINAL
  SPACE - O
434 CD - B-CARDINAL
infants NOUN - O
exposed VERB - O
to ADP - O
ondansetron NN - B-MEDICINE
. PUNCT - O

A DET - O
case NOUN - O
- PUNCT - O
control NOUN - O
study NOUN - O
identified VERB - O
an DET - O
association NOUN - O
between ADP - O
prenatal ADJ - O
exposure NOUN - O
to ADP - O
ondansetron NN - B-MEDICINE
and CCONJ - O
cleft VERB - O
palate NOUN - O
, PUNCT - O
and CCONJ - O
one CD - B-CARDINAL
cohort NOUN - O
study NOUN - O
found VERB - O
an DET - O
increased VERB - O
risk NOUN - O
of ADP - O
cardiovascular ADJ - O
defects NOUN - O
. PUNCT - O

While ADP - O
further ADJ - O
investigation NOUN - O
of ADP - O
the DET - O
literature NOUN - O
is VERB - O
needed VERB - O
, PUNCT - O
our ADJ - O
results NOUN - O
highlight VERB - O
the DET - O
paucity NOUN - O
of ADP - O
evidence NOUN - O
linking VERB - O
prenatal ADJ - O
exposure NOUN - O
to ADP - O
ondansetron NN - B-MEDICINE
to ADP - O
an DET - O
increased VERB - O
risk NOUN - O
of ADP - O
congenital ADJ - O
malformations NOUN - O
. PUNCT - O

There ADV - O
is VERB - O
a DET - O
need NOUN - O
for ADP - O
additional ADJ - O
epidemiologic ADJ - O
studies NOUN - O
to PART - O
confirm VERB - O
whether ADP - O
ondansetron NN - B-MEDICINE
represents VERB - O
a DET - O
safe ADJ - O
and CCONJ - O
effective ADJ - O
alternative ADJ - O
treatment NOUN - O
for ADP - O
nausea NOUN - O
and CCONJ - O
vomiting VERB - O
in ADP - O
pregnancy NOUN - O
and CCONJ - O
hyperemesis NOUN - O
gravidarum NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Is VERB - O
there ADV - O
an DET - O
association NOUN - O
between ADP - O
ondansetron NN - B-MEDICINE
administration NOUN - O
and CCONJ - O
the DET - O
presence NOUN - O
of ADP - O
persistent ADJ - O
post ADJ - O
- ADJ - O
concussion ADJ - O
symptoms NOUN - O
at ADP - O
1 CD - B-DATE
week NN - I-DATE
and CCONJ - O
1 CD - B-DATE
month NN - I-DATE
in ADP - O
children NOUN - O
? PUNCT - O

This DET - O
observational ADJ - O
study NOUN - O
found VERB - O
that ADP - O
the DET - O
use NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
among ADP - O
children NOUN - O
presenting VERB - O
to ADP - O
the DET - O
emergency NOUN - O
department NOUN - O
with ADP - O
an DET - O
acute ADJ - O
concussion NOUN - O
was VERB - O
associated VERB - O
with ADP - O
a DET - O
higher ADJ - O
risk NOUN - O
of ADP - O
persistent ADJ - O
symptoms NOUN - O
at ADP - O
1 CD - B-DATE
month NN - I-DATE
. PUNCT - O

The DET - O
treatment NOUN - O
of ADP - O
short ADJ - O
- PUNCT - O
term NOUN - O
symptoms NOUN - O
of ADP - O
a DET - O
concussion NOUN - O
should VERB - O
be VERB - O
balanced VERB - O
with ADP - O
the DET - O
potential ADJ - O
long ADJ - O
- PUNCT - O
term NOUN - O
harm NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Association NOUN - O
between ADP - O
ondansetron NN - B-MEDICINE
use NOUN - O
and CCONJ - O
symptom NOUN - O
persistence NOUN - O
in ADP - O
children NOUN - O
with ADP - O
concussions NOUN - O
: PUNCT - O
A DET - O
5P NN - B-ORG
substudy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Initial ADJ - O
studies NOUN - O
of ADP - O
94 CD - B-CARDINAL
different ADJ - O
drugs NOUN - O
and CCONJ - O
medical ADJ - O
devices NOUN - O
had VERB - O
negative ADJ - O
results NOUN - O
, PUNCT - O
until ADP - O
a DET - O
second JJ - B-ORDINAL
analysis NOUN - O
of ADP - O
specific ADJ - O
blisters NOUN - O
and CCONJ - O
their ADJ - O
pharmaceutical ADJ - O
matrix NOUN - O
selected VERB - O
by ADP - O
epidemiological ADJ - O
criteria NOUN - O
identified VERB - O
an DET - O
intrinsic ADJ - O
contamination NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
blisters NOUN - O
from ADP - O
a DET - O
specific ADJ - O
producer NOUN - O
used VERB - O
in ADP - O
all ADJ - O
the DET - O
patients NOUN - O
. PUNCT - O

A DET - O
recall NOUN - O
of ADP - O
contaminated ADJ - O
ondansetron NN - B-MEDICINE
blisters NOUN - O
was VERB - O
performed VERB - O
in ADP - O
all ADJ - O
the DET - O
country NOUN - O
, PUNCT - O
after ADP - O
which ADJ - O
the DET - O
outbreak NOUN - O
was VERB - O
contained VERB - O
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Outbreak NOUN - O
of ADP - O
fungemias NOUN - O
by ADP - O
Sarocladium NNP - B-ORG
kiliense NOUN - O
in ADP - O
eight CD - B-CARDINAL
public ADJ - O
hospitals NOUN - O
per ADP - O
intrinsic ADJ - O
contamination NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
intravenous]. ADJ - O

-DOCSTART- -X- - O

The DET - O
study NOUN - O
aims VERB - O
to PART - O
evaluate VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
in ADP - O
preventing VERB - O
post ADJ - O
- ADJ - O
spinal ADJ - O
headache NOUN - O
, PUNCT - O
considering VERB - O
the DET - O
high ADJ - O
prevalence NOUN - O
of ADP - O
the DET - O
headache NOUN - O
in ADP - O
pregnant ADJ - O
women NOUN - O
and CCONJ - O
the DET - O
common ADJ - O
use NOUN - O
of ADP - O
the DET - O
adjuvants NOUN - O
for ADP - O
prophylaxis NOUN - O
against ADP - O
post ADJ - O
- ADJ - O
operative ADJ - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
( PUNCT - O
PONV PROPN - O
) PUNCT - O
. PUNCT - O

Participants NOUN - O
in ADP - O
the DET - O
first JJ - B-ORDINAL
, PUNCT - O
second JJ - B-ORDINAL
, PUNCT - O
and CCONJ - O
control NOUN - O
groups NOUN - O
received VERB - O
8 CD - B-CARDINAL
mg NOUN - O
, PUNCT - O
4 CD - B-QUANTITY
mg NN - I-QUANTITY
of ADP - O
ondansetron NN - B-MEDICINE
, PUNCT - O
and CCONJ - O
normal ADJ - O
saline NOUN - O
, PUNCT - O
respectively ADV - O
, PUNCT - O
5 CD - B-TIME
minutes NNS - I-TIME
before ADP - O
surgery NOUN - O
. PUNCT - O

The DET - O
incidence NOUN - O
of ADP - O
post ADJ - O
- ADJ - O
spinal ADJ - O
headache NOUN - O
was VERB - O
significantly ADV - O
higher ADJ - O
in ADP - O
the DET - O
placebo NOUN - O
group NOUN - O
than ADP - O
in ADP - O
the DET - O
ondansetron NN - B-MEDICINE
8-mg CD - B-PRODUCT
and CCONJ - O
4-mg CD - B-CARDINAL
groups NOUN - O
at ADP - O
24 CD - B-TIME
hours NNS - I-TIME
after ADP - O
surgery NOUN - O
( PUNCT - O
P NOUN - O
< X - O
0.010 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

But CCONJ - O
, PUNCT - O
no DET - O
significant ADJ - O
difference NOUN - O
was VERB - O
observed VERB - O
between ADP - O
two CD - B-CARDINAL
ondansetron NN - B-MEDICINE
groups NOUN - O
( PUNCT - O
P NOUN - O
≤ NOUN - O
0.05 NUM - O
) PUNCT - O
. PUNCT - O

The DET - O
overall ADJ - O
incidence NOUN - O
of ADP - O
the DET - O
headache NOUN - O
was VERB - O
generally ADV - O
lower ADJ - O
in ADP - O
ondansetron NN - B-MEDICINE
8-mg CD - B-CARDINAL
( PUNCT - O
26.66 CD - B-PERCENT
% NN - I-PERCENT
vs. ADP - O
33.68.05 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
and CCONJ - O
31.66 CD - B-PERCENT
% NN - I-PERCENT
in ADP - O
ondansetron NN - B-MEDICINE
4-mg NUM - O
( PUNCT - O
P NOUN - O
< X - O
0.001 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

The DET - O
ondansetron NN - B-MEDICINE
8-mg CD - B-CARDINAL
dose NOUN - O
can VERB - O
be VERB - O
effective ADJ - O
to PART - O
prevent VERB - O
headache NOUN - O
after ADP - O
spinal ADJ - O
anesthesia NOUN - O
for ADP - O
C PROPN - O
/ SYM - O
S. PROPN - O
Moreover ADV - O
, PUNCT - O
the DET - O
ondansetron NN - B-MEDICINE
8-mg CD - B-PRODUCT
and CCONJ - O
ondansetron NN - B-MEDICINE
4-mg NUM - O
have VERB - O
same ADJ - O
effect NOUN - O
in ADP - O
control NOUN - O
of ADP - O
PONV PROPN - O
after ADP - O
spinal ADJ - O
anesthesia NOUN - O
for ADP - O
C NNP - B-ORG
/ SYM - I-ORG
S. NNP - I-ORG

-DOCSTART- -X- - O

An DET - O
assay ADJ - O
method NOUN - O
to PART - O
quantify VERB - O
ondansetron NN - B-MEDICINE
( PUNCT - O
OND NNP - B-ORG
) PUNCT - O
, PUNCT - O
granisetron NOUN - O
( PUNCT - O
GRA NNP - B-ORG
) PUNCT - O
and CCONJ - O
tropisetron NOUN - O
( PUNCT - O
TRO NOUN - O
) PUNCT - O
in ADP - O
goat NOUN - O
plasma NOUN - O
has VERB - O
been VERB - O
successfully ADV - O
developed VERB - O
and CCONJ - O
validated VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Quantification NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
, PUNCT - O
granisetron NOUN - O
and CCONJ - O
tropisetron NOUN - O
in ADP - O
goat NOUN - O
plasma NOUN - O
using VERB - O
hydrophilic ADJ - O
interaction NOUN - O
liquid ADJ - O
chromatography NOUN - O
- PUNCT - O
solid ADJ - O
phase NOUN - O
extraction NOUN - O
coupled VERB - O
with ADP - O
hydrophilic ADJ - O
interaction NOUN - O
liquid ADJ - O
chromatography NOUN - O
- PUNCT - O
triple ADJ - O
quadrupole NOUN - O
tandem NOUN - O
mass NOUN - O
spectrometry NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Most ADJ - O
PD PROPN - O
- PUNCT - O
DDIQT PROPN - O
involved VERB - O
metoclopramide NOUN - O
with ADP - O
ondansetron NN - B-MEDICINE
or CCONJ - O
amiodarone ADJ - O
, PUNCT - O
and CCONJ - O
ondansetron NN - B-MEDICINE
with ADP - O
ciprofloxacin PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
evaluate VERB - O
the DET - O
association NOUN - O
of ADP - O
anti ADJ - O
- ADJ - O
emetic ADJ - O
efficacy NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
with ADP - O
18792A NNP - B-DATE
> X - O
G NOUN - O
polymorphism NOUN - O
in ADP - O
the DET - O
target NOUN - O
gene NOUN - O
of ADP - O
5-hydroxytryptamine CD - B-CARDINAL
type NOUN - O
3 CD - B-CARDINAL
subtype NOUN - O

All ADJ - O
the DET - O
patients NOUN - O
were VERB - O
given VERB - O
anti ADJ - O
- ADJ - O
emetic ADJ - O
ondansetron NN - B-MEDICINE
( PUNCT - O
4 CD - B-CARDINAL
mg NUM - O
) PUNCT - O
intravenously ADV - O
30 CD - B-TIME
minutes NNS - I-TIME
before ADP - O
the DET - O
end NOUN - O
of ADP - O
surgery NOUN - O
. PUNCT - O

Within ADP - O
the DT - B-TIME
first JJ - I-TIME
two CD - I-TIME
hours NNS - I-TIME
after ADP - O
surgery NOUN - O
the DET - O
response NOUN - O
to ADP - O
ondansetron NN - B-MEDICINE
was VERB - O
noted VERB - O
down PART - O
. PUNCT - O

No DET - O
significant ADJ - O
association NOUN - O
was VERB - O
found VERB - O
between ADP - O
the DET - O
incidence NOUN - O
of ADP - O
vomiting NOUN - O
and CCONJ - O
the DET - O
18792A PROPN - O
> X - O
G NOUN - O
genotypes NOUN - O
at ADP - O
2 CD - B-TIME
hours NNS - I-TIME
after ADP - O
surgery NOUN - O
( PUNCT - O
p>0.05).No DET - O
association NOUN - O
of ADP - O
anti ADJ - O
- ADJ - O
emetic ADJ - O
efficacy NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
with ADP - O
18792A PROPN - O
> X - O
G NOUN - O
polymorphism NOUN - O
in ADP - O
the DET - O
target NOUN - O
gene NOUN - O
of ADP - O
5-hydroxytryptamine CD - B-CARDINAL
type NOUN - O
3 CD - B-CARDINAL
subtype NOUN - O
B PROPN - O
was VERB - O
found VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Objective ADJ - O
To PART - O
evaluate VERB - O
the DET - O
application NOUN - O
of ADP - O
adding VERB - O
ondansetron NN - B-MEDICINE
in ADP - O
morphine ADJ - O
intravenous ADJ - O
analgesia NOUN - O
pump NOUN - O
for ADP - O
prevention NOUN - O
of ADP - O
postoperative ADJ - O
nausea NOUN - O
and CCONJ - O
vomiting(PONV)in VERB - O
women NOUN - O
. PUNCT - O

Based VERB - O
on ADP - O
whether ADP - O
ondansetron NN - B-MEDICINE
was VERB - O
added VERB - O
, PUNCT - O
patients NOUN - O
were VERB - O
divided VERB - O
into ADP - O
the DET - O
observation NOUN - O
group(n=834 NOUN - O
) PUNCT - O
and CCONJ - O
the DET - O
control NOUN - O
group(n=856 NOUN - O
) PUNCT - O
. PUNCT - O

Logistic ADJ - O
regression NOUN - O
analysis NOUN - O
showed VERB - O
that ADP - O
adding VERB - O
ondansetron NN - B-MEDICINE
in ADP - O
morphine ADJ - O
intravenous ADJ - O
analgesia NOUN - O
pump NOUN - O
was VERB - O
an DET - O
independent ADJ - O
influencing VERB - O
factor NOUN - O
of ADP - O
reduced VERB - O
postoperative ADJ - O
nausea NOUN - O
. PUNCT - O

Conclusion NOUN - O
Adding VERB - O
ondansetron NN - B-MEDICINE
in ADP - O
morphine ADJ - O
intravenous ADJ - O
analgesia NOUN - O
pump NOUN - O
may VERB - O
reduce VERB - O
PONV PROPN - O
in ADP - O
women NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
aim NOUN - O
of ADP - O
this DET - O
study NOUN - O
is VERB - O
to PART - O
evaluate VERB - O
the DET - O
analgesic ADJ - O
efficacy NOUN - O
of ADP - O
tramadol NOUN - O
infusion NOUN - O
versus ADP - O
tramadol ADV - O
plus CCONJ - O
ondansetron VB - B-MEDICINE
infusion NOUN - O
in ADP - O
Medical NNP - B-ORG
Intensive NNP - I-ORG
Care NNP - I-ORG
Unit NNP - I-ORG
( PUNCT - O
ICU NNP - B-ORG
) PUNCT - O
patients NOUN - O
. PUNCT - O

Both CCONJ - O
the DET - O
groups NOUN - O
initially ADV - O
received VERB - O
50 CD - B-CARDINAL
mg NOUN - O
of ADP - O
tramadol NOUN - O
intravenously ADV - O
over ADP - O
10 CD - B-QUANTITY
min NN - I-QUANTITY
followed VERB - O
by ADP - O
Group NNP - B-ORG
T+O NNP - I-ORG
received VERB - O
10 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
h NOUN - O
tramadol NOUN - O
+ CCONJ - O
0.4 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
h X - O
ondansetron NN - B-MEDICINE
as ADP - O
an DET - O
infusion NOUN - O
. PUNCT - O

We PRON - O
conclude VERB - O
that ADP - O
co NOUN - O
- NOUN - O
administration NOUN - O
of ADP - O
tramadol NOUN - O
and CCONJ - O
ondansetron NN - B-MEDICINE
can VERB - O
be VERB - O
practiced VERB - O
in ADP - O
medical ADJ - O
ICU NNP - B-ORG
patients NOUN - O
without ADP - O
any DET - O
higher ADJ - O
requirement NOUN - O
in ADP - O
dosage NOUN - O
of ADP - O
tramadol NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Guidelines NOUN - O
recommend VERB - O
oral ADJ - O
rehydration NOUN - O
therapy NOUN - O
( PUNCT - O
ORT PROPN - O
) PUNCT - O
and CCONJ - O
avoidance NOUN - O
of ADP - O
laboratory NOUN - O
tests NOUN - O
and CCONJ - O
intravenous ADJ - O
fluids NOUN - O
for ADP - O
mild ADJ - O
to PART - O
moderate ADJ - O
dehydration NOUN - O
in ADP - O
children NOUN - O
with ADP - O
gastroenteritis NOUN - O
; PUNCT - O
oral ADJ - O
ondansetron NN - B-MEDICINE
has VERB - O
been VERB - O
shown VERB - O
to PART - O
be VERB - O
an DET - O
effective ADJ - O
adjunct NOUN - O
. PUNCT - O

The DET - O
aim NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
determine VERB - O
if ADP - O
a DET - O
triage NOUN - O
- PUNCT - O
based VERB - O
, PUNCT - O
nurse NOUN - O
- PUNCT - O
initiated VERB - O
protocol NOUN - O
for ADP - O
early ADJ - O
provision NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
and CCONJ - O
ORT PROPN - O
could VERB - O
safely ADV - O
improve VERB - O
the DET - O
care NOUN - O
of ADP - O
pediatric ADJ - O
emergency NOUN - O
department NOUN - O
( PUNCT - O
ED NNP - B-ORG
) PUNCT - O
patients NOUN - O
with ADP - O
symptoms NOUN - O
of ADP - O
gastroenteritis NOUN - O
. PUNCT - O

This DET - O
study NOUN - O
evaluated VERB - O
a DET - O
protocol NOUN - O
prompting VERB - O
triage NOUN - O
nurses NOUN - O
to PART - O
assess VERB - O
dehydration NOUN - O
in ADP - O
gastroenteritis NOUN - O
patients NOUN - O
and CCONJ - O
initiate ADJ - O
ondansetron NN - B-MEDICINE
and CCONJ - O
ORT PROPN - O
if ADP - O
indicated VERB - O
. PUNCT - O

Time NOUN - O
to PART - O
ondansetron VB - B-MEDICINE
decreased VERB - O
from ADP - O
60 CD - B-TIME
minutes NNS - I-TIME
to IN - I-TIME
30 CD - I-TIME
minutes NNS - I-TIME
( PUNCT - O
P NOUN - O
= SYM - O
0.004 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

Fifty CD - B-PERCENT
- HYPH - I-PERCENT
two CD - I-PERCENT
percent NN - I-PERCENT
of ADP - O
postintervention NOUN - O
patients NOUN - O
were VERB - O
discharged VERB - O
with ADP - O
prescriptions NOUN - O
for ADP - O
ondansetron NN - B-MEDICINE
. PUNCT - O

A DET - O
triage NOUN - O
nurse NOUN - O
- PUNCT - O
initiated VERB - O
protocol NOUN - O
for ADP - O
early ADJ - O
use NOUN - O
of ADP - O
oral ADJ - O
ondansetron NN - B-MEDICINE
and CCONJ - O
ORT PROPN - O
in ADP - O
children NOUN - O
with ADP - O
evidence NOUN - O
of ADP - O
gastroenteritis NOUN - O
is VERB - O
associated VERB - O
with ADP - O
increased ADJ - O
and CCONJ - O
earlier ADJ - O
use NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
and CCONJ - O
ORT PROPN - O
and CCONJ - O
decreased VERB - O
use NOUN - O
of ADP - O
IV NNP - B-ORG
fluids NOUN - O
and CCONJ - O
blood NOUN - O
testing NOUN - O
without ADP - O
lengthening VERB - O
ED NNP - B-ORG
stays VERB - O
or CCONJ - O
increasing VERB - O
rates NOUN - O
of ADP - O
admission NOUN - O
or CCONJ - O
unscheduled ADJ - O
return NOUN - O
to PART - O
care NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Acupressure NOUN - O
decreases VERB - O
the DET - O
requirement NOUN - O
of ADP - O
rescue NOUN - O
antiemetics NOUN - O
( PUNCT - O
OR CCONJ - O
: PUNCT - O
0.06 CD - B-CARDINAL
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NOUN - O
: PUNCT - O
0.01 CD - B-CARDINAL
, PUNCT - O
0.44 CD - B-CARDINAL
) PUNCT - O
; PUNCT - O
ondansetron NN - B-MEDICINE
with ADP - O
reduced ADJ - O
hospital NOUN - O
stay NOUN - O
( PUNCT - O
WMD PROPN - O
: PUNCT - O
-0.2 VERB - O
; PUNCT - O

-DOCSTART- -X- - O

The DET - O
aim NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
test VERB - O
the DET - O
hypothesis NOUN - O
that ADJ - O
ramosetron NOUN - O
is VERB - O
comparable ADJ - O
to PART - O
ondansetron VB - B-MEDICINE
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
established VERB - O
PONV PROPN - O
after ADP - O
laparoscopic ADJ - O
surgery NOUN - O
using VERB - O
a DET - O
prospective ADJ - O
, PUNCT - O
randomized VERB - O
, PUNCT - O
double ADJ - O
- PUNCT - O
blinded ADJ - O
, PUNCT - O
noninferiority NOUN - O
study NOUN - O
. PUNCT - O

Patients NOUN - O
who NOUN - O
developed VERB - O
PONV PROPN - O
within ADP - O
the DET - O
first JJ - B-ORDINAL
2 CD - B-CARDINAL
h NOUN - O
after ADP - O
anesthesia NOUN - O
received VERB - O
ondansetron NN - B-MEDICINE
( PUNCT - O
4 CD - B-CARDINAL
mg NUM - O
) PUNCT - O
or CCONJ - O
ramosetron NOUN - O
( PUNCT - O
0.3 CD - B-CARDINAL
mg NOUN - O
) PUNCT - O
intravenously ADV - O
in ADP - O
a DET - O
randomized VERB - O
double ADJ - O
- PUNCT - O
blind ADJ - O
manner NOUN - O
. PUNCT - O

Among ADP - O
the DET - O
583 CD - B-CARDINAL
patients NOUN - O
, PUNCT - O
210 CD - B-CARDINAL
( PUNCT - O
36.0 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
developed VERB - O
PONV PROPN - O
and CCONJ - O
were VERB - O
randomized VERB - O
to ADP - O
either CCONJ - O
the DET - O
ondansetron NN - B-MEDICINE
( PUNCT - O
n=105 FW - B-CARDINAL
) PUNCT - O
or CCONJ - O
ramosetron NOUN - O
( PUNCT - O
n=105 NNP - B-CARDINAL
) PUNCT - O
group NOUN - O
. PUNCT - O

The DET - O
complete ADJ - O
response NOUN - O
rate NOUN - O
was VERB - O
44.1 CD - B-PERCENT
% NN - I-PERCENT
in ADP - O
the DET - O
ondansetron NN - B-MEDICINE
group NOUN - O
and CCONJ - O
52.9 CD - B-PERCENT
% NN - I-PERCENT
in ADP - O
the DET - O
ramosetron NOUN - O
group NOUN - O
after ADP - O
24 CD - B-CARDINAL
h DET - O
of ADP - O
initial ADJ - O
antiemetic ADJ - O
administration NOUN - O
. PUNCT - O

We PRON - O
found VERB - O
evidence NOUN - O
to PART - O
support VERB - O
the DET - O
noninferiority NOUN - O
of ADP - O
ramosetron NOUN - O
( PUNCT - O
0.3 CD - B-CARDINAL
mg NOUN - O
) PUNCT - O
compared VERB - O
to ADP - O
ondansetron NN - B-MEDICINE
( PUNCT - O
4 CD - B-CARDINAL
mg NUM - O
) PUNCT - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
established VERB - O
PONV PROPN - O
in ADP - O
moderate ADJ - O
to ADP - O
high ADJ - O
- PUNCT - O
risk NOUN - O
patients NOUN - O
undergoing VERB - O
laparoscopic ADJ - O
surgery NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparison NOUN - O
of ADP - O
ramosetron NOUN - O
and CCONJ - O
ondansetron NN - B-MEDICINE
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
established VERB - O
postoperative ADJ - O
nausea NOUN - O
and CCONJ - O
vomiting VERB - O
after ADP - O
laparoscopic ADJ - O
surgery NOUN - O
: PUNCT - O
a DET - O
prospective ADJ - O
, PUNCT - O
randomized VERB - O
, PUNCT - O
double ADJ - O
- PUNCT - O
blinded ADJ - O
multicenter NOUN - O
trial NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

All DET - O
of ADP - O
the DET - O
six CD - B-CARDINAL
drugs NOUN - O
examined VERB - O
, PUNCT - O
including VERB - O
amitriptyline NOUN - O
, PUNCT - O
fluoxetine NOUN - O
, PUNCT - O
imipramine ADJ - O
, PUNCT - O
irinotecan ADJ - O
, PUNCT - O
ondansetron NN - B-MEDICINE
, PUNCT - O
and CCONJ - O
verapamil NOUN - O
, PUNCT - O
were VERB - O
inhibitors NOUN - O
of ADP - O
OCT1/2-mediated ADJ - O
morphine NOUN - O
uptake NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
test VERB - O
the DET - O
hypothesis NOUN - O
that ADJ - O
IKAS PROPN - O
inhibition NOUN - O
contributes VERB - O
to ADP - O
drug NOUN - O
- PUNCT - O
induced VERB - O
long ADJ - O
QT PROPN - O
syndrome NOUN - O
( PUNCT - O
diLQTS PROPN - O
) PUNCT - O
, PUNCT - O
we PRON - O
screened VERB - O
for ADP - O
KCNN NNP - B-ORG
variants NOUN - O
among ADP - O
patients NOUN - O
with ADP - O
diLQTS PROPN - O
, PUNCT - O
determined VERB - O
the DET - O
properties NOUN - O
of ADP - O
heterologously ADV - O
expressed VERB - O
wild ADJ - O
- PUNCT - O
type NOUN - O
( PUNCT - O
WT NNP - B-ORG
) PUNCT - O
and CCONJ - O
variant ADJ - O
KCNN NNP - B-ORG
channels NOUN - O
, PUNCT - O
and CCONJ - O
determined VERB - O
if ADP - O
the DET - O
5-HT3 JJ - B-CARDINAL
receptor NOUN - O
antagonist NOUN - O
ondansetron NN - B-MEDICINE
blocks VERB - O
IKAS PROPN - O
. PUNCT - O

DNA NOUN - O
sequencing NOUN - O
discovered VERB - O
a DET - O
heterozygous ADJ - O
KCNN2 PROPN - O
variant NOUN - O
( PUNCT - O
p X - O
. PUNCT - O
F503L PROPN - O
) PUNCT - O
in ADP - O
a DET - O
52-yr CD - B-MONEY
- HYPH - I-MONEY
old JJ - I-MONEY
woman NOUN - O
presenting VERB - O
with ADP - O
corrected ADJ - O
QT NNP - B-ORG
interval ADJ - O
prolongation NOUN - O
at ADP - O
baseline NOUN - O
( PUNCT - O
473 CD - B-CARDINAL
ms NOUN - O
) PUNCT - O
and CCONJ - O
further ADV - O
corrected VERB - O
QT NNP - B-ORG
interval NOUN - O
lengthening NOUN - O
( PUNCT - O
601 CD - B-CARDINAL
ms NOUN - O
) PUNCT - O
after ADP - O
oral ADJ - O
administration NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
. PUNCT - O

NOTEWORTHY PROPN - O
We PRON - O
showed VERB - O
that ADP - O
ondansetron NN - B-MEDICINE
, PUNCT - O
a DET - O
5-HT3 ADJ - O
receptor NOUN - O
antagonist NOUN - O
, PUNCT - O
blocks VERB - O
small ADJ - O
- PUNCT - O
conductance NOUN - O
Ca2 NOUN - O
+ SYM - O

-DOCSTART- -X- - O

The DET - O
rash NOUN - O
started VERB - O
2 CD - B-DATE
  _SP - I-DATE
days NNS - I-DATE
after ADP - O
the DET - O
patient NOUN - O
had VERB - O
started VERB - O
taking VERB - O
ondansetron NN - B-MEDICINE
8 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
for ADP - O
alleviation NOUN - O
of ADP - O
moderate ADJ - O
- PUNCT - O
to ADP - O
- PUNCT - O
severe ADJ - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
of ADP - O
pregnancy NOUN - O
. PUNCT - O

Analysis NOUN - O
of ADP - O
the DET - O
case NOUN - O
using VERB - O
the DET - O
Naranjo NNP - B-PERSON
adverse ADJ - O
drug NOUN - O
reaction NOUN - O
probability NOUN - O
scale NOUN - O
indicated VERB - O
that ADP - O
ondansetron NN - B-MEDICINE
was VERB - O
the DET - O
probable ADJ - O
cause NOUN - O
of ADP - O
the DET - O
pityriasis ADJ - O
rosea NOUN - O
- PUNCT - O
like ADJ - O
eruption NOUN - O
. PUNCT - O

This DET - O
is VERB - O
the DET - O
first JJ - B-ORDINAL
case NOUN - O
report NOUN - O
of ADP - O
pityriasis ADJ - O
rosea NOUN - O
related VERB - O
to ADP - O
ondansetron NN - B-MEDICINE
therapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pityriasis ADJ - O
rosea NOUN - O
- PUNCT - O
like ADJ - O
eruption NOUN - O
associated VERB - O
with ADP - O
ondansetron NN - B-MEDICINE
use NOUN - O
in ADP - O
pregnancy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
assessed VERB - O
the DET - O
non ADJ - O
- ADJ - O
inferiority NOUN - O
of ADP - O
palonosetron NOUN - O
versus X - O
ondansetron NN - B-MEDICINE
in ADP - O
prevention NOUN - O
of ADP - O
acute ADJ - O
chemotherapy NOUN - O
- PUNCT - O
induced VERB - O
vomiting NOUN - O
in ADP - O
children NOUN - O
with ADP - O
cancer NOUN - O
in ADP - O
2 CD - B-CARDINAL
- SYM - O
18 NUM - O
  SPACE - O
years NNS - B-DATE
of IN - I-DATE
age NN - I-DATE
. PUNCT - O

In ADP - O
this DET - O
single ADJ - O
- PUNCT - O
center NOUN - O
, PUNCT - O
open ADJ - O
- PUNCT - O
label NOUN - O
, PUNCT - O
randomized VERB - O
study NOUN - O
, PUNCT - O
children NOUN - O
receiving VERB - O
moderate ADJ - O
and CCONJ - O
high ADJ - O
emetogenic ADJ - O
chemotherapy NOUN - O
were VERB - O
assigned VERB - O
to PART - O
get VERB - O
either DET - O
ondansetron NN - B-MEDICINE
or CCONJ - O
palonosetron NOUN - O
in ADP - O
addition NOUN - O
to ADP - O
other ADJ - O
antiemetic ADJ - O
prophylaxis NOUN - O
. PUNCT - O

During ADP - O
the DET - O
acute ADJ - O
phase NOUN - O
, PUNCT - O
complete ADJ - O
responses NOUN - O
were VERB - O
recorded VERB - O
in ADP - O
72.2 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
39/54 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O
83.3 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
45/54 CD - B-CARDINAL
) PUNCT - O
receiving VERB - O
ondansetron NN - B-MEDICINE
and CCONJ - O
palonosetron NOUN - O
, PUNCT - O
respectively ADV - O
( PUNCT - O
ΔCR PROPN - O
+ CCONJ - O
  SPACE - O
11.1 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
. PUNCT - O

The DET - O
cost NOUN - O
associated VERB - O
with ADP - O
ondansetron NN - B-MEDICINE
administration NOUN - O
was VERB - O
significantly ADV - O
higher ADJ - O
compared VERB - O
to ADP - O
palonosetron NOUN - O
. PUNCT - O

Palonosetron NNP - B-ORG
is VERB - O
non ADJ - O
- ADJ - O
inferior ADJ - O
and CCONJ - O
cost NOUN - O
- PUNCT - O
effective ADJ - O
compared VERB - O
to ADP - O
ondansetron NN - B-MEDICINE
for ADP - O
prevention NOUN - O
of ADP - O
acute ADJ - O
chemotherapy NOUN - O
- PUNCT - O
induced VERB - O
vomiting NOUN - O
( PUNCT - O
CIV NNP - B-ORG
) PUNCT - O
in ADP - O
children NOUN - O
receiving VERB - O
moderate ADJ - O
and CCONJ - O
high ADJ - O
emetogenic ADJ - O
chemotherapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
randomized VERB - O
, PUNCT - O
open ADJ - O
- PUNCT - O
label NOUN - O
non ADJ - O
- ADJ - O
inferiority ADJ - O
study NOUN - O
to PART - O
compare VERB - O
palonosetron NOUN - O
and CCONJ - O
ondansetron NN - B-MEDICINE
for ADP - O
prevention NOUN - O
of ADP - O
acute ADJ - O
chemotherapy NOUN - O
- PUNCT - O
induced VERB - O
vomiting NOUN - O
in ADP - O
children NOUN - O
with ADP - O
cancer NOUN - O
receiving VERB - O
moderate ADJ - O
or CCONJ - O
high ADJ - O
emetogenic ADJ - O
chemotherapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
postoperative ADJ - O
adults NOUN - O
, PUNCT - O
ondansetron NN - B-MEDICINE
has VERB - O
been VERB - O
shown VERB - O
to PART - O
prolong VERB - O
the DET - O
corrected VERB - O
QT NNP - B-ORG
( PUNCT - O
QTc PROPN - O
) PUNCT - O
. PUNCT - O

The DET - O
aim NOUN - O
of ADP - O
the DET - O
study NOUN - O
was VERB - O
to PART - O
evaluate VERB - O
the DET - O
effect NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
on ADP - O
the DET - O
QT NNP - B-ORG
at ADP - O
peak NOUN - O
effect NOUN - O
and CCONJ - O
at ADP - O
1-hour NUM - O
postpeak NOUN - O
effect NOUN - O
in ADP - O
pediatric ADJ - O
patients NOUN - O
. PUNCT - O

This DET - O
was VERB - O
an DET - O
observational ADJ - O
study NOUN - O
looking VERB - O
at ADP - O
patients NOUN - O
aged VERB - O
6 CD - B-DATE
months NNS - I-DATE
to IN - I-DATE
18 CD - I-DATE
years NNS - I-DATE
receiving VERB - O
intravenous ADJ - O
ondansetron NN - B-MEDICINE
for ADP - O
nausea NOUN - O
, PUNCT - O
vomiting NOUN - O
, PUNCT - O
or CCONJ - O
the DET - O
inability NOUN - O
to PART - O
take VERB - O
fluids NOUN - O
in ADP - O
the DET - O
emergency NOUN - O
department NOUN - O
. PUNCT - O

Patients NOUN - O
had VERB - O
electrocardiogram NOUN - O
performed VERB - O
at ADP - O
baseline NOUN - O
, PUNCT - O
at ADP - O
ondansetron NN - B-MEDICINE
's PART - O
peak ADJ - O
effect NOUN - O
, PUNCT - O
and CCONJ - O
1 CD - B-TIME
hour NN - I-TIME
postpeak NOUN - O
effect NOUN - O
. PUNCT - O

Peak NOUN - O
effect NOUN - O
of ADP - O
intravenous ADJ - O
ondansetron NN - B-MEDICINE
is VERB - O
3 CD - B-TIME
minutes NNS - I-TIME
. PUNCT - O

The DET - O
mean ADJ - O
( PUNCT - O
range NOUN - O
) PUNCT - O
change NOUN - O
in ADP - O
QTc NOUN - O
at ADP - O
peak NOUN - O
effect NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
was VERB - O
3 CD - B-CARDINAL
( PUNCT - O
-40 NOUN - O
to ADP - O
65 CD - B-CARDINAL
) PUNCT - O
milliseconds NOUN - O
( PUNCT - O
P NOUN - O
= SYM - O
0.072 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

The DET - O
change NOUN - O
in ADP - O
QTc NOUN - O
1-hour NUM - O
postpeak ADJ - O
effect NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
was VERB - O
3 CD - B-CARDINAL
( PUNCT - O
-43 PUNCT - O
to ADP - O
45 CD - B-CARDINAL
) PUNCT - O
milliseconds NOUN - O
( PUNCT - O
P NOUN - O
= SYM - O
0.082 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

To ADP - O
date NOUN - O
, PUNCT - O
there ADV - O
have VERB - O
been VERB - O
no DET - O
studies NOUN - O
evaluating VERB - O
the DET - O
effect NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
in ADP - O
this DET - O
acutely ADV - O
ill ADJ - O
population NOUN - O
; PUNCT - O
therefore ADV - O
, PUNCT - O
a DET - O
larger ADJ - O
study NOUN - O
should VERB - O
be VERB - O
completed VERB - O
to PART - O
confirm VERB - O
these DET - O
data NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
compare VERB - O
aromatherapy NOUN - O
with ADP - O
inhaled VERB - O
isopropyl ADJ - O
alcohol NOUN - O
versus ADP - O
oral ADJ - O
ondansetron NN - B-MEDICINE
for ADP - O
treating VERB - O
nausea NOUN - O
among ADP - O
emergency NOUN - O
department NOUN - O
( PUNCT - O
ED NNP - B-ORG
) PUNCT - O
patients NOUN - O
not ADV - O
requiring VERB - O
immediate ADJ - O
intravenous ADJ - O
access NOUN - O
. PUNCT - O

We PRON - O
randomized VERB - O
subjects NOUN - O
to ADP - O
1 CD - B-CARDINAL
of ADP - O
3 CD - B-CARDINAL
arms NOUN - O
: PUNCT - O
inhaled VERB - O
isopropyl ADJ - O
alcohol NOUN - O
and CCONJ - O
4 CD - B-CARDINAL
mg NOUN - O
oral ADJ - O
ondansetron NN - B-MEDICINE
, PUNCT - O
inhaled VERB - O
isopropyl ADJ - O
alcohol NOUN - O
and CCONJ - O
oral ADJ - O
placebo NOUN - O
, PUNCT - O
and CCONJ - O
inhaled VERB - O
saline NOUN - O
solution NOUN - O
placebo NOUN - O
and CCONJ - O
4 CD - B-CARDINAL
mg NOUN - O
oral ADJ - O
ondansetron NN - B-MEDICINE
. PUNCT - O

Of ADP - O
randomized VERB - O
subjects NOUN - O
, PUNCT - O
40 CD - B-CARDINAL
received VERB - O
inhaled VERB - O
isopropyl ADJ - O
alcohol NOUN - O
and CCONJ - O
oral ADJ - O
ondansetron NN - B-MEDICINE
, PUNCT - O
41 CD - B-CARDINAL
received VERB - O
inhaled VERB - O
isopropyl ADJ - O
alcohol NOUN - O
and CCONJ - O
oral ADJ - O
placebo NOUN - O
, PUNCT - O
and CCONJ - O
41 CD - B-CARDINAL
received VERB - O
inhaled VERB - O
saline NOUN - O
solution NOUN - O
placebo NOUN - O
and CCONJ - O
oral ADJ - O
ondansetron NN - B-MEDICINE
. PUNCT - O

Among ADP - O
ED NNP - B-ORG
patients NOUN - O
with ADP - O
acute ADJ - O
nausea NOUN - O
and CCONJ - O
not ADV - O
requiring VERB - O
immediate ADJ - O
intravenous ADJ - O
access NOUN - O
, PUNCT - O
aromatherapy NOUN - O
with ADP - O
or CCONJ - O
without ADP - O
oral ADJ - O
ondansetron NN - B-MEDICINE
provides VERB - O
greater ADJ - O
nausea NOUN - O
relief NOUN - O
than ADP - O
oral ADJ - O
ondansetron NN - B-MEDICINE
alone ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
patient NOUN - O
received VERB - O
benzodiazepines NOUN - O
and CCONJ - O
ondansetron NN - B-MEDICINE
for ADP - O
symptomatic ADJ - O
treatment NOUN - O
when ADV - O
he PRON - O
arrived VERB - O
in ADP - O
the DT - B-ORG
Emergency NNP - I-ORG
Department NNP - I-ORG
( PUNCT - O
ED NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

administration NOUN - O
of ADP - O
a DET - O
single ADJ - O
dose NOUN - O
of ADP - O
4 CD - B-QUANTITY
mg NN - I-QUANTITY
of ADP - O
ondansetron NN - B-MEDICINE
was VERB - O
associated VERB - O
with ADP - O
QT NNP - B-ORG
interval NOUN - O
prolongation NOUN - O
in ADP - O
emergency NOUN - O
department NOUN - O
( PUNCT - O
ED NNP - B-ORG
) PUNCT - O
patients NOUN - O
are VERB - O
reported VERB - O
. PUNCT - O

In ADP - O
a DET - O
prospective ADJ - O
observational ADJ - O
study NOUN - O
conducted VERB - O
at ADP - O
an DET - O
urban ADJ - O
academic ADJ - O
medical ADJ - O
center NOUN - O
ED NNP - B-ORG
, PUNCT - O
a DET - O
convenience NOUN - O
sample NOUN - O
of ADP - O
adult NOUN - O
ED NNP - B-ORG
patients NOUN - O
treated VERB - O
with ADP - O
ondansetron NN - B-MEDICINE
4 CD - B-CARDINAL
mg PRON - O
i.v VERB - O
. PUNCT - O
were VERB - O
enrolled VERB - O
. PUNCT - O

A DET - O
12-lead CD - B-CARDINAL
electrocardiogram NOUN - O
( PUNCT - O
ECG NNP - B-ORG
) PUNCT - O
was VERB - O
obtained VERB - O
immediately ADV - O
before ADV - O
and CCONJ - O
5 CD - B-TIME
minutes NNS - I-TIME
after ADP - O
ondansetron NN - B-MEDICINE
administration NOUN - O
. PUNCT - O

The DET - O
primary ADJ - O
objective NOUN - O
was VERB - O
to PART - O
measure VERB - O
the DET - O
QTc NOUN - O
change NOUN - O
from ADP - O
baseline NOUN - O
after ADP - O
ondansetron NN - B-MEDICINE
administration NOUN - O
. PUNCT - O

Interactions NOUN - O
between ADP - O
ondansetron NN - B-MEDICINE
and CCONJ - O
patients NOUN - O
' PART - O
home NOUN - O
medications NOUN - O
or CCONJ - O
ED NNP - B-ORG
- PUNCT - O
provided VERB - O
medications NOUN - O
were VERB - O
analyzed VERB - O
. PUNCT - O

Among ADP - O
patients NOUN - O
included VERB - O
in ADP - O
the DET - O
data NOUN - O
analysis NOUN - O
( PUNCT - O
n NOUN - O
= SYM - O
20 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
ondansetron NN - B-MEDICINE
administration NOUN - O
was VERB - O
associated VERB - O
with ADP - O
a DET - O
mean NOUN - O
QTc ADJ - O
increase NOUN - O
of ADP - O
16.2 CD - B-CARDINAL
msec NOUN - O
( PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
confidence NOUN - O
interval NOUN - O
, PUNCT - O
4.2 CD - B-CARDINAL
- SYM - O
28.2 NUM - O
msec NOUN - O
; PUNCT - O
p PUNCT - O
= SYM - O
0.01 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O
a DET - O
median ADJ - O
increase NOUN - O
of ADP - O
12 CD - B-CARDINAL
msec NOUN - O
( PUNCT - O
interquartile ADJ - O
range NOUN - O
, PUNCT - O
5.5 CD - B-CARDINAL
- SYM - O
18.0 NUM - O
msec NOUN - O
; PUNCT - O
p X - O
< X - O
0.01 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

One CD - B-CARDINAL
patient NOUN - O
had VERB - O
a DET - O
significant ADJ - O
cardiac ADJ - O
event NOUN - O
( PUNCT - O
pulseless VERB - O
electrical ADJ - O
activity NOUN - O
) PUNCT - O
that ADJ - O
was VERB - O
likely ADV - O
unrelated ADJ - O
to ADP - O
ondansetron NN - B-MEDICINE
use NOUN - O
. PUNCT - O

dose NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
. PUNCT - O

None NOUN - O
of ADP - O
the DET - O
patients NOUN - O
had VERB - O
an DET - O
ondansetron RB - B-MEDICINE
- PUNCT - O
related VERB - O
cardiac ADJ - O
adverse ADJ - O
event NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

ondansetron NN - B-MEDICINE
on ADP - O
QTc NOUN - O
interval NOUN - O
in ADP - O
emergency NOUN - O
department NOUN - O
patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Should VERB - O
ondansetron RB - B-MEDICINE
be VERB - O
used VERB - O
as ADP - O
a DET - O
routine ADJ - O
prophylaxis NOUN - O
agent NOUN - O
for ADP - O
postoperative ADJ - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
? PUNCT - O

-DOCSTART- -X- - O

Further ADV - O
, PUNCT - O
patients NOUN - O
with ADP - O
a DET - O
history NOUN - O
of ADP - O
pneumothorax NOUN - O
or CCONJ - O
genetically ADV - O
predisposed VERB - O
to PART - O
pneumothorax VERB - O
should VERB - O
be VERB - O
considered VERB - O
for ADP - O
an DET - O
alternative ADJ - O
antiemetic NOUN - O
to PART - O
ondansetron VB - B-MEDICINE
hydrochloride NOUN - O
, PUNCT - O
due ADJ - O
to ADP - O
increased VERB - O
odds NOUN - O
associated VERB - O
with ADP - O
the DET - O
drug NOUN - O
and CCONJ - O
adverse ADJ - O
event NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
frequency NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
( PUNCT - O
n CCONJ - O
  SPACE - O
= PUNCT - O
  SPACE - O
100 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O
metoclopramide NOUN - O
( PUNCT - O
n CCONJ - O
  SPACE - O
= PUNCT - O
  SPACE - O
27 CD - B-CARDINAL
) PUNCT - O
in ADP - O
the DET - O
no DET - O
droperidol NOUN - O
treatment NOUN - O
group NOUN - O
was VERB - O
double ADJ - O
that DET - O
of ADP - O
the DET - O
droperidol NOUN - O
group NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
SDS NNP - B-ORG
/ SYM - I-ORG
FeSP NNP - I-ORG
nanocomposite NOUN - O
was VERB - O
investigated VERB - O
as ADP - O
a DET - O
drug NOUN - O
carrier NOUN - O
for ADP - O
ondansetron NN - B-MEDICINE
. PUNCT - O

The DET - O
cumulative ADJ - O
drug NOUN - O
release NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
was VERB - O
observed VERB - O
at ADP - O
various ADJ - O
pH PROPN - O
values NOUN - O
for ADP - O
different ADJ - O
time NOUN - O
intervals NOUN - O
, PUNCT - O
i.e. X - O
, PUNCT - O
from ADP - O
20 CD - B-QUANTITY
min NN - I-QUANTITY
to ADP - O
48 CD - B-CARDINAL

-DOCSTART- -X- - O

Both DET - O
regimens NOUN - O
included VERB - O
dexamethasone NOUN - O
and CCONJ - O
ondansetron NN - B-MEDICINE
on ADP - O
day NN - B-DATE
1 CD - I-DATE
, PUNCT - O
with ADP - O
ondansetron NN - B-MEDICINE
continuing VERB - O
through ADP - O
day NN - B-DATE
3 CD - I-DATE
in ADP - O
the DET - O
control NOUN - O
arm NOUN - O
only ADV - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
unique ADJ - O
schedule NOUN - O
of ADP - O
palonosetron NOUN - O
, PUNCT - O
ondansetron NN - B-MEDICINE
, PUNCT - O
and CCONJ - O
dexamethasone NOUN - O
for ADP - O
the DET - O
prevention NOUN - O
of ADP - O
delayed VERB - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
in ADP - O
patients NOUN - O
receiving VERB - O
myeloablative ADJ - O
chemotherapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Areas NOUN - O
covered VERB - O
: PUNCT - O
A DET - O
systematic ADJ - O
literature NOUN - O
search NOUN - O
was VERB - O
conducted VERB - O
using VERB - O
four CD - B-CARDINAL
databases NOUN - O
to PART - O
identify VERB - O
papers NOUN - O
describing VERB - O
adverse ADJ - O
effects NOUN - O
in ADP - O
pediatric ADJ - O
patients NOUN - O
receiving VERB - O
aprepitant NOUN - O
, PUNCT - O
dexamethasone NOUN - O
, PUNCT - O
granisetron NOUN - O
, PUNCT - O
ondansetron NN - B-MEDICINE
, PUNCT - O
palonosetron NOUN - O
, PUNCT - O
or CCONJ - O
tropisetron ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Two CD - B-CARDINAL
trials NOUN - O
investigated VERB - O
the DET - O
antishivering VERB - O
effect NOUN - O
of ADP - O
intravenous ADJ - O
ondansetron NN - B-MEDICINE
. PUNCT - O

Appropriate ADJ - O
use NOUN - O
of ADP - O
dexmedetomidine NOUN - O
, PUNCT - O
fentanyl NOUN - O
, PUNCT - O
sufentanil NOUN - O
, PUNCT - O
ketamine NOUN - O
, PUNCT - O
meperidine NOUN - O
, PUNCT - O
tramadol NOUN - O
and CCONJ - O
MgSO4 PROPN - O
may VERB - O
effectively ADV - O
reduce VERB - O
the DET - O
incidence NOUN - O
and CCONJ - O
severity NOUN - O
of ADP - O
shivering VERB - O
during ADP - O
CSs NOUN - O
under ADP - O
NA NNP - B-ORG
, PUNCT - O
while ADP - O
trials NOUN - O
on ADP - O
the DET - O
effect NOUN - O
of ADP - O
intravenous ADJ - O
ondansetron NN - B-MEDICINE
reached VERB - O
inconclusive ADJ - O
results NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Paracetamol PROPN - O
( PUNCT - O
acetaminophen ADV - O
in ADP - O
the DET - O
USA NNP - B-GPE
and CCONJ - O
Canada NNP - B-GPE
) PUNCT - O
and CCONJ - O
ondansetron NN - B-MEDICINE
were VERB - O
given VERB - O
as ADP - O
supportive ADJ - O
management NOUN - O
for ADP - O
headache NOUN - O
and CCONJ - O
nausea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Enhanced VERB - O
transdermal ADJ - O
delivery NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
using VERB - O
nanovesicular ADJ - O
systems NOUN - O
: PUNCT - O
Fabrication NOUN - O
, PUNCT - O
characterization NOUN - O
, PUNCT - O
optimization NOUN - O
and CCONJ - O
ex NOUN - O
- NOUN - O
vivo NOUN - O
permeation NOUN - O
study NOUN - O
- PUNCT - O
Box PROPN - O
- PUNCT - O
Cox PROPN - O
transformation NOUN - O
practical ADJ - O
example NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
describes VERB - O
prescribing VERB - O
patterns NOUN - O
for ADP - O
ondansetron NN - B-MEDICINE
and CCONJ - O
assesses VERB - O
the DET - O
effects NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
home NOUN - O
prescription NOUN - O
on ADP - O
rate NOUN - O
of ADP - O
return NOUN - O
. PUNCT - O

The DT - B-ORG
All NNP - I-ORG
Ondansetron NNP - I-ORG
Group NNP - I-ORG
included VERB - O
any DET - O
child NOUN - O
prescribed VERB - O
ondansetron NN - B-MEDICINE
at ADP - O
discharge NOUN - O
. PUNCT - O

Patterns NNS - B-PERSON
of ADP - O
ondansetron NN - B-MEDICINE
use NOUN - O
and CCONJ - O
3- CD - B-DATE
and CCONJ - O
7-day CD - B-DATE
ED NN - B-ORG
return NOUN - O
rate NOUN - O
were VERB - O
assessed VERB - O
for ADP - O
both DET - O
groups NOUN - O
. PUNCT - O

Of ADP - O
these DET - O
, PUNCT - O
76 CD - B-PERCENT
% NN - I-PERCENT
received VERB - O
ondansetron NN - B-MEDICINE
in ADP - O
the DET - O
ED NNP - B-ORG
, PUNCT - O
and CCONJ - O
71 CD - B-PERCENT
% NN - I-PERCENT
were VERB - O
discharged VERB - O
with ADP - O
prescriptions NOUN - O
for ADP - O
ondansetron NN - B-MEDICINE
. PUNCT - O

A DET - O
total NOUN - O
of ADP - O
2287 CD - B-DATE
patients NOUN - O
received VERB - O
home NOUN - O
prescriptions NOUN - O
for ADP - O
ondansetron NN - B-MEDICINE
. PUNCT - O

Home NOUN - O
- PUNCT - O
use NOUN - O
ondansetron NN - B-MEDICINE
is VERB - O
widely ADV - O
prescribed VERB - O
in ADP - O
this DET - O
urban ADJ - O
academic ADJ - O
pediatric NOUN - O
ED NNP - B-ORG
for ADP - O
a DET - O
variety NOUN - O
of ADP - O
indications NOUN - O
, PUNCT - O
without ADP - O
effect NOUN - O
on ADP - O
3- CD - B-CARDINAL
or CCONJ - O
7-day CD - B-DATE
ED NN - B-PERSON
return NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
we PRON - O
investigated VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
fosaprepitant NOUN - O
, PUNCT - O
a DET - O
neurokinin-1 NOUN - O
( PUNCT - O
NK1 NNP - B-ORG
) PUNCT - O
receptor NOUN - O
antagonist NOUN - O
, PUNCT - O
compared VERB - O
to ADP - O
ondansetron NN - B-MEDICINE
, PUNCT - O
a DET - O
selective ADJ - O
5-hydroxytryptamine NUM - O
type NOUN - O
3 CD - B-CARDINAL
( PUNCT - O
5-HT3 PROPN - O
) PUNCT - O
receptor NOUN - O
antagonist NOUN - O
, PUNCT - O
in ADP - O
moderate ADJ - O
to ADP - O
high ADJ - O
PONV PROPN - O
risk NOUN - O
patients NOUN - O
from ADP - O
our ADJ - O
previous ADJ - O
randomized VERB - O
controlled VERB - O
trials NOUN - O
. PUNCT - O

( PUNCT - O
NK1 NNP - B-ORG
group NOUN - O
, PUNCT - O
n NOUN - O
= SYM - O
82 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O
intravenous ADJ - O
ondansetron NN - B-MEDICINE
4 CD - B-CARDINAL
  SPACE - O
mg PRON - O
( PUNCT - O
ONS NOUN - O
group NOUN - O
, PUNCT - O
n NOUN - O
= SYM - O
89 CD - B-CARDINAL
) PUNCT - O
before ADP - O
induction NOUN - O
of ADP - O
anesthesia NOUN - O
. PUNCT - O

In ADP - O
moderate ADJ - O
to PART - O
high ADJ - O
PONV PROPN - O
risk NOUN - O
patients NOUN - O
, PUNCT - O
fosaprepitant NOUN - O
decreased VERB - O
the DET - O
incidence NOUN - O
of ADP - O
vomiting NOUN - O
and CCONJ - O
was VERB - O
superior ADJ - O
to ADP - O
ondansetron NN - B-MEDICINE
in ADP - O
preventing VERB - O
postoperative ADJ - O
vomiting VERB - O
0 CD - B-TIME
- SYM - I-TIME
48 CD - I-TIME
hours NNS - I-TIME
after ADP - O
surgery NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
examined VERB - O
the DET - O
effect NOUN - O
of ADP - O
the DET - O
following VERB - O
drugs NOUN - O
on ADP - O
impulsive ADJ - O
choice NOUN - O
: PUNCT - O
a DET - O
5-HT JJ - B-ORG
reuptake NOUN - O
inhibitor NOUN - O
( PUNCT - O
paroxetine NOUN - O
) PUNCT - O
, PUNCT - O
a DET - O
5-HT1A NNP - B-CARDINAL
receptor NOUN - O
agonist NOUN - O
( PUNCT - O
8-OH NUM - O
- PUNCT - O
DPAT PROPN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
two CD - B-CARDINAL
5-HT3 ADJ - O
receptor NOUN - O
antagonists NOUN - O
( PUNCT - O
granisetron NOUN - O
and CCONJ - O
ondansetron NN - B-MEDICINE
) PUNCT - O
. PUNCT - O

Granisetron NNP - B-ORG
and CCONJ - O
ondansetron NN - B-MEDICINE
, PUNCT - O
but CCONJ - O
not ADV - O
paroxetine VERB - O
or CCONJ - O
8-OH CD - B-NORP
- HYPH - I-NORP
DPAT NNS - I-NORP
, PUNCT - O
decreased VERB - O
discounting VERB - O
rates NOUN - O
without ADP - O
affecting VERB - O
sensitivity NOUN - O
to PART - O
reinforcer VERB - O
magnitude NOUN - O
. PUNCT - O

